b
r
l
granov
h
f
public
health
institut
health
center
sarajevo
pediatr
depart
sarajevo
bosnia
herzegovina
pediatr
clinik
jezero
pulmonolog
depart
sarajevo
bosnia
herzegovina
privat
laboratori
jelah
biochemisteri
depart
tesanj
bosnia
herzegovina
clinic
medic
center
sarajevo
biochemistri
microbiolog
laboratori
sarajevo
bosnia
herzegovina
institut
clinic
sahlgrenska
univers
gothenburg
depart
orthopaed
gothenburg
sweden
background
aim
pneumonia
infect
lung
alveoli
alveolar
wall
bag
diagnosi
pneumonia
quit
obviou
howev
mani
organ
caus
pneumonia
determin
caus
specif
case
difficult
almost
imposs
outpati
present
time
necessari
appli
appropri
diagnost
method
proper
treatment
heal
method
monitor
done
basi
fall
crp
valu
initi
therapi
main
object
master
degre
determin
correl
crp
initi
control
h
hour
antibiot
therapi
possibl
percentag
declin
determin
success
particular
antibiot
therapi
studi
includ
children
pneumonia
area
sarajevo
canton
sex
age
month
less
year
research
undertaken
pediatr
health
center
sarajevo
relat
period
time
begin
octob
end
april
result
expect
valu
vari
depend
child
age
gender
initi
increas
valu
crp
season
type
antibiot
thu
result
plu
minu
one
standard
deviat
outpati
condit
rang
less
extrem
low
valu
unsuccess
therapi
fall
crp
conclus
use
monitor
crp
first
control
day
pneumonia
children
condit
gold
standard
diagnosi
unavoid
physic
examin
pediatr
monitor
pneumonia
success
antibiot
treatment
europ
includ
bosnia
herzegovina
significantli
reduc
due
effici
prompt
treatment
dormanc
leviti
seriou
consequ
tv
tho
gener
hospit
respiratori
tho
vietnam
shiga
univers
medic
scienc
center
epidemiolog
research
asia
kusatsu
japan
background
aim
commun
pneumonia
commun
acquir
pneumonia
common
seen
diseas
clinic
practic
especi
children
elderli
caus
great
mortal
hospit
set
pneumonia
easili
term
clinic
practic
sometim
pneumonia
diagnosi
initi
present
respiratori
infect
symptom
moist
rale
lung
pure
vagu
radiographi
lung
posit
result
microbiolog
test
respiratori
track
secret
commonli
inappropri
manag
commun
pneumonia
misus
antibiot
estim
unnecessari
hospit
result
overload
hospit
increas
treatment
cost
drug
resist
decreas
treatment
effect
purpos
work
perform
practic
approach
relat
etiolog
clinic
present
manag
treatment
commun
pneumonia
adult
patient
method
expert
opinion
guidanc
result
patient
commun
pneumonia
often
present
fever
chill
fatigu
dyspnea
rigor
chest
pain
physician
understand
etiolog
diseas
assess
need
hospit
use
predict
tool
mortal
sever
score
score
pneumonia
sever
index
combin
clinic
judgment
patient
commun
acquir
pneumonia
treat
promptli
empir
antibiot
protocol
antibiot
initi
base
sever
evalu
mild
pneumonia
treat
macrolid
fluoroquinolon
moder
pneumonia
start
parenter
cephalosporin
plu
fluoroquinolon
carbapenem
plu
fluoroquinolon
recommend
sever
pneumonia
plu
inhibitor
select
pneumonia
pathogen
patient
also
evalu
pseudomon
risk
factor
patient
switch
parenter
antibiot
oral
antibiot
symptom
improv
afebril
abl
use
oral
medic
patient
receiv
pneumococc
vaccin
influenza
vaccin
tobacco
cessat
counsel
elig
conclus
ngamwongwan
b
w
kantakamalakul
n
horthongkham
siriraj
hospit
mahidol
univers
faculti
medicin
bangkok
thailand
background
aim
rsv
common
caus
respiratori
tract
infect
rti
children
induc
reactiv
airway
diseas
epidemiolog
evid
support
caus
rti
adult
howev
data
limit
thai
patient
method
cohort
studi
conduct
determin
clinic
manifest
rsv
infect
adult
hospit
patient
spirometri
methacholin
challeng
test
also
perform
recoveri
rsv
infect
week
patient
preexist
airway
diseas
result
patient
includ
studi
mean
age
year
except
one
underli
diseas
pulmonari
diseas
cardiovascular
diseas
diabet
immumocompromis
host
common
asthma
common
pulmonari
diseas
asthma
copd
previou
tuberculosi
treatment
bronchiectasi
common
present
symptom
rsv
infect
cough
dyspnea
fever
median
durat
ill
day
rhonchi
andor
wheez
common
physic
find
fever
found
patient
thirti
one
patient
diagnos
pneumonia
common
abnorm
radiograph
bilater
interstiti
opac
twenti
four
patient
develop
respiratori
failur
patient
respiratori
failur
higher
mortal
rate
longer
hospit
without
respiratori
failur
thirteen
patient
underw
spirometri
obstruct
eight
patient
normal
spirometri
underw
methacholin
challeng
test
borderlin
bronchial
hyperrespons
conclus
cough
dyspnea
fever
common
present
symptom
rsv
infect
adult
hospit
patient
wheez
rhonchi
commonli
found
patient
rsv
infect
caus
airway
obstruct
bronchial
hyperrespons
ebisudani
kameda
medic
center
pulmonari
medicin
kamogawa
chiba
japan
background
aim
thoracoscop
surgic
decort
vatsd
report
minim
invas
effect
treatment
acut
thorac
empyema
howev
report
influenc
preoper
clinic
featur
postop
hospit
stay
recurr
patient
underw
vatsd
acut
thorac
empyema
method
retrospect
review
patient
acut
thorac
empyema
underw
vatsd
april
march
analyz
clinic
featur
serolog
bacteriolog
studi
radiolog
find
treatment
outcom
antibiot
initi
diagnosi
continu
normal
inflamm
paramet
bodi
temperatur
result
total
patient
men
women
underw
vatsd
mean
age
year
comorbid
hypertens
case
diabet
mellitu
mental
ill
neoplasm
median
durat
symptom
oper
day
averag
oper
time
minut
cultur
pleural
effus
certifi
caus
organ
case
isol
organ
sensit
administr
antibiot
durat
antibiot
day
day
durat
chest
drainag
day
day
postop
surgic
site
infect
seen
case
recurr
seen
case
extern
fistula
multilocul
septal
format
concomit
ga
median
postop
hospit
stay
day
howev
two
case
show
prolong
hospit
stay
conclus
multilocul
septal
format
concomit
ga
might
prolong
durat
postop
hospit
stay
increas
risk
recurr
acut
thorac
empyema
addit
case
extern
fistula
also
risk
recurr
mc
j
c
rww
gosford
australia
depart
respiratori
gosford
australia
gosford
australia
pharmaci
depart
gosford
australia
background
aim
commun
acquir
pneumonia
cap
lead
caus
infect
relat
morbid
mortal
inappropri
antibiot
treatment
associ
increas
risk
antibiot
resist
advers
clinic
outcom
aim
studi
evalu
empir
antibiot
prescript
cap
comparison
current
australian
antibiot
guidelin
assess
impact
antimicrobi
stewardship
am
program
method
retrospect
studi
compar
patient
admit
cap
complianc
empir
antibiot
treatment
determin
current
guidelin
base
pneumonia
sever
calcul
score
impact
am
implement
antibiot
prescript
evalu
compar
antibiot
complianc
rate
inpati
mortal
readmiss
rate
length
stay
two
period
result
consecut
patient
includ
period
n
n
overal
antibiot
complianc
rate
significantli
higher
am
implement
vs
p
seen
antibiot
choic
cover
typic
organ
vs
p
atyp
organ
vs
p
proport
cap
case
treat
ceftriaxon
azithromycin
significantli
lower
vs
p
vs
p
respect
inpati
mortal
vs
p
ns
readmiss
rate
vs
p
ns
two
period
similar
mean
length
stay
lower
vs
day
p
conclus
antimicrobi
stewardship
significantli
improv
empir
antibiot
guidelin
complianc
cap
reduc
use
broad
spectrum
antibiot
cap
appear
reduct
length
stay
without
impact
inpati
mortal
readmiss
rate
implement
prospect
studi
need
confirm
result
studi
saito
tomoko
k
niitsuma
aizu
medic
center
infecti
disea
pulmonari
medicin
japan
background
aim
pulmonari
mycetoma
consid
result
saprophyt
growth
mycelia
within
caviti
case
aspergillu
spp
caus
develop
multipl
cyst
caviti
lesion
allerg
bronchopulmonari
aspergillosi
abpa
method
result
male
past
histori
asthma
year
admit
hospit
complain
dri
cough
slight
fever
month
left
pneumothorax
multipl
cyst
caviti
found
partial
cystectomi
left
upper
lung
perform
mycelium
resect
tissu
detect
final
diagnos
pulmonari
mycetoma
histopatholog
find
furthermor
diagnos
possibl
abpa
mycetoma
may
pulmonari
aspergillosi
administr
antifung
agent
one
month
continu
oral
agent
month
final
multipl
cyst
caviti
disappear
conclus
aspergillu
infect
usual
result
saprophyt
growth
within
caviti
controversi
case
multipl
cyst
caviti
may
caus
aspergillu
infect
extrem
rare
suppos
cyst
caviti
might
form
check
valv
mechan
ld
dj
ai
mf
abdul
mohd
univers
teknolog
mara
respiratori
unit
selangor
malaysia
hospit
sungai
buloh
medicin
selangor
malaysia
background
aim
histoplasmosi
chronic
granulomat
system
fungal
diseas
endem
region
global
although
caus
sever
infect
immunocompromis
rel
small
case
report
immunocompet
result
report
previous
fit
well
male
present
symptom
chest
find
suggest
tuberculosi
tb
prolong
cough
weight
loss
dysphagia
hoars
voic
henc
commenc
clinic
examin
reveal
cachet
individu
otherwis
normal
system
examin
despit
complet
intens
phase
improv
show
gastric
ulcer
neg
malign
comput
tomographi
ct
scan
show
incident
find
pulmonari
embol
pe
splenomegali
also
bilater
adren
mass
septic
work
tumour
marker
hiv
test
serial
sputum
acid
fast
bacilli
afb
neg
sputum
cultur
reveal
atyp
mycobacterium
bone
marrow
aspir
neg
malign
adren
biopsi
inconclus
laryngoscopi
suggest
granulomat
lesion
anticoagul
pe
commenc
view
persist
symptom
despit
treatment
neg
microbiolog
withheld
repeat
biopsi
vocal
cord
upper
oesophag
sphincter
plasma
antigen
test
posit
histoplasmosi
oral
itraconazol
start
chang
intraven
amphotericin
b
improv
oral
itraconazol
resum
follow
year
good
weight
gain
dysphagia
hoars
voic
improv
unfortun
develop
hypocorticol
adren
involv
requir
oral
steroid
conclus
conclud
patient
poor
respons
medic
thorough
investig
perform
look
caus
mimic
appear
case
particularli
reinforc
statement
cs
ng
ci
soo
ayl
ban
ah
faisal
hassan
roslina
ukmmc
respiratori
depart
intern
hospit
cancelor
tuanku
univers
kebangsaan
malaysia
medic
centr
kuala
lumpur
malaysia
background
aim
myriad
etiolog
link
adult
cervic
lymphadenopathi
report
case
adult
present
recurr
cervic
aden
despit
extens
workup
treatment
resolut
cervic
aden
eventu
achiev
commenc
treatment
mycobacterium
ntm
base
singl
posit
sputum
cultur
result
man
smoker
present
initi
cervic
lymphadenopathi
durat
repeat
inconclus
lymph
node
fine
needl
aspir
cytolog
excis
biopsi
result
neg
tuberculosi
workup
initi
antitubercul
therapi
despit
compliant
medic
suffer
frequent
recurr
new
old
cervic
aden
secondari
bacteri
infect
occas
patient
initi
intraven
amikacin
clarithromycin
ciprofloxacin
mycobacteria
base
singl
posit
sputum
cultur
exclus
possibl
caus
possibl
histori
treatment
respons
carbapenem
anoth
medic
institut
subsequ
review
next
twelv
month
show
recurr
conclus
diagnos
cervic
lymphadenopathi
secondari
mycobacteri
infect
challeng
poor
respons
therapi
alarm
clinician
exclud
possibl
consid
rare
infect
li
shanshan
z
ying
c
chengshui
first
affili
hospit
wenzhou
medic
univers
depart
respiratori
critic
medicin
wenzhou
china
explor
risk
factor
prognost
factor
invas
pulmonari
aspergillosi
ipa
patient
chronic
obstruct
pulmonari
diseas
copd
method
conduct
retrospect
studi
copd
patient
ipa
copd
control
patient
without
ipa
carri
depart
respiratori
critic
care
medicin
first
affili
hospit
wenzhou
medic
univers
china
januari
august
diagnost
criteria
ipa
adapt
bulpa
et
al
result
aecopd
admiss
isol
aspergillu
lrt
sampl
case
diagnos
colon
confirm
ipa
enrol
case
group
mortal
rate
ipa
copd
multivari
analysi
five
variabl
independ
risk
factor
associ
ipa
copd
statist
signific
durat
antibiot
longer
day
admiss
ci
p
system
use
steroid
admiss
ci
p
lymphocyt
lower
ci
p
temperatur
higher
ci
p
worsen
radiolog
find
ci
p
prognost
factor
independ
associ
ipa
patient
copd
includ
mechan
ventil
ci
p
consolid
chest
imag
ci
p
durat
antifung
treatment
ci
p
conclus
system
use
steroid
month
prior
admiss
antibiot
treatment
longer
day
lymphocyt
lower
temperatur
higher
worsen
radiolog
find
strong
predict
risk
factor
associ
ipa
copd
consolid
chest
imag
mechan
ventil
short
durat
antifung
treatment
associ
poor
outcom
ipa
copd
p
n
hospit
medicin
nakhon
pathom
thailand
chulalongkorn
univers
medicin
bangkok
thailand
chulalongkorn
univers
parasitolog
bangkok
thailand
background
aim
pneumocysti
jiroveci
pneumonia
pjp
common
opportunist
infect
hiv
immunocompromis
patient
find
organ
alveolar
tissu
gold
standard
pjp
diagnosi
altern
posit
polymeras
chain
reaction
pcr
immunofluoresc
assay
ifa
respiratori
specimen
includ
sputum
bronchoalveolar
lavag
bal
fluid
aim
evalu
diagnost
yield
altern
method
retrospect
analyz
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
accuraci
name
giemsa
gomori
methenamin
silver
gm
toluidin
tbo
wright
stain
pcr
ifa
pjp
diagnosi
hiv
immunocompromis
patient
clinic
suspect
pjp
admit
hospit
januari
may
includ
defin
patient
posit
pneumocysti
jiroveci
stain
alveolar
tissu
patient
clinic
respond
without
find
organ
respiratori
specimen
result
patient
clinic
suspect
pjp
includ
studi
pjp
definit
diagnos
patient
approxim
analyz
patient
infect
hiv
accuraci
diagnost
method
shown
due
number
ifa
best
accuraci
bal
fluid
pcr
reach
highest
accuraci
sputum
addit
pcr
benefici
exclus
specif
lowest
notic
gm
method
use
pjp
diagnosi
sputum
furthermor
pneumocysti
jiroveci
frequent
found
bal
fluid
compar
sputum
conclus
ifa
pcr
recommend
method
pjp
diagnosi
due
high
accuraci
kimura
k
obata
seki
takeda
honma
itoigawa
fujikawa
k
kudo
n
tamura
koto
hospit
medic
center
respiratori
infecti
diseas
tokyo
japan
background
aim
syndrom
wc
rare
disord
character
congenit
defici
cartilag
subsegment
bronchi
lead
cystic
bronchiectasi
airway
collaps
expir
caus
repeat
airway
infect
first
year
life
mani
patient
die
respiratori
failur
childhood
howev
prognosi
patient
surviv
childhood
improv
age
result
case
present
woman
admit
hospit
histori
worsen
dyspnea
product
cough
short
breath
wheez
infanc
dyspnea
could
hardli
play
outdoor
childhood
year
old
exert
dyspnea
allevi
got
weld
job
iron
factori
later
marri
gave
birth
histori
tuberculosi
sinus
smoke
mother
exhibit
similar
symptom
oxygen
satur
room
air
white
blood
cell
count
protein
level
markedli
elev
immunoglobulin
aspergillu
antigen
level
within
normal
rang
pseudomona
aeruginosa
detect
sputum
cultur
ct
reveal
widespread
cystic
bronchiectasi
subsegment
bronchi
collaps
cystic
area
expir
diagnos
wc
administr
antibiot
start
conclus
difficult
obtain
patholog
specimen
bronchoscopi
show
defici
cartilag
bronchial
wall
diagnosi
base
characterist
ct
find
exclus
possibl
caus
includ
cystic
fibrosi
ciliari
dyskinesia
immunoglobulin
defici
allerg
bronchopulmonari
aspergillosi
treatment
aim
control
respiratori
infect
suppress
respiratori
failur
main
bacteria
caus
adult
respiratori
infect
pseudomona
aeruginosa
mycobacterium
avium
haemophilu
influenza
claritheromycin
therapi
often
perform
chronic
infect
japan
earli
introduct
home
oxygen
therapi
recommend
hr
huang
kb
cheng
shanghai
pulmonari
hospit
deptment
respiratori
critic
care
medicin
shanghai
china
background
aim
pulmonari
cryptococcosi
pc
refer
acut
subacut
infect
lung
caus
cryptococcu
occur
immunocompromis
host
clinic
manifest
pc
variabl
untyp
cough
fever
chest
pain
symptom
ct
find
pc
may
easili
confus
tumor
tuberculosi
lead
misdiagnosi
cryptococcu
latex
agglutin
test
commonli
use
clinic
practic
serolog
detect
method
pc
show
high
sensit
specif
howev
pc
patient
neg
la
test
result
studi
aim
analyz
clinic
manifest
ct
find
host
immun
statu
pulmonari
cryptococcosi
patient
accord
differ
latex
agglutin
test
la
result
method
retrospect
review
clinic
data
patient
diagnosi
pulmonari
cryptococcosi
shanghai
pulmonari
hospit
period
patient
categor
accord
latex
agglutin
test
result
differ
clinic
characterist
analyz
result
patient
posit
la
result
patient
neg
la
result
averag
age
la
posit
group
younger
host
patient
basic
diseas
risk
factor
like
present
posit
la
result
patient
neg
la
result
often
symptom
sign
ct
find
present
solitari
nodul
mass
la
posit
patient
variabl
symptom
cough
fever
dyspnea
etc
great
divers
chest
ct
manifest
shown
la
posit
patient
multipl
nodul
mass
patchi
shadow
interstiti
infiltr
diffus
granular
shadow
patient
solitari
nodul
mass
lower
titer
type
conclus
differ
clinic
characterist
la
posit
neg
patient
la
test
result
associ
clinic
manifest
ct
find
host
immun
statu
pulmonari
cryptococcosi
patient
h
nakaoka
k
ishii
r
tsugitomi
tanigawa
k
okafuji
kitamura
tomishima
jinta
n
nishimura
tamura
n
chohnabayashi
st
luke
intern
hospit
divis
pulmonari
medicin
tokyo
japan
background
aim
nocardiosi
uncommon
caus
pneumonia
primarili
occur
immunocompromis
patient
gener
impli
poor
prognosi
past
report
describ
comput
tomographi
ct
featur
pulmonari
nocardiosi
usual
variou
combin
nodulemass
opac
interlobular
septal
thicken
bronchial
wall
thicken
consolid
cavit
find
often
multipl
report
case
caus
rare
strain
nocardia
speci
atyp
radiolog
present
method
case
report
caucasian
male
travel
northern
australia
known
diabet
mellitu
chronic
obstruct
pulmonari
diseas
congest
heart
failur
transfer
hospit
gradual
onset
dyspnea
cruis
tour
septic
arriv
respiratori
failur
suppur
skin
lesion
arm
ct
scan
show
randomli
distribut
miliari
shadow
upper
lobe
predomin
multipl
nodul
variou
size
lung
wound
cultur
grew
nocardia
speci
later
identifi
nocardia
terpenica
rrna
sequenc
known
resist
treatment
select
consist
intraven
meropenem
minocyclin
linezolid
follow
improv
chang
oral
clarithromycin
minocyclin
result
discuss
limit
inform
concern
nocardia
terpenica
infect
patient
case
isol
individu
sinc
first
descript
miliari
pattern
lung
shadow
often
suggest
infect
miliari
tuberculosi
invas
fungal
diseas
dissemin
nocardiosi
diagnos
basi
wound
cultur
respons
treatment
miliari
diffus
granular
pattern
nocardiosi
scarc
report
upon
literatur
search
conclus
nocardiosi
import
differenti
diagnosi
pneumonia
present
miliari
lung
shadow
especi
conjunct
lung
diseas
immunocompromis
prompt
recognit
would
enabl
laboratori
awar
lead
earli
optim
manag
hc
djc
arana
perpetu
succour
hospit
pulmonari
depart
intern
medicin
cebu
citi
philippin
background
aim
patient
hiv
monitor
close
increas
risk
opportunist
pulmonari
infect
also
increas
risk
acquir
common
infect
develop
fulmin
cours
compar
immunocompet
patient
common
pulmonari
infect
also
possibl
increas
morbid
mortal
patient
hiv
research
aim
determin
frequenc
etiolog
agent
pulmonari
infect
hiv
patient
admit
perpetu
succour
hospit
method
survey
done
tertiari
hospit
admit
patient
diagnos
hiv
hiv
screen
test
reactiv
confirm
western
blot
treat
pulmonari
infect
includ
studi
frequenc
pulmonari
infect
among
hiv
patient
determin
type
pulmonari
infect
well
diagnost
modal
use
determin
etiolog
agent
talli
result
studi
period
patient
hiv
admit
pulmonari
infect
major
patient
n
male
averag
age
year
old
n
patient
current
antiretrovir
therapi
time
admiss
rest
patient
diagnos
hiv
current
admiss
common
pulmonari
infect
pneumocysti
pneumonia
n
howev
diagnos
clinic
cultur
pneumocysti
growth
isol
follow
pulmonari
tuberculosi
n
diagnos
afb
sputum
smear
pneumocysti
pneumonia
also
lead
caus
mortal
n
patient
eventu
develop
sepsi
andor
ard
eventu
requir
mechan
ventil
conclus
opportunist
pulmonari
infect
includ
pneumocysti
pneumonia
pulmonari
tuberculosi
major
sourc
morbid
patient
hiv
effort
start
antiretrovir
therapi
hiv
diagnos
encourag
hy
k
jin
l
jong
r
chin
uijeongbu
st
mari
hospit
divis
respiratori
critic
care
republ
korea
seoul
st
mari
hospit
divis
depart
intern
cathol
univers
korea
seoul
republ
korea
seoul
st
mari
hospit
divis
pulmonari
critic
care
depart
intern
cathol
univers
korea
seoul
republ
korea
background
aim
pneumocysti
jirovecii
one
common
pathogen
caus
pneumonia
patient
hematolog
malign
howev
studi
describ
clinic
characterist
prognosi
pneumocysti
pneumonia
pcp
patient
lack
method
retrospect
analyz
baselin
clinic
characterist
treatment
outcom
among
patient
diagnos
pneumocysti
pneumonia
feb
juli
result
total
possibl
patient
identifi
posit
polymeras
chain
reaction
pcr
result
bronchoscop
wash
fluid
among
clinic
diagnos
pcp
posit
pcr
result
relev
chest
comput
tomographi
find
patient
diagnos
lymphoid
malign
activ
diseas
marrow
transplant
bmt
statu
common
combin
infect
viral
infect
bacteri
infect
patient
receiv
andor
pentamidin
diseas
relat
mortal
patient
transfer
intens
care
unit
mechan
ventil
nasal
cannula
hfnc
supplement
univari
analysi
show
lymphoid
malign
statu
applic
mechan
ventil
hfnc
associ
mortal
addit
variabl
combin
bacteri
infect
p
use
pentamidin
p
associ
mechan
ventil
addit
lymphoid
malign
p
statu
p
conclus
patient
hematolog
malign
underli
lymphoid
malign
statu
combin
bacteri
infect
elev
risk
mechan
ventil
associ
high
diseas
relat
mortal
k
hirai
homma
h
sato
uno
fujiwara
u
yoshitaka
miyata
jinno
h
mizuma
kishino
murata
ohta
kusumoto
yamamoto
k
ando
tanaka
yoko
ohnishi
h
sagara
showa
univers
divis
allergolog
respiratori
depart
intern
medicin
japan
background
aim
pneumonia
common
lead
caus
mortal
among
elder
variou
prognost
score
pneumonia
develop
estim
mortal
develop
score
system
highli
predict
outcom
howev
also
complic
number
assess
requir
uncommon
laboratori
test
therefor
aim
develop
easi
assess
system
predict
final
outcom
method
retrospect
analyz
adult
patient
admit
hospit
pneumonia
pneumonia
februari
june
group
two
group
base
mortal
day
admiss
mortal
n
evalu
vital
sign
blood
exam
first
day
togeth
portion
everyday
dietari
intak
result
analyz
use
fisher
exact
test
p
consid
signific
result
compar
survivor
n
n
day
admiss
significantli
elder
p
score
higher
p
less
serum
albumin
p
dietari
intak
less
p
use
fisher
exact
test
odd
ratio
serum
albumin
concentr
less
mgl
ci
associ
mortal
score
greater
point
ci
novel
find
patient
took
dietari
intak
half
show
highest
regard
mortal
ci
conclus
result
demonstr
portion
everyday
dietari
intak
hospit
predict
mortal
assess
dietari
intak
concis
almost
cost
mayb
use
medic
care
suppli
system
limit
k
murakami
k
tobino
munechika
sueyasu
iizuka
hospit
respiratori
medicin
iizuka
japan
introduct
herein
report
first
case
cardiac
tamponad
fatal
arrhythmia
due
cardiac
actinomycosi
attribut
actinomyc
meyeri
patient
surviv
medic
manag
case
present
japanes
man
refer
hospit
dyspnea
hypotens
chest
ct
scan
show
mass
left
upper
lobe
cavitari
lesion
left
lower
lobe
lll
bilater
pleural
effus
pericardi
effus
underw
pericardi
pleural
drainag
intraven
ceftriaxon
therapi
start
gram
stain
cytolog
examin
pericardi
pleural
fluid
show
organ
also
malign
cell
admiss
patient
condit
improv
pericardi
tube
remov
sixth
day
ninth
day
patient
suddenli
becam
atrial
fibril
subsequ
becam
asystol
cardiac
arrest
immedi
cardiopulmonari
resuscit
perform
restor
sinu
rhythm
blood
pressur
thereaft
pneumocentesi
cavitari
lesion
lll
perform
cultur
fluid
grew
meyeri
antibiot
chang
intraven
penicillin
day
complet
total
antibiot
therapi
success
improv
gener
condit
discuss
cardiac
actinomycosi
report
case
actinomycosi
cardiac
involv
usual
result
direct
extens
thorac
diseas
patient
also
concomit
pulmonari
involv
probabl
primari
site
infect
prognosi
actinomycosi
depend
earli
diagnosi
howev
diagnosi
gener
hamper
difficulti
isol
cultur
organ
case
fortun
could
detect
pathogen
pneumocentesi
conclus
knowledg
first
case
surviv
cardiac
tamponad
fatal
arrhythmia
caus
cardiac
actinomycosi
attribut
meyeri
jc
sw
ty
sy
univers
intern
medicin
seoul
republ
korea
gimpo
woori
hospit
intern
medicin
seoul
republ
korea
background
aim
although
mycobacterium
avium
complex
mac
lung
diseas
need
immedi
treatment
long
term
natur
cours
mac
lung
diseas
without
treatment
well
establish
therefor
want
identifi
long
term
natur
cours
nodular
bronchiectat
form
mac
lung
diseas
without
treatment
analyz
serial
chest
comput
tomograph
ct
find
method
patient
mac
lung
diseas
select
untreat
nodular
bronchiectat
form
mac
lung
diseas
patient
serial
ct
least
month
interv
mean
year
chest
radiologist
review
retrospect
initi
last
ct
scan
ct
studi
assess
presenc
extent
bronchiectasi
cellular
bronchiol
consolid
caviti
nodul
maximum
score
result
patient
patient
progress
overal
total
score
show
statist
signific
overal
differ
p
bronchiectasi
patient
increas
number
lung
segment
involv
mean
initi
number
lung
segment
involv
ct
scan
respect
p
cellular
bronchiol
patient
increas
number
lung
segment
involv
mean
initi
number
respect
p
conclus
without
treatment
patient
demonstr
progress
diseas
serial
ct
mean
period
year
j
meng
xiangya
hospit
central
south
univers
respiratori
medicin
changsha
china
background
aim
invas
pulmonari
aspergillosi
opportunist
mycosi
difficult
diagnos
furthermor
invas
pulmonari
aspergillosi
aspergillu
empyema
exist
one
man
rare
sever
aspergillu
infect
earli
detect
treatment
may
reduc
rate
mortal
method
eastern
asian
man
develop
invas
pulmonari
aspergillosi
bronchopleur
fistula
empyema
suffer
year
hemoptysi
bronchiectasi
oper
lobectomi
year
ago
oper
biopsi
examin
reveal
pulmonari
aspergillosi
sadli
receiv
therapi
time
year
lobectomi
patient
complain
cough
expector
weight
loss
admiss
bronchopleur
fistula
right
main
stem
bronchu
pleural
caviti
bilater
pulmonari
consolid
seen
comput
tomographi
ct
scan
bronchoscopi
biopsi
taken
wall
pleural
caviti
reveal
larg
pleural
aspergillosi
lesion
result
despit
combin
system
treatment
voriconazol
open
window
thoracostomi
patient
condit
rapid
exacerb
die
conclus
present
rare
case
invas
aspergillosi
infect
lobectomi
year
ago
therapi
may
necessari
patient
remov
lesion
aspergillosi
otherwis
fumigatu
might
exist
bodi
long
period
k
yagyu
izumi
municip
hospit
respiratori
medicin
izumi
citi
japan
background
aim
mycobacterium
kansasii
kansasii
second
popular
nontubercul
mycobacteria
follow
mycobacterium
avium
complex
mac
especi
radiolog
find
kansasii
resembl
pulmonari
tuberculosi
aim
examin
clinic
radiolog
featur
mkansaii
method
eight
case
diagnos
kansasii
izumi
municip
hospit
year
diagnos
basi
result
sputum
cultur
andor
bronchial
wash
retrospect
analyz
total
patient
femal
male
mean
age
year
clinic
radiolog
featur
result
cough
sputum
includ
hemoptysi
common
n
patient
infect
kansasii
previou
lung
tuberculosi
lung
diseas
emphysema
pulmonari
aspergillosi
mac
infect
seen
major
except
one
femal
patient
smoker
mean
brickman
index
chest
ct
scan
reveal
locat
main
abnorm
follow
two
one
three
one
one
caviti
format
observ
case
mean
maximum
diamet
caviti
wall
thick
mm
mm
respect
lesion
classifi
type
follow
larg
caviti
irregular
form
mm
two
small
oval
form
mm
two
tubular
caviti
one
nodul
bronchiectasi
two
micronodul
one
conclus
demonstr
case
diagnos
kansasii
includ
two
femal
patient
might
connect
kansasii
infect
smoke
ct
find
reveal
caviti
format
upper
lobe
predominantli
wall
thick
kansasii
thinner
one
tuberculosi
ct
scan
also
show
nodul
bronchiectasi
micronodul
lesion
kansaii
atyp
studi
indic
kansasii
infect
similar
clinic
featur
mac
infect
k
bg
cx
td
j
k
teikyo
univers
school
medicin
depart
hygien
public
health
tokyo
japan
waseda
univers
organ
region
stidi
tokyo
japan
teikyo
univers
graduat
school
public
health
tokyo
japan
center
medic
statist
administr
tokyo
japan
bach
mai
hospit
intens
care
unit
hanoi
vietnam
nation
center
global
health
medicin
depart
respiratori
medicin
tokyo
japan
background
aim
human
case
highli
pathogen
avian
influenza
viru
infect
continu
occur
southeast
asia
object
studi
identifi
human
case
occur
vietnam
situat
chang
begin
outbreak
assist
implement
method
target
diseas
manag
method
assess
diseas
cluster
season
variat
human
case
vietnam
evalu
geograph
monthli
time
trend
cluster
case
associ
mortal
examin
three
time
period
outbreak
period
recent
period
use
flexibl
shape
scan
statist
like
case
elev
risk
incid
mortal
assess
via
calcul
rel
risk
rr
case
season
variat
analys
cyclic
trend
incid
data
use
roger
statist
test
result
case
rr
p
mortal
rr
p
significantli
cluster
northern
vietnam
case
tend
occur
border
cambodia
south
mortal
cluster
significantli
mekong
delta
area
rr
p
signific
season
variat
observ
p
higher
incid
morbid
decemb
april
conclus
find
indic
clinic
prepared
vietnam
need
strengthen
southern
vietnam
f
g
di
f
l
gm
zambon
spa
corpor
respiratori
medic
affair
bresso
milan
itali
univers
santa
maria
all
scott
univers
hospit
depart
medic
biotechnolog
siena
itali
degli
studi
di
milano
depart
pathophysiolog
transplant
milan
itali
univers
rome
tor
vergata
depart
system
medicin
rome
itali
univers
careggi
univers
hospit
depart
experiment
clinic
medicin
florenc
itali
background
aim
discord
data
report
effect
nac
activ
import
antibiot
class
particular
recent
studi
suggest
antagon
previous
observ
fluoroquinolon
macrolid
aminoglycosid
like
due
experiment
confound
factor
ie
low
ph
nac
solut
distil
water
nac
aim
investig
nac
effect
neutral
ph
activ
sever
antibiot
larg
collect
relev
respiratori
method
antibiot
suscept
refer
strain
clinic
isol
respiratori
infect
sever
bacteri
speci
staphylococcu
aureu
streptococcu
pneumonia
streptococcu
pyogen
corynebacterium
striatum
pseudomona
aeruginosa
acinetobact
baumannii
stenotrophomona
maltophilia
haemophilu
influenza
moraxella
catarrhali
klebsiella
spp
escherichia
coli
enterobact
cloaca
test
nac
absenc
presenc
mgml
mgml
accord
clinic
laboratori
standard
institut
guidelin
antibiot
test
includ
aminoglycosid
colistin
fluoroquinolon
linezolid
macrolid
minocyclin
vancomycin
modulatori
effect
consid
modif
minimum
inhibitori
concentr
mic
result
nac
nt
interfer
activ
antibiot
test
except
carbapenem
imipenem
meropenem
ertapenem
antagonist
effect
observ
test
speci
conclus
nac
antagonist
antibiot
use
treatment
respiratori
infect
except
carbapenem
c
mander
philippin
heart
center
adult
pulmonari
critic
care
divis
quezon
citi
philippin
background
aim
cryptococccu
neoforman
encapsul
fungu
inhal
organ
usual
rout
infect
may
persist
lung
dissemin
central
nervou
system
bone
skin
method
old
male
admit
due
dyspnea
nonproduct
cough
fever
asthmat
diabet
hypertens
chronic
kidney
diseas
hemodialysi
prior
ptb
treatment
pe
low
grade
fever
bilater
crackl
cxr
show
pneumonia
given
antibiot
still
worsen
dyspnea
ctpa
show
x
cm
saccular
pulmonari
arteri
aneurysm
medial
basal
segment
right
lower
lung
soft
tissu
lesion
right
hilum
infrahilum
subcarin
space
encas
right
main
bronchu
close
associ
esophagu
possibl
infiltr
ct
fine
needl
aspir
cytolog
cell
block
right
lung
mass
perform
reveal
fungal
microorgan
consist
cryptococcu
neoforman
amphotericin
b
given
hiv
screen
nonreact
patient
condit
deterior
eventu
lead
demis
result
cryptococc
infect
common
immunocompromis
host
hiv
malign
organ
transplant
diabet
condit
impair
mediat
immun
radiograph
pulmonari
cryptococcosi
base
studi
benquan
wu
et
al
present
pulmonari
nodul
consolid
even
cavit
may
misdiagnos
lung
tumor
mass
densiti
infiltr
may
consid
pneumonia
patient
ctpa
reveal
soft
tissu
lesion
compress
esophagu
well
right
lower
lung
nodul
conclus
sinc
common
radiograph
present
pulmonari
cryptococcu
multipl
nodul
mass
therefor
mistaken
lung
tumor
noteworthi
includ
cryptococc
infect
differenti
diagnosi
lung
mass
mainli
local
lung
base
immunocompet
patient
recognit
possibl
critic
institut
appropri
therapi
k
n
k
h
k
izumi
municip
hospit
depart
respiratori
medicin
izumi
japan
osaka
citi
univers
graduat
school
faculti
medicin
depart
respiratori
medicin
osaka
japan
background
aim
influenza
pneumonia
diseas
high
mortal
rate
pandem
attack
studi
examin
characterist
bronchoalveolar
lavag
fluid
balf
patient
influenza
pneumonia
method
retrospect
analyz
balf
assess
chest
comput
tomographi
ct
scan
patient
femal
male
diagnos
influenza
pneumonia
april
march
result
five
patient
influenza
two
one
two
influenza
b
two
diagnos
rapid
influenza
diagnost
test
ridt
nasopharyng
swab
rest
five
diagnos
revers
chain
reaction
balf
five
case
andor
serolog
test
four
case
influenza
viru
pneumonia
complic
bacteri
pneumonia
two
case
cultur
balf
confirm
staphylococcu
aureu
infect
one
seven
case
balf
sampl
bloodi
ct
find
follow
two
show
shadow
two
show
airspac
opac
two
show
diffus
airspac
opac
one
show
focal
airspac
opac
conclus
diagnos
influenza
viru
infect
ridt
wide
use
standard
test
studi
five
seven
case
neg
ridt
show
posit
result
influenza
viru
balf
serolog
test
bloodi
balf
suggest
diffus
alveolar
hemorrhag
repres
sever
lung
injuri
regardless
clinic
imag
characterist
balf
use
reveal
presenc
influenza
viru
indic
method
might
consid
addit
diagnost
test
prove
influenza
viral
infect
epidem
influenza
suspect
influenza
viral
infect
clinic
cours
ct
find
sever
pneumonia
patient
examin
balf
serum
antibodi
respons
diagnos
influenza
pneumonia
even
though
ridt
neg
k
h
h
k
k
k
yamagata
prefectur
central
hospit
respiratori
support
team
yamagata
japan
yamagata
prefectur
central
hospit
depart
infecti
diseas
infect
control
yamagata
japan
yamagata
prefectur
univers
health
scienc
depart
physic
therapi
yamagata
japan
yamagata
prefectur
central
hospit
infect
control
team
yamagata
japan
background
aim
respiratori
support
team
rst
organ
hospit
provid
continu
respiratori
support
servic
patient
respiratori
failur
meanwhil
pneumonia
one
common
critic
complic
patient
requir
respiratori
support
servic
rst
initi
consist
respiratori
nurs
specialist
physic
therapist
moreov
infecti
diseas
specialist
infect
control
team
idict
collabor
rst
approach
patient
term
treatment
prevent
pneumonia
hap
sinc
last
year
aim
studi
evalu
role
idict
collabor
rst
method
patient
elig
studi
year
older
support
rst
yamagata
prefectur
central
hospit
april
march
patient
divid
two
group
follow
rst
support
without
idict
rst
support
idict
rst
idict
clinic
paramet
eg
patient
characterist
develop
hap
durat
hospit
stay
retrospect
assess
group
result
total
case
men
women
enrol
studi
median
age
case
year
year
case
rst
idict
significantli
less
frequent
develop
hap
rst
support
rst
idict
compar
vs
case
respect
p
test
durat
hospit
stay
rst
support
significantli
shorter
rst
idict
vs
day
respect
p
wilcoxon
test
multivari
analysi
indic
rst
support
without
idict
independ
risk
factor
increas
frequenc
hap
rst
support
odd
ratio
confid
interv
conclus
collabor
idict
would
benefici
rst
support
suggest
proper
manag
respiratori
infect
improv
outcom
respiratori
failur
stella
v
pelita
harapan
univers
medic
faculti
medicin
karawaci
tangerang
banten
indonesia
pelita
harapan
univers
pulmonolog
respiratori
medicin
karawaci
tangerang
banten
indonesia
pelita
harapan
univers
public
health
karawaci
tangerang
banten
indonesia
background
aim
commun
acquir
pneumonia
cap
lead
caus
death
indonesia
serum
procalcitonin
pct
promis
result
sever
assess
hamper
cost
access
especi
develop
countri
recent
count
ratio
nlcr
prove
simpl
better
marker
predict
bacteremia
purpos
studi
evalu
use
nlcr
compar
pct
predictor
sever
mortal
hospit
cap
method
cross
section
studi
cover
cap
case
admit
siloam
hospit
lippo
villag
tangerang
indonesia
june
mei
met
inclus
criteria
patient
measur
differenti
count
procalcitonin
analysi
spearman
correl
receiv
oper
characterist
roc
curv
use
result
observ
subject
consist
male
femal
vs
mean
age
year
level
pct
nlcr
significantli
correl
p
level
nlcr
also
significantli
relat
mortal
p
length
stay
p
nt
show
signific
associ
stronger
correl
observ
pct
compar
nlcr
r
p
vs
r
p
howev
roc
analysi
nlcr
predict
sever
vs
mortal
vs
show
area
curv
auc
higher
pct
nlcr
sensit
specif
predict
sever
rather
mortal
cut
point
conclus
nlcr
sensit
predict
sever
mortal
cap
compar
pct
keyword
pneumonia
mortal
count
ratio
procalcitonin
musa
ai
ismail
mohd
zim
ny
mohd
esa
univers
teknolog
mara
uitm
faculti
medicin
sungai
buloh
malaysia
background
aim
actinomycosi
rare
infect
mimic
diseas
often
pose
challang
diagnosi
treatabl
high
cure
rate
good
prognosi
report
case
lung
actinomycosi
differ
present
case
year
old
ladi
refer
incident
find
cystic
mass
left
upper
lobe
asymptomat
unremark
clinic
examin
ct
thorax
show
left
upper
lobe
fibrosi
bronchiectasi
cystic
lesion
x
x
cm
bronchoscopi
show
cauliflow
like
mass
biopsi
bal
cytolog
histopatholog
lesion
confirm
actinomycosi
subsequ
commenc
oral
augmentin
case
year
old
housewif
present
signific
loss
weight
lethargi
clinic
examin
reveal
palpabl
mass
suprapub
area
ct
scan
show
heterogen
pelvic
mass
multipl
lung
nodul
suggest
metastasi
examin
gynaecologist
reveal
retain
intrauterin
contracept
devic
subsequ
cervic
biopsi
confirm
actinomycosi
start
augmentin
month
repeat
ct
scan
show
resolut
lung
nodul
mark
clinic
improv
case
man
initi
treat
commun
acquir
pneumonia
follow
product
cough
loss
weight
loss
appetit
howev
month
discharg
hospit
present
worsen
respiratori
symptom
radiolog
evid
lung
cavit
intracavitari
lesion
resembl
aspergilloma
associ
surround
consolid
unfortun
remain
symptomat
despit
antifung
therapi
repeat
ct
demonstr
persist
cavit
lesion
develop
necrot
pneumonia
underw
lobectomi
histopatholog
analysi
resect
specimen
howev
reveal
diagnosi
actinomycosi
conclus
actinomycosi
mani
present
biopsi
area
involv
vital
give
right
diagnosi
k
yamagata
citi
hospit
saiseikan
depart
respiratori
medicin
yamagata
japan
yamagata
prefectur
central
hospit
depart
infecti
diseas
infect
control
yamagata
japan
background
aim
respiratori
tract
infect
pneumonia
could
one
major
complic
among
patient
lung
cancer
respiratori
tract
colon
variou
kind
bacteria
fungi
caus
respiratori
infect
howev
bacteri
fungal
profil
colon
microb
patient
lung
cancer
fulli
investig
aim
studi
evalu
clinic
relat
colon
microb
patient
lung
cancer
method
patient
elig
studi
underw
fiberopt
bronchoscopi
fb
diagnos
lung
cancer
yamagata
citi
hospit
saiseikan
april
may
patient
classifi
tnm
classif
stage
lung
cancer
bronchial
aspir
obtain
fb
subject
microbiolog
cultur
clinic
paramet
eg
patient
characterist
stage
lung
cancer
isol
microb
bronchial
aspir
retrospect
assess
result
total
case
men
women
diagnos
lung
cancer
enrol
studi
median
age
elig
case
year
year
case
clinic
stage
iiia
less
case
stage
iiib
one
specif
microb
sm
eg
staphylococcu
aureu
candida
speci
etc
isol
case
wherea
normal
flora
nf
cultur
case
nf
sm
iiia
case
nf
sm
iiib
case
p
test
multivari
analysi
indic
follow
independ
factor
relat
isol
bronchial
aspir
factor
odd
ratio
confid
interv
iiib
ci
conclus
data
suggest
colon
microb
would
alter
respiratori
system
patient
advanc
lung
cancer
b
p
p
ramathibodi
mahidol
univers
divis
pulmonari
critic
depart
faculti
medicin
bangkok
thailand
ramathibodi
mahidol
univers
divis
infecti
depart
faculti
medicin
bangkok
thailand
invas
zygomycosi
fatal
due
complic
poor
respons
medic
therapi
pulmonari
zygomycosi
without
affect
organ
rare
describ
herein
report
man
diagnos
isol
pulmonari
zygomycosi
present
concomitantli
diabet
ketoacidosi
dka
chronic
cough
without
dyspnea
fever
weight
loss
month
becam
deterior
develop
diabet
crisi
refer
investig
past
histori
reveal
myocardi
infarct
hypertens
deni
smoke
consumpt
alcohol
illicit
drug
examin
afebril
respiratori
rate
puls
rate
blood
pressur
mmhg
lung
auscult
normal
complet
blood
count
reveal
wbc
pmn
l
hb
gdl
chemistri
show
creatinin
mgdl
fast
plasma
glucos
mgdl
liver
function
test
normal
result
neg
chest
radiograph
comput
tomographi
ct
chest
demonstr
consolid
apic
segment
left
upper
lobe
lul
bronchoscopi
transbronchi
biopsi
perform
bronchoalveolar
lavag
fluid
reveal
numer
pmn
without
organ
gm
stain
histopatholog
show
acut
necrot
granulomat
inflamm
fragment
fungal
hypha
morpholog
consist
zygomycosi
refus
symptom
sinus
headach
ent
examin
show
evid
sinus
ct
brain
paranas
sinus
normal
liposom
amphotericin
b
mgkgday
given
two
week
withhold
worsen
renal
failur
underw
lul
resect
liposom
amphotericin
resum
improv
discharg
posaconazol
conclus
report
patient
isol
pulmonari
zygomycosi
coincid
dka
high
suspicion
obtain
tissu
histopatholog
make
earli
diagnosi
earli
surgic
erad
antifung
therapi
effect
jy
bj
kh
yi
hallym
univers
sacr
heart
hospit
allergi
critic
care
medicin
anyang
republ
korea
arm
forc
daejeon
hospit
intern
medicin
daejeon
republ
korea
background
aim
risk
factor
infect
mode
transmiss
middl
east
respiratori
syndrom
coronaviru
unknown
may
june
larg
outbreak
occur
korea
method
perform
cohort
analysi
identifi
risk
factor
transmiss
secondari
outbreak
hospit
healthcar
contact
assign
hospit
isol
home
isol
result
evalu
individu
hospit
isol
cohort
n
inpati
healthcar
worker
hcw
hcw
home
quarantin
cohort
directli
contact
index
case
n
one
hcw
confirm
infect
hcw
identifi
probabl
case
hcw
case
confirm
probabl
visit
index
case
hospit
room
compar
hcw
case
control
signific
risk
factor
transmiss
index
patient
cough
contact
vs
p
signific
differ
two
group
includ
contact
durat
number
contact
medic
activ
figur
flow
chart
patient
quarantin
group
figur
factor
associ
transmiss
mer
healthcar
worker
acquisit
statu
conclus
transmit
via
minim
contact
healthcar
facil
therefor
recommend
earli
extend
contact
manag
may
success
reduc
infect
prevent
transmiss
suleesathira
p
ratanawatkul
w
reechaipichitkul
faculti
medicinekhon
kaen
univers
divis
pulmonari
critic
depart
medicin
khon
kaen
thailand
background
aim
mucormycosi
opportunist
fungal
infect
occur
immunocompromis
host
rhinocerebr
infect
common
form
usual
occur
poorli
control
diabet
patient
especi
diabet
ketoacidosi
pulmonari
mucormycosi
howev
rare
clinic
present
method
result
studi
report
male
teacher
live
chaiyaphum
provinc
present
subacut
fever
kg
hemoptysi
symptom
sinus
underli
diseas
diabet
mellitu
recent
diagnos
month
histori
diabet
ketoacidosi
physic
examin
reveal
fever
bronchial
breath
sound
increas
vocal
reson
left
upper
lung
chest
radiograph
show
dens
consolid
left
upper
lung
initi
investig
leukocytosi
normal
blood
sugar
organ
sputum
gram
stain
afb
smear
melioid
titer
ct
chest
reveal
area
consolid
anterior
segment
left
upper
lung
hypodens
lesion
within
consolid
underw
bronchoscopi
transbronchi
lung
biopsi
specimen
show
broad
hypha
perpendicular
branch
pulmonari
mucormycosi
diagnos
treat
amphotericin
b
follow
posaconazol
month
antifung
therapi
patient
symptom
improv
left
upper
lung
lesion
still
persist
left
upper
lobe
lobectomi
done
conclus
pulmonari
mucormycosi
concern
diabet
patient
even
though
well
control
blood
sugar
patient
diabet
cours
may
subacut
hematolog
malign
organ
transplant
patient
treatment
combin
therapi
surgic
remov
x
tingt
p
luo
c
xin
zhujiang
southern
medic
guangzhou
c
depart
respiratori
medicin
guangzhou
china
background
aim
detect
viru
use
ploymeras
chain
reaction
pcr
technolog
hospit
patient
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
investig
preval
viral
infect
risk
factor
aecopd
method
retrospect
investig
patient
aecopd
may
may
collect
patient
basic
inform
clinic
data
length
hospit
stay
analysi
viru
epidemiolog
use
pcr
logist
regress
analysi
perform
investig
risk
factor
result
patient
aecopd
includ
studi
episod
yield
posit
viral
pcr
result
one
viru
infect
episod
mix
infect
episod
aecopd
patient
viral
infect
associ
longer
hospit
stay
vs
p
multipl
regress
analysi
show
smoke
p
diabet
p
respiratori
failur
p
frequenc
exacerb
previou
year
p
risk
factor
conclus
preval
respiratori
viral
infect
high
hospit
patient
aecopd
length
hospit
stay
longer
aecopd
patient
viru
isol
smoke
diabet
respiratori
failur
frequenc
exacerb
previou
year
risk
factor
viral
infect
earli
identif
risk
factor
may
help
reduc
incid
aecopd
phatharodom
n
chierakul
faculti
medicin
siriraj
hospit
divis
respiratori
diseas
tuberculosi
bangkok
thailand
background
aim
histoplasmosi
infecti
diseas
caus
agentu
histoplasma
capsulatum
dimorph
fungu
grow
myceli
phase
soil
especi
soil
enrich
avian
bat
infect
h
capsulatum
develop
infecti
microconidia
inhal
lung
transform
pathogen
organ
pulmonari
manifest
may
acut
pulmonari
chronic
cavitari
dissemin
infect
method
male
poorli
control
type
diabet
mellitu
hypertens
chronic
kidney
diseas
present
fever
cough
malais
anorexia
week
physic
examin
remark
fever
cbc
show
normocyt
anemia
eosinophilia
eosinophil
count
chest
reveal
lung
mass
left
upper
lung
zone
alveolar
opac
lung
comput
tomographi
demonstr
irregular
soft
tissu
densiti
lung
mass
base
along
posterolater
aspect
upper
left
chest
wall
x
x
cm
pulmonari
nodul
result
bronchoscopi
perform
bronchoalveolar
lavag
show
nucleat
cell
n
l
alveolar
macrophag
stain
cultur
bacteria
mycobacteria
fungi
neg
cytolog
reveal
intracytoplasm
organ
favor
histoplasma
spp
transbronchi
lung
biopsi
histopatholog
show
necrot
granulomat
pneumonia
numer
extracellular
tini
uniform
round
organ
consist
histoplasma
spp
serolog
hiv
posit
treatment
antifung
antiretrovir
drug
improv
clinic
radiolog
conclus
pulmonari
histoplasmosi
granulomat
infect
occur
immunocompet
immunosuppress
host
clinic
featur
radiograph
find
mimic
pulmonari
tb
may
simul
primari
metastat
lung
cancer
earli
diagnosi
prompt
definit
treatment
essenti
favor
outcom
dpa
r
faculti
airlangga
rsu
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
faculti
airlangga
rsu
dr
soetomo
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
background
aim
swine
influenza
highli
contagi
respiratori
diseas
caus
swine
influenza
virus
ittend
caus
high
morbid
low
mortal
rate
death
relat
sever
complic
respiratori
failur
result
sever
pneumonia
acut
respiratori
distress
syndrom
method
present
case
woman
short
breath
sinc
day
admit
hospit
suspect
avian
influenza
first
due
tocontact
histori
bird
chest
show
bilater
infiltr
suggest
pneumonia
pcr
test
confirm
swine
influenza
posit
leukocytosi
complet
blood
count
sputum
cultur
isol
elizabethkingia
meningoseptica
bacteria
hospit
decreas
conscious
arteri
blood
ga
indic
respiratori
failur
mechan
ventil
perform
antivir
antibiot
support
treatment
given
serial
evalu
chest
laboratori
result
result
posit
respons
shown
improv
clinic
manifest
reduc
infiltr
chest
decreas
white
blood
cell
neg
result
pcr
nasopharyng
swab
conclus
case
illustr
pneumonia
acut
respiratori
distress
syndrom
sever
complic
swine
flu
earli
diagnosi
accompani
appropri
treatment
reduc
complic
lower
morbid
mortal
rate
h
hasan
airlangga
univers
faculti
medicin
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
background
aim
primari
resist
resist
occur
patient
never
receiv
treatment
oat
ever
receiv
treatment
oat
less
month
incid
primari
mdr
central
java
extrapulmonari
tb
case
tb
tb
lymphaden
highest
form
extrapulmonari
tb
patient
decreas
immun
system
sle
increas
incid
tb
research
spain
get
higher
tb
incid
patient
sle
method
present
case
year
old
woman
sle
receiv
treatment
month
whose
came
short
breath
chronic
cough
sinc
month
prior
admiss
physic
examin
found
right
left
submandibula
lymphonodi
enlarg
solid
slightli
mobil
nodul
diamet
cm
chest
x
ray
show
lung
inflamm
suspicion
specif
process
minim
left
pleural
effus
conclud
pulmonari
tb
fnab
confirm
lymphaden
tb
granulomat
inflamm
one
afb
result
posit
gene
xpert
mtb
posit
rifampicin
resist
make
patient
categor
primari
mdr
tb
lymphaden
tb
patient
receiv
pirazinamid
mg
ethambutol
mg
kanamicin
mg
levofloxacin
mg
ethionamid
mg
cicloserin
mg
mg
result
patient
receiv
pirazinamid
mg
ethambutol
mg
kanamicin
mg
levofloxacin
mg
ethionamid
mg
cicloserin
mg
mg
conclus
mdr
tb
gener
occur
patient
histori
oat
previou
tb
mdr
tb
secondari
primari
mdr
tb
lymphaden
tb
rare
case
occur
condit
decreas
immun
system
one
sle
involv
multipl
immun
disord
caus
use
immunosuppress
therapi
p
j
z
j
second
hospit
jilin
univeristi
depart
pediatr
changchun
china
second
hospit
jilin
univers
depart
respiratori
medicin
changchun
china
second
hospit
jilin
univeristi
depart
respiratori
medicin
changchun
china
background
aim
order
observ
express
gene
differ
express
gene
small
cell
lung
cancer
method
express
gene
small
cell
lung
cancer
control
group
detect
result
result
show
express
level
small
cell
lung
cancer
tissu
significantli
higher
adjac
tissu
express
gene
statist
differ
two
group
p
express
gene
adenocarcinoma
ac
much
higher
squamou
cell
carcinoma
scc
p
signific
differ
moder
sever
subtyp
conclus
show
express
highli
small
cell
lung
cancer
research
establish
basi
function
assay
small
lung
cancer
p
j
j
w
z
second
hospit
jilin
univers
depart
pediatr
changchun
china
second
hospit
jilin
univers
depart
radiolog
changchun
china
second
hospit
jilin
univers
depart
respiratori
medicin
changchun
china
background
aim
order
studi
clinic
effect
advers
drug
reaction
azithromycin
montelukast
treatment
children
mycoplasma
pneumonia
method
exampl
mycoplssma
pneumonia
children
patient
randomli
divid
treatment
group
control
group
group
case
given
azithromycin
day
static
drop
everi
four
day
oral
cycl
treatment
discontinu
medicin
day
four
day
treatment
group
treatment
everi
night
oral
montelukast
mg
result
treatment
group
cough
properti
chang
significantli
reduc
day
requir
reduc
risk
breath
asthma
induc
conclus
azithromycin
montelukast
obviou
effect
treatment
children
mycoplasma
pneumonia
ab
ar
lc
bg
univers
technolog
sydney
school
medic
molecular
bioscienc
sydney
australia
woolcock
institut
medic
research
univers
sydney
nsw
australia
st
vincent
hospit
depart
thorac
medicin
sydney
australia
concord
repatri
gener
hospit
depart
thorac
medicin
concord
australia
background
aim
introduct
respiratori
virus
recognis
abil
caus
flu
like
symptom
exacerb
asthma
copd
howev
possibl
abil
virus
exist
symbiot
within
lung
yet
explor
aim
determin
incid
asymptomat
viral
carriag
clinic
stabl
asthma
copd
patient
undergo
bronchoscopi
method
asymptomat
patient
recent
current
viral
symptom
undergo
bronchoscopi
recruit
exhal
breath
three
forc
expiratori
maneuv
collect
via
spirometri
filter
ml
bronchoalveolar
lavag
bal
collect
panel
respiratori
virus
human
rhinoviru
hrv
respiratori
syncyti
viru
influenza
influenza
b
parainfluenza
viru
human
metapneumoviru
hmpv
assay
use
sensit
match
sampl
viru
detect
classifi
posit
follow
visualis
weak
strong
band
result
pair
bal
exhal
breath
sampl
collect
patient
underli
respiratori
condit
patient
respiratori
secret
posit
viru
panel
patient
report
symptom
viral
infect
use
common
cold
questionnair
patient
virus
detect
concurr
hrv
hmpv
patient
virus
detect
hrv
influenza
b
hmpv
use
nest
real
time
pcr
exhal
breath
sampl
bal
sampl
show
human
rhinoviru
posit
low
viral
load
conclus
preliminari
analysi
suggest
asymptomat
carriag
virus
may
common
previous
recogn
respiratori
virus
probabl
contribut
microbiom
lung
especi
patient
asthma
copd
import
lung
virom
yet
establish
thu
research
hope
investig
interact
resid
bacteria
viral
speci
cp
yt
mackay
memori
hospit
divis
chest
depart
intern
medicin
taipei
taiwan
mackay
memori
hospit
depart
medic
research
taipei
taiwan
background
aim
tuberculosi
tb
risk
might
increas
diabet
factor
hyperglycemia
dyslipidemia
host
lipid
essenti
energi
sourc
use
mycobacteria
persist
latent
tb
state
potenti
therapi
target
cholesterol
catabol
mycobacteria
propos
effect
drug
still
remain
unclear
purpos
studi
determin
effect
ezetimib
cholesterol
absorpt
inhibitor
intracellular
mycobacteria
surviv
dormanc
method
intracellular
mycobacteria
surviv
determin
measur
atp
activ
unit
gene
express
profil
dormant
mycobacterium
tuberculosi
mtb
analyz
pcr
flow
cytometri
microscopi
analysi
use
measur
lipid
load
human
macrophag
without
ezetimib
treatment
gold
tube
assay
perform
diagnos
latent
tuberculosi
infect
level
intracellular
cholesterol
triglycerid
measur
enzymat
fluorometr
method
result
ezetimib
capabl
effect
lower
intracellular
growth
mtb
dormant
mtb
signific
decreas
mtb
growth
leukocyt
patient
diabet
term
atp
level
intracellular
mycobacteria
cfu
format
also
patient
receiv
ezetimib
therapi
associ
lower
preval
latent
tuberculosi
lower
intracellular
lipid
content
conclus
ezetimib
current
market
drug
hold
promis
adjunct
therapi
tb
phan
pnt
hospit
tb
depart
hcm
citi
vietnam
background
aim
oropharyng
tuberculosi
usual
secondari
pulmonari
tuberculosi
rare
manifest
report
case
oropharyng
tuberculosi
old
man
tuberculosi
depart
male
pham
ngoc
thach
hospit
method
man
patient
transfer
oncolog
hospit
diagnosi
oropharyng
tuberculosi
biopsi
present
tuberculosi
depart
chief
complaint
sorethroat
loss
appetit
odynophagia
malais
unabl
swallow
liquid
solid
food
lost
kg
bodi
weight
within
last
two
month
right
cervic
lymph
node
detect
oral
oropharyng
examin
show
posterior
oropharyng
wall
mucosa
hyperem
cover
multipl
larg
plagu
vari
size
chest
radiograph
show
nonhomogen
opac
right
lung
infiltr
left
lung
blood
test
within
normal
limit
hiv
test
neg
sputum
afb
posit
biopsi
lymph
node
show
tuberculosi
patient
start
treatment
drug
result
nearli
month
treatment
recov
symptom
normal
appear
oropharyng
mucosa
transfer
local
tb
unit
continu
treatment
conclus
possibl
tuberculosi
keep
mind
especi
develop
countri
incid
tuberculosi
high
case
ulcer
lesion
oropharynx
oral
caviti
respond
antibiot
therapi
biopsi
necessari
tool
diagnosi
k
aga
khan
univers
hospit
pulmonari
medicin
karachi
pakistan
aga
khan
univers
hospit
intern
medicin
karachi
pakistan
background
aim
tuberculosi
tb
remain
one
lead
infecti
caus
morbid
mortal
worldwid
diagnosi
reli
sputum
smear
whose
sensit
low
sputum
cultur
afb
time
consum
past
decad
diagnost
techniqu
base
nucleic
acid
amplif
develop
studi
done
see
diagnost
accuraci
xpert
mtbrif
bronchoalveolar
lavag
sampl
popul
method
retrospect
studi
patient
underw
bronchoscopi
evalu
tuberculosi
pulmonari
section
aga
khan
univers
hospit
karachi
june
dec
includ
file
review
ethic
approv
total
file
review
patient
met
inclus
criteria
sensit
specif
xpert
mtbrif
cultur
refer
method
determin
result
total
patient
confirm
pulmonari
tb
cultur
male
mean
age
year
known
histori
tb
contact
diabet
common
present
complaint
fever
cough
mean
durat
symptom
month
common
chest
find
infiltr
cavit
miliari
pattern
patient
mdr
tb
cultur
patient
xdr
tb
afb
smear
posit
patient
sensit
ci
specif
ci
xpert
mtbrif
posit
patient
sensit
ci
specif
ci
sensit
xpert
mtbrif
rifampin
resist
detect
assay
specif
conclus
xpert
mtbrif
detect
tb
case
accur
rapidli
bal
smear
earli
detect
mdr
tb
use
xpert
mtbrif
bal
tb
diagnosi
lead
earli
appropri
treatment
case
set
k
sakashita
takamori
k
murata
wada
tokyo
metropolitan
tama
medic
center
depart
respiratori
medicin
tokyo
japan
background
aim
standard
drug
regimen
sometim
caus
sever
renal
dysfunct
howev
detail
remain
unknown
aim
establish
standard
manag
renal
dysfunct
due
drug
base
retrospect
data
method
retrospect
analyz
clinic
featur
activ
tb
patient
develop
renal
dysfunct
start
standard
drug
singl
tb
hospit
result
activ
tb
patient
develop
sever
renal
dysfunct
start
tb
treatment
mean
age
year
old
patient
femal
median
onset
time
renal
dysfunct
rang
day
mean
serum
creatinin
level
mgdl
start
treatment
peak
serum
creatinin
level
show
renal
dysfunct
mgdl
acut
interstiti
nephriti
confirm
renal
biopsi
patient
patient
clinic
diagnos
acut
interstiti
nephriti
base
urin
find
abnorm
result
steroid
administ
case
presum
acut
interstiti
nephriti
renal
function
fulli
recov
patient
patient
show
renal
dysfunct
despit
stop
treatment
administ
steroid
rifampicin
presum
drug
caus
renal
dysfunct
case
conclus
result
suggest
renal
dysfunct
mostli
occur
intens
phase
standard
treatment
rifampicin
lead
candid
found
avoid
rifampicin
gener
effect
complet
treatment
without
relaps
renal
dysfunct
temporarili
discontinu
therapi
although
controversi
thought
administr
steroid
short
period
accept
suspect
confirm
acut
interstiti
nephriti
case
discontinu
drug
suffici
improv
renal
function
villalobo
univers
gener
hospit
depart
medicin
manila
philippin
introduct
pulmonari
pleural
ectop
thyroid
tissu
rare
never
describ
curiou
case
highlight
approach
diagnosi
pleural
effus
includ
imag
invas
techniqu
arriv
correct
diagnosi
guid
proper
manag
case
present
previous
diagnos
multinodular
toxic
goiter
underw
total
thyroidectomi
year
ago
asymptomat
biochem
euthyroid
mainten
medic
well
year
prior
experienc
recurr
pleural
effus
left
reliev
repeat
thoracentesi
workup
reveal
equivoc
find
subsequ
underw
tube
thoracostomi
chest
ct
scan
reveal
multipl
mass
biopsi
immunohistochem
stain
reveal
benign
ectop
thyroid
tissu
neck
ultrasound
also
reveal
left
thyroid
nodul
follicular
adenoma
biopsi
pleural
fluid
posit
medic
start
eventu
underw
talc
pleurodesi
chest
tube
remov
howev
week
admiss
hematochezia
colonoscopi
show
larg
tubular
adenoma
obstruct
distal
colon
colectomi
resect
plan
howev
succumb
acut
myocardi
infarct
week
admiss
discuss
present
ectop
thyroid
tissu
rang
asymptomat
devast
dyspnea
hemoptysi
postul
aris
aberr
embryogenesi
thyroid
develop
predict
common
site
involv
thyroid
tract
ascend
primit
foregut
case
inde
rare
case
sinc
pleura
thyroid
gland
relat
embryolog
pleural
effus
ectop
thyroid
tissu
report
recent
literatur
manag
case
involv
surgic
resect
pleural
implant
togeth
radioiodin
therapi
control
symptom
b
hamidiy
etfal
educ
research
hospit
pulmonolog
depart
istanbul
turkey
hamidiy
etfal
educ
research
hospit
clinic
microbiolog
depart
istanbul
turkey
background
aim
report
case
patient
sever
bronchiectasi
hiv
nonsmok
develop
activ
diseas
abscessu
mabscessu
part
environment
mycobacteriamost
pathogen
chemotherapi
resist
ntmcommonli
effect
patient
underli
chronic
lung
diseas
patient
year
womanpres
coughbreathlessnessfatigu
repeat
sputum
cultur
persist
yield
ntm
identifi
subsequ
mabscessu
isol
suscept
ciprofloxacin
amikacin
first
thorax
ct
scan
show
extens
bronchiectasi
diffus
nodular
lung
bud
appear
method
base
initi
find
clarithromycin
grday
amoxicillinclavulan
acid
grday
administ
seven
day
result
increas
complaint
clinic
improv
parenter
antibiot
treatment
hospit
admiss
recommend
couldt
therefor
ciprofloxacin
amikacin
could
nt
administ
prefer
gemifloxasin
mgrday
sinc
gemifloxasin
could
taken
daili
oral
therapi
could
continu
week
howev
feel
better
refus
therapi
final
gemifloxasin
intak
week
result
treatment
outcom
favor
symptom
mostli
resolv
week
radiography
find
improv
slowlier
week
thorax
ct
scan
reveal
signific
chang
conclus
mabscessu
lung
diseas
may
progress
slowli
therefor
treatment
complex
therapi
aim
improv
symptom
radiograph
regress
sputum
convers
neg
amikacin
clarithromycin
cefoxitin
test
suscept
mabscessu
variant
antibiot
bacteriostat
effect
mabscessu
within
macrophag
refractori
invas
pulmonari
infect
antibiot
therapi
explain
sinc
fluoroquinolon
administ
daili
oral
long
period
time
highli
attract
therapi
mabscessu
sever
patient
treat
mabscessu
combin
fluoroquinolon
clarithromycin
howev
activ
still
unclear
mabscessu
therapi
yet
could
nt
optim
regimen
combin
amikacin
cefoxitin
imipenem
clarithromycin
fluoroquinolon
still
plenti
problem
solv
phetsuriyawong
w
reechaipichitkul
srinagarind
hospit
medicin
khon
kaen
thailand
background
aim
tuberculosi
mtb
remain
one
common
caus
death
among
infecti
pathogen
rapid
diagnosi
treatment
pulmonari
tuberculosi
still
great
challeng
genexpert
mtbrif
assay
novel
integr
diagnost
system
rapid
detect
mtb
pathogen
rifampicin
resist
strain
object
studi
evalu
diagnost
perform
sputum
genexpert
mtbrif
smear
neg
pulmonari
tb
high
burden
countri
thailand
method
diagnost
test
studi
suspect
tb
patient
neg
two
smear
afbresult
srinagarind
hospit
result
least
neg
sputum
afb
stain
result
patient
diagnos
smear
neg
pulmonari
tb
case
pulmonari
tb
sputum
cultur
grew
tuberculosi
pulmonari
tb
patient
sensit
genexpert
mtbrif
assay
ci
specif
ci
posit
predict
valu
ppv
neg
predict
valu
npv
ci
ci
respect
likelihood
ratio
posit
lr
likelihood
ratio
neg
ci
ci
respect
case
suspect
pulmonari
tb
concord
two
test
mtuberculosi
cultur
growth
genexpert
mtbrif
result
genexpert
mtbrif
assay
detect
mtb
sputum
sampl
confirm
drug
suscept
test
dst
conclus
conclus
genexpert
mtbrif
assay
high
sensit
specif
diagnosi
smear
neg
pulmonari
tb
genexpert
mtbrif
assay
recommend
suspici
pulmonari
tb
case
two
sputum
afb
stain
result
neg
benefit
assay
could
report
quicker
cultur
result
yield
cultur
detect
rifampicin
resist
strain
cs
ayl
ci
ah
nd
ukmmc
respiratori
depart
intern
hospit
cancelor
tuanku
univers
kebangsaan
malaysia
medic
centr
kuala
lumpur
malaysia
usim
respiratori
univers
sain
islam
malaysia
kuala
lumpur
malaysia
upm
respiratori
univers
putra
malaysia
serdang
malaysia
background
aim
past
intrapleur
administr
fibrinolyt
agent
shown
good
outcom
complic
pleural
infect
although
contrari
evid
shown
variou
small
studi
nowaday
surgic
intervent
includ
thoracotomi
decort
advoc
fibrothorax
present
case
tubercul
fibrothorax
obviat
need
surgic
referr
treat
effect
via
medic
therapi
case
histori
male
present
us
short
breath
left
side
pleurit
chest
pain
kg
weight
loss
two
month
histori
fever
pleuroscopi
perform
larg
symptomat
left
pleural
effus
pleural
drainag
hamper
presenc
multipl
locul
separ
thick
fibrin
wall
intrapleur
fibrinolyt
streptokinas
given
administ
intraven
antibiot
agent
continu
chest
tube
drainag
nearli
month
subsequ
pleuroscopi
show
resolut
fibrothorax
conclus
streptokinas
may
consid
reason
option
case
pleural
infect
complic
fibrothorax
medic
facil
limit
resourc
ra
n
f
faculti
medicin
universita
airlangga
medicin
surabaya
indonesia
faculti
medicin
universita
airlangga
public
health
surabaya
indonesia
background
aim
tuberculosi
tb
remain
one
major
concern
peopl
live
poverti
one
therapeut
challeng
patient
treatment
antituberculosi
drug
resist
occur
due
newli
acquir
mutat
antituberculosi
treatment
aim
studi
assess
determin
antituberculosi
treatment
includ
drop
lost
follow
pulmonari
tb
patient
live
poverti
east
java
indonesia
method
studi
among
tb
patient
age
year
conduct
primari
outcom
socioeconom
variabl
lack
money
lack
social
support
famili
commun
distanc
treatment
centr
secondari
outcom
individu
behaviour
variabl
fear
stigma
feel
better
week
treatment
knowledg
tb
treatment
durat
curabl
side
effect
alcohol
tobacco
use
result
total
tb
patient
experienc
treatment
includ
case
loss
patient
took
drug
strict
direct
observ
supervis
health
care
worker
factor
analys
suggest
patient
live
km
treatment
centr
pr
less
incom
rp
us
month
pr
like
pulmonari
tuberculosi
treatment
social
support
supervis
famili
pr
higher
educ
level
pr
protect
factor
conclus
found
risk
popul
pulmonari
tb
treatment
character
east
java
indonesia
sociodemograph
clinic
characterist
determin
treatment
lost
follow
need
done
enhanc
treatment
supervis
polici
financi
support
health
care
worker
pulmonari
tuberculosi
patient
cs
ayl
ci
ah
nd
ukmmc
respiratori
depart
intern
hospit
cancelor
tuanku
univers
kebangsaan
malaysia
medic
centr
kuala
lumpur
malaysia
usim
respiratori
univers
sain
islam
malaysia
kuala
lumpur
malaysia
upm
respiratori
univers
putra
malaysia
serdang
malaysia
background
aim
mycobacterium
tuberculosi
mycobacterium
lepra
emerg
epidem
centuri
especi
last
ten
decad
malaysia
sinc
erad
leprosi
declin
tubercul
case
toward
end
last
centuri
increas
report
either
case
local
leprosi
incid
rose
case
everi
popul
case
everi
popul
time
local
tubercul
incid
report
around
case
per
peopl
nevertheless
rate
coinfect
hardli
report
best
knowledg
second
report
case
dual
infect
southeast
asian
region
sinc
last
report
year
case
descript
year
old
man
diabet
histori
diagnos
lepromat
leprosi
first
present
intermitt
gener
rash
diagnosi
confirm
follow
skin
biopsi
commenc
rifampicin
clofazimin
dapson
three
month
later
came
us
weight
loss
kg
past
one
month
associ
dysphagia
chronic
cough
chest
radiograph
reveal
right
upper
zone
infiltr
subsequ
bronchoscopi
establish
diagnosi
mycobacterium
tuberculosi
drug
start
symptom
improv
thereaft
conclus
around
globe
case
report
describ
past
exact
mechan
yet
elucid
similar
case
report
first
interv
two
fall
within
expect
durat
rang
earli
two
month
fifteen
secondli
tuberculosi
follow
leprosi
infect
summari
case
alert
us
recognis
two
entiti
allow
us
start
formul
strategi
earli
detect
deliveri
better
care
patient
k
h
gener
hospit
depart
respiratori
medicin
kanagawa
japan
tokyo
metropolitan
health
medic
treatment
ebara
hospit
depart
intern
medicin
tokyo
japan
showa
univers
school
medicin
divis
respiratori
depart
intern
medicin
tokyo
japan
background
aim
releas
assay
igra
use
detect
activ
tuberculosi
tb
infect
presum
latent
tb
infect
ltbi
igra
test
superior
earlier
tb
test
sensit
specif
howev
also
prone
fals
neg
activ
tb
infect
method
retrospect
review
medic
record
patient
suspect
tb
test
use
sputum
bronchial
lavag
fluid
cultur
polymeras
chain
reaction
pcr
decemb
februari
assess
diagnost
accuraci
case
result
patient
patient
sputum
bronchial
lavag
fluid
cultur
pcr
assay
reveal
seven
true
result
four
fals
result
activ
tb
cultur
pcr
result
neg
activ
tb
remain
case
indic
result
fals
posit
result
truli
neg
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
activ
tb
infect
respect
four
patient
fals
neg
result
discuss
case
present
conclus
fals
neg
result
may
result
complic
factor
common
among
igra
immunosuppress
reaction
blood
sampl
issu
abnorm
transport
time
nonstandard
test
method
judgment
error
anoth
possibl
caus
fals
neg
tb
cell
produc
consist
life
cycl
exhibit
good
perform
detect
activ
prior
tb
infect
howev
sometim
yield
fals
neg
result
activ
tb
ohnishi
showa
univers
respiratori
allergi
divis
depart
intern
medicin
tokyo
japan
background
aim
introduct
incid
pulmonari
nontubercul
mycobacteri
ntm
diseas
increas
global
first
quarter
nationwid
survey
japan
found
incid
pulmonari
tuberculosi
tb
ntm
diseas
case
case
per
present
studi
examin
period
incid
pulmonari
ntm
diseas
among
patient
showa
univers
hospit
method
subject
method
januari
march
case
bacilli
mycobacteriosi
examin
case
pulmonari
ntm
diseas
diagnos
accord
statement
american
thorac
societyinfecti
diseas
societi
america
incid
pulmonari
ntm
diseas
estim
refer
patient
pulmonari
tb
result
antiacid
bacteria
identifi
tb
activ
pulmonari
tb
extrapulmonari
tb
remain
pulmonari
ntm
diseas
due
follow
bacteria
mycobacterium
avium
mycobacterium
intracerul
case
mycobacterium
abscessu
mycobacterium
gordona
group
mycobacterium
kansasii
mycobacterium
szulgai
diagnosi
definit
ntm
diagnos
studi
start
regist
survey
investig
anoth
diagnos
definit
diagnosi
obtain
definit
diagnos
case
follow
avium
case
intracerul
abscessu
ntm
group
incid
pulmonari
ntm
diseas
showa
univers
case
per
time
nationwid
survey
conclus
high
incid
pulmonari
ntm
diseas
hospit
suggest
epidemiolog
properti
consid
statu
investig
pulmonari
ntm
diseas
facil
taken
account
ci
ys
r
ck
z
abu
ayl
ar
abdul
univers
kebangsaan
malaysia
medic
centr
respiratori
depart
intern
medicin
kuala
lumpur
malaysia
kuala
lumpur
gener
hospit
intern
medicin
kuala
lumpur
malaysia
respiratori
kuala
lumpur
hospit
respiratori
kuala
lumpur
malaysia
univers
malaya
medic
centr
respiratori
depart
intern
medicin
kuala
lumpur
malaysia
background
aim
agent
associ
mild
sever
cutan
advers
reaction
major
case
mild
cutan
reaction
easili
manag
cessat
offend
agent
dress
rare
potenti
life
threaten
drug
induc
hypersensit
reaction
skin
erupt
system
symptom
involv
organ
method
highlight
case
smear
neg
cultur
posit
tubercul
lymphaden
man
develop
dress
syndrom
follow
treatment
first
line
medic
subsequ
drug
desensitis
treatment
util
second
line
agent
proof
futil
patient
either
develop
recurr
dress
advers
reaction
follow
conserv
approach
employ
view
signific
improv
patient
clinic
radiolog
featur
remain
symptom
free
subsequ
review
conclus
although
consid
rare
dress
syndrom
secondari
agent
remain
challeng
treatment
tuberculosi
fundament
initi
termin
treatment
select
medic
drug
desensit
approach
crucial
prevent
increas
morbid
mortal
k
promthong
p
kittivoravitkul
n
wattanathum
phramongkutklao
hospit
pulmonari
critic
care
divis
rajchatheve
thailand
background
aim
standard
treatment
pulmonari
tuberculosi
tb
requir
least
six
month
patient
receiv
incomplet
treatment
may
cure
drug
resist
may
develop
directli
observ
therapi
dot
specif
strategi
endors
world
health
organ
improv
adher
howev
dot
strategi
requir
high
cost
huge
manpow
requir
treatment
smartphon
medic
applic
remind
take
medicin
regularli
may
improv
adher
standard
treatment
determin
effect
use
smartphon
medic
applic
remind
improv
treatment
outcom
complet
rate
sputum
afb
convers
method
blind
random
control
trial
conduct
octob
decemb
tb
clinic
phramongkutklao
hospit
bangkok
patient
older
year
new
case
pulmonari
tuberculosi
smear
posit
randomli
assign
intervent
group
control
group
control
group
treat
standard
regimen
intervent
group
treat
regimen
control
group
use
tb
remind
applic
patient
mobil
phone
primari
outcom
success
complet
cours
treatment
sputum
convers
rate
month
treatment
result
patient
enrol
studi
patient
male
mean
age
patient
year
treatment
complet
patient
intervent
group
patient
control
group
p
sputum
convers
rate
month
patient
intervent
group
patient
control
group
p
conclus
use
tb
remind
applic
mobil
phone
improv
complet
rate
standard
regimen
treatment
sputum
convers
rate
month
treatment
may
new
method
improv
adher
standard
treatment
r
l
dl
chong
hua
hospit
depart
section
pediatr
pulmonolog
cebu
citi
philippin
chong
hua
hospit
depart
section
pediatr
pulmonolog
cebi
citi
philippin
background
aim
progress
primari
tuberculosi
tb
less
common
cours
tb
infect
among
infant
lesion
progress
area
advanc
penumonia
advent
therapi
children
progress
primari
tb
diseas
die
howev
prompt
diagnosi
appropri
therapi
prognosi
excel
result
old
male
infant
present
persist
cough
month
fever
month
suspect
exposur
nanni
chronic
cough
chest
show
complet
opacif
left
hemithorax
cardiomediastin
structur
slightli
shift
right
suggest
massiv
left
pleural
effus
versu
tumor
cbc
show
leukocytosi
thrombocytosi
monocytosi
erythrocyt
sediment
rate
elev
thoracentesi
yield
dri
tap
percutan
needl
lung
biopsi
done
histopatholog
studi
tuberculin
skin
test
mm
hour
gastric
aspir
acid
fast
bacilli
afb
done
thrice
neg
ct
scan
chest
show
consolid
left
lung
area
necrosi
suggest
chronic
granulomat
infect
malign
metastas
cytolog
report
indic
chronic
granulomat
process
togeth
ceftriaxon
oxacillin
patient
start
quadrupl
therapi
isoniazid
rifampicin
pyrazinamid
ethambutol
patient
discharg
symptom
control
outpati
month
treatment
show
minim
improv
left
lung
consolid
begin
atelectasi
conclus
case
highlight
difficulti
diagnosi
infantil
tb
absenc
gold
standard
cultur
valu
complet
histori
emphasi
close
contact
adult
activ
pulmonari
tb
prompt
diagnosi
help
clinic
practic
guidelin
avail
diagnost
test
procedur
critic
institut
appropri
therapi
prevent
patient
deterior
demis
igk
sajinadiyasa
yuwono
soeroto
p
santoso
faculti
medicin
padjadjaran
universityhasan
sadikin
gener
hospit
intern
medicin
bandung
indonesia
background
aim
global
estim
peopl
develop
multidrug
resist
tuberculosi
peopl
die
diseas
indonesia
estim
new
case
everi
year
new
case
previous
treat
global
succes
treatment
outcom
die
treatment
outcom
document
interrupt
treatment
treatment
fail
aim
studi
determin
predictor
factor
treament
fail
patient
unit
hasan
sadikin
gener
hospit
bandung
indonesia
method
studi
match
studi
patient
treament
fail
case
group
patient
succes
outcom
control
group
match
sex
age
data
taken
medic
record
tb
patient
unit
hasan
sadikin
gener
hospit
april
may
result
april
may
found
patien
treament
fail
case
group
comfar
patient
succes
treatment
control
group
predictor
treatment
fail
delay
sputum
cultur
convers
month
ci
ofloxacin
resist
ci
conclus
predictor
treatment
fail
among
patient
delay
cultur
convers
li
bascara
jc
arana
perpetu
succour
hospit
pulmonolog
cebu
philippin
background
aim
sputum
smear
microscopi
remain
cornerston
case
detect
howev
util
limit
poor
sensit
world
health
organ
reduc
minimum
number
sputum
smear
specimen
examin
owe
low
increment
yield
sputum
smear
specimen
howev
differ
yield
pattern
sputum
smear
across
studi
differ
countri
note
signific
diagnost
yield
sputum
smear
note
high
burden
diseas
area
util
third
sputum
smear
underestim
high
burden
diseas
set
increas
risk
popul
philippin
method
studi
retrospect
chart
review
design
includ
presumpt
pulmonari
tuberculosi
patient
age
year
prior
histori
pulmonari
tuberculosi
subject
sputum
smear
microscopi
percentag
posit
smear
increment
yield
sputum
smear
posit
rate
combin
analyz
result
studi
show
sputum
smear
detect
major
case
n
smear
ad
minim
diagnost
yield
n
howev
note
smear
posit
rate
increas
succeed
sputum
smear
specimen
compar
posit
rate
smear
among
posit
combin
significantli
higher
rate
smear
posit
higher
increment
increas
posit
rate
note
specimen
combin
conclus
smear
specimen
case
detect
pulmonari
tuberculosi
diagnost
yield
succeed
specimen
significantli
higher
rate
smear
posit
observ
specimen
less
c
intani
r
ratnawati
e
burhan
universita
indonesia
pulmonolog
dan
kedokteran
respirasi
jakarta
indonesia
background
aim
studi
compar
tst
igra
healthcar
worker
diagnos
ltbi
method
healthcar
worker
bbkpm
bandung
examin
tst
igra
new
ltbi
tst
indur
mm
subject
done
anamnesi
physic
examin
chest
sputum
smear
exclud
activ
tuberculosi
result
subject
vaccin
bcg
subject
igra
posit
neg
subject
subject
respect
tst
mm
subject
posit
test
subject
subject
receiv
vaccin
posit
igra
subject
get
vaccin
tst
mm
subject
subject
receiv
vaccin
neg
igra
subject
get
vaccin
tst
mm
subject
subject
receiv
vaccin
posit
igra
subject
get
vaccin
tst
mm
subject
subject
get
vaccin
neg
igra
subject
get
vaccin
tst
result
mm
subject
agreement
igra
tst
suffici
kappa
characterist
subject
male
subject
femal
subject
mean
age
year
risk
factor
statist
signific
length
employ
bcg
vaccin
age
highest
sensit
specif
igra
respect
conclus
studi
show
comparison
igra
tst
healthcar
worker
bbkpm
bandung
agreement
tst
igra
suffici
signific
correl
posit
test
result
risk
factor
length
employ
bcg
vaccin
age
studi
recommend
igra
good
use
screen
test
replac
tst
mj
de
philippin
heart
center
pulmonari
depart
quezon
citi
philippin
philippin
heart
center
adult
pulmonari
quezon
citi
philippin
introduct
pseudoaneurysm
dilat
branch
pulmonari
arteri
call
rasmussen
aneurysm
rare
sequala
pulmonari
tuberculosi
life
threaten
massiv
hemoptysi
ruptur
aneurysm
uncommon
complic
cavitari
tuberculosi
case
present
year
old
woman
complain
massiv
hemoptysi
start
hour
prior
admiss
nonsmok
examin
pale
diaphoret
normotens
tachycard
normal
respiratori
rate
fine
crackl
lung
field
note
chest
lung
examin
chest
xray
reveal
pulmonari
congest
antifibrinolyt
agent
given
intraven
condit
patient
resolv
temporarili
hospit
day
ctpa
reveal
saccular
aneurysm
rasmussen
segment
branch
right
pulmonari
arteri
measur
x
cm
suppli
medial
segment
right
middl
lobe
multipl
pulmonari
nodul
due
infecti
process
hospit
day
massiv
hemoptysi
recur
approxim
amount
cc
blood
pressur
drop
palpatori
mmhg
went
cardiac
arrest
subsequ
patient
expir
figur
saccular
aneurysm
rasmussen
segment
branch
right
pulmonari
arteri
figur
cavitari
lesion
secondari
pulmonari
tuberculosi
discuss
pulmonari
tuberculosi
result
eros
adjac
structur
lung
tubercul
process
occur
near
vessel
wall
lead
thicken
intima
protrus
aneurysm
result
medic
manag
employ
hemoptysi
minim
howev
recommend
surgeri
perform
patient
episod
massiv
hemoptysi
conclus
rasmussen
aneurysm
rare
tubercul
sequela
literatur
report
hemoptysi
usual
massiv
entail
need
earli
aggress
manag
r
satya
wardhana
rrd
handayani
ad
susanto
universita
indonesia
faculti
medicin
depart
pulmonolog
respiratori
medicin
jakarta
indonesia
background
aim
latent
tuberculosi
ltbi
defin
state
persist
immun
respons
stimul
mycobacterium
tuberculosi
antigen
without
evid
clinic
manifest
activ
tuberculosi
tb
infect
control
high
risk
place
dormitori
import
control
tb
transmiss
factor
like
household
surveil
contact
trace
tb
regard
essenti
measur
prevent
tb
dissemin
commun
preliminari
cross
section
studi
contact
investig
pulmonari
tb
patient
colleg
dormitori
jakarta
indonesia
approv
ethic
committ
faculti
medicin
universita
indonesia
method
fifti
seven
femal
student
age
year
old
whose
live
dormitori
index
case
tb
patient
acid
fast
bacilli
posit
three
month
diagnos
subject
interview
regard
past
present
tb
histori
follow
chest
x
ray
xpert
mtb
rif
sputum
interferon
gamma
releas
assay
igra
quantiferron
test
ltbi
defin
igra
test
posit
test
neg
three
subject
exclud
due
lack
tool
perform
igra
result
bacillu
calmett
guerin
bcg
vaccin
subject
present
symptom
proven
non
tb
moment
four
subject
without
past
present
tb
histori
exhibit
posit
igra
result
show
radiolog
result
subject
show
neg
xpert
mtb
rif
sputum
examin
limit
studi
unabl
differenti
ltbi
contact
dormitori
contact
conclus
contact
investig
dormitori
abl
indic
subject
whose
suggest
ltbi
recommend
studi
explor
environ
nutrit
educ
infect
control
hj
sy
jb
ep
mh
ms
korean
institut
tuberculosi
technic
cooper
republ
korea
korean
institut
tuberculosi
epidemiolog
investig
republ
korea
korea
nation
research
institut
health
tuberculosi
bacteri
respiratori
infect
republ
korea
background
aim
serial
test
releas
assay
igra
show
convers
revers
health
care
worker
limit
studi
varianc
igra
result
close
contact
infecti
tuberculosi
tb
patient
studi
aim
know
varianc
igra
respons
serial
test
method
prospect
follow
famili
school
contact
infecti
tb
case
year
exposur
quantiferon
gold
assay
chest
follow
initi
month
year
year
last
exposur
prevent
treatment
recommend
igra
posit
respond
result
total
close
contact
mean
age
year
old
recruit
index
case
initi
igra
posit
contact
complet
follow
examin
without
prevent
treatment
among
initi
posit
respond
contact
revert
howev
eight
convert
five
contact
revert
overal
posit
among
initi
posit
respond
among
initi
neg
respond
contact
convert
howev
contact
revert
five
contact
convert
follow
igra
test
poorli
conduct
contact
start
prevent
treatment
three
among
contact
start
prevent
treatment
initi
posit
convers
revert
conclus
close
contact
infecti
tb
case
show
variou
convers
revers
rate
serial
test
igra
studi
suggest
simpl
dichotom
definit
igra
neg
posit
may
suitabl
diagnost
valu
serial
test
jy
kang
hs
kang
js
kim
sc
kim
sy
lee
ch
kim
jh
ahn
yk
kim
hs
moon
colleg
cathol
univers
korea
intern
medicin
seoul
republ
korea
background
aim
given
advanc
detect
tool
mycobacterium
tuberculosi
mtb
expect
patient
confirm
tubercul
pleurisi
microbiolog
evid
past
studi
investig
clinic
featur
accord
cultur
tb
patient
tb
pleurisi
method
jan
dec
medic
record
adult
patient
diagnos
treat
tb
pleurisi
review
retrospect
seoul
st
mari
hospit
bucheon
st
mari
hospit
result
among
patient
tb
pleurisi
patient
confirm
posit
cultur
mtb
posit
group
mtb
cultur
show
young
age
frequent
autoimmun
diseas
compar
neg
group
regardless
presenc
mtb
pleural
specimen
sputum
studi
mtb
infect
stain
acid
fast
bacilli
cultur
pcr
mtb
reveal
posit
result
half
patient
group
case
vs
case
analysi
pleural
effus
posit
group
mtb
significantli
lower
level
percentag
lymphocyt
glucos
neg
group
cure
complet
rate
diseas
group
group
littl
differ
treatment
respons
includ
relaps
surviv
two
group
conclus
find
prove
improv
diagnost
technolog
mtb
patient
tb
pleurisi
show
frequent
microbiolog
evid
unlik
past
addit
studi
confirm
posit
cultur
mtb
associ
lower
lymphocytosi
glucos
pleural
fluid
howev
exist
cultur
mtb
influenc
treatment
outcom
nurhayati
arto
yuwono
soeroto
faculti
medicin
padjadjaran
universityhasan
sadikin
gener
hospit
intern
respirolog
divis
bandung
indonesia
background
aim
multidrug
resist
tuberculosi
mdr
tb
preval
caus
death
world
health
organ
report
whole
proport
new
tb
case
world
multidrug
resist
current
indonesia
place
second
rank
number
tb
case
world
establish
diagnosi
sputum
cultur
tuberculosi
resist
test
take
least
week
result
delay
mdr
tb
treatment
commenc
increas
risk
infect
spread
assess
tool
produc
quicker
diagnost
result
greatli
need
elev
level
interleukin
mdr
tb
patient
could
one
measur
new
assess
tool
earli
detect
mdr
tb
method
studi
design
cross
section
sixti
mdr
tb
suffer
seek
treatment
mdr
tb
polyclin
dr
hasan
sadikin
hospit
bandung
period
result
result
level
rang
pgml
median
valu
pgml
averag
level
mdr
tb
group
pgml
tb
patient
pgml
signific
differ
two
group
p
conclus
conclus
studi
signific
differ
level
mdr
tb
group
tb
group
maguslog
quezon
citi
philippin
background
aim
aim
paper
present
case
came
due
difficulti
breath
cough
fluctuant
mass
right
thigh
diagnos
septicem
melioidosisbas
blood
sputum
wound
cultur
also
diagnos
pulmonari
tuberculosi
manag
accordingli
addit
paper
also
strive
creat
awar
among
local
healthcar
profession
melioidosi
possibl
pulmonari
tuberculosi
high
risk
patient
method
report
case
live
bulacan
philippin
poultri
raiser
veget
farmer
week
histori
right
thigh
abscess
also
complain
cough
fever
dyspnea
weight
loss
result
patient
initi
diagnos
right
thigh
abscess
commun
acquir
pneumonia
moder
risk
consider
concomit
pulmonari
tuberculosi
also
thought
b
pseudomallei
isol
cultur
blood
sputum
wound
diagnosi
septicemicmelioidosi
entertain
therapi
melioidosi
start
patient
despit
antibiot
patient
still
observ
low
grade
fever
although
patient
sputum
afb
result
neg
given
follow
risk
factor
poorli
control
diabet
high
index
suspicion
pulmonari
tuberculosi
consid
sinc
patient
diagnos
treat
tuberculosi
earlier
empir
treat
quadrupl
fix
dose
combin
medic
conclus
patient
present
clinic
featur
tuberculosi
must
investig
work
rule
melioidosi
possibl
tuberculosi
earli
diagnosi
treatment
reduc
risk
death
caus
melioidosi
melioidosi
pulmonari
tuberculosi
extrem
rare
awar
possibl
exist
occurr
deter
clinician
treat
diseas
entiti
manalo
philippin
heart
center
pulmonari
critic
care
medicin
quezon
citi
philippin
background
aim
childhood
tuberculosi
increas
incid
worldwid
occurr
repres
import
event
indic
recent
transmiss
identif
surrog
biomark
treatment
respons
risk
poor
outcom
tuberculosi
benefici
tool
patient
manag
thu
biomark
like
high
sensit
protein
hscrp
propos
prognost
marker
method
children
diagnos
tuberculosi
base
philippin
pediatr
societi
nation
tuberculosi
program
guidelin
includ
clinic
data
review
record
blood
sampl
collect
serum
hscrp
determin
treatment
intens
phase
data
analysi
done
use
stata
se
version
mean
standard
deviat
frequenc
percent
distribut
pair
test
scatter
plot
use
level
signific
set
result
subject
pulmonari
tuberculosi
particip
male
femal
age
rang
year
mean
age
particip
complet
studi
analysi
data
show
level
serum
hscrp
intens
phase
treatment
significantli
lower
compar
level
treatment
p
valu
hand
bodi
mass
index
use
one
object
paramet
treatment
respons
children
demonstr
statist
signific
differ
intens
phase
p
valu
hscrp
bmi
indirectli
correl
howev
statist
insignific
conclus
studi
shown
statist
signific
lower
serum
hscrp
level
intens
phase
treatment
among
pediatr
patient
tuberculosi
therefor
conclud
hscrp
addit
paramet
evalu
treatment
respons
earli
month
treatment
r
k
j
k
ida
hospit
depart
pulmonari
medicin
kawasaki
japan
ida
hospit
depart
infecti
diseas
kawasaki
japan
background
aim
ada
pleural
effus
known
use
tool
make
diagnosi
tubercul
pleurisi
hospit
tuberculosi
control
unit
littl
chanc
see
patient
tubercul
infect
howev
still
experi
patient
high
level
ada
pleural
effus
without
tubercul
infect
aim
studi
examin
background
patient
high
ada
pleural
effus
characterist
natur
pleural
effus
method
patient
receiv
pleurocentesi
hospit
enrol
clinic
chart
patient
whose
ada
pleural
effus
iul
review
result
patient
patient
receiv
pleurocentesi
iul
ada
pleural
effus
sampl
met
light
criteria
exud
pleural
effus
averag
age
year
old
men
includ
patient
underli
diseas
tuberculosi
pleurisi
malign
diseas
pneumonia
associ
pleural
effus
rheumatoid
arthriti
undiagnos
seem
differ
natur
pleural
effus
among
underli
diseas
except
pneumonia
associ
pleural
effus
effus
show
high
ldh
high
polynuclear
leukocyt
cell
low
ph
low
glucos
conclus
percentag
tuberculosi
pleurisi
varieti
underli
diseas
caus
high
ada
pleural
effus
ada
pleural
effus
use
tool
diagnosi
tuberculosi
pleurisi
detail
evalu
necessari
accur
diagnosi
n
n
z
n
n
k
nation
center
tuberculosi
lung
diseas
research
depart
tbilisi
georgia
nation
center
tuberculosi
lung
diseas
surveil
strateg
plan
depart
tbilisi
georgia
nation
center
tuberculosi
lung
diseas
tbilisi
georgia
nation
center
tuberculosi
lung
diseas
clinic
depart
tbilisi
georgia
sharp
corpor
health
environ
system
divis
osaka
japan
background
aim
tuberculosi
tb
remain
major
public
health
problem
georgia
estim
incid
preval
per
popul
respect
littl
evid
exist
global
burden
hospit
acquir
tb
infect
among
health
care
worker
hcw
impact
differ
infect
control
ic
measur
reduc
risk
nosocomi
acquir
tuberculosi
method
evalu
perform
commerci
avail
equip
plasma
cluster
ion
gener
sharp
corpor
reduct
latent
tuberculosi
infect
ltbi
risk
among
hcw
special
tb
hospit
nation
center
tuberculosi
lung
diseas
nctld
plasma
cluster
unit
place
per
manufactur
recommend
two
four
therapeut
depart
ident
administr
engin
person
protect
ic
measur
baselin
six
month
apart
two
test
gold
quest
diagnost
perform
compar
risk
tuberculosi
infect
among
plasma
cluster
expos
group
result
total
hcw
screen
ltbi
baselin
expos
mix
place
work
exclud
analysi
group
qft
neg
baselin
hcw
remain
neg
becam
posit
expos
group
remain
neg
becam
posit
group
qft
tast
base
qft
convers
data
subject
within
plasma
cluster
set
show
time
greater
risk
acquir
tuberculosi
infect
compar
subject
within
plasma
cluster
set
ci
fisher
exact
conclus
plasma
cluster
ion
gener
technolog
shown
good
perform
feasibl
use
tuberculosi
hospit
substanti
decreas
risk
tuberculosi
infect
among
hcw
r
abdul
ci
f
abdul
tm
ayl
ra
raja
r
abdul
univers
kebangsaan
malaysia
medic
centr
gastroenterolog
hepatolog
depart
intern
medicin
kuala
lumpur
malaysia
univers
teknolog
hospit
selayang
gastroenterolog
hepatolog
depart
medicin
kuala
lumpur
malaysia
univers
kebangsaan
malaysia
medic
centr
respiratori
depart
intern
medicin
kuala
lumpur
malaysia
background
aim
advanc
lung
cancer
usual
metastas
adren
gland
bone
liver
brain
upper
gastrointestin
haemorrhag
ugih
result
gastrointestin
metastas
rare
initi
present
present
two
patient
initi
present
malaena
secondari
duoden
metastasi
primari
lung
cancer
method
first
patient
man
smoker
present
melaena
hemoptysi
lethargi
lost
weight
two
month
durat
oesophagogastroduodenoscopi
ogd
show
multipl
polypoid
mass
forrest
ulcer
duodenum
histopatholog
examin
immunohistochem
stain
confirm
primari
lung
adenocarcinoma
thorax
reveal
right
upper
lobe
mass
measur
cm
liver
mesenter
contralater
lung
metastas
second
patient
ladi
came
recurr
episod
melaena
symptom
anemia
weight
loss
three
month
durat
ogd
show
presenc
larg
circumferenti
mass
measur
cm
ulcer
base
third
part
duodenum
histopatholog
examin
confirm
duoden
metastasi
secondari
poorli
differenti
adenocarcinoma
subsequ
thorax
guid
biopsi
confirm
primari
lung
adenocarcinoma
result
lung
adenocarcinoma
upper
gastrointestin
haemorrhag
due
duoden
metastasi
uncommon
treatment
modal
avail
includ
combin
surgeri
endoscop
resect
chemotherapi
conclus
upper
gastrointestin
haemorrhag
initi
present
distant
metastasi
lung
adenocarcinoma
uncommon
consid
clinician
manag
group
patient
abdul
f
abdul
ci
n
ayl
tm
ja
abdul
r
abdul
respiratori
depat
intern
medicin
univers
kebangsaan
malaysia
medic
centr
kuala
lumpur
malaysia
univers
sain
islam
malaysia
respiratori
depart
intern
medicin
kuala
lumpur
malaysia
hospit
serdang
depart
patholog
selangor
malaysia
univers
kebangsaan
malaysia
medic
centr
depart
oncolog
kuala
lumpur
malaysia
hospit
serdang
pulmonolog
unit
selangor
malaysia
background
aim
synovi
sarcoma
ss
destruct
atyp
tumour
origin
mesenchym
tissu
account
approxim
soft
tissu
sarcoma
infrequ
lung
primari
well
younger
patient
report
rare
case
primari
endotrach
synovi
sarcoma
man
present
symptom
respond
well
radiotherapi
method
man
present
histori
intermitt
short
breath
signific
famili
histori
asthma
atopi
minim
crepit
lung
auscult
evid
airway
obstruct
spirometri
l
fvc
l
revers
comput
tomographi
hrct
thorax
howev
reveal
peduncul
endotrach
mass
confirm
bronchoscopi
histopatholog
examin
show
epithelioid
morpholog
immunohistochem
studi
show
tumour
cell
diffus
posit
focal
posit
cytokeratin
consist
diagnosi
synovi
sarcoma
patient
underw
radiotherapi
treatment
total
week
repeat
bronchoscopi
ct
thorax
show
reduct
tumour
size
repeat
spirometri
also
show
improv
level
airway
obstruct
l
fvc
l
post
treatment
current
well
clinic
month
conclus
knowledg
report
case
synovi
sarcoma
endobronchi
tree
mainstay
treatment
soft
tissu
sarcoma
surgic
remov
tumour
patient
show
mark
improv
symptom
size
lesion
radiotherapi
treatment
k
k
k
h
h
akita
univers
graduat
school
medicin
depart
intern
divis
cardiovascular
respiratori
medicin
akita
japan
akita
univers
hospit
depart
pharmaci
akita
japan
akita
univers
graduat
school
health
scienc
depart
physic
therapi
akita
japan
background
aim
relationship
pharmacokinet
effect
gefitinib
patient
epiderm
growth
factor
receptor
egfr
cell
lung
cancer
nsclc
unknown
studi
examin
correl
gefitinib
plasma
concentr
surviv
pf
patient
two
common
type
egfr
mutat
delet
exon
point
mutat
exon
method
retrospect
analysi
examin
patient
administ
mg
gefitinib
daili
patient
diagnos
treat
advanc
clinic
stage
iiib
v
cell
lung
carcinoma
sensit
egfr
mutat
januari
novemb
akita
univers
hospit
akita
japan
day
treatment
initi
plasma
sampl
collect
prior
first
administr
gefitinib
plasma
concentr
gefitinib
measur
liquid
chromatographi
hplc
patient
divid
four
group
trough
plasma
concentr
high
low
mutat
type
exon
delet
exon
point
mutat
pf
respons
rate
toxic
effect
analyz
four
group
result
exclud
patient
remain
success
analyz
signific
differ
pf
exon
delet
exon
point
mutat
group
median
surviv
v
month
p
patient
exon
delet
signific
differ
pf
high
low
plasma
concentr
group
median
surviv
vs
month
p
contrast
pf
significantli
prolong
patient
exon
point
mutat
high
vs
low
concentr
gefitinib
median
surviv
vs
month
p
conclus
result
suggest
high
plasma
concentr
gefitinib
patient
egfr
exon
point
mutat
compar
low
plasma
concentr
pf
prolong
la
mantia
e
franco
r
cantil
rocco
r
de
chiara
martucci
n
rocco
g
primari
intrapulmonari
malign
peripher
nerv
sheath
tumor
mimick
lung
cancer
j
thorac
di
chao
bh
stogner
ka
kiev
j
smith
tj
intrathorac
malign
peripher
nerv
sheath
tumor
neurofibromatosi
j
clin
oncol
c
chee
ck
yk
ks
ck
jl
faculti
univers
malaya
depart
medicin
kuala
lumpur
malaysia
faculti
univers
malaysia
sarawak
depart
medicin
kota
samarahan
malaysia
background
aim
lung
carcinoma
lead
caus
cancer
death
worldwid
includ
malaysia
adenocarcinoma
common
histolog
subtyp
lung
carcinoma
major
patient
lung
cancer
diagnos
advanc
stage
diseas
preclud
cur
treatment
studi
aim
survey
treatment
prefer
malaysian
patient
upon
diagnosi
advanc
lung
adenocarcinoma
method
retrospect
observ
studi
treatment
receiv
patient
newli
diagnos
advanc
lung
adenocarcinoma
stage
iiib
stage
iv
univers
malaya
medic
centr
august
juli
result
patient
diagnos
advanc
lung
adenocarcinoma
tumour
harbour
activ
epiderm
growth
factor
receptor
egfr
mutat
egfr
tumour
tabl
patient
egfr
mutant
tumour
treat
kinas
inhibitor
tki
patient
receiv
best
support
care
bsc
cytotox
chemotherapi
hand
patient
egfr
tumour
receiv
bsc
upon
diagnosi
cytotox
chemotherapi
receiv
request
conclus
unlik
western
countri
bsc
includ
altern
complementari
treatment
popular
treatment
option
among
malaysian
patient
advanc
lung
adenocarcinoma
probabl
due
cultur
belief
h
tsubouchi
h
onomura
h
yanagi
h
iiboshi
n
matsumoto
nakazato
univers
miyazaki
depart
intern
medicin
miyazaki
japan
background
aim
cancer
cachexia
affect
patient
advanc
cancer
account
nearli
death
despit
recent
advanc
understand
patholog
mechan
cancer
cachexia
therapeut
option
current
avail
ghrelin
endogen
ligand
growth
hormon
secretagogu
receptor
ghsr
produc
stomach
suppress
inflamm
prevent
muscl
catabol
stimul
food
intak
activ
npi
agrp
signal
hypothalamu
investig
express
energi
homeostasi
relat
molecul
stomach
hypothalamu
pharmacolog
potenti
ghrelin
treatment
cancer
cachexia
method
gener
postnat
bronchioalveol
mous
strain
administ
urethan
intraperiton
wild
type
mice
ghrelin
pb
given
mice
daili
four
week
begin
five
month
urethan
inject
correspond
time
point
lung
adenocarcinoma
format
measur
ghrelin
level
mice
lung
cancer
patient
analyz
elisa
express
level
energi
homeostasi
relat
molecul
hypothalamu
examin
quantit
pcr
result
mice
develop
lung
adenocarcinoma
plasma
ghrelin
level
mice
lung
cancer
patient
undergo
chemotherapi
significantli
lower
mice
healthi
volunt
respect
mice
smaller
reduct
food
intak
bodi
weight
skelet
muscl
mass
intraabdomin
fat
weight
mice
ghrelin
treatment
increas
express
level
npi
agrp
mrna
addit
ghrelin
restor
increas
level
proopiomelanocortin
pomc
cocain
amphetamin
regul
transcript
cart
mrna
hypothalamu
mice
conclus
pleiotrop
effect
ghrelin
activ
npyagrp
signal
suppress
cytokin
level
hypothalamu
may
attract
therapeut
target
patient
cancer
cachexia
kiribayashi
n
hironobu
h
osahiko
yoshihisa
k
nathuya
w
manabu
n
yoichi
yasushi
koji
e
toshiyuki
k
shinya
toho
univers
ohashi
medic
center
surgeri
tokyo
japan
background
aim
smoke
lead
caus
lung
cancer
spontan
pneumothorax
smoker
surgic
hospit
like
good
motiv
quit
smoke
method
data
collect
respiratori
surgeri
patient
april
june
primari
lung
cancer
case
metastat
lung
cancer
case
spontan
pneumothorax
case
smoke
histori
number
cigarett
smoke
per
day
number
year
smoke
brinkman
index
bi
nicotin
depend
test
td
enforc
case
check
case
hospit
hospit
main
outcom
set
smoke
statu
discharg
one
month
discharg
three
month
discharg
patient
smoke
oper
specif
given
attent
see
whether
instruct
becom
motiv
quit
result
patient
smoke
histori
case
case
case
bi
averag
td
averag
patient
smoke
oper
case
case
case
achiev
rate
instruct
three
month
conclus
patient
achiev
nonsmok
statu
undergo
surgeri
given
instruct
suggest
hospit
respiratori
surgeri
becom
motiv
smoker
quit
habit
sueyasu
k
tobino
k
murakami
goto
munechika
nishizawa
yoshimatsu
k
yoshimin
ko
asaji
k
tsuruno
h
miyajima
mukasa
n
ebi
iizuka
hospit
respiratori
medicin
iizuka
japan
introduct
herein
report
case
penil
mondor
diseas
rare
present
lung
adenocarcinoma
complic
trousseau
syndrom
case
present
man
present
hospit
cough
rash
lower
leg
one
month
two
month
recogn
funicular
palpabl
indur
penil
dorsal
surfac
color
doppler
sonographi
show
blood
flow
signal
superfici
dorsal
penil
vein
also
superfici
leg
vein
comput
tomographi
pet
reveal
solitari
pulmonari
nodul
left
upper
lobe
multipl
lymphadenopathi
multipl
hepat
mass
transbronchi
biopsi
pulmonari
nodul
reveal
adenocarcinoma
epiderm
growth
factor
receptor
egfr
gene
mutat
delet
exon
final
patient
diagnos
stage
iv
adenocarcinoma
complic
trousseau
syndrom
afatinib
edoxaban
start
temporarili
effect
howev
multipl
cerebr
infarct
nonbacteri
thrombot
endocard
occur
edoxaban
chang
heparin
administr
heparin
recurr
thrombosi
discuss
penil
mondor
diseas
superfici
thrombophleb
dorsal
vein
peni
rare
clinic
diagnosi
knowledg
first
case
report
condit
associ
lung
cancer
risk
venou
thrombosi
lung
cancer
patient
increas
compar
gener
popul
retrospect
studi
report
preval
cell
lung
cancer
patient
migratori
superfici
thrombophleb
heparin
consid
agent
control
thrombosi
associ
trousseau
syndrom
conclus
patient
present
uniqu
trousseau
syndrom
caus
penil
mondor
diseas
primari
present
case
highlight
import
includ
trousseau
syndrom
etiolog
penil
mondor
diseas
pertiwi
e
syahruddin
andarini
univers
indonesia
depart
pulmonolog
respiratori
universita
persahabatan
jakarta
east
jakarta
indonesia
background
aim
lung
cancer
patient
diagnos
advanc
stage
reason
delay
diagnosi
might
patient
andor
health
system
current
indonesia
nation
health
insur
system
jaminan
kesehatan
nasion
situat
made
increas
number
patient
come
referr
hospit
persahabatan
nation
referr
respiratori
diseas
maximum
time
interv
lung
cancer
diagnosi
set
two
week
howev
sever
case
delay
conduct
studi
evalu
time
diagnosi
time
lung
cancer
method
perform
simpl
observ
studi
persahabatan
hospit
jakarta
januari
fifti
new
patient
recruit
studi
evalu
long
time
need
first
visit
initi
diagnosi
histopatolog
obtain
also
evalu
factor
correl
procedur
diagnosi
result
fifti
patient
enrol
studi
thirti
five
fifti
male
femal
median
age
year
old
rang
year
old
data
shown
patient
diagnos
target
time
week
diagnost
time
week
diagnost
delay
correl
earli
stage
diseas
poor
perform
statu
respiratori
distress
conclus
stage
perform
statu
initi
present
respiratori
distress
associ
diagnosi
delay
lung
cancer
hospit
w
sl
faculti
universita
persahabatan
hospit
depart
pulmonolog
respiratori
jakarta
indonesia
cancer
kalgen
laboratori
cancer
diagnost
research
jakarta
indonesia
background
aim
new
target
therapi
recommend
therapi
patient
nsclcc
mutat
egfr
data
efficaci
toxic
new
target
therapi
nsclc
patient
mutat
egfr
compar
chemotradiotherapi
wild
type
patient
persahabatan
hospit
jakarta
method
design
studi
retrospect
cohort
medic
record
nsclc
patient
depart
pulmonolog
respiratori
persahabatan
hospit
januari
juli
sampl
techniqu
consecut
patient
consist
patient
nsclc
mutat
egfr
treat
new
target
therapi
patient
egfr
wild
type
treat
chemoradiotherapi
result
characterist
nsclc
patient
mutat
egfr
mostli
equal
proport
exon
insertiondelet
exon
codon
mutat
surviv
mean
time
progress
ttp
day
patient
egfr
domin
male
smoker
surviv
mean
ttp
day
overal
surviv
day
independ
test
show
signific
relationship
new
target
therapi
ttp
p
common
advers
event
group
nausea
vomitu
diarrhea
alopecia
rash
chemotherapi
group
anemia
leucopenia
thrombocytopenia
conclus
treatment
patient
basi
egfr
mutat
improv
ttp
accept
toxic
prabowo
e
syahruddin
univers
indonesia
depart
pulmonolog
respiratori
faculti
universita
persahabatan
jakarta
east
jakarta
indonesia
background
aim
manag
lung
cancer
multimod
therapi
surgeri
chemotherapi
radiotherapi
target
therapi
tyrosin
kinas
inhibitor
indic
lung
adenocarcinoma
egfr
mutat
evalu
efficaci
ttp
surviv
combin
gefitinib
radiotherapi
lung
adenocarcinoma
egfr
mutat
method
eight
patient
evalu
ongo
studi
male
femal
femal
patient
mutat
exon
delet
exon
point
mutat
result
gefitinib
given
rang
week
dose
radiat
given
rang
gy
data
shown
median
ttp
week
rang
week
median
overal
surviv
rang
week
one
femal
still
aliv
treat
chemotherapi
progres
diseas
other
hand
find
sever
toxic
gefitinib
conclus
efficaci
combin
gefitinib
radiaotherapi
similiar
median
surviv
advanc
stage
lung
cancer
ny
mohd
esa
musa
mr
isa
n
nordin
mohd
zim
ai
ismail
univers
teknolog
mara
uitm
intern
medicin
sungai
buloh
malaysia
background
aim
lung
cancer
third
common
cancer
report
malaysia
howev
pauciti
data
look
novel
profil
egfr
posit
mutat
lung
adenocarcinoma
patient
analysi
sought
look
specif
paramet
use
profil
egfr
posit
mutat
lung
adenocarcinoma
patient
malaysian
popul
method
prospect
analysi
baselin
subsequ
visit
patient
attend
uitm
selayang
uitm
sungai
buloh
respiratori
clinic
till
besid
clinic
assess
patient
given
appropri
treatment
patient
inform
clinic
data
obtain
uitm
clinic
onlin
system
analys
via
statist
packag
social
scienc
spss
softwar
statist
analysi
result
total
egfr
posit
lung
adenocarcinoma
ac
patient
male
femal
recruit
age
yo
n
malay
n
n
diagnos
via
ct
guid
biopsi
n
mutat
detect
delet
exon
patient
present
stage
iv
diseas
ecog
cough
normal
bmi
famili
histori
cancer
normal
albumin
level
posit
ihc
opt
chemotherapi
conclus
find
previou
find
major
egfr
posit
lung
ac
patient
femal
new
find
patient
get
younger
normal
bmi
good
ecog
good
nutrit
statu
cachect
malnourish
find
explain
advanc
technolog
abl
detect
cancer
earlier
patient
progress
malnourish
state
becom
sever
symptomat
studi
still
earli
phase
statist
signific
data
yield
moment
signific
data
anticip
follow
futur
hw
seo
chonnam
nation
univers
hwasun
hospit
lung
esophag
cancer
clinic
republ
korea
background
aim
epiderm
growth
factor
receptor
egfr
mutat
predict
marker
kinas
inhibitor
tki
therapi
compar
sensit
egfr
mutat
detect
techniqu
match
tumor
tissu
peripher
blood
sampl
patient
lung
adenocarcinoma
method
collect
pair
sampl
plasma
tumor
tissu
patient
dna
extract
perform
use
qiaamp
minelut
viru
spin
kit
egfr
mutat
analysi
done
two
detect
method
one
pcr
clamp
select
amplifi
mutat
target
dna
sequenc
minor
portion
mixtur
major
wild
type
dna
sequenc
egfr
kit
use
pna
fluoresc
melt
curv
analysi
perform
mutat
detect
genotyp
degre
agreement
evalu
cohen
kappa
valu
result
egfr
mutat
rate
tumor
tissu
degre
agreement
tissu
plasma
sampl
better
k
p
k
p
sensit
plasma
egfr
mutat
higher
vs
p
fals
neg
rate
lower
test
vs
p
respons
correl
plasma
egfr
mutat
p
unlik
p
conclus
sensit
strength
agreement
test
better
standard
test
techniqu
use
detect
egfr
mutat
circul
dna
sampl
jh
lim
chonnam
nation
univers
hwasun
hospit
lung
esophag
cancer
clinic
republ
korea
background
aim
failur
epiderm
growth
factor
kinas
inhibitor
may
help
understand
resist
mechan
guid
treatment
decis
howev
still
challeng
due
sever
hurdl
tissu
avail
procedur
feasibl
limit
new
drug
aim
studi
assess
feasibl
advanc
cell
lung
cancer
nsclc
set
method
retrospect
review
clinic
patholog
data
advanc
nsclc
patient
diseas
progress
previou
singl
institut
januari
februari
result
nineti
one
patient
diseas
progress
use
among
thirti
three
patient
underw
histolog
sampl
obtain
surgeri
case
bronchoscopi
case
needl
biopsi
case
lymph
node
excis
biopsi
case
cytolog
sampl
obtain
thoracentesi
case
pericardiocentesi
case
spinal
tap
case
one
patient
nt
get
malign
cell
three
patient
experienc
pneumothorax
howev
one
patient
requir
close
thoracostomi
patient
perform
egfr
mutat
test
among
patient
activ
mutat
initi
mutat
found
case
mutat
found
case
case
initi
egfr
mutat
longer
found
patient
younger
vs
p
longer
respons
durat
vs
p
patient
nt
conclus
advanc
nsclc
feasibl
real
practic
especi
younger
patient
patient
longer
respons
durat
nsa
ai
nm
mam
ne
mahsa
univers
faculti
pharmaci
kuala
lumpur
malaysia
univers
teknolog
mara
faculti
pharmaci
puncak
alam
malaysia
univers
teknolog
mara
respiratori
faculti
medicin
batu
cave
malaysia
hospit
kuala
lumpur
depart
oncolog
radiotherapi
kuala
lumpur
malaysia
background
aim
determin
surviv
prognosi
defin
appropri
therapi
patient
lung
cancer
challeng
major
patient
diagnos
later
cancer
stage
object
studi
investig
effect
differ
treatment
group
surviv
malaysian
patient
live
end
stage
cell
lung
cancer
nsclc
method
retrospect
studi
medic
record
nsclc
patient
review
hospit
kuala
lumpur
malaysia
data
extract
relev
inform
data
abstract
form
result
treatment
group
case
case
chemotherapi
case
radiotherapi
review
wherea
case
includ
treatment
group
review
case
censor
case
ie
aliv
found
chemotherapi
convers
none
aliv
case
found
radiotherapi
treatment
group
estim
mean
time
event
death
occur
day
chemotherapi
day
radiotherapi
day
treatment
groupth
overal
mean
surviv
time
day
standard
error
day
median
surviv
time
treatment
death
day
chemotherapi
radiotherapi
treatment
group
respect
comparison
test
result
surviv
time
statist
signific
p
among
differ
group
find
multivari
analysi
keep
treatment
group
refer
suggest
death
proport
hazard
patient
undergo
chemotherapi
time
lower
undergo
radiotherapi
time
lower
patient
treatment
group
conclus
result
indic
improv
surviv
patient
undergo
chemotherapi
radiotherapi
compar
patient
treatment
end
stage
diseas
g
samosir
medan
indonesia
background
aim
subclin
activ
coagul
fibrinolysi
system
lung
cancer
alter
hemostat
system
seen
frequent
lung
cancer
correl
prognosi
diseas
oncolog
practic
use
tumor
marker
may
help
diagnosi
patholog
classif
tumor
tumor
marker
may
reflect
stage
diseas
prognosi
aim
research
see
relationship
paramet
chemoterapi
patient
lung
cancer
method
rectropect
studi
lung
cancer
patient
underw
chemotherapi
haji
adam
malik
gener
hospit
januari
march
measur
serum
level
hemostat
paramet
pt
inr
aptt
tt
control
ngml
tumor
marker
cea
ngml
ngml
nse
ngml
cycl
chemotherapi
cycl
chemotherapi
result
patient
found
serum
level
hemostat
paramet
significantli
correl
serum
level
tumor
marker
pt
r
inr
r
aptt
r
tt
r
r
sig
f
chang
signific
conclus
signific
correl
hemostat
paramet
tumor
marker
patient
underw
chemotherapi
studi
longer
period
need
make
better
conclus
h
nishimuta
k
takaharu
h
osahiko
k
shinya
toho
univers
ohashi
medic
center
surgeri
tokyo
japan
background
aim
manag
malign
pleural
effus
tube
drainag
pleurodesi
standard
treatment
pleurodesi
use
wide
japan
talc
also
got
use
commerci
pleurodesi
septemb
assess
efficaci
safeti
talc
pleurodesi
compar
pleurodesi
talc
method
design
retrospect
method
pleurodesi
perform
use
talc
pleurodesi
perform
whth
use
g
strile
talc
slurri
patient
receiv
pleurodesi
via
tube
thoracostomi
medic
center
octob
juli
result
patient
receiv
pleurodesi
success
rate
number
time
durat
chest
drainag
durat
pleurodesi
drain
remov
fever
occur
pleurodesi
majar
complic
report
conclus
talc
pleurodesi
effect
safe
pleurodesi
n
r
faculti
siriraj
mahidol
univers
medicin
bangkok
thailand
faculti
siriraj
mahidol
univers
patholog
bangkok
thailand
background
aim
mucoepidermoid
carcinoma
mec
rare
tumor
lung
account
primari
lung
tumor
classifi
low
intermedi
high
grade
base
histolog
featur
surgic
intervent
treatment
choic
patient
mec
distant
metastas
unresect
lesion
method
man
without
past
medic
histori
present
dri
cough
occasion
wheez
year
treat
allerg
rhiniti
gastroesophag
reflux
diseas
symptom
improv
came
siriraj
hospit
due
persist
cough
non
massiv
hemoptysi
day
physic
examin
reveal
rhonchi
lower
part
left
lung
chest
radiograph
demonstr
abnorm
comput
tomographi
chest
show
enhanc
mass
protrud
left
main
bronchu
cm
size
bronchoscop
find
demonstr
endobronchi
mass
left
main
bronchu
tissu
biopsi
compat
mec
patient
underw
left
lower
lung
sleev
lobectomi
histopatholog
examin
reveal
mec
margin
lymph
node
metastas
postop
cours
good
without
sign
tumor
recurr
adjuv
treatment
given
result
mec
lung
rare
malign
usual
aris
mainstem
bronchi
tumor
long
natur
histori
rare
metastas
tumor
aggress
prone
local
invas
earli
metastasi
radic
surgeri
lymph
node
dissect
treatment
choic
mec
patient
low
intermedi
grade
tumor
expect
cure
follow
complet
resect
patient
adjuv
therapi
indic
conclus
patient
low
intermedi
grade
mec
good
prognosi
complet
surgic
resect
n
w
price
songkhla
univers
songkhla
thailand
price
songkhla
univers
medicin
songkhla
thailand
background
aim
background
presenc
epiderm
growth
factor
receptor
egfr
mutat
lung
adenocarcinoma
known
predict
marker
good
respons
egfr
tki
treatment
approxim
patient
east
asia
tumor
associ
egfr
mutat
mutat
occur
within
egfr
exon
egfr
mutat
usual
heterozyg
common
egfr
mutat
exon
delet
exon
point
mutat
egfr
mutat
rare
epidemiolog
clinic
signific
clearli
establish
object
compar
clinic
characterist
consequ
uncommon
common
egfr
mutat
advanc
stage
adenocarcinoma
lung
method
histor
cohort
studi
conduct
songklanagarind
hospit
june
decemb
patient
patholog
confirm
advanc
stage
lung
adenocarcinoma
posit
egfr
mutat
treat
songklanagarind
hospit
includ
clinic
characterist
outcom
data
includ
overal
surviv
respons
treatment
analyz
compar
purpos
two
group
uncommon
common
egfr
mutat
result
nineti
patient
elig
analysi
common
uncommon
mutat
confirm
patient
respect
baselin
clinic
characterist
ie
mean
age
gender
smoke
histori
perform
statu
differ
group
patient
uncommon
egfr
mutat
associ
significantli
shorter
surviv
month
patient
common
egfr
mutat
month
p
moreov
respons
treatment
patient
uncommon
egfr
mutat
significantli
less
common
egfr
mutat
versu
p
conclus
differ
clinic
characterist
uncommon
versu
common
egfr
mutat
note
advanc
stage
adenocarcinoma
lung
patient
howev
patient
uncommon
egfr
mutat
associ
significantli
shorter
surviv
decreas
respons
treatment
compar
common
egfr
mutat
r
r
royal
darwin
hospit
depart
respiratori
medicin
darwin
australia
era
lucknow
medic
colleg
hospit
depart
pulmonari
medicin
lucknow
india
king
georg
medic
univers
depart
pulmonari
medicin
lucknow
india
background
aim
ppnet
malign
neuroectoderm
origin
consid
member
ewingpnet
famili
tumor
predominantli
aris
soft
tissu
bone
thorac
region
tumor
commonli
seen
origin
chest
wall
askintumor
pulmonari
ppnet
highli
malign
poor
prognosi
extrem
rare
case
describ
english
literatur
literatur
review
show
male
predomin
mean
age
year
tumor
describ
larg
aris
peripher
parenchyma
cough
fever
dyspnea
chest
pain
present
symptom
differenti
diagnosi
thorac
ppnet
includ
small
cell
carcinoma
small
tumor
histochem
immunohistochem
studi
perform
confirm
diagnosi
posit
suggest
ppnet
ppnet
also
character
presenc
reciproc
transloc
cytogenet
studi
treatment
choic
combin
radic
surgic
resect
neoadjuv
adjuv
chemotherapi
irradi
describ
ppnet
lung
girl
rapid
progress
diseas
lethal
outcom
method
case
femal
child
refer
dyspnea
fever
cough
chest
radiograph
show
right
hemithorax
opac
tomograph
scan
show
heterogen
enhanc
mass
lesion
measur
cm
lymphadenopathi
effus
histochem
studi
follow
ultrasound
guid
transthorac
biopsi
show
small
round
tumor
cell
arrang
sheet
high
nucleocytoplasm
ratio
background
necrot
debri
suggest
malign
round
cell
tumor
result
immunohistochemistri
show
vimentin
posit
confirm
diagnosi
ppnet
lung
surgeri
along
plan
patient
die
initi
conclus
normal
fals
fals
fals
ja
immunohistochemistri
help
tremend
differenti
diagnosi
small
round
cell
tumor
lung
facilit
earli
manag
pulmonari
pnet
aggress
neoplasm
high
mortal
rate
treatment
choic
earli
surgic
remov
intens
prognosi
remain
dismal
marukawa
hiraba
n
suzaki
nagata
tada
kagawa
rosai
hospit
respiratori
medicin
marugam
citi
japan
background
aim
epiderm
growth
factor
receptor
egfr
mutat
common
mechan
acquir
resist
kinas
inhibitor
tki
studi
analyz
statu
clinic
cours
patient
underw
rebiopsi
acquir
resist
method
investig
patient
harbor
mutat
examin
emerg
tki
failur
peptid
nucleic
nucleic
acid
polymeras
chain
reaction
clamp
method
use
egfr
mutat
analys
patient
characterist
age
gender
histolog
clinic
stage
egfr
mutat
site
surviv
initi
tki
rebiopsi
site
genet
chang
analyz
result
patient
male
femal
median
age
year
patient
activ
egfr
mutat
six
exon
delet
mutat
exon
point
mutat
develop
resist
identifi
six
lesion
lung
tissu
pleural
effus
pericardi
effus
detect
central
nervou
system
cerebrospin
fluid
patient
underw
anoth
biopsi
failur
system
chemotherapi
statu
chang
posit
neg
result
abl
select
rechalleng
treatment
patient
although
invas
biopsi
associ
risk
encount
signific
complic
seri
patient
conclus
tumor
rebiopsi
perform
develop
resist
identifi
best
treatment
option
patient
h
h
h
h
k
h
nagasaki
univers
graduat
school
biomed
second
depart
intern
medicin
nagasaki
japan
nagasaki
univers
hospit
second
depart
intern
medicin
nagasaki
japan
sasebo
gener
hospit
depart
respiratori
medicin
nagasaki
japan
fukuoka
seisyuukai
hospit
depart
respiratori
medicin
fukuoka
japan
isahaya
gener
hospit
depart
respiratori
medicin
nagasaki
japan
japanes
red
cross
nagasaki
genbaku
hospita
depart
respiratori
medicin
nagasaki
japan
nagasaki
univers
hospit
clinic
research
center
nagasaki
japan
tochigi
cancer
center
depart
medic
oncolog
utsunomiya
japan
nagasaki
univers
hospit
clinic
oncolog
center
nagasaki
japan
nagasaki
medic
center
depart
respiratori
medicin
nagasaki
japan
background
aim
prospect
evalu
efficaci
toxic
triplet
regimen
consist
paclitaxel
irinotecan
bevacizumab
patient
advanc
cell
lung
cancer
nsclc
expect
platinum
resist
method
patient
diagnos
nsclc
use
endobronchi
ultrasonographi
guid
sheath
system
defin
core
biopsi
rna
immedi
isol
unfix
biopsi
specimen
quantit
revers
transcriptas
pcr
assay
perform
determin
excis
repair
mrna
express
patient
advanc
untreat
nsclc
show
high
level
enter
phase
ii
trial
triplet
regimen
paclitaxel
day
irinotecan
day
bevacizumab
mgkg
day
administ
everi
week
primari
end
point
object
respons
rate
orr
assum
standard
therapi
target
therapi
estim
requir
total
number
patient
simon
optim
design
result
total
untreat
patient
receiv
evalu
express
patient
enter
trial
orr
ci
median
surviv
day
grade
thrombosi
occur
one
patient
toxic
mild
patient
treat
regimen
patient
respond
orr
ci
patient
high
level
patient
respond
patient
low
level
patient
respond
p
fisher
exact
test
conclus
triplet
combin
paclitaxel
irinotecan
bevacizumab
might
effect
patient
advanc
untreat
nsclc
overexpress
mrna
level
extract
unfix
lung
biopsi
specimen
obtain
also
might
predict
factor
regimen
e
n
j
k
st
vincent
hospit
thorac
medicin
kinghorn
cancer
centr
darlinghurst
australia
univers
sydney
nhmrc
clinic
trial
sydney
medic
school
sydney
australia
univers
technolog
sydney
faculti
health
sydney
australia
univers
queensland
uq
thorac
research
princ
charl
hospit
brisban
australia
univers
sydney
professor
research
implement
scienc
health
eris
sydney
australia
background
aim
larg
scale
health
data
collect
attract
much
recent
interest
administr
databas
provid
sourc
data
studi
lung
cancer
surviv
practic
pattern
multidisciplinari
care
adher
guidelin
australia
routin
collect
data
goe
repositori
gener
avail
clinician
data
often
sever
year
old
tailor
need
clinician
rational
descript
studi
three
main
object
character
relev
lung
cancer
data
repositori
australia
natur
data
collect
pattern
data
flow
linkag
repositori
barrier
access
ii
identifi
particular
gap
inconsist
includ
rang
data
collect
miss
crucial
data
item
tnm
stage
dataset
age
inform
collect
time
delay
access
failur
link
data
individu
case
separ
dataset
iii
identifi
potenti
innov
data
strategi
clinician
includ
routin
collect
small
prospect
dataset
highli
relev
readili
avail
feedback
clinic
practic
set
method
exist
databas
registri
australia
canvass
publicli
avail
sourc
includ
databas
websit
registri
websit
public
research
output
posit
paper
relev
data
custodian
contact
question
content
remit
linkag
databas
test
data
question
develop
applic
current
set
identifi
key
data
gap
clinic
practic
exampl
proport
stage
iiia
lung
cancer
patient
australia
treatment
includ
surgeri
result
conclus
result
studi
help
clinician
understand
strength
limit
current
avail
dataset
relev
lung
cancer
help
build
strategi
improv
access
relev
data
lung
cancer
clinic
care
australia
ys
wh
se
sh
ws
ks
hs
k
jh
pusan
nation
univers
yangsan
hospit
intern
medicin
yangsan
republ
korea
pusan
nation
univers
hospit
nuclear
medicin
busan
republ
korea
wallac
memori
baptist
hospit
intern
medicin
busan
republ
korea
background
aim
efficaci
fdg
petct
controversi
region
endem
granulomat
diseas
accuraci
specif
fdg
pet
substanti
reduc
fals
increas
fdg
uptak
inflammatori
node
aim
studi
evalu
qualit
interpret
evalu
mediastin
node
distinguish
malign
benign
lesion
compar
qualit
paramet
method
patient
patholog
document
cell
lung
carcinoma
show
bilater
fdg
avid
mediastin
lymph
node
stage
fdg
petct
imag
includ
prospect
cohort
studi
mediastin
node
patholog
analyz
endobronchi
ultrasound
transbronchi
needl
aspir
lymph
node
dissect
suvmax
suvmaxliv
suvmaxblood
pool
suvmaxcontra
suvmax
significantli
hypermetabol
lymph
node
adjust
suvmax
contralater
interlobar
hilar
lymph
node
increas
glucos
metabol
obtain
quantit
paramet
identifi
metastat
mediastin
node
result
qualit
evalu
show
sensit
specif
posit
predict
valu
neg
predict
valu
separ
metastat
lymph
node
benign
reactiv
hyperplasia
suvmax
normal
suvmax
liver
blood
pool
significantli
differenti
benign
metastat
lesion
howev
suvmaxcontra
significantli
higher
metastat
lesion
benign
lesion
p
deriv
suvmaxcontra
cutoff
area
curv
sensit
specif
conclus
qualit
interpret
fdg
petct
superior
quantit
paramet
discrimin
metastat
lymph
node
benign
reactiv
hyperplasia
patient
bilater
fdg
avid
mediastin
lymph
node
suvmaxcontra
better
sensit
specif
suvmax
suvmaxliv
suvmaxblood
pool
lr
ra
ff
ra
dr
soetomo
gener
hospit
surgeri
surabaya
indonesia
faculti
medicin
universita
airlangga
medicin
surabaya
indonesia
faculti
medicin
universita
airlangga
clinic
research
surabaya
indonesia
dr
soetomo
gener
hospit
radiolog
surabaya
indonesia
dr
soetomo
gener
hospit
pulmonolog
surabaya
indonesia
background
aim
lung
cancer
second
highest
case
tb
incid
preval
pulmonolog
depart
drsoetomo
gener
hospit
sinc
lung
cancer
uniqu
dynam
chang
type
cell
sex
age
object
understand
lung
cancer
distribut
pattern
base
gender
age
patient
histopatholog
type
lung
cancer
method
descript
analyt
studi
use
design
data
retriev
medic
record
among
patient
admit
lung
ward
dr
soetomo
gener
hospit
januari
may
result
research
reveal
preval
lung
cancer
period
patient
lung
cancer
frequent
male
femal
male
vs
femal
base
age
span
lung
cancer
patient
admit
lung
ward
group
year
old
patient
base
cell
type
common
histopatholog
diagnost
adenocarcinoma
patient
follow
squamou
cell
carcinoma
patient
larg
cell
lung
carcinoma
patient
least
small
cell
lung
carcinoma
patient
conclus
lung
cancer
three
time
frequent
men
women
women
lung
cancer
younger
men
smoke
less
intens
adenocarcinoma
observ
women
squamou
cell
carcinoma
often
found
men
women
lung
cancer
better
prognosi
men
z
b
e
trakya
faculti
medicin
radiat
oncolog
edirn
turkey
trakya
faculti
medicin
medic
oncolog
edirn
turkey
trakya
faculti
medicin
patholog
edirn
turkey
trakya
faculti
medicin
thorac
surgeri
edirn
turkey
background
aim
ectop
thymoma
account
less
thymoma
occur
neck
posterior
middl
mediastinum
lung
pleura
rare
present
huge
pulmonari
mass
method
rare
case
giant
intrathorac
ectop
thymoma
signific
respons
chemoradiotherapi
describ
result
male
consult
hospit
two
giant
lesion
left
hemi
thorax
detect
chest
comput
tomographi
ct
histori
histori
cough
dyspnea
chest
pain
fatigu
chest
ct
show
paramediastin
soft
tissu
mass
cm
anterior
left
upper
lobe
anoth
mass
cm
cm
superior
segment
left
lower
lobe
extend
hilum
level
hemi
diaphragm
cm
sub
pleural
nodul
posterior
segment
left
upper
lobe
definit
diagnosi
could
made
two
transthorac
needl
biopsi
local
hospit
progress
lesion
thoracotomi
perform
multipl
biopsi
center
thoracotomi
lesion
found
unresect
due
invas
chest
wall
mediastinum
major
vascular
structur
histolog
mass
consist
type
type
thymoma
larg
volum
lesion
first
treat
chemotherapi
cours
etoposid
cisplatin
respons
chemotherapi
partial
receiv
extern
radiotherapi
dose
fraction
good
partial
respons
obtain
ct
scan
thorax
four
month
radiotherapi
conclus
patient
present
intrathorac
giant
mass
ectop
thymoma
consid
differenti
diagnosi
k
k
h
h
akita
univers
graduat
school
medicin
cardiovascular
respiratori
medicin
akita
japan
akita
univers
graduat
school
health
scienc
physic
therapi
akita
japan
background
aim
tumor
angiogenesi
import
relat
growth
metastasi
lung
cancer
number
endotheli
progenitor
cell
epc
angiogenesi
marker
differenti
tumor
vessel
high
concentr
epc
associ
acceler
angiogenesi
evalu
relationship
number
epc
treat
chemotherapi
combin
bevacizumab
cur
effect
lung
cancer
patient
method
untreat
patient
diagnos
lung
cancer
enrol
epc
defin
antibodi
posit
vascular
endotheli
growth
factor
antibodi
posit
flow
cytometri
use
measur
number
circul
epc
peripher
blood
chemotherapi
patient
divid
two
group
rel
level
epc
high
epc
group
low
epc
group
group
compar
tumor
reduct
ratio
surviv
object
respons
ratio
diseas
control
ratio
without
administ
bevacizumab
combin
result
low
epc
group
signific
differ
tumor
reduct
ratio
surviv
object
respons
ratio
diseas
control
ratio
presenc
absenc
bevacizumab
howev
high
epc
group
chemotherapi
combin
bevacizumab
produc
higher
tumor
reduct
ratio
longer
surviv
compar
absenc
bevacizumab
conclus
lung
cancer
effect
chemotherapi
may
improv
patient
high
epc
combin
bevacizumab
k
h
showa
univers
divis
respiratori
medicin
intern
medicin
tokyo
japan
showa
univers
depart
divis
medic
oncolog
tokyo
japan
showa
univers
institut
molecular
oncolog
tokyo
japan
background
aim
lung
cancer
patient
diagnos
age
elderli
patient
higher
risk
death
toxicityth
aim
present
studi
assess
antitumor
activ
toxic
chemotherapi
elderli
patient
previous
untreat
sclc
retrospect
method
jarnuray
decemb
patient
sclc
year
older
treat
chemotherapi
showa
univers
result
median
age
patient
year
rang
year
patient
limit
diseas
patient
extens
diseas
chemotherapi
regimen
carboplatin
etoposid
concurrenttrt
n
cisplatin
etoposid
concurrenttrt
n
carboplatin
etoposid
n
cisplatin
etoposid
n
carboplatin
irinoteecan
n
etoposid
alon
n
irinotecan
alon
n
overal
respons
rate
ci
median
surviv
time
month
median
progress
free
surviv
time
month
grade
hematolog
toxic
includ
neutropenia
patient
thrombocytopenia
anemia
grade
nonhematolog
toxic
includ
diarrhea
patient
infect
appetit
loss
death
due
infect
drug
induc
pneumon
conclus
combin
chemotherapi
effect
sclc
toler
elderli
patient
cs
ci
ayl
ct
effa
mr
mw
ah
nd
ukmmc
respiratori
depart
intern
hospit
cancelor
tuanku
univers
kebangsaan
malaysia
medic
centr
kuala
lumpur
malaysia
ukmmc
depart
hospit
cancelor
tuanku
univers
kebangsaan
malaysia
medic
centr
kuala
lumpur
malaysia
univers
sain
islam
malaysia
respiratori
univers
sain
islam
malaysia
kuala
lumpur
malaysia
upm
respiratori
univers
putra
malaysia
serdang
malaysia
background
aim
thymic
larg
cell
neuroendocrin
carcinoma
belong
subgroup
thymic
carcinoid
part
thymic
carcinoma
accord
classif
poorli
differenti
thu
far
report
incid
thymic
carcinoid
male
preponder
symptomat
two
third
describ
first
local
encount
rare
tumour
share
experi
clinch
diagnosi
review
past
literatur
rare
case
result
man
came
tertiari
hospit
histori
hoars
voic
associ
dri
cough
first
assess
otorhinolaryngologist
laryngoscopi
reveal
paralysi
left
vocal
cord
subsequ
comput
tomographi
ct
imag
demonstr
anterior
mediastin
mass
x
x
cm
compress
recurr
laryng
nerv
left
pleural
effus
figur
succeed
ultrasound
guid
biopsi
mass
confirm
diagnosi
thymic
larg
cell
neuroendocrin
tumour
index
option
surgic
resect
follow
adjuv
chemoradi
explor
nonetheless
opt
tradit
treatment
two
month
later
present
us
acut
dyspnoea
complic
cardiac
tamponad
succumb
death
due
sever
respiratori
distress
conclus
larg
cell
neuroendocrin
thymic
carcinoma
subcategori
carri
worst
prognosi
italian
case
seri
surviv
rate
document
difficult
diagnos
via
standard
needl
biopsi
due
inhomogen
natur
thymic
although
thymic
carcinoid
recogn
nearli
half
centuri
till
date
standardis
treatment
modal
case
highlight
aggress
natur
diseas
dismal
outcom
hope
stir
continu
search
optim
manag
strategi
type
malign
hr
kim
j
j
wonkwang
univers
hospit
intern
medicin
iksan
republ
korea
background
aim
serv
posit
regul
emt
howev
addit
celecoxib
chemotherapi
clinic
trial
fail
benefit
surviv
nsclc
patient
studi
therapeut
potenti
celecoxib
nsclc
herein
attempt
examin
cellular
impact
celecoxib
nsclc
cell
particular
emt
process
method
evalu
efficaci
celecoxib
depend
amount
dose
emt
molecular
alter
detect
western
blot
eci
addit
akt
knock
overexpress
determin
role
prevent
emt
celecoxib
result
celecoxib
high
dose
effect
prevent
emt
indic
upregul
downregul
mesenchym
marker
transcript
factor
hand
celecoxib
low
dose
rather
promot
emt
found
array
kit
differ
effect
result
two
differ
dose
celecoxib
use
relat
stat
akt
protein
addit
akt
downregul
enhanc
revers
emt
high
dose
celecoxib
contrast
akt
upregul
relev
role
emt
conclus
differ
dose
celecoxib
use
show
opposit
effect
emt
akt
pathway
show
first
time
molecular
mechan
underli
efficaci
celecoxib
nsclc
cell
c
chee
ck
liam
yk
ks
ck
jl
faculti
univers
malaya
depart
medicin
kuala
lumpur
malaysia
faculti
univers
malaysia
sarawak
depart
medicin
kota
samarahan
malaysia
background
aim
randomis
control
trial
demonstr
pemetrex
combin
platinum
effect
gemcitabin
combin
platinum
advanc
lung
adenocarcinoma
date
studi
malaysia
compar
efficaci
pemetrex
versu
gemcitabin
combin
platinum
treatment
advanc
lung
adenocarcinoma
studi
aim
compar
surviv
pf
overal
surviv
os
object
respons
rate
orr
diseas
control
rate
dcr
malaysian
patient
advanc
lung
adenocarcinoma
receiv
chemotherapi
pemetrexedcarboplatin
versu
gemcitabinecarboplatin
method
retrospect
analysi
patient
advanc
lung
adenocarcinoma
stage
iiib
stage
iv
receiv
chemotherapi
pemetrexedcarboplatin
versu
gemcitabinecarboplatin
univers
malaya
medic
centr
august
juli
dose
pemetrex
gemcitabin
carboplatin
auc
respect
result
patient
receiv
pemetrexedcarboplatin
patient
receiv
gemcitabinecarboplatin
differ
term
pf
month
versu
month
hr
ci
p
figur
os
month
versu
month
hr
ci
p
figur
patient
receiv
pemetrexedcarboplatin
versu
gemcitabinecarboplatin
chemotherapi
patient
treat
pemetrexedcarboplatin
numer
better
orr
versu
ci
p
dcr
versu
ci
p
patient
treat
gemcitabinecarboplatin
differ
statist
signific
conclus
malaysian
patient
advanc
lung
adenocarcinoma
appear
similar
pf
os
orr
dcr
irrespect
whether
receiv
pemetrexedcarboplatin
gemcitabinecarboplatin
treatment
howev
appar
lack
differ
could
due
small
sampl
size
sm
kwak
k
jung
soo
js
ryu
inha
univers
hospit
intern
divis
pulmonari
critic
care
incheon
republ
korea
background
aim
famili
histori
valuabl
tool
era
big
data
genom
medicin
studi
report
associ
famili
histori
lung
cancer
egfr
activ
mutat
howev
impact
surviv
lung
cancer
patient
remain
investig
method
consecut
patient
histolog
diagnos
lung
cancer
januari
januari
receiv
analysi
egfr
activ
mutat
prospect
lung
cancer
cohort
includ
studi
associ
egfr
mutat
famili
histori
lung
cancer
rel
evalu
multivari
logist
regress
analysi
impact
surviv
patient
famili
histori
estim
cox
proport
hazard
model
result
seventi
five
patient
famili
histori
lung
cancer
egfr
mutat
commonli
observ
patient
famili
histori
compar
without
famili
histori
v
famili
histori
shown
significantli
associ
egfr
mutat
aor
ci
p
patient
famili
histori
margin
longer
surviv
compar
without
famili
histori
mst
v
month
p
presenc
egfr
mutat
signific
impact
surviv
patient
without
famili
histori
ahr
ci
p
impact
observ
patient
famili
histori
ahr
ci
p
conclus
famili
histori
lung
cancer
associ
preval
egfr
mutat
may
modifi
impact
egfr
mutat
surviv
lung
cancer
patient
b
j
hj
jh
hk
kyung
hee
univers
hospit
gangdong
depart
pulmonari
critic
care
medicin
seoul
republ
korea
kyung
hee
univers
depart
biomed
engin
seoul
republ
korea
kyung
hee
univers
depart
pharmacolog
seoul
republ
korea
background
aim
epigenet
rais
hallmark
cancer
last
decad
play
key
role
function
regul
gene
without
alter
nucleotid
sequenc
object
studi
develop
detect
quantif
modif
dna
methyl
earli
cancer
diagnost
test
method
oligonucleotid
design
base
bisulfit
modif
method
use
methyl
probe
contain
methyl
cytosin
mc
unmethyl
probe
contain
thymin
instead
uracil
base
previou
studi
ref
shin
et
al
methyl
unmethyl
target
complementari
sequenc
methyl
unmethyl
probe
respect
hybrid
dna
target
bind
analysi
oligonucleotid
dissolv
dnase
rnase
free
water
methyl
unmethyl
target
ad
methyl
unmethyl
probe
ratio
mixtur
incub
min
room
temperatur
hybrid
raman
spectroscopi
raman
spectra
bench
top
type
taken
use
spectroscopi
bruko
german
diod
laser
beam
excit
wavelength
nm
bench
top
raman
scatter
light
signal
collect
object
len
laser
sourc
power
mw
focus
sampl
spot
diamet
result
observ
raman
spectra
met
methyl
probe
similar
unmet
unmethyl
probe
like
raman
spectra
met
target
similar
unmet
target
consid
mixtur
shown
figur
also
differenti
other
conclus
raman
detect
system
help
develop
diagnost
chip
dna
methyl
detect
clinic
cancer
research
nw
candrawati
ib
ngurah
rai
rsup
sanglah
pulmonolog
denpasar
indonesia
background
aim
atrial
fibril
common
arrhytmia
preval
increas
age
cardiac
rhythm
disturb
common
concern
among
patient
neoplast
diseas
arrhytmia
may
due
effect
tumor
extrins
compress
heart
involv
coronari
vasculatur
treatment
neoplast
process
metabol
autonom
instabl
relationship
chemotherapi
arrhytmia
well
establish
monitor
would
prudent
lung
cancer
patient
atrial
fibril
receiv
chemotherapi
case
report
balines
male
present
dyspnea
dizzi
palpit
cough
examin
reveal
mass
right
upper
chest
atrial
fibril
postur
drop
blood
pressur
ct
scan
thorax
show
hyperdens
mass
high
contrast
enhanc
right
pleural
effus
metastat
process
sternum
corpu
vertebra
thorac
biopsi
mass
chest
reveal
squamou
cell
carcinoma
treat
system
chemotherapi
use
carboplatin
vinorelbin
follow
treatment
patient
experienc
progress
atrial
fibril
discuss
treatment
lung
cancer
chemotherapi
patient
atrial
fibril
done
close
monitor
chemotherapi
agent
chosen
base
report
regard
atrial
fibril
induc
cancer
chemotherapi
incid
sever
drug
induc
atrial
fibril
depend
drug
use
dose
schedul
employ
particularli
combin
therapi
age
patient
presenc
arrhythmogen
substrat
creat
cancer
andor
chemotherapi
regimen
chosen
combin
carboplatin
vinorelbin
less
atrial
fibril
side
effect
n
kanauchi
w
isamu
nihonkai
gener
hospit
thorac
surgeri
sakata
japan
background
aim
pulmonari
embol
potenti
complic
lung
cancer
surgeri
remain
difficult
challeng
thorac
surgeon
purpos
studi
assess
measur
concentr
preoper
screen
test
venou
thromboembol
patient
cell
lung
cancer
method
august
decemb
preoper
plasma
concentr
determin
patient
cell
lung
cancer
underw
surgeri
male
femal
patient
median
age
year
patholog
diagnosi
adenocarcinoma
patient
squamou
cell
carcinoma
patholog
stage
patient
stage
stage
ii
stage
iii
diseas
concentr
determin
use
latex
agglutin
assay
lower
limb
venou
ultrasonographi
perform
patient
plasma
concentr
higher
valu
result
median
preoper
concentr
rang
patient
concentr
higher
valu
posit
deep
vein
thrombosi
venou
ultrasonographi
anticoagul
therapi
administ
patient
postop
period
high
risk
pulmonari
embol
none
studi
patient
develop
postop
pulmonari
embol
conclus
preoper
measur
concentr
lung
cancer
patient
may
use
screen
method
identifi
patient
high
risk
pulmonari
embol
j
villalon
chines
gener
hospit
medic
center
pulmonari
section
manila
philippin
background
aim
risk
malign
increas
person
live
hiv
plhiv
lung
cancer
incid
increas
plhiv
pulmonari
adenocarcinoma
repres
major
defin
lesion
concurr
use
cytotox
chemotherapi
therapi
art
may
result
addit
cytotox
interact
may
enhanc
immunosuppress
date
data
exist
efficaci
toxic
chemotherapi
method
report
case
lung
adenocarcinoma
plhiv
filipino
male
present
histori
product
cough
initi
treat
pulmonari
tuberculosi
progress
sign
symptom
diagnost
reveal
result
cellul
cell
count
also
present
pleural
effus
cell
block
cytolog
reveal
adenocarcinoma
patient
present
two
major
problem
need
prompt
treatment
start
oral
chemotherapeut
agent
erlotinib
therapi
regimen
result
presenc
activ
mutat
within
epiderm
growth
factor
receptor
egfr
gene
lung
cancer
cell
make
tumor
highli
sensit
tyrosin
kinas
inhibitor
tki
erlotinib
gefitinib
mutat
incid
lung
cancer
known
data
exist
chemotherapi
ongo
antiretrovir
therapi
revers
immunosuppress
plhiv
import
median
surviv
improv
cell
count
simultan
use
arv
chemotherapeut
agent
challeng
due
signific
increas
myelosuppress
efavirenz
could
potenti
decreas
erlotinib
concentr
concurr
arv
expect
exacerb
side
effect
chemotherapi
perhap
make
cancer
therapi
intoler
conclus
import
consid
choic
chemotherapi
antiretrovir
treatment
manag
lung
adenocarcinoma
plhiv
strict
monitor
done
note
drug
interact
minim
prevent
advers
interact
therebi
provid
optim
treatment
diseas
n
c
f
west
china
hospit
sichuan
univers
depart
respiratori
critic
care
medicin
chengdu
china
state
key
laboratori
biotherapi
sichuan
univers
divis
pulmonari
diseas
chengdu
china
background
aim
imbal
endogen
proteas
inhibitor
proteas
one
critic
mechan
chronic
obstruct
pulmonari
diseas
copd
cystatin
c
classic
inhibitor
endogen
cystein
proteas
associ
copd
limit
studi
aim
investig
serum
level
cystatin
c
copd
patient
discuss
potenti
clinic
signific
method
serum
sampl
collect
copd
health
control
subject
finish
standard
lung
function
test
serum
level
cystatin
c
protein
determin
relationship
cystatin
c
concentr
lung
function
crp
indic
assess
pearson
correl
test
result
mean
serum
level
cystatin
c
significantli
higher
copd
patient
control
versu
mgl
p
serum
level
crp
also
significantli
higher
copd
patient
versu
mgl
p
serum
level
cystatin
c
copd
patient
correl
invers
predict
index
lung
function
r
p
correl
posit
protein
level
indic
system
inflamm
r
p
copd
assess
test
score
r
p
conclus
result
suggest
serum
level
cystatin
c
increas
copd
patient
associ
lung
function
copd
assess
test
score
system
inflamm
copd
patient
futur
studi
perform
determin
cystatin
c
play
role
copd
ebihara
tokai
univers
tokyo
hospit
pulmonolog
tokyo
japan
background
aim
bronchial
asthma
patient
smoke
histori
number
patient
includ
ratio
copd
new
phenotyp
call
asthma
copd
overlap
syndrom
aco
elder
patient
year
seem
difficult
differenti
asthma
copd
studi
asthma
patient
smoke
histori
went
whether
retrospect
analysi
much
aco
includ
method
total
subject
male
femal
age
year
old
year
old
sd
enrol
studi
inform
consent
obtain
juli
august
erimo
town
clinic
hokkaidoit
retrospect
studi
analysi
perform
asthma
control
statu
medic
histori
smoke
histori
result
control
state
mild
intermitt
type
mild
persist
type
moder
persist
sever
persist
medic
histori
ic
singl
agent
peopl
ic
saba
ic
laba
ic
leukotrien
antagonist
ic
saba
leukotrien
ic
laba
leukotrien
theophyllin
addit
lama
five
conclus
concept
aco
mani
case
treat
separ
asthma
copd
among
aco
expect
uncontrol
asthma
patientsin
treatment
elderli
patient
asthma
suggest
need
aggress
use
lama
consider
aco
chen
wang
n
zeng
wu
xu
f
wen
l
chen
west
china
hospit
sichuan
univers
divis
pulmonari
state
key
laboratori
biotherapi
china
depart
respiratori
medicin
chengdu
china
background
aim
cigarett
smoke
cs
exposur
associ
increas
risk
copd
level
inflamm
high
lung
tissu
copd
patient
receptor
advanc
glycat
end
product
rage
multiligand
receptor
amplifi
inflammatori
respons
studi
investig
role
rage
signal
respons
induc
cs
method
balbc
wt
mice
rage
knockout
ko
mice
expos
mainstream
cs
room
air
hour
twice
daili
day
per
week
week
bronchoalveolar
lavag
fluid
balf
acquir
cell
count
measur
cytokin
level
lung
tissu
collect
histolog
examin
gene
express
profil
affymetrix
mous
genom
genechip
result
compar
control
neutrophil
count
cytokin
level
balf
significantli
increas
cs
exposur
mice
well
thicken
airway
epithelium
peribronchi
inflammatori
cell
infiltr
airway
obstruct
howev
knockout
rage
significantli
attenu
inflammatori
respons
histolog
alter
mous
airway
furthermor
compar
cs
wt
mice
total
upregul
gene
downregul
gene
cs
ko
well
time
rage
common
ligand
decreas
conclus
result
suggest
rage
signal
potenti
import
therapeut
target
contribut
significantli
cigarett
lung
system
inflamm
acknowledg
studi
support
part
grant
nation
natur
scienc
foundat
china
grant
scienc
foundat
outstand
young
scholar
sichuan
univers
yoshida
k
asai
sugiyama
kyomoto
kawamoto
k
sato
kureya
okamoto
k
yamada
n
yoshii
watanab
uji
h
kanazawa
k
hirata
osaka
citi
univers
depart
respiratori
medicin
osaka
japan
background
aim
irisin
one
myokin
newli
identifi
hormon
secret
skelet
muscl
irisin
propos
mediat
variou
benefici
effect
metabol
disord
diabet
mellitu
osteoporosi
cachexia
sarcopenia
loss
skelet
muscl
mass
strength
one
comorbid
chronic
obstruct
pulmonari
diseas
copd
subject
might
lead
poor
qol
prognosi
studi
design
evalu
irisin
level
copd
subject
sarcopenia
examin
relationship
irisin
level
pulmonari
function
measur
copd
subject
method
stabl
male
copd
subject
enrol
pulmonari
function
test
perform
bodi
composit
evalu
method
bia
sarcopenia
defin
skelet
muscl
index
smi
peripher
blood
irisin
level
measur
elisa
result
irisin
level
significantli
correl
muscl
mass
fat
free
mass
ffm
fat
free
mass
index
ffmi
bodi
mass
index
bmi
howev
differ
irisin
level
copd
subject
without
sarcopenia
reach
statist
signific
subject
stratifi
algorithm
includ
smi
grip
strength
irisin
level
significantli
correl
dlva
correl
fvc
conclus
irisin
level
relat
loss
muscl
mass
copd
subject
furthermor
irisin
level
relat
impair
pulmonari
function
copd
subject
irisin
might
biomark
vice
versa
interact
copd
subject
investig
desir
ia
k
hyun
hj
yb
c
yi
sy
kh
konkuk
univers
medic
center
divis
pulmonolog
allegi
medicin
seoul
republ
korea
konkuk
univers
medic
center
depart
intern
divis
pulmonari
critic
care
medicin
seoul
republ
korea
hallym
univers
medic
center
depart
intern
divis
pulmonari
critic
care
medicin
seoul
republ
korea
cathol
univers
korea
school
medicin
depart
intern
divis
pulmonari
critic
care
medicin
seoul
republ
korea
colleg
hallym
univers
medic
depart
intern
divis
pulmonari
critic
care
medicin
seoul
republ
korea
kangbuk
samsung
sungkyunkwan
univers
school
medicin
depart
pulmonari
critic
care
medicin
seoul
republ
korea
background
aim
st
georg
respiratori
questionnair
score
sgrq
develop
instrument
assess
health
statu
patient
copd
longitudin
chang
health
statu
well
describ
less
known
baselin
characterist
patient
deterior
health
statu
mild
moder
copd
studi
aim
investig
baselin
characterist
aggrav
sgrq
group
identifi
factor
associ
aggrav
chang
sgrq
score
method
st
georg
respiratori
questionnair
score
sgrq
develop
instrument
assess
health
statu
patient
copd
longitudin
chang
health
statu
well
describ
less
known
baselin
characterist
patient
deterior
health
statu
mild
moder
copd
studi
aim
investig
baselin
characterist
aggrav
sgrq
group
identifi
factor
associ
aggrav
chang
sgrq
score
result
total
patient
belong
improv
group
patient
stabl
group
aggrav
group
compar
baselin
characterist
group
deterior
group
lower
group
p
modifi
medic
research
council
mmrc
score
higher
significantli
p
use
anova
addit
risk
factor
deterior
sgrq
group
mmrc
p
acut
exacerb
p
logist
regress
analysi
analyz
year
chang
paramet
group
bmi
decreas
mmrc
increas
significantli
deterior
group
deterior
group
acut
exacerb
frequent
odd
ratio
confid
interv
p
conclus
predictor
sgrq
aggrav
lower
p
higher
mmrc
p
baselin
acut
exacerb
follow
period
c
inderawati
bandung
indonesia
background
aim
exacerb
common
caus
hospit
admiss
copd
vari
sever
increas
health
care
cost
lead
decreas
qualiti
life
diminish
lung
function
weak
reexacerb
rehospit
even
death
accur
prognost
tool
acut
exacerb
help
assess
appropri
manag
improv
outcom
howev
prognost
tool
exacerb
limit
bourk
etal
nafa
etal
studi
show
decaf
score
promis
tool
aecopd
simpl
effect
predictor
mortal
aim
studi
valid
decaf
score
promis
prognost
tool
aecopd
compar
accuraci
decaf
score
versu
predict
mortal
risk
among
aecopd
method
aecopd
patient
admit
august
august
invit
particip
studi
voluntarili
inform
would
keep
confidenti
particip
assess
stratifi
use
decaf
score
predict
mortal
risk
day
length
hospit
stay
time
next
exacerb
statist
analysi
done
use
epi
spss
pearson
anova
analysi
result
pictur
copd
patient
csmc
similar
world
elderi
xovlin
major
men
mostli
histori
heavi
smoker
pack
year
xovlin
howev
studi
fail
affirm
previou
studi
decaf
score
promis
prognost
tool
aecopd
assess
conclus
decaf
score
probabl
superior
prognost
tool
aecopd
limit
studi
enough
sampl
size
get
valid
result
suggest
improv
studi
prolong
studi
multicent
studi
wj
kim
mn
lim
hong
kangwon
nation
univers
depart
intern
medicin
chuncheon
republ
korea
background
aim
chronic
obstruct
pulmonari
diseas
copd
heterogen
diseas
differ
clinic
manifest
structur
chang
respons
treatment
aim
identifi
subgroup
copd
cohort
studi
use
cluster
analysi
baselin
assess
clinic
outcom
subgroup
one
year
method
analyz
patient
copd
dusti
area
cohort
main
factor
select
highest
load
variabl
use
princip
compon
analysi
pca
baselin
copd
patient
classifi
use
hierarch
cluster
analysi
clinic
physiolog
imag
data
base
data
clinic
paramet
evalu
among
subgroup
subgroup
also
evalu
clinic
outcom
one
year
result
pca
show
six
independ
compon
account
varianc
three
distinct
subgroup
identifi
cluster
analysi
subgroup
includ
younger
patient
mild
stage
gold
fewer
exacerb
hospit
one
year
subgroup
includ
femal
patient
milder
sever
sever
respiratori
symptom
show
progress
symptom
subgroup
includ
sever
subject
largest
declin
exacerb
one
year
conclus
cluster
analysi
use
baselin
data
copd
cohort
identifi
three
distinct
subgroup
differ
clinic
paramet
clinic
outcom
find
suggest
identifi
subgroup
may
repres
clinic
meaning
subtyp
copd
n
n
n
nippon
koukan
hospit
intern
medicin
kanagawa
japan
keiyu
hospit
intern
medicin
kanagawa
japan
nippon
koukan
hospit
rehabilit
kanagawa
japan
background
aim
believ
lung
function
test
indispens
diagnosi
chronic
obstruct
pulmonari
diseas
copd
howev
test
depend
inspect
procedur
patient
effort
enforc
mani
facil
herein
confirm
correl
chest
radiographi
find
moreov
also
report
rvtlc
ictlc
ratio
associ
acut
exacerb
prognosi
copd
patient
aim
determin
chest
radiographi
use
predict
precis
respiratori
function
copd
patient
method
fourteen
patient
diagnos
copd
base
japanes
respiratori
societi
copd
guidelin
underw
chest
radiographi
hospit
analyz
use
clinic
imag
viewer
shadequestviewc
measur
vertic
direct
apex
diaphragm
anteroposterior
diamet
thorac
caviti
calcul
caviti
area
associ
measur
precis
breath
function
test
valu
investig
result
signific
correl
diamet
apex
diaphragm
anteroposterior
diamet
thorac
caviti
rv
rvtlc
ratio
note
particular
rvtlc
ratio
show
strong
correl
differ
vertic
size
inspiratori
expiratori
chest
radiographi
r
p
cutoff
valu
set
mm
rvtlc
could
detect
sensit
specif
area
curv
howev
signific
relationship
among
diamet
frc
tlc
ictlc
dlcova
observ
conclus
chest
radiograph
consid
use
predict
precis
respiratori
function
copd
patient
gp
taytay
philippin
philippin
heart
center
divis
pulmonari
critic
care
medicin
quezon
citi
philippin
background
aim
copd
exacerb
associ
decreas
lung
function
qualiti
life
identif
specif
factor
may
affect
prognosi
manag
outcom
exacerb
though
sever
score
system
propos
remain
subject
difficult
evalu
furthermor
clinic
laboratori
marker
deem
import
certain
studi
includ
base
previou
studi
aim
studi
determin
factor
affect
outcom
acut
exacerb
copd
method
subject
admit
due
acut
exacerb
copd
age
year
old
includ
patient
chart
retriev
specif
factor
record
outcom
mortal
need
mechan
ventil
icu
admiss
record
logist
regress
analysi
done
determin
statist
signific
result
patient
includ
studi
show
age
year
old
p
bmi
p
mrc
dyspnea
score
p
serum
albumin
p
serum
urea
p
hemoglobin
p
arteri
ph
p
associ
increas
mortal
acut
exacerb
copd
also
observ
need
invas
mechan
ventil
icu
admiss
addit
mrc
dyspnea
score
found
signific
need
invas
mechan
ventil
p
need
icu
admiss
p
howev
presenc
diabet
mellitu
p
found
protect
factor
mortal
conclus
prognost
factor
older
age
malnutrit
sever
mrc
dyspnea
score
hypoalbuminemia
elev
urea
anemia
sever
acidosi
significantli
increas
mortal
need
invas
mechan
ventil
icu
admiss
acut
exacerb
copd
hand
control
diabet
mellitu
shown
lower
risk
mortal
b
batanga
philippin
quezon
citi
philippin
background
aim
chronic
obstruct
pulmonari
diseas
copd
etim
affect
popul
worldwid
import
caus
mortal
morbid
tradit
spirometr
measur
correl
poorli
exercis
toler
exert
dyspnea
associ
lung
hyperinfl
measur
lung
volum
studi
research
identifi
presenc
hyperinfl
associ
even
mild
stage
among
increas
level
copd
sever
method
prospect
cohort
analyt
studi
among
copd
patient
diagnos
pulmonari
function
test
consist
airflow
obstruct
lung
volum
studi
done
among
lung
volum
studi
analysi
varianc
use
associ
tlc
rv
rvtlc
ratio
differ
level
copd
sever
base
gold
citeria
valu
consid
signific
result
patient
includ
studi
patient
male
femal
mean
age
studi
popul
year
old
major
patient
smoker
mean
predict
studi
patient
gold
patient
observ
copd
sever
increas
also
increas
rvtlc
ratio
howev
look
chang
one
categori
next
chang
rvtlc
significantli
increas
gold
gold
conclus
rvtlc
ratio
serv
good
object
paramet
hyperinfl
ratio
increas
direct
associ
increas
copd
sever
associ
significantli
note
copd
patient
gold
cataegori
w
antono
f
yunu
dwi
susanto
univers
indonesia
pulmonolog
respiratori
medicin
east
jakarta
indonesia
background
aim
chronic
obstruct
pulmonari
diseas
copd
import
diseas
worldwid
countri
year
estim
copd
rank
fifth
among
condit
high
burden
societi
third
among
import
caus
death
gender
worldwid
sweep
work
job
employ
special
thought
consid
menial
one
sweep
activ
sweeper
expos
dust
caus
variou
ill
effect
bodi
street
dust
complex
mixtur
soil
dust
plant
fragment
dust
motor
vehicl
biolog
materi
street
sweeper
expos
dust
particl
bioaerosol
variou
harm
gase
street
sweeper
usual
would
use
protect
devic
exposur
air
pollut
sweep
may
contribut
increas
preval
copdthi
preliminari
cross
section
studi
preval
copd
among
street
sweeper
jakarta
indonesia
approv
ethic
committe
faculti
medicin
universita
indonesia
method
research
design
subject
street
sweeper
jakarta
sampl
collect
use
cluster
random
sampl
questionnair
copd
assess
test
cat
modifi
british
medic
research
council
mmrc
spirometri
examin
base
pneumobil
project
indonesia
bronchodil
test
inclus
criteria
male
femal
abl
perform
spirometri
sign
inform
consent
year
old
work
period
year
result
thirti
subject
particip
studi
age
year
male
femal
preval
copd
among
street
sweeper
area
conclus
preval
copd
among
street
sweeper
jakarta
wedzicha
ja
et
al
n
eng
j
med
wedzicha
ja
et
al
n
engl
j
med
ja
c
f
c
r
nation
heart
lung
imperi
colleg
london
airway
diseas
section
london
unit
kingdom
univers
marburg
respiratori
diseas
marburg
germani
novarti
pharma
ag
respiratori
basel
switzerland
novarti
pharmaceut
corpor
respiratori
east
nj
usa
background
aim
baselin
eosinophil
level
may
predict
efficaci
inhal
corticosteroid
prevent
copd
exacerb
analysi
flame
studi
present
evalu
time
first
moder
sever
exacerb
indacaterolglycopyrronium
indgli
compar
salmeterolfluticason
sfc
sever
copd
patient
stratifi
baselin
blood
eosinophil
level
method
flame
multicent
studi
random
patient
predict
histori
exacerb
previou
year
receiv
either
indgli
sfc
data
analyz
subgroup
defin
percentag
blood
eosinophil
absolut
blood
eosinophil
level
result
patient
random
indgli
n
sfc
n
patient
includ
analysi
time
first
moder
sever
exacerb
significantli
delay
indgli
compar
sfc
subgroup
patient
stratifi
percentag
blood
eosinophil
absolut
blood
eosinophil
furthermor
numer
improv
exacerb
risk
term
time
first
moder
sever
exacerb
observ
subgroup
patient
eosinophil
count
tabl
conclus
studi
patient
high
risk
exacerb
indacaterolglycopyrronium
significantli
better
delay
time
first
moder
sever
exacerb
salmeterolfluticason
eosinophil
cutoff
given
eosinophil
cutoff
salmeterolfluticason
found
better
indacaterolglycopyrronium
delay
time
first
moder
sever
exacerb
studi
fund
novarti
pharma
ag
c
ngo
quy
bach
mai
hospit
respiratori
center
hanoi
vietnam
background
aim
background
estim
million
peopl
moder
sever
chronic
obstruct
pulmonari
diseas
copd
million
peopl
die
copd
correspond
death
global
known
almost
copd
death
occur
countri
across
nation
region
level
limit
polici
need
challeng
obstacl
effect
care
need
remov
need
robust
polici
framework
allow
healthcar
profession
identifi
patient
earlier
make
necessari
intervent
tackl
diseas
effect
method
implement
effect
treatment
manag
protocol
smoke
cessat
step
wise
approach
treatment
recommend
global
initi
chronic
obstruct
lung
diseas
guidelin
diseas
progress
may
delay
result
expect
outcom
increas
number
stakehold
train
copd
advocaci
provid
copd
advocaci
train
technic
assist
patient
partner
region
andor
local
advocaci
increas
number
legisl
better
understand
copd
relat
polici
program
increas
public
fund
copd
activ
region
better
tobacco
control
clean
air
polici
local
region
level
conclus
address
escal
burden
copd
need
clear
implement
strategi
across
asia
apsr
local
societi
work
partnership
improv
diagnosi
manag
also
educ
copd
ai
mf
abd
kk
mam
ne
mahsa
univers
faculti
pharmaci
kuala
lumpur
malaysia
univers
teknolog
mara
respiratori
faculti
medicin
batu
cave
malaysia
univers
teknolog
mara
uitm
faculti
pharmaci
puncak
alam
malaysia
background
aim
chronic
obstruct
pulmonari
diseas
copd
frequent
caus
morbid
mortal
develop
countri
might
attribut
lack
knowledg
copd
patient
main
object
studi
evalu
knowledg
copd
among
malaysian
patient
live
copd
method
post
ethic
approv
written
consent
copd
patient
year
old
diagnos
respiratori
diseas
nil
cognit
disabl
attend
appoint
chest
clinic
hospit
melaka
recruit
patient
medic
data
record
patient
knowledg
copd
assess
use
malay
version
bristol
copd
knowledg
questionnair
assess
patient
knowledg
epidemiolog
physiolog
aetiolog
common
symptom
breathless
phlegm
chest
infect
exercis
smoke
immun
inhal
bronchodil
antibiot
oral
steroid
inhal
steroid
base
answer
scheme
score
given
correct
answer
wrong
answer
highest
possibl
score
result
enrol
copd
patient
n
patient
possess
poor
score
knowledg
n
patient
moder
level
score
knowledg
half
enrol
patient
respond
correctli
six
main
domain
copd
knowledg
includ
common
symptom
phlegm
aetiolog
chest
infect
breathless
oral
steroid
convers
patient
respond
poorli
domain
inhal
bronchodil
immun
conclus
none
patient
studi
sampl
possess
good
level
knowledg
copd
signific
gap
copd
patient
knowledg
ill
respect
manag
result
present
studi
alert
healthcar
polici
maker
administr
need
intervent
aim
increas
knowledg
copd
patient
thu
ensur
better
manag
copd
dk
jh
ch
sy
ckr
kh
jh
jk
ey
hs
seoul
nation
univers
colleg
borama
medic
center
depart
intern
medicin
seoul
republ
korea
seoul
nation
univers
hospit
intern
medicin
seoul
republ
korea
kangbuk
samsung
sungkyunkwan
univers
school
medicin
depart
medicin
seoul
republ
korea
cathol
univers
seoul
st
mari
hospit
intern
medicin
seoul
republ
korea
konkuk
univers
medic
konkuk
univers
school
medicin
intern
medicin
seoul
republ
korea
background
aim
recent
blood
eosinophil
emphas
candid
biomark
relat
acut
exacerb
therapeut
respons
inhal
corticosteroid
ic
copd
howev
role
blood
eosinophil
might
overestim
includ
patient
overlap
syndrom
aco
investig
clinic
impact
blood
eosinophil
patient
copd
method
korean
copd
subtyp
studi
kocoss
ongo
cohort
includ
patient
copd
exclud
patient
aco
defin
spanish
aco
criteria
analyz
blood
cell
count
epidemiolog
spirometr
data
event
copd
exacerb
copd
clinic
outcom
includ
dyspnea
qualiti
life
qol
moder
sever
exacerb
copd
aecopd
declin
lung
function
compar
accord
quartil
blood
eosinophil
count
percent
result
exclud
patient
defin
spanish
criteria
aco
patient
copd
final
analyz
median
valu
eosinophil
percent
count
eosinophilsul
total
white
blood
cell
count
neutrophil
percent
invers
correl
eosinophil
percent
p
sgrq
cat
score
frequenc
aecopd
associ
blood
eosinophil
percent
count
p
even
multivari
logist
regress
analysi
adjust
age
sex
use
ic
eosinophil
count
percent
signific
risk
factor
declin
frequenc
aecopd
p
conclus
patient
copd
blood
eosinophil
associ
symptom
qol
risk
factor
declin
aecopd
role
blood
eosinophil
may
limit
overestim
biomark
patient
copd
fd
er
mariu
nasta
institut
pneumolog
pulmonolog
bucharest
romania
novarti
pharma
servic
novarti
pharma
servic
bucharest
romania
background
aim
year
world
copd
day
romania
run
copd
awar
campaign
offer
free
spirometri
gener
public
conduct
day
campaign
bucharest
use
case
find
approach
questionnair
plu
free
spirometri
method
questionnair
question
address
differ
issu
like
possibl
suggest
symptom
risk
factor
smoke
previou
respiratori
function
investig
spirometri
exist
respiratori
therapi
statist
analysi
done
use
microsoft
offic
excel
result
lot
person
mean
age
year
screen
spirometri
lung
function
impair
mean
male
repres
case
year
year
old
respiratori
symptom
symptomat
one
dyspnea
indic
cough
chest
tight
wheez
accus
symptom
although
case
histori
obstruct
diseas
spirometri
last
month
questionnair
analysi
reveal
previous
undiagnos
patient
detect
lung
impair
symptomat
normal
spirometri
sever
diseas
case
experienc
exacerbationyear
least
exacerbationsyear
receiv
antibiot
treatment
present
emerg
room
case
requir
hospit
conclus
romania
due
copd
awar
campaign
address
access
spirometri
increas
year
year
howev
treat
copd
remain
deficitari
respect
patient
known
diagnos
obstruct
disord
actual
treat
copd
awar
campaign
questionnair
plu
spirometri
use
detect
new
case
alreadi
undertr
diagnos
case
k
k
k
k
k
h
kobe
univers
graduat
school
health
scienc
depart
commun
health
scienc
hyogo
japan
nurs
station
wakakusa
home
visit
nurs
nagano
japan
nation
hospit
organ
higashi
nagano
hospit
depart
respiretori
medicin
nagano
japan
background
aim
chronic
obstruct
pulmonari
diseas
copd
patient
becom
malnourish
weight
loss
consid
independ
prognost
factor
provid
nurs
intervent
program
copd
patient
complet
pulmonari
rehabilit
studi
aim
evalu
effect
longitudin
chang
percentag
ideal
bodi
weight
ibw
copd
patient
receiv
nurs
method
subject
compris
copd
patient
follow
year
among
patient
receiv
nurs
use
age
ibw
lung
function
arteri
blood
ga
activ
daili
live
adl
score
walk
distanc
chronic
respiratori
diseas
questionnair
crq
paramet
evalu
calcul
regress
line
ibw
year
furthermor
defin
increas
ibw
regress
line
slope
group
n
decreas
ibw
regress
line
slope
group
b
n
compar
result
measur
two
group
result
baselin
group
significantli
lower
ibw
group
b
howev
significantli
differ
measur
two
group
first
third
year
group
significantli
higher
crq
total
score
group
bin
third
year
group
significantli
lower
adl
score
baselin
group
significantli
lower
first
yearin
third
year
group
significantli
higher
crq
total
crq
emot
crq
masteri
score
baselin
conclus
function
declin
activ
restrict
occur
ill
age
howev
studi
suggest
nutrit
manag
nurs
help
maintain
high
qualiti
life
copd
patient
r
k
k
fukuoka
univers
school
medicin
nurs
fukuoka
japan
fukuoka
univers
school
medicin
respiratori
medicin
fukuoka
japan
nishi
fukuoka
hospit
respiratori
medicin
fukuoka
japan
fukuseikai
hospit
respiratori
medicin
fukuoka
japan
nishi
fukuoka
hospit
nurs
fukuoka
japan
hiroshima
univers
graduat
school
biomed
health
scienc
hiroshima
japan
background
aim
research
conduct
aim
clarifi
characterist
copd
patient
diseas
stage
appropri
prevent
behavior
respiratori
infect
method
subject
copd
patient
visit
depart
respiratori
medicin
three
medic
facil
includ
univers
hospit
fukuoka
citi
novemb
june
acquir
basic
inform
subject
medic
record
conduct
copd
assess
test
cat
use
survey
sheet
respiratori
infect
prepar
research
research
conduct
approv
clinic
research
support
committe
fukuoka
univers
hospit
result
subject
male
femal
subject
year
number
patient
stage
ii
iii
iv
respect
bodi
mass
index
bmi
averag
level
vital
capac
forc
expiratori
volum
one
second
declin
diseas
stage
progress
averag
age
across
stage
subject
averag
age
subject
stage
iv
year
time
diagnos
copd
cat
score
show
signific
differ
stage
point
stage
iv
point
signific
differ
prevent
behavior
respiratori
infect
across
stage
six
subject
stage
iv
smoke
conclus
patient
stage
iv
diagnos
copd
averag
age
therefor
durat
ill
long
necessit
lengthi
would
also
consid
patient
stage
iv
advanc
diseas
continu
smoke
lack
knowledg
diseas
might
also
prevent
engag
prevent
behavior
respiratori
infect
r
chiang
mai
univers
commun
faculti
medicin
chiang
mai
thailand
chiang
mai
univers
intern
faculti
medicin
chiang
mai
thailand
chiang
mai
univers
physic
faculti
associ
medic
scien
chiang
mai
thailand
background
aim
chronic
obstruct
pulmonari
diseas
copd
great
impact
qualiti
life
qol
howev
evalu
qol
lack
northern
thailand
due
complex
questionnair
difficulti
commun
especi
minor
elderli
peopl
bode
index
use
predict
long
term
outcom
aim
studi
find
correl
bode
index
qol
method
studi
conduct
copd
patient
chiang
dao
district
chiang
mai
thailand
patient
assess
qol
thai
version
st
georg
respiratori
questionnair
sgrq
associ
bode
index
includ
compon
sgrq
evalu
pearson
correl
bode
quartil
sgrq
evalu
spearman
correl
result
baselin
characterist
show
mean
age
year
male
mean
postbronchodil
predict
bode
quartil
moder
associ
total
sgrq
score
r
p
sgrq
subscal
symptom
activ
impact
compon
bode
index
better
correl
sgrq
sum
bode
index
except
mmrc
r
p
conclus
bode
index
could
better
marker
qol
among
copd
patient
bodi
mass
index
lung
function
exercis
capac
l
pm
n
ra
queen
univers
centr
infect
immun
northern
ireland
unit
kingdom
institut
age
chronic
univers
liverpool
clinic
scienc
centr
liverpool
unit
kingdom
boehring
ingelheim
pharma
gmbh
co
kg
respiratori
medicin
ingelheim
rhein
germani
boehring
ingelheim
pharma
gmbh
co
kg
biostatist
data
scienc
europ
biberach
der
riss
germani
john
hopkin
univers
school
medicin
divis
pulmonari
critic
care
depart
medicin
md
usa
univers
texa
health
scienc
south
texa
veteran
health
care
system
pulmonarycrit
care
san
tx
usa
hospit
univers
pari
descart
depart
pneumolog
pari
franc
background
aim
littl
known
effect
product
cough
outcom
patient
chronic
obstruct
pulmonari
diseas
copd
aim
assess
baselin
characterist
outcom
mortal
exacerb
cardiac
event
patient
without
product
cough
baselin
receiv
tiotropium
mainten
therapi
tiotropium
safeti
perform
trial
method
n
random
trial
compar
tiotropium
tiotropium
base
similar
efficaci
safeti
result
primari
analysi
treatment
arm
pool
patient
classifi
presenc
baselin
product
cough
hazard
ratio
confid
interv
calcul
time
event
use
cox
regress
model
result
overal
patient
classifi
baselin
product
cough
ye
n
baselin
characterist
concomit
medic
mostli
similar
howev
patient
product
cough
like
current
smoker
exacerb
last
year
slightli
wors
lung
function
patient
without
product
cough
tabl
product
cough
baselin
associ
higher
risk
death
figur
patient
product
cough
similar
risk
exacerb
versu
without
product
cough
risk
sever
exacerb
requir
hospit
significantli
increas
figur
risk
major
advers
cardiovascular
event
mace
fatal
mace
independ
baselin
product
cough
figur
conclus
presenc
product
cough
may
indic
higher
risk
sever
exacerb
patient
copd
receiv
bronchodil
mainten
therapi
howev
product
cough
associ
increas
risk
death
exacerb
cardiovascular
event
acknowledg
editori
write
support
provid
jennif
fuch
parexel
fund
boehring
ingelheim
w
agung
ia
faculti
airlangga
rsu
dr
soetomo
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
faculti
airlangga
rsu
drsoetomo
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
background
aim
primit
neuro
ectoderm
tumor
pnet
lung
infrequ
case
elderli
peopl
rare
incid
tumor
caus
diagnost
pitfal
biopsi
continu
imunohistochemistri
examin
standard
test
confirm
diagnosi
method
present
case
women
chief
complain
cough
accompani
chest
pain
sinc
month
admit
hospit
thorac
ct
contrast
show
solid
mass
posterior
segment
left
lung
superior
lobe
fnab
fine
needl
aspir
biopsi
ct
guid
perform
obtain
patholog
diagnosisth
first
fnab
ct
guid
result
adenocarcinoma
lung
diagnosi
still
uncertain
second
fnab
ct
guid
perform
result
malign
round
cell
tumor
differenti
diagnosi
result
immunohistochemistri
result
posit
vimetin
antibodi
confirm
pnet
definit
diagnosi
patient
left
lung
pneumectomi
perform
adjuv
chemotherapi
plan
yet
patient
die
within
month
diagnos
due
rapid
aggress
progress
tumor
conclus
case
illustr
pnet
infrequ
case
aggress
clinic
characterist
poor
outcom
need
prompt
diagnosi
treatment
ra
faculti
airlangga
rsu
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
faculti
airlangga
rsu
dr
soetomo
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
background
aim
multipl
primari
malign
make
approxim
carcinoma
case
literatur
second
primari
tumor
might
develop
treatment
first
primari
tumor
might
reflect
underli
genet
immunolog
defect
patient
damag
environment
exposur
carcinogen
method
present
case
woman
malign
teratoma
anterior
mediastinum
lung
squamou
cell
carcinoma
thorac
ct
contrast
show
anterior
mediastin
mass
mass
lingular
segment
left
lung
fnab
ct
guid
result
mediastin
mass
malign
teratoma
dysgerminoma
two
cycl
bep
regiment
chemotherapi
cycl
radiotherapi
done
result
complet
resolut
mediastin
mass
wedg
resect
mass
lingular
segment
done
tissu
patholog
result
poorli
differenti
squamou
cell
carcinoma
lung
result
pet
scan
result
show
metastat
nodul
liver
chemotherapi
given
evalu
thorac
ct
show
good
result
conclus
case
illustr
multipl
primari
malign
involv
anterior
mediastin
lung
mass
earli
diagnosi
modern
chemotherapyradi
therapi
improv
surviv
rate
remiss
patient
cancer
allow
patient
neoplast
diseas
surviv
long
enough
develop
subsequ
primari
tumor
hw
faculti
airlangga
rsu
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
faculti
airlangga
rsu
dr
soetomo
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
background
aim
thymoma
mediastin
primari
tumour
mediastinum
associ
varieti
autoimmun
disord
often
link
mediat
autoimmun
paraneoplast
pemphigu
pnp
immunolog
mediat
skin
diseas
character
epiderm
blister
may
occurin
associ
thymic
non
thymic
neoplasm
method
year
old
man
came
hospit
vesicl
ulcu
whole
bodi
sinc
week
patient
diagnos
pemphigu
vulgari
thymoma
sinc
year
patient
hospit
time
case
patient
underw
chemotherapi
seri
respons
document
patient
suggest
undergo
resect
thymoma
prevent
exacerb
pemphigu
refus
medic
given
aim
reduc
exacerb
pemphigu
result
pnp
character
product
autoantibodi
variou
target
antigen
mainli
plakin
famili
protein
desmoglein
pnp
result
antitumor
immun
respons
normal
epitheli
protein
therebi
induc
autoimmun
molecular
mimicri
pnp
sera
bind
homolog
region
within
carboxyterminu
member
plakin
gene
familyther
also
involv
dysregul
develop
conclus
pemphigu
rare
associ
thymoma
fact
associ
thymoma
pemphigu
accord
fact
everi
patient
pemphigu
suspect
malign
especi
thymoma
rule
p
j
z
j
l
second
hospit
jilin
univeristi
depart
pediatr
changchun
china
second
hospit
jilin
univeristi
depart
radiolog
changchun
china
second
hospit
jilin
univeristi
depart
respiratori
medicin
changchun
china
second
hospit
jilin
univeristi
depart
neurolog
changchun
china
second
hospit
jilin
univeristi
depart
anesthesia
changchun
china
background
aim
observ
prolifer
lung
cancer
cell
line
rnai
order
provid
basi
treatment
lung
cancer
method
lentiviru
particl
infect
cell
order
silenc
express
interf
effici
plasmid
gene
detect
western
blot
method
analyz
prolifer
cell
cycl
mtt
assay
result
mrna
level
gene
could
inhibit
prolifer
cell
statist
signific
differ
mtt
assay
conclus
prolifer
cell
inhibit
silenc
gene
gene
may
play
role
develop
lung
cancer
may
benefici
cure
lung
cancer
e
ar
e
dharmai
cancer
hospit
gener
practition
jakarta
barat
indonesia
dharmai
cancer
hospit
respiratori
medicin
jakarta
barat
indonesia
background
aim
malign
pleural
effus
mpe
sign
advanc
stage
lung
cancerth
frequenc
mpe
lung
cancer
relat
poor
prognosi
five
year
surviv
advanc
stage
lung
cancer
studi
aim
identifi
prognost
factor
surviv
time
patient
mpe
lung
cancer
method
retropect
studi
held
dharmai
nation
cancer
hospit
januari
decemb
prognost
factor
sex
age
stage
iva
ivb
therapi
analys
techniqu
compar
use
test
cox
regress
method
use
determin
sever
prognost
factor
respect
surviv
time
result
patient
includ
studi
men
women
median
age
year
old
rang
year
old
patient
patient
die
patient
system
therapi
median
overal
surviv
patient
day
rang
day
univari
analysi
show
surviv
significantli
relat
stage
hazard
ratio
hr
confid
interv
ci
p
therapi
hr
ci
p
prognost
factor
examin
appear
affect
overal
surviv
sex
p
age
p
conclus
mpe
lung
cancer
associ
poor
prognosi
lower
stage
system
therapi
lung
cancer
signific
prognost
factor
improv
patient
surviv
lung
cancer
mpe
gr
maravillosa
go
c
rivera
univers
santo
toma
hospit
pediatr
manila
philippin
background
aim
breath
disord
srbd
known
signific
underdiagnos
caus
morbid
children
clinic
present
includ
snore
nocturn
arous
restless
sleep
enuresi
daytim
sleepi
hyperact
method
help
identifi
srbd
without
expens
gold
standard
diagnosi
overnight
polysomnographi
could
greatli
facilit
clinic
epidemiolog
research
screen
tool
cultur
appropri
linguist
access
instrument
among
filipino
assess
sleep
qualiti
children
great
valu
aim
studi
cultur
valid
filipino
version
srbd
subscal
within
pediatr
sleep
questionnair
psq
method
srbd
subscal
within
psq
forward
translat
filipino
synthes
english
version
panel
expert
review
filipino
version
done
valid
final
version
done
result
total
parent
caregiv
children
vari
age
group
includ
studi
result
show
filipino
version
srbd
subscal
within
psq
accur
reliabl
intern
consist
reliabl
analysi
yield
overal
cronbach
confirm
questionnair
consist
cronbach
filipino
srbd
subscal
within
psq
rang
reliabl
item
robust
correct
item
kappa
statist
rang
conclus
filipino
version
srbd
subscal
within
psq
suffici
reliabl
valid
measur
sleep
disord
breath
outcom
effect
origin
english
version
n
ki
keio
univers
divis
drug
discoveri
faculti
pharmaci
tokyo
japan
musashino
univers
research
institut
pharmaceut
scienc
nishitokyo
japan
background
aim
idiopath
pulmonari
fibrosi
ipf
involv
alveolar
epitheli
injuri
abnorm
collagen
product
lung
myofibroblast
produc
consider
amount
extracellular
matrix
compon
like
collagen
may
give
rise
abnorm
fibrosi
transform
growth
factor
tgf
appear
stimul
activ
fibroblast
myofibroblast
collagen
synthesi
thu
chemic
capabl
suppress
product
collagen
repres
good
candid
treat
ipf
patient
studi
screen
chemic
capabl
inhibit
collagen
product
cultur
fibroblast
medicin
alreadi
clinic
use
method
collagen
level
cultur
medium
determin
sircol
assay
sever
pulmonari
fibrosi
assess
base
histopatholog
evalu
lung
mechan
respiratori
function
result
select
felodipin
base
extent
collagen
product
inhibit
clinic
safeti
profil
pharmacolog
activ
felodipin
channel
blocker
use
clinic
treat
patient
high
blood
pressur
felodipin
suppress
collagen
product
within
cell
lung
fibroblast
ipf
patient
presenc
absenc
intratrach
administr
felodipin
prevent
pulmonari
fibrosi
alter
lung
mechan
respiratori
dysfunct
felodipin
also
improv
pulmonari
fibrosi
well
lung
respiratori
function
administ
fibrosi
develop
furthermor
administr
felodipin
suppress
increas
activ
fibroblast
lung
also
found
channel
blocker
nifedipin
benidipin
inhibit
collagen
product
vitro
also
prevent
pulmonari
fibrosi
alter
lung
mechan
respiratori
dysfunct
vivo
conclus
result
suggest
felodipin
inhibit
fibrosi
blockad
channel
activ
propos
felodipin
may
therapeut
benefici
ipf
patient
h
k
k
h
n
intern
univers
health
welfar
shioya
hospit
depart
intern
medicin
japan
nation
hospit
organ
murayama
medic
center
clinic
research
center
japan
fujita
health
univers
fujita
memori
nanakuri
institut
japan
intern
univers
health
welfar
depart
school
pharmaci
ootawara
japan
tokyo
univers
depart
diabet
metabol
graduat
school
medicin
tokyo
japan
background
aim
intermitt
hypoxia
ih
one
import
pathophysiolog
compon
sleep
apnea
report
produc
weight
loss
anim
howev
sleep
apnea
convers
induc
weight
gain
properli
treat
better
understand
appar
paradox
effect
ih
bodi
weight
intend
analyz
effect
ih
bodi
weight
exclud
influenc
food
intak
method
expos
femal
mice
n
week
old
hour
ih
altern
hypoxia
normoxia
sham
intermitt
hypoxia
sih
n
without
food
get
ih
sih
chamber
mice
given
diet
result
increas
bodi
weight
ih
group
significantli
sih
group
day
start
ih
p
unpair
month
start
ih
ih
hour
without
food
load
ih
group
statist
signific
reappear
consum
food
weight
ih
group
sih
group
conclus
ih
without
food
caus
bodi
weight
gain
mice
sih
reproduc
ih
alway
produc
weight
loss
mice
ih
may
pathophysiolog
factor
increas
bodi
weight
sleep
apnea
may
worsen
sleep
apnea
thu
caus
viciou
cycl
k
h
saitama
medic
univers
respiratori
medicin
saitama
japan
matsuda
hospit
respiratori
medicin
sendai
miyagi
japan
background
aim
previou
report
regard
sleep
disord
allerg
diseas
includ
asthma
limit
sleep
disord
known
caus
fatigu
daytim
sleepi
may
worsen
asthma
control
qualiti
life
moreov
increas
risk
variou
diseas
hypertens
diabet
cardiovascular
diseas
although
sleep
disord
consid
one
high
risk
factor
system
inflamm
associ
sleep
disord
asthma
fulli
clarifi
furthermor
asthma
obstruct
sleep
apnea
osa
common
diseas
may
coexist
howev
preval
osa
asthmat
well
document
therefor
focus
associ
asthma
osa
util
screen
questionnair
method
studi
particip
enrol
studi
consist
asthma
patient
regularli
visit
saitama
medic
univers
hospit
screen
questionnair
includ
physiqu
asthma
control
test
act
pittsburgh
sleep
qualiti
index
psqi
berlin
questionnair
epworth
sleepi
scale
ess
hospit
anxieti
depress
scale
had
sleep
studi
carri
asthma
patient
suspici
osa
questionnair
n
result
total
patient
asthma
divid
group
suspici
osa
suspici
signific
differ
act
psqi
berlin
questionnair
ess
had
group
furthermor
asthmat
suspici
osa
n
treat
cpap
sleep
studi
conclus
result
demonstr
high
preval
sleep
apnea
patient
asthma
multipl
questionnair
may
use
screen
sleep
apnea
patient
asthma
k
r
h
c
j
j
tokyo
women
medic
univers
first
depart
medicin
tokyo
japan
tokyo
metropolitan
health
medic
treatment
ohkubo
hospit
depart
medicin
tokyo
japan
background
aim
obstruct
sleep
apnea
syndrom
osa
common
disord
associ
impair
qualiti
life
increas
risk
motor
vehicl
accid
cardiovascular
diseas
continu
posit
airway
pressur
cpap
therapi
wide
use
treatment
osa
howev
patient
discontinu
cpap
therapi
earli
stage
determin
whether
educ
system
base
cpap
adher
track
system
reduc
earli
discontinu
cpap
therapi
patient
osa
method
patient
osa
start
cpap
divid
two
group
good
adher
least
hoursnight
night
consecut
period
poor
adher
use
adher
track
system
furthermor
poor
adher
classifi
two
pattern
averag
dairi
usag
time
use
day
short
period
user
less
hoursnight
period
user
hoursnight
new
educ
system
conform
pattern
poor
adher
group
start
short
period
user
use
everi
day
use
long
possibl
use
period
user
increas
number
use
day
result
patient
start
cpap
therapi
lack
daytim
symptom
significantli
higher
poor
adher
monthli
averag
usag
time
cpap
similar
short
period
user
period
user
wherea
dropout
rate
significantli
higher
short
period
user
new
educ
system
introduc
dropout
rate
significantli
reduc
p
conclus
short
period
usag
cpap
may
predict
factor
earli
discontinu
therapi
use
educ
content
adapt
pattern
poor
adher
may
use
improv
continu
cpap
therapi
patient
osa
darwin
australia
royal
darwin
hospit
respiratori
sleep
darwin
australia
background
aim
well
known
indigen
peopl
high
risk
develop
chronic
medic
condit
cardiovascular
respiratori
diabet
renal
diseas
contribut
higher
morbiditymort
popul
sleep
disord
breathingobstruct
sleep
apnoea
known
contribut
advers
health
consequ
popul
around
world
howev
publish
data
preval
obstruct
sleep
indigen
popul
especi
australian
aborigin
peopl
indigen
peopl
make
nation
indigen
popul
live
remot
commun
method
retrospect
studi
involv
peopl
indigen
origin
northern
territori
australia
year
period
undergon
diagnost
sleep
studi
clinic
diagnosi
obstruct
sleep
apnoea
demograph
clinic
characterist
presenc
medic
condit
polysomnographi
psg
data
examin
sever
sleep
paramet
includ
presenc
sever
sleep
apnoea
result
result
studi
discuss
confer
data
still
analys
conclus
interim
analysi
data
suggest
may
significantli
high
preval
sleep
disord
breathingobstruct
sleep
apnoea
indigen
popul
addit
presenc
signific
medic
condit
osa
may
contribut
advers
health
consequ
v
v
ramathibodi
univers
divis
pulmonari
critric
medicin
bangkok
thailand
ramathibodi
univers
divis
pulmonari
critic
medicin
bangkok
thailand
ramathibodi
univers
divis
depart
medicin
bangkok
thailand
background
aim
sleep
disord
breath
sdb
report
acut
decompens
heart
failur
adhf
patient
expedit
treatment
sdb
transit
period
may
potenti
benefit
heart
failur
outcom
howev
standard
polysomnographi
psg
limit
given
critic
condit
object
compar
perform
cardiopulmonari
monitor
type
unattend
psg
type
diagnosi
sdb
adhf
method
studi
design
studi
popul
method
patient
hospit
adhf
age
year
recruit
ramathibodi
hospit
psg
type
perform
consecut
night
result
seventeen
subject
male
mean
age
bodi
mass
index
year
includ
left
ventricular
eject
fraction
rang
mean
sd
patient
sdb
index
ahi
patient
ahi
index
lower
type
monitor
psg
type
median
iqr
versu
despit
good
correl
r
p
compar
psg
type
type
cardiopulmonari
monitor
sensit
specif
area
roc
curv
auc
diagnosi
sdb
osa
ahi
respect
respect
conclus
sleep
disord
breath
highli
preval
adhf
patient
major
moder
sever
sever
psg
type
feasibl
adhf
even
type
monitor
show
good
perform
high
specif
screen
sdb
adhf
may
potenti
role
improv
current
heart
failur
treatment
r
machida
k
urushihata
yamanaka
ushiki
yasuo
h
yamamoto
hanaoka
shinshu
univers
first
depart
intern
medicin
matsumoto
japan
background
aim
obstruct
sleep
apnea
syndrom
osa
relat
narrow
airway
forc
oscil
techniqu
fot
noninvas
method
evalu
resist
reactanc
airway
system
method
examin
respiratori
resist
patient
osa
awaken
sit
supin
left
later
recumb
posit
use
fot
instrument
result
observ
signific
correl
index
ahi
respiratori
resist
hz
predict
index
upper
airway
resist
sit
r
p
supin
r
p
left
later
recumb
posit
r
p
conclus
fot
might
use
techniqu
estim
pathophysiolog
sever
osa
hs
moon
hh
kang
sh
lee
hs
joo
colleg
st
paul
cathol
univers
korea
intern
medicin
seoul
republ
korea
background
aim
sleep
problem
common
caus
signific
disrupt
qualiti
life
chronic
pulmonari
diseas
copd
patient
littl
data
impact
sleep
qualiti
qualiti
life
patient
copd
korea
purpos
studi
determin
associ
obstruct
sleep
apnea
osa
sleep
qualiti
qualiti
life
copd
patient
method
two
hundr
patient
men
mild
sever
copd
enrol
prospect
patient
evalu
pulmonari
function
test
determin
sever
copd
mild
moder
sever
modifi
medic
research
council
scale
berlin
questionnair
pittsburgh
sleep
qualiti
index
psqi
st
georg
respiratori
questionnair
sgrq
employ
assess
patient
result
patient
high
risk
osa
patient
show
poor
qualiti
sleep
patient
osa
copd
wors
qualiti
sleep
compar
copd
without
osa
psqi
versu
p
qualiti
life
copd
patient
significantli
correl
qualiti
sleep
r
p
predict
r
p
sever
dyspnea
r
p
conclus
osa
common
patient
copd
sleep
qualiti
also
poor
among
group
qualiti
life
copd
patient
associ
sleep
qualiti
underli
lung
function
degre
dyspnea
recommend
adequ
attent
need
manag
sleep
problem
copd
patient
h
huang
x
lin
hunan
provinci
peopl
hospit
paediatr
changsha
china
background
aim
investig
util
smart
phone
applic
wechat
follow
obstruct
sleep
syndrom
osah
children
method
recruit
case
osah
children
randomli
divid
wechat
group
tradit
telephon
group
follow
patient
follow
monthli
three
month
collect
lost
follow
rate
complianc
patient
satisfact
work
time
complet
degre
patient
data
collect
result
wechat
group
significantli
lower
group
lost
follow
rate
higher
complianc
patient
satisfact
health
knowledg
score
decreas
follow
work
time
p
conclus
util
wechat
smart
phone
base
applic
follow
osah
children
feasibl
significantli
decreas
lost
follow
rate
increas
complianc
patient
satisfact
follow
work
effici
greatli
improv
integr
collect
medic
data
ibrahim
ai
ismail
univers
teknolog
mara
medic
faculti
sg
buloh
malaysia
introduct
narcolepsi
character
tetrad
excess
daytim
sleepi
cataplexi
hypnogog
hallucin
sleep
paralysi
similar
symptomatolog
narcolepsi
across
differ
background
howev
mean
given
narcolepsi
aetiolog
interpret
determin
factor
also
influenc
patient
reaction
symptom
willing
seek
medic
attent
present
case
narcolepsi
cataplexi
experienc
clergyman
malaysia
present
debilit
sleep
attack
episod
give
sermon
religi
lectur
also
episod
continu
uninterrupt
sleep
day
attribut
episod
supernatur
event
polysomnographi
studi
multipl
sleep
latenc
test
confirm
diagnosi
narcolepsi
howev
patient
doubt
diagnosi
declin
medic
treatment
discuss
case
describ
patient
doubt
diagnosi
treatment
narcolepsi
despit
diagnosi
multipl
sleep
latenc
test
polysomnographi
studi
highlight
vital
role
understand
local
background
process
narcolepsi
manag
malaysia
r
abd
n
hospit
sultanah
aminah
respiratori
medicin
johor
bahru
malaysia
divis
pulmonari
critic
care
medicin
depart
medicin
faculti
medicin
chulalongkorn
univers
bangkok
thailand
excel
center
sleep
disord
king
chulalongkorn
memori
hospit
thai
red
cross
societi
bangkok
thailand
hospit
taip
chest
depart
taip
malaysia
rajamangala
univers
technolog
suvarnabhumi
section
faculti
scienc
technolog
phranakhon
si
ayutthaya
thailand
background
aim
sleep
discrep
differ
subject
object
measur
sleep
known
observ
patient
paradox
insomnia
theoret
obstruct
sleep
apnea
osa
patient
may
also
exhibit
sleep
discrep
due
sleep
disrupt
studi
want
determin
discrep
subject
object
sleep
paramet
osa
method
patient
diagnos
osa
juli
till
juli
excel
center
sleep
disord
king
chulalongkorn
memori
hospit
bangkok
thailand
age
year
old
includ
retrospect
studi
patient
sleep
disord
besid
osa
includ
period
limb
movement
disord
insomnia
sleep
bruxism
parasomnia
exclud
studi
result
total
patient
includ
studi
baselin
demograph
data
show
sampl
popul
male
mean
age
year
mean
epworth
sleepi
scale
score
mean
apnea
hypopnea
index
respiratori
disturb
index
respect
pair
comparison
versu
sleep
paramet
show
statist
signific
differ
mean
sleep
latenc
minut
vs
p
mean
total
sleep
time
minut
vs
p
mean
sleep
effici
vs
p
overal
patient
accur
predict
sleep
latenc
within
minut
total
sleep
time
minut
discrep
sleep
effici
least
conclus
result
show
obstruct
sleep
apnea
patient
tend
overestim
sleep
onset
latenc
underestim
total
sleep
time
underestim
sleep
effici
x
tingt
p
luo
c
xin
zhujiang
southern
medic
guangzhou
c
depart
respiratori
medicin
guangzhou
china
background
aim
investig
effect
ofinh
bronchodil
diaphragm
function
neural
respiratori
drive
patient
chronic
obstruct
pulmonari
diseas
copd
maxim
isocapn
ventil
miv
method
copd
patient
random
four
group
placebo
group
n
salbutamol
group
n
ipratropium
group
n
combin
group
salbutamol
ipratropium
n
subject
initi
perform
miv
three
minut
baselin
repeat
miv
minut
inhal
placebo
salbutamol
ipratropium
combin
inhal
salbutamol
ipratropium
base
group
paramet
diaphragm
function
neural
respiratori
drive
monitor
continu
calcul
miv
result
miv
group
experienc
linear
increas
root
mean
squar
rm
diaphragm
electromyogram
show
gradual
decreas
intransdiaphragmat
pressur
pdi
minut
ventil
verm
inhal
bronchodil
paramet
salbutamol
group
ipratropium
group
combin
group
improv
significantli
comparison
placebo
group
valu
rm
borg
score
group
time
point
decreas
significantli
pdi
verm
increas
significantli
comparison
monotherapi
group
combin
group
greater
verm
p
significantli
correl
respect
p
conclus
inhal
bronchodil
allevi
diaphragm
fatigu
copd
patient
miv
increas
lung
ventil
reduc
neural
respiratori
drive
improv
coupl
might
underli
reduct
dyspnoea
copd
patient
moreov
combin
agonist
antagonist
show
superior
efficaci
n
j
r
faculti
medicin
siriraj
mahidol
universityl
divis
respiratori
diseas
tuberculosi
bangkok
thailand
faculti
medicin
siriraj
mahidol
univers
divis
respiratori
diseas
tuberculosi
bangkok
thailand
faculti
medicin
siriraj
mahidol
univers
depart
patholog
bangkok
thailand
background
aim
pulmonari
histiocytosi
csh
rare
condit
associ
lymphoprolif
plasma
cell
disord
date
littl
inform
avail
regard
treatment
prognosi
pulmonari
csh
method
woman
present
fever
product
cough
consolid
right
lower
lobe
initi
diagnos
pneumonia
also
pancytopenia
acut
kidney
injuri
investig
diagnos
multipl
myeloma
made
chest
show
progress
pulmonari
infiltr
despit
cours
antibiot
bronchoscopi
perform
transbronchi
lung
biopsi
show
intraalveolar
mononuclear
cell
contain
abund
eosinophil
cytoplasm
microglobul
without
organ
pulmonari
csh
diagnos
two
week
cours
dexamethason
treatment
chest
almost
clear
result
multipl
myeloma
variou
form
pulmonari
involv
thorac
skelet
involv
common
site
wherea
parenchym
infiltr
found
almost
pneumonia
histiocytosi
rare
find
character
histiocyt
accumul
intracytoplasm
immunoglobulin
crystal
csh
underli
lymphoproliferativeplasma
cell
disord
diseas
involv
variou
site
occur
local
form
gener
form
lung
pleura
second
common
site
local
csh
case
seri
patient
pulmonari
csh
usual
present
singl
multipl
pulmonari
nodul
diagnosi
base
patholog
find
exclus
condit
date
littl
inform
avail
accord
treatment
prognosi
pulmonari
csh
conclus
pulmonari
csh
one
rare
lung
parenchym
involv
multipl
myeloma
sever
manifest
mainstay
manag
condit
treatment
underli
condit
cs
ng
ci
soo
yl
ban
ukmmc
respiratori
depart
intern
hospit
cancelor
tuanku
univers
kebangsaan
malaysia
medic
centr
kuala
lumpur
malaysia
background
aim
desquam
interstiti
pneumonia
among
myriad
scarc
subcategori
idiopath
interstiti
lung
diseas
predisposit
factor
appear
relat
tobacco
case
age
onset
around
male
preponder
report
case
multipl
admiss
pneumonia
later
found
desquam
interstiti
pneumon
case
descript
year
old
male
smoker
background
diabet
hypertens
chronic
kidney
diseas
ischem
heart
diseas
present
us
relaps
fever
dyspnoea
occur
period
six
month
multipl
antibiot
exposur
includ
carbapenem
group
meropenem
antifung
fluconazol
chest
radiographi
reveal
right
lower
zone
pleural
effus
exud
natur
cytolog
neg
bronchoscopi
inconclus
thorac
comput
tomographi
ct
demonstr
right
upper
lower
zone
consolid
peripher
ground
glass
opac
air
bronchogram
evid
malign
found
imag
ct
guid
lung
biopsi
consist
desquam
interstiti
pneumon
steroid
subsequ
commenc
smoke
cessat
time
submiss
good
clinic
respons
attain
well
conclus
rare
entiti
gener
consid
better
outcom
subtyp
idiopath
interstiti
pneumonia
thu
prompt
identif
treatment
initi
key
retard
progress
nevertheless
common
differenti
exclud
first
encount
patient
unrespons
antibiot
therapi
pneumonia
cs
ng
ci
soo
yl
ban
ukmmc
pulmonari
depart
intern
hospit
cancelor
tuanku
univers
kebangsaan
malaysia
medic
centr
kuala
lumpur
malaysia
background
aim
pulmonari
alveolar
proteinosi
rare
entiti
interstiti
lung
diseas
could
often
mimic
common
respiratori
condit
initi
stage
report
pregnant
ladi
malaysia
chronic
dyspnoea
respond
diuret
antibiot
diagnos
later
scarc
diseas
unev
deliveri
case
descript
present
year
old
ladi
gravida
para
week
gestat
background
histori
mild
intermitt
asthma
present
clinic
histori
short
breath
dri
cough
otherwis
afebril
symptom
variabl
daytim
night
time
associ
constitut
symptom
report
risk
factor
pulmonari
embol
identifi
clinic
respiratori
failur
lung
clear
connect
tissu
screen
neg
treat
initi
one
week
antibiot
cours
commun
acquir
pneumonia
privat
centr
trial
diuret
given
well
centr
presum
mild
pulmonari
edema
due
unrespons
antibiot
therapi
deliv
unev
via
elect
caesarean
section
one
week
visit
chest
radiographi
show
bilater
hilar
opac
subsequ
thorac
comput
tomographi
reveal
crazi
pave
pattern
bronchoalveolar
lavag
posit
period
acid
schiff
stain
whole
lung
bronchopulmonari
lavag
done
month
symptom
resolv
improv
lung
function
walk
test
conclus
case
highlight
anoth
case
pulmonari
alveolar
proteinosi
present
pregnanc
howev
respiratori
function
compromis
abl
undergo
lavag
postpartum
period
anoth
point
emphas
clinician
alway
first
consid
pneumonia
common
respiratori
diseas
approach
pregnant
ladi
chronic
dyspnoea
cough
think
rare
entiti
pulmonari
alveolar
proteinosi
p
panyarath
juthong
princ
songkhla
hospit
medicin
hatyai
thailand
background
aim
background
fibrosi
bronchiectasi
character
airway
inflamm
lead
recurr
respiratori
infect
roflumilast
oral
phosphodiesteras
decreas
airway
inflamm
test
hypothesi
roflumilast
decreas
exacerb
frequenc
bronchiectasi
patient
object
primari
endpoint
rate
exacerb
treatment
period
two
group
secondari
endpoint
chang
bronchodil
use
chang
total
score
st
georg
respiratori
questionnair
sgrq
chang
distanc
period
method
particip
patient
diagnos
bronchiectasi
defin
hrct
least
one
pulmonari
exacerb
requir
antibiot
treatment
past
year
randomli
assign
patient
receiv
mg
roflumilast
placebo
daili
month
ratio
patient
investig
mask
treatment
alloc
result
roflumilast
placebo
group
patient
rate
exacerb
per
patient
per
patient
roflumilast
placebo
group
respect
treatment
period
rate
ratio
p
prebronchodil
increas
l
baselin
roflumilast
group
decreas
l
placebo
group
differ
signific
l
ci
p
signific
differ
found
chang
sgrq
total
score
roflumilast
unit
placebo
group
unit
differ
ci
p
chang
distanc
differ
roflumilast
meter
placebo
group
meter
differ
meter
ci
p
conclus
signific
differ
observ
rate
exacerb
bronchiectasi
patient
receiv
roflumilast
placebo
month
phan
saigon
vietnam
background
aim
bronchopulmonari
sequestr
uncommon
congenit
lung
malform
character
segment
lung
parenchyma
without
normal
connect
tracheobronchi
tree
method
report
case
intralobar
sequestr
male
present
pham
ngoc
thach
pnt
hospit
symptom
mass
haemoptysi
ml
long
histori
dri
cough
diagnos
pharyng
bronchiti
treat
antibiot
two
month
pnt
admiss
complain
sputum
product
hemoptysi
right
chest
pain
mild
dyspnea
two
week
ago
develop
mass
haemoptysi
immedi
admit
pnt
hospit
patient
unremark
physic
exam
chest
radiographi
show
consolid
lower
lobe
chest
ct
scan
confirm
featur
identifi
chest
radiograph
show
consolid
caviti
right
lower
lobe
anomal
arteri
note
abdomin
aorta
enter
consolid
bronchoscopi
show
pu
come
right
lower
lobe
base
chest
radiographi
ct
scan
diagnos
case
intralobar
pulmonari
sequestr
right
lower
lobe
patient
refer
surgeri
depart
standard
thoracotomi
lobectomi
right
lower
lobe
resect
ligat
aberr
arteri
perform
success
without
complic
patholog
examin
resect
right
lower
lobe
show
featur
consist
intralobar
sequestr
associ
infect
actinomyc
haemorrhag
result
patient
later
discharg
good
health
postop
day
conclus
case
illustr
typic
present
intralobar
bronchopulmonari
sequestr
pulmonari
sequestr
consid
patient
repeat
pulmonari
infect
hemoptysi
persist
lower
lobe
abnorm
chest
radiograph
ct
scan
surgeri
mainstay
treatment
lobectomi
ligat
aberr
arteri
yc
lai
nation
univers
hospit
depart
medicin
yilan
taiwan
background
aim
hip
fractur
import
health
care
issu
older
peopl
one
year
mortal
hip
fractur
postop
pulmonari
complic
occur
patient
hip
fractur
surgeri
sever
complic
pneumonia
respiratori
failur
pulmonari
rehabilit
effect
reduc
postop
pulmonari
complic
especi
high
risk
surgic
patient
howev
pulmonari
rehabilit
focus
patient
hip
surgeri
today
present
retrospect
studi
effect
elderli
hip
fractur
patient
accept
comprehens
pulmonari
rehabilit
program
hip
surgeri
method
includ
elderli
patient
older
year
old
develop
new
hip
fractur
sinc
will
accept
postop
pulmonari
rehabilit
program
pulmonari
rehabilit
program
start
patient
refus
rehabilit
surgic
intervent
exclud
collect
age
sex
comorbid
lab
data
oper
type
oper
date
pneumonia
date
analysi
result
total
patient
women
men
case
case
characterist
age
sex
comorbid
lab
data
surgic
type
reveal
signific
differ
patient
total
patient
develop
pneumonia
patient
diagnos
pneumonia
found
older
year
old
cancer
patient
without
postop
pulmonari
rehabilit
program
higher
risk
pneumonia
develop
multivari
analysi
old
age
odd
ratio
stroke
diabet
patient
higher
probabl
pneumonia
conclus
older
patient
hip
fractur
surgeri
accept
postop
pulmonari
rehabilit
program
could
decreas
pneumonia
incid
studi
first
trial
prove
postop
pulmonari
rehabilit
program
effect
hip
surgeri
patient
cs
ci
ayl
ah
nd
ukmmc
respiratori
depart
intern
hospit
cancelor
tuanku
univers
kebangsaan
malaysia
medic
centr
kuala
lumpur
malaysia
usim
respiratori
univers
sain
islam
malaysia
kuala
lumpur
malaysia
upm
respiratori
univeris
putra
malaysia
serdang
malaysia
background
aim
major
incapac
detect
incident
treat
conserv
surgic
intervent
seldom
requir
highlight
case
emphas
import
recogn
entiti
mimic
underli
pneumonia
method
woman
consult
orthopaed
team
right
lung
basal
consolid
initi
impress
orthostat
pneumonia
underli
hypertens
present
orthopaed
team
lumbar
epidur
abscess
drainag
done
patient
treat
six
week
intraven
tazobactampiperacillin
howev
diaphragmat
paralysi
demonstr
chest
conclus
exact
occurr
diaphragmat
paralysi
worldwid
still
unclear
due
rariti
asymptomat
natur
case
could
mistakenli
treat
pneumonia
chest
ultrasonographi
appear
reason
diagnost
modal
identifi
condit
hz
chai
sk
tan
lc
leow
th
ong
singapor
gener
hospit
respiratori
critic
care
medicin
singapor
singapor
background
aim
home
mechan
ventil
hmv
shown
improv
surviv
qualiti
life
wide
varieti
indic
howev
pauciti
real
world
data
guid
optim
time
initi
hmv
indic
unclear
earlier
initi
lead
better
outcom
aim
review
impact
acut
versu
elect
initi
hmv
patient
outcom
method
conduct
retrospect
analysi
patient
hmv
singapor
gener
hospit
march
novemb
compar
outcom
acut
versu
elect
initi
hmv
result
patient
includ
tabl
mask
ventil
except
tracheostom
patient
hmv
initi
acut
respiratori
failur
elect
initi
tracheostom
patient
acut
initi
hmv
indic
similar
acut
elect
group
exclud
tracheostom
patient
two
group
similar
demograph
machin
set
complianc
elect
initi
patient
better
continu
rate
figur
surviv
longer
compar
requir
acut
initi
mortal
versu
p
conclus
data
suggest
patient
elect
initi
hmv
improv
surviv
better
continu
rate
differ
could
attribut
time
hmv
initi
differ
diseas
sever
lead
time
bia
research
need
determin
optim
time
hmv
initi
hz
cg
j
tb
changi
gener
hospit
respiratori
critic
care
medicin
singapor
singapor
st
andrew
commun
hospit
nurs
singapor
singapor
background
aim
massiv
haemoptysi
emerg
requir
prompt
recognit
time
intervent
airway
protect
measur
institut
follow
therapeut
intervent
review
literatur
show
studi
evalu
quantif
haemoptysi
healthcar
profession
aim
evalu
healthcar
profession
definit
massiv
haemoptysi
abil
quantifi
expector
blood
volum
accur
method
conduct
survey
doctor
nurs
changi
gener
hospit
respond
ask
defin
massiv
haemoptysi
estim
amount
moulag
blood
present
sputum
cup
consist
moulag
blood
figur
result
total
healthcar
profession
survey
thirteen
defin
massiv
haemoptysi
volum
expector
blood
defin
volum
expector
blood
incomplet
data
estim
amount
moulag
blood
indic
indic
indic
indic
respond
accur
identifi
sputum
sampl
vari
quantiti
respond
none
correct
respond
correct
answer
respect
incomplet
answer
conclus
signific
dispar
definit
estim
massiv
haemoptysi
amongst
healthcar
profession
urgent
need
educ
train
improv
recognit
massiv
haemoptysi
e
b
canakkal
onsekiz
mart
univers
medic
faculti
forens
medicin
canakkal
turkey
canakkal
onsekiz
mart
univers
medic
faculti
chest
diseas
canakkal
turkey
canakkal
ezin
state
hospit
chest
diseas
canakkal
turkey
background
aim
occult
pneumothorax
radiolog
patholog
determin
chest
visual
comput
tomographi
ct
especi
case
trauma
candid
mechan
ventil
progress
even
small
lesion
tension
pneumothorax
import
problem
hand
earli
diagnosi
also
import
regard
evalu
ct
investig
thorac
trauma
reveal
exist
patholog
howev
matter
debat
appli
ct
everi
case
regard
cost
high
level
radiat
slow
turnov
emerg
clinic
current
studi
investig
clinic
radiolog
characterist
accompani
case
occult
pneumothorax
order
determin
indic
thorac
ct
case
trauma
method
case
thorac
trauma
select
case
medicoleg
report
evalu
forens
medicin
depart
three
year
data
obtain
medic
file
medicoleg
report
patient
retrospect
case
admit
emerg
clinic
trauma
underw
thorac
ct
pneumothorax
assess
case
result
detect
four
case
chest
ratio
occult
pneumothorax
calcul
blunt
trauma
presenc
head
trauma
extens
subcutan
emphysema
multipl
rib
fractur
common
characterist
case
detect
ct
conclus
case
patholog
recommend
investig
comput
tomographi
regard
presenc
pneumothorax
r
k
h
k
yodogawa
christian
hospit
respiratori
medicin
osaka
japan
iizuka
hospit
respiratori
medicin
iizuka
japan
yodogawa
christian
hospit
thorac
surgeri
osaka
japan
background
aim
congenit
tracheal
stenosi
ct
rare
disord
almost
alway
diagnos
infanc
due
respiratori
failur
often
complic
cardiopulmonari
abnorm
patient
requir
earli
surgic
intervent
extrem
rare
patient
surviv
undiagnos
experienc
adult
case
ct
undiagnos
intub
method
case
report
literatur
review
result
femal
admit
spontan
pneumothorax
past
medic
histori
spontan
pneumothorax
three
time
past
year
bronchial
asthma
atop
dermat
recurr
pneumothorax
indic
possibl
catameni
pneumothorax
thoracoscopi
plan
definit
diagnosi
induct
gener
anesthesia
routin
intub
possibl
due
tracheal
stenosi
variou
trial
intub
final
success
uncuf
pediatr
endotrach
tube
intern
diamet
mm
visibl
bleb
ectop
endometrium
pleura
surgeri
postop
cours
unev
chest
comput
tomographi
imag
show
bronchial
stenosi
unnot
prior
surgeri
postop
bronchoscopi
reveal
tracheal
stenosi
due
complet
tracheal
ring
find
suggest
underli
acquir
diseas
therefor
diagnos
ct
conclus
experienc
rare
case
adult
ct
english
japanes
literatur
report
case
adult
ct
four
case
diagnos
imag
studi
prior
intub
case
report
case
found
routin
intub
procedur
unsuccess
case
requir
postpon
surgeri
case
requir
adjust
intub
procedur
addit
invas
method
highlight
import
observ
bronchu
care
imag
studi
prior
intub
moreov
patient
recurr
asthmat
episod
resist
treatment
possibl
ct
kept
mind
p
p
faculti
medicin
ramathibodi
hospit
mahidol
univers
pulmonari
critic
care
medicin
bangkok
thailand
silpakorn
univers
faculti
pharmaci
nakhon
pathom
thailand
background
aim
leicest
cough
questionnair
lcq
valid
qol
measur
use
assess
treatment
efficaci
cough
includ
physic
psycholog
social
aspect
thai
version
lcq
recent
valid
aim
investig
mcid
method
patient
week
cough
enrol
pulmonari
allergi
clinic
ramathibodi
hospit
borg
cough
scale
initi
repeat
questionnair
global
rate
chang
grc
scale
period
categor
base
previous
report
respons
given
treatment
specif
diseas
group
week
week
week
method
mcid
defin
chang
score
correspond
smallest
improv
grc
perceiv
patient
method
mcid
calcul
standard
error
measur
sem
half
standard
deviat
sd
result
total
patient
mean
sd
age
year
includ
etiolog
cough
coughand
acut
bronchiti
n
asthma
n
rhinosinus
n
copd
n
bronchiectasi
n
mcid
total
physic
social
psycholog
domain
respect
mcid
use
sem
total
domain
use
half
sd
respect
conclus
clinic
relev
chang
score
mcid
total
physic
social
psycholog
domain
mcid
could
appli
sampl
size
determin
futur
clinic
trial
w
chan
f
gho
tey
w
sim
j
arputaan
abisheganaden
lim
tan
tock
seng
hospit
respiratori
critic
care
medicin
singapor
singapor
background
aim
bronchiectasi
complex
chronic
inflammatori
airway
diseas
signific
morbid
mortal
fatigu
complex
disabl
symptom
measur
object
limit
studi
fatigu
bronchiectasi
relationship
qualiti
life
qol
anxieti
depress
lower
limb
muscl
strength
exacerb
rate
airflow
obstruct
unclear
aim
studi
associ
fatigu
function
outcom
airflow
obstruct
method
conduct
exploratori
studi
consecut
patient
attend
bronchiectasi
specialist
clinic
april
septemb
demograph
sputum
microbiolog
bodi
mass
index
bmi
lung
function
test
st
georg
respiratori
questionnair
sgrq
repetit
test
modifi
medic
research
council
dyspnoea
score
mmrc
score
bcss
hospit
anxieti
depress
score
had
sputum
colour
hospit
admiss
emerg
depart
ed
attend
rate
analys
fatigu
measur
function
assess
chronic
ill
score
result
patient
femal
median
iqr
age
year
studi
median
iqr
percent
predict
bmi
respect
none
current
smoker
patient
signific
fatigu
anxieti
depress
fatigu
significantli
correl
had
anxieti
depress
r
p
r
p
respect
posit
correl
number
ed
attend
hospit
admiss
r
p
r
p
respect
correct
fatigu
bmi
sgrq
bcss
predict
conclus
fatigu
anxieti
depress
common
patient
bronchiectasi
fatigu
correl
anxieti
depress
had
lower
limb
strength
posit
correl
rate
hospit
admiss
ed
attend
potenti
novel
predictor
exacerb
bronchiectasi
monitor
treatment
outcom
h
phiphitthanaban
phramongkutklao
hospit
colleg
medicin
intern
medicin
bangkok
thailand
background
aim
solitari
pulmonari
nodul
frequent
encount
chest
computer
tomographi
scan
chest
differenti
diagnosi
board
rang
benign
granulomata
malign
establish
etiolog
spn
accur
manner
assum
critic
import
sinc
surgic
resect
patient
lung
cancer
provid
highest
chanc
cure
token
avoid
thorac
surgeri
benign
spn
whenev
possibl
obviat
signific
morbid
present
decis
serial
ct
chest
obtain
tissu
diagnosi
depend
pretest
probabl
malign
characterist
find
ct
chest
inform
obtain
foreign
countri
nt
actual
data
thailand
preval
tuberculosi
high
object
studi
associ
characterist
chest
ct
find
patholog
diagnosi
patient
spn
phramongkutklao
hospit
method
retrospect
studi
includ
patient
spn
undergon
chest
ct
obtain
patholog
diagnosi
phramongkutklao
hospit
result
patient
mean
age
year
studi
male
forti
patient
histori
smoke
sixteen
patient
previou
malign
mean
diamet
spn
mm
locat
upper
lobe
patient
lower
lobe
patient
patholog
find
reveal
malign
spn
patient
granuloma
patient
presenc
smooth
border
associ
benign
spn
pr
p
spicul
border
associ
increas
preval
rate
malign
spn
pr
p
satellit
nodul
associ
benign
spn
pr
p
pleural
retract
associ
increas
preval
rate
malign
spn
pr
p
conclus
spicul
border
pleural
retract
chest
ct
associ
malign
spn
wherea
smooth
border
satellit
nodul
associ
benign
spn
p
petborom
hrh
princess
maha
chakri
sirindhorn
medic
center
hospit
srinakharinwirot
uni
depart
faculti
nakhon
nayok
thailand
background
aim
mesothelioma
common
primari
malign
tumor
pleura
aris
mesotheli
surfac
pleura
predomin
caus
exposur
asbesto
approxim
patient
document
asbesto
exposur
method
male
farmer
present
right
pleurit
chest
pain
nonproduct
cough
low
grade
fever
week
also
dyspnea
exert
weight
loss
kg
physic
examin
reveal
c
rr
respiratori
system
show
dull
percuss
decreas
breath
sound
rll
chest
radiograph
demonstr
right
pleural
effusionchest
ct
show
cm
enhanc
soft
tissu
lesion
right
hilar
region
multifoc
pleural
thicken
anterior
later
posterior
right
upper
hemithorax
moder
amount
right
pleural
effus
figur
pleural
fluid
anaylsi
demonstr
yellow
color
rbc
wbc
mononuclear
pmn
pleural
fluid
protein
gdl
serum
protein
gdl
pleural
fluid
ldh
ul
serum
ldh
ul
pleural
fluid
ada
ul
pleural
fluid
acid
fast
stain
neg
pleural
fluid
cytolog
neg
malign
result
patholog
find
right
pleural
biopsi
show
sever
fibrosi
area
hyalin
diffus
infiltr
solid
sheet
small
larg
cell
contain
irregular
nuclei
fine
vesicular
chromatin
promin
nucleoli
immunohistochem
find
tumor
cell
posit
calretinin
figur
ema
conclus
infiltr
tumor
malign
mesothelioma
epitheloid
variant
poor
perform
statu
patient
receiv
palli
treatment
insert
icd
releas
pleural
fluid
conclus
associ
asbesto
exposur
develop
malign
mesothelioma
well
known
nonetheless
proport
patient
suffer
diseas
appear
document
exposur
asbesto
fiber
known
sourc
p
nipatta
phramonkutklao
hospit
colleg
medicin
divis
pulmonari
critic
care
medicin
bangkok
thailand
background
aim
appli
continu
posit
airway
pressur
cpap
acceler
absorpt
pleural
effus
due
sever
patholog
condit
assess
effect
cpap
fluid
absorpt
talc
pleurodesi
outcom
order
control
malign
pleural
effus
method
case
control
studi
design
compar
patient
underw
talc
pleurodesi
januari
decemb
primari
end
point
procedur
durat
chest
tube
drain
ctd
day
compar
patient
appli
cpap
pressur
hour
per
day
remov
ctd
talc
pleurodesi
control
group
convent
post
procedur
care
secondari
end
point
pleurodesi
success
rate
result
among
patient
twelv
group
procedur
durat
trend
shorter
cpap
group
day
day
control
group
median
day
day
ci
p
cpap
group
trend
higher
success
pleurodesi
control
group
ci
p
conclus
cpap
appli
talc
pleurodesi
trend
shorter
ctd
durat
less
failur
compar
convent
care
cpap
applic
addit
care
post
pleurodesi
patient
howev
addit
studi
larg
scale
patient
need
confirm
find
rj
castillo
l
idolor
lung
center
philippin
depart
critic
care
sleep
medicin
quezon
citi
philippin
background
aim
hypothyroid
etiolog
bilater
pleural
effus
rare
first
case
pleural
effus
associ
hypothyroid
report
schneierson
katz
describ
year
old
male
myxedema
right
side
pleural
effus
resolv
follow
thyroid
hormon
replac
paper
report
case
year
old
filipino
femal
present
one
week
histori
dyspnea
method
examin
bradycardia
bpm
hypothermia
facial
edema
decreas
bibas
breath
sound
grade
biped
edema
initi
chest
radiograph
reveal
bilater
pleural
effus
chest
ultrasound
show
ml
right
ml
left
also
massiv
pericardi
effus
tamponad
underw
thoracentesi
right
pericardiostomi
provid
relief
dyspnea
result
differ
etiolog
bilater
pleural
effus
includ
heart
failur
liver
cirrhosi
hypoalbuminemia
urem
pleuriti
connect
tissu
diseas
pulmonari
tuberculosi
malign
rule
base
avail
clinic
data
laboratori
examin
request
thyroid
function
test
reveal
elev
tsh
uiuml
decreas
pmoll
decreas
pmoll
patient
diagnos
hypothyroid
myxedema
crisi
start
levothyroxin
day
patient
remain
hemodynam
stabl
eventu
disharg
improv
follow
two
month
resolut
dyspnea
biped
edema
repeat
chest
reveal
clear
lung
field
repeat
thyroid
function
test
also
improv
less
elev
tsh
normal
uiuml
pmoll
pmoll
respect
conclus
hypothyroid
appear
rare
caus
pleural
effus
usual
diagnosi
exclus
therefor
clinician
care
investig
clinic
sign
symptom
along
judici
use
avail
laboratori
test
utmost
import
fulli
establish
diagnosi
kaya
f
k
erol
ankara
univers
school
medicin
chest
diseas
ankara
turkey
background
aim
woman
present
dypsnea
chest
back
pain
suffer
progress
dyspnea
year
receiv
ltot
bronchodil
therapi
copd
respiratori
failur
method
physic
examin
bilater
fine
crackl
admit
intens
care
unit
connect
niv
respiratori
failur
result
anemia
elev
creatinin
potassium
crp
level
also
posit
vascul
primarili
consid
differenti
diagnosi
system
steroid
start
dose
mgday
mgkgday
vital
sign
improv
blood
ph
arteri
blood
ga
normal
transfer
regular
ward
howev
develop
cardiorespiratori
arrest
day
admiss
intub
connect
mechan
ventil
thorac
ct
demonstr
bilater
newli
develop
pleural
effus
predominantli
peribronchovascularli
peripher
locat
area
consolid
patchi
ground
glass
opac
lung
figur
gener
statu
suddenli
deterior
also
develop
anemia
sign
ct
find
alveolar
hemorrhag
consid
administ
puls
steroid
mgday
therapi
alveolar
hemorrhag
secondari
microscop
polyangi
mpa
howev
die
six
hour
connect
mechan
ventil
conclus
mpa
rare
small
vessel
vascul
unknown
etiolog
patholog
hallmark
includ
alveolar
hemorrhag
due
fibrinoid
necrosi
capillar
lung
focal
segmentari
necrot
glomerulonephr
kidney
prognosi
pulmonari
hemorrhag
quit
poor
treatment
depend
sever
includ
corticosteroid
cyclophosphamid
rituximab
mycophenol
mofetyl
plasmapheresi
mpa
shuld
consid
anca
level
determin
case
constitut
symptom
dyspnea
accompani
chronic
renal
failur
musa
kn
mohd
hirmizi
ai
ismail
mohd
zim
univers
teknolog
mara
faculti
medicin
sungai
buloh
malaysia
background
aim
choriocarcinoma
rare
malign
trophoblast
cell
metastas
lung
case
year
old
ladi
diagnos
choriocarcinoma
lung
metastasi
without
progress
primari
site
tumour
result
patient
initi
diagnos
molar
pregnanc
complet
cycl
methotrex
cycl
emaco
obstetr
histori
reveal
miscarriag
follow
children
deliv
via
present
dysfunct
uterin
bleed
diagnos
uterin
fibroid
treat
oral
contracept
pill
march
amenorrhea
suggest
myomectomi
howev
opt
conserv
manag
start
dydrogesteron
april
rais
iu
subsequ
total
abdomin
hysterectomi
may
confirm
trophoblast
tumour
subsequ
follow
transabdomin
ultrasound
note
recurr
diseas
serial
persist
iu
year
later
increas
iu
repeat
transabdomin
ultrasound
show
cystic
lesion
measur
cm
howev
remain
asymptomat
static
level
static
size
cystic
lesion
serial
ultrasound
unfortun
august
level
start
increas
trend
contrast
ct
tap
done
show
larg
left
lung
lesion
left
lower
lobe
cm
histopatholog
ct
guid
lung
biopsi
confirm
metastat
trophoblast
choriocarcinoma
subsequ
refer
oncolog
manag
conclus
case
highlight
lung
metastasi
occur
without
local
recurr
choriocarcinoma
suspect
earli
increas
trend
kinjo
yamazato
nabeya
haranaga
j
fujita
univers
ryukyu
depart
infecti
digest
medicin
okinawa
japan
background
aim
abnorm
find
chest
imag
patient
earli
stage
allerg
bronchopulmonari
aspergillosi
abpa
diagnosi
often
difficult
although
articl
show
chang
abnorm
find
chest
abpa
patient
time
paper
describ
chest
ct
imag
report
case
male
abpa
past
histori
bronchial
asthma
upper
pharyng
cancer
annual
chang
observ
chest
ct
year
method
chest
ct
perform
annual
abnorm
find
diagnosi
abpa
made
use
greenberg
patterson
diagnost
criteria
result
initi
chest
ct
follow
radiat
therapi
radic
lymph
node
dissect
pharyng
cancer
reveal
mucoid
impact
bronchial
wall
thicken
within
year
abnorm
find
repeatedli
withdrawn
exacerb
diagnosi
abpa
made
lung
abnorm
improv
initi
corticosteroid
antifung
medic
conclus
patient
misdiagnos
bronchopneumonia
year
follow
initi
ct
present
case
result
find
illustr
remind
consid
abpa
patient
bronchial
asthma
ct
find
che
sayuti
hospit
raja
perempuan
zainab
ii
medic
kota
bharu
malaysia
background
aim
inflamm
one
serou
membran
result
pleural
periton
pericardi
effus
common
patient
sle
howev
case
chylou
ascit
chylothorax
extrem
rare
herein
report
case
chylothorax
sle
patient
case
present
malay
ladi
pariti
chief
complaint
fever
associ
cough
short
breath
associ
pleurit
chest
pain
progress
oedema
abdomin
distens
past
year
manag
centr
medic
histori
reveal
patient
diagnos
sle
bilater
pleural
effus
follow
persist
pleural
effus
physic
examin
reveal
tachypnea
reduc
breath
sound
lung
crepit
lower
zone
stoni
dull
percuss
reduc
vocal
reson
laboratori
test
show
high
twc
indic
infect
ct
thorax
reveal
worsen
seros
massiv
pleural
effus
chest
tube
insert
reveal
chylothorax
pleuroscopi
reveal
adhes
chalki
white
effus
hyperaem
pleural
whitish
patch
bilater
chest
drainag
reveal
exud
effus
liter
pleural
fluid
analysi
reveal
mgl
protein
triglycerid
mmoll
mgdl
patient
requir
prolong
chest
drainag
suitabl
candid
surgeri
view
high
risk
bleed
restart
high
dose
prednisolon
mg
od
hcq
mg
od
azathioprin
mg
od
three
month
taper
dose
prednisolon
effus
reduc
base
cxr
clinic
remain
asymptomat
discuss
conclus
chylou
ascit
chylothorax
rare
describ
patient
sle
therefor
besid
analysi
blood
sampl
detail
analysi
effus
serou
membran
carri
h
kim
cs
kim
je
chang
jy
hwang
sw
min
jm
lee
borama
medic
center
depart
anesthesiolog
seoul
republ
korea
background
aim
neg
pressur
pulmonari
edema
nppe
secondari
post
upper
airway
obstruct
phenomenon
incid
rare
import
differ
diagnosi
fast
intervent
nppe
experienc
nppe
post
extub
emerg
gener
anesthesia
want
share
experi
happen
goe
healthi
man
underw
endoscop
pansinu
procedur
follow
administr
mg
lidocain
fentanyl
mg
propofol
mg
rocuronium
easili
intub
oral
endotrach
tube
anesthesia
maintain
use
sevofluran
rocuronium
follow
fentanyl
analgesia
patient
underw
unev
surgeri
last
hour
anesthesia
emerg
lot
bleed
patient
nose
oral
caviti
agit
cough
sever
time
given
inform
place
situat
patient
calm
breath
spontan
extub
adequ
breath
show
around
transfer
post
anesthesia
care
unit
pacu
immedi
arriv
pacu
check
oxygen
lmin
suppli
via
non
breath
facial
mask
rose
last
minut
decreas
patient
deni
dyspnea
start
sweat
even
though
administr
sugammadex
mg
lasix
mg
pulmonari
edema
show
postop
chest
hypoxemia
aggrav
decreas
chekc
mmhg
suppli
manual
ventil
assist
administr
midazolam
mg
cisatracurium
mg
reintub
easili
transfer
surgic
intens
care
unit
mechan
ventil
begun
approxim
day
later
pulmonari
edema
complet
resolv
radiograph
clinic
patient
wean
ventil
extub
day
oper
day
transfer
gener
ward
observ
night
discharg
home
without
complic
j
dechsanga
phramonkutklao
hospit
colleg
medicin
pulmonari
critic
care
depart
bangkok
thailand
method
amyloidosi
rare
diseas
caus
deposit
abnorm
protein
call
amyloid
fibril
caus
disrupt
normal
tissu
amyloid
fibril
confin
deposit
one
organ
mani
organ
caus
local
amyloidosi
system
amyloidosi
howev
respiratori
involv
amyloidosi
rare
seen
report
case
tracheobronchi
amyloidosi
result
thai
man
present
left
eyelid
mass
year
ophthalmologist
decid
remov
mass
preoper
investig
within
normal
limit
intub
intraop
period
unev
finish
surgeri
extub
period
anesthesiologist
found
ml
bright
red
blood
came
endotrach
tube
massiv
hemoptysi
continu
admit
icu
prior
histori
respiratori
tract
diseas
except
occasion
scanti
hemoptysi
never
mention
cbc
coagulogram
blood
chemistri
urin
analysi
normal
sign
system
bleed
chest
ct
scan
show
multifoc
consolid
ground
glass
opac
scatter
lung
circumferenti
wall
thicken
along
trachea
rightleft
main
bronchi
calcifi
bronchial
wall
underw
bronchoscopi
besid
tracheobronchomalacia
found
irregular
airway
mucosa
extend
subglott
area
second
gener
bronchu
contact
bleed
lesion
tri
stop
bleed
fail
massiv
hemoptysi
continu
need
blood
transfus
everyday
patient
suffer
pneumonia
dead
later
patholog
report
tracheal
tissu
eyelid
mass
consist
amyloidosi
conclus
case
repres
rare
clinic
manifest
tracheobronchi
amyloidosi
caus
bleed
patient
due
fragil
blood
vessel
infiltr
amyloid
protein
disabl
normal
vasoconstrict
properti
p
arttawejkul
n
kongpolprom
faculti
chulalongkorn
univers
medicin
bangkok
thailand
background
aim
scleros
pneumocytoma
sp
rare
primari
pulmonari
tumor
first
describ
liebow
hubbel
gener
classifi
benign
howev
occasion
metastas
organ
surgic
resect
cur
treatment
report
case
sp
present
slow
grow
lung
mass
method
case
presentationin
june
asymptomat
femal
visit
hospit
evalu
slow
grow
lung
mass
detect
chest
homogen
mass
border
first
observ
annual
screen
chest
computer
tomographi
chest
reveal
cm
heterogen
enhanc
mass
without
calcif
later
basal
segment
left
lower
lobe
patient
initi
diagnos
possibl
earli
stage
lung
cancer
grow
tumor
thu
refer
cardiothorac
clinic
surgic
evalu
underw
lobectomi
left
lower
lung
gross
patholog
examin
reveal
cm
well
circumscrib
mass
microscop
examin
show
mass
compos
numer
space
line
endotheli
ciliat
columnar
cell
papillari
arrang
remain
stroma
show
hypercellular
altern
sclerot
hyalin
edemat
area
stromal
cell
possess
rather
monoton
round
basophil
nuclei
inconspicu
nucleoli
mitot
figur
rare
seen
find
compat
benign
scleros
pneumocytoma
patient
schedul
annual
year
period
evid
tumor
recurr
discuss
demonstr
patient
primari
pulmonari
sp
rare
tumor
occur
predominantli
age
women
major
case
present
asymptomat
abnorm
thorac
imag
without
pathognomon
radiograph
find
lead
difficulti
make
correct
preoper
diagnosi
miyuki
k
tobino
sueyasu
k
murakami
iizuka
hospit
respiratri
medicin
iizuka
japan
introduct
lymphat
venou
malform
lvm
consid
lesion
combin
dysplast
lymphat
venou
vessel
structur
herein
present
rare
case
huge
mediastin
lvm
case
present
asymptomat
man
present
evalu
mediastin
mass
chest
comput
tomographi
scan
mass
demonstr
contrast
enhanc
multipl
scatter
calcif
mr
imag
reveal
heterogen
mass
low
intermedi
signal
intens
mr
imag
reveal
hyperintens
mass
lesion
flow
void
repres
enlarg
vein
drain
superior
inferior
vena
cava
svc
ivc
mr
imag
reveal
mass
multilocular
margin
enhanc
imag
find
mass
diagnos
mediastin
lvm
lvm
larg
remov
moreov
lvm
abund
blood
flow
also
direct
connect
svc
ivc
surgeri
sclerotherapi
thought
high
risk
complic
bleed
system
infarct
therefor
decid
patient
without
treatment
mass
remain
stabl
ct
imag
obtain
six
month
discuss
vascular
malform
mediastinum
rare
account
mediastin
tumor
today
case
mediastin
lvm
report
biopsi
need
definit
diagnosi
howev
could
confer
risk
bleed
treatment
choic
vascular
malform
surgeri
sclerotherapi
patient
treat
surgeri
patient
lvm
larg
remov
complet
conclus
conclus
present
case
huge
lvm
mediastinum
diagnos
imag
find
condit
rare
biopsi
sometim
difficult
therefor
characterist
imag
find
import
definit
diagnosi
nj
valmoria
r
bayot
philippin
heart
center
divis
pulmonari
critic
care
medicin
quezon
citi
philippin
background
aim
introduct
spontan
pneumothorax
sp
primari
psp
secondari
ssp
base
absenc
presenc
underli
lung
diseas
respectivelyit
associ
high
recurr
rate
untreatedherein
present
uniqu
case
old
male
right
upper
lobe
mass
present
recurr
spontan
pneumothorax
case
present
male
year
pta
sudden
chest
painno
symptomspneumothorax
left
seen
chest
thoracostomi
left
donechest
ct
scan
unremarkableh
year
pta
sudden
chest
painchest
show
pneumothorax
therapi
givenchest
ct
scan
unremarkablepneumothorax
resolveddischarg
week
pta
sudden
chest
pain
dyspneano
symptomspneumothorax
right
note
chest
thoracostomi
right
donechest
ct
scan
biapic
bleb
hazi
confluent
densiti
rul
bronchiectasi
right
posterior
basal
therapi
startedh
refer
institutionh
bmi
pulmonari
evalu
donedu
fail
vat
open
thoracotomi
rightblebectomi
andvwedg
resect
pulmonari
mass
done
mechan
pleurodesisbiopsi
mass
tuberculomapostop
period
unremark
discharg
therapi
complet
discuss
psp
develop
among
without
underli
lung
diseaseit
common
among
young
tall
thin
male
like
patient
ssp
seriou
psp
exist
pulmonari
conditionsour
patient
type
spontan
pneumothorax
recurr
exact
pathogenesi
psp
remain
unknown
may
due
spontan
ruptur
subpleur
bleb
bulla
manag
may
surgic
nonsurg
depend
size
pneumothorax
symptomatolog
recurr
retrospect
surgic
intervent
alreadi
indic
patienthowev
vat
readili
avail
countri
conclus
exact
pathogenesi
psp
still
unknown
close
episod
sp
need
spontan
pneumothorax
address
advanc
surgic
intervent
indic
nj
valmoria
limpin
philippin
heart
center
divis
pulmonari
critic
care
medicin
quezon
citi
philippin
background
aim
exud
pleural
effus
determin
use
light
criteriath
common
caus
exud
pleural
effus
pneumonia
tuberculosi
malignancythi
studi
done
determin
use
serum
pleural
protein
pr
lactat
dehydrogenas
ldh
ratio
diagnosi
effus
secondari
diseas
entitiesth
pilot
studi
made
talasaz
et
alit
show
signific
differ
mean
serum
pleural
prldh
among
parapneumon
malign
tuberculosi
group
method
total
adult
patient
includ
studi
admit
seen
philippin
heart
center
januari
june
patient
diagnos
exud
pleural
effus
wherein
caus
establish
base
clinic
data
pleural
fluid
analysi
andor
biopsi
need
subsequ
group
parapneumon
tubercul
malign
pleural
effus
data
summar
mean
standard
deviat
numer
variabl
frequenc
percentag
categor
variabl
homogen
characterist
three
group
test
use
analysi
varianc
anova
quantit
variabl
fisher
exact
test
qualit
variabl
comparison
mean
serum
pleural
fluid
prldh
ratio
three
group
ie
malign
tb
parapneumon
determin
test
use
anova
tukey
hsd
test
done
signific
anova
result
level
signific
alpha
set
result
presenc
cancer
coronari
arteri
diseas
play
role
develop
exud
pleural
effus
respect
accordingli
signific
differ
serum
pleural
ldh
serum
pleural
protein
group
well
serum
pleural
prldh
ratio
conclus
serum
pleural
prldh
ratio
unabl
differenti
underli
caus
exud
pleural
effus
madegedara
rajapaks
teach
hospit
respiratori
kandi
sri
lanka
background
aim
describ
valu
pleural
effus
analysi
diagnos
pleural
infect
n
resourc
poor
set
tb
endem
countri
method
prospect
collect
result
pleural
effus
pe
period
ofeight
month
may
patient
pe
standard
investig
diagnosi
includ
biochemistri
microbiolog
inflammatori
marker
chest
x
ray
chest
ultra
sound
ct
chest
mantoux
thoracoscopi
pleural
biopsi
need
result
male
mean
age
year
present
pe
diagnos
tubercul
pe
tpe
parapneumon
pe
pppe
malign
tabl
pf
adenosin
deaminas
ada
cut
iul
good
sensit
specif
posit
neg
predict
valu
ppv
npv
good
overal
valid
tpe
cut
iul
show
better
specif
virtual
exclud
chronic
pppe
low
sensit
npv
pf
lymphocytosi
sensit
detect
tbe
low
specif
neutrophil
predomin
present
among
pppe
npv
tbeboth
tbe
pppe
mean
pf
sugar
mgdl
howev
find
neither
sensitv
specif
tabl
pf
biochemistri
differ
type
effus
conclus
exud
pe
infect
origin
pf
lymphocytosi
ada
help
diagnosi
tb
pe
specif
earli
diagnosi
mandatori
definit
treatment
prevent
long
term
complicationscytolog
assess
use
ada
level
use
earli
diagnosi
madegedara
r
mirihella
teach
hospit
respiratori
kandi
sri
lanka
background
aim
osa
physiopatholog
disord
commonli
encount
clinic
practic
still
diagnos
adequ
diagnos
treat
osa
associ
sever
commod
howev
failur
recogn
clinic
signific
osa
particular
import
associ
signific
morbid
mortal
import
recogn
demo
graphic
clinic
paramet
osa
among
patient
method
retrospect
analysi
done
use
data
clinic
note
individu
patient
attend
sleep
clinic
respiratori
treatment
unit
kandi
polysomnographi
demonstr
osa
year
diagnos
osa
patient
categor
age
sever
group
mild
moder
sever
clinic
demograph
analyz
result
total
number
patient
underw
polysomnographi
diagnos
osa
among
mild
moder
sever
osa
respect
diagnos
osa
patient
male
patient
diagnos
osa
age
male
predomin
age
group
male
femal
ratio
increas
increas
sever
patient
present
snore
alon
patient
multipl
symptom
patient
morbid
obes
polysomnographi
demonstr
osa
patient
osa
bmi
mallampati
score
osa
patient
hypertens
diabet
respect
conclus
studi
obstruct
sleep
apnoea
common
among
male
male
femal
ratio
male
femal
ratio
increas
increas
sever
osa
common
age
group
associ
co
morbid
like
diabet
hypertens
common
among
osa
patient
increas
bmi
mallampati
score
neck
circumfer
go
togeth
increas
sever
osa
therefor
demograph
pattern
osa
last
two
year
central
sri
lanka
similar
establish
demograph
descript
world
univers
utah
intern
medicin
pulmonarycrit
care
divis
salt
lake
citi
usa
intermountain
inc
pulmonarycrit
care
murray
usa
background
aim
spirometri
perform
pulmonari
laboratori
physician
offic
publish
report
qualiti
spirogram
spirometr
interpret
low
loop
inadequ
evalu
assur
adequ
test
qualiti
forc
expiratori
maneuv
involv
variabl
flow
volum
time
rotat
axe
one
obtain
curv
spirometri
devic
commonli
recogn
short
exhal
time
usual
identifi
end
exhal
inspir
begin
regardless
breathhold
short
expir
time
truncat
forc
expir
produc
high
ratio
approach
forc
expiratori
time
approach
second
therefor
short
forc
expiratori
time
mask
airway
obstruct
inform
curv
curv
complementari
aim
illustr
inadequaci
curv
use
isol
pft
interpret
method
use
clinic
spirogram
pulmonari
function
laboratori
intermountain
healthcar
inc
result
breath
hold
forc
expir
obviou
curv
difficult
identifi
curv
red
arrow
figur
normal
spirogram
figur
mimick
short
exhalt
time
figur
appar
curv
examin
well
figur
breath
hold
short
exhal
time
recogn
dash
red
line
figur
indic
second
breath
hold
becom
clear
exhal
time
figur
report
spriometri
devic
second
right
red
arrowhead
dash
vertic
line
wherea
true
exhal
time
second
left
arrowhead
dash
vertic
line
conclus
spirometri
interpret
includ
examin
curv
qualiti
assur
achiev
curv
alon
kh
j
univers
utah
intern
medicin
pulmonarycrit
care
divis
salt
lake
citi
usa
gleneagl
hospit
asian
american
liver
centr
singapor
singapor
background
aim
current
approach
clinic
base
individu
expert
consid
larg
amount
inform
individu
expert
make
variabl
decis
face
inform
much
variat
unwarr
link
good
evid
medic
care
qualiti
reduc
unwarr
variat
clinic
decis
institut
physician
major
reduct
unwarr
variat
gener
requir
effect
physician
howev
provid
person
instruct
match
individu
patient
need
goal
met
almost
current
guidelin
protocol
use
replic
clinician
decis
method
produc
consist
person
patient
care
instruct
detail
comput
protocol
protocol
rule
appli
prospect
time
clinician
produc
replic
decis
decis
differ
clinician
figur
protocol
rule
deriv
retrospect
databas
analysi
aim
describ
differ
method
guidelin
protocol
rule
gener
retrospect
data
analysi
method
develop
implement
clinic
detail
comput
protocol
manag
mechan
ventil
iv
fluid
blood
glucos
manag
pulmonari
function
interpret
past
year
export
protocol
across
cultur
includ
singapor
across
medic
disciplin
clinician
complianc
protocol
instruct
result
common
protocol
variabl
comparison
studi
result
becom
difficult
lead
conflict
result
figur
illustr
variabl
insulin
dose
recommend
publish
protocol
gray
area
iv
insulin
infus
rate
insulin
unit
hour
van
den
bergh
protocol
dash
line
one
detail
comput
protocol
develop
intermountain
ld
hospit
conclus
detail
comput
protocol
use
feasibl
usa
singapor
implement
detail
comput
protocol
asian
pacif
region
increas
qualiti
care
scientif
credibl
clinic
research
kh
j
univers
utah
intern
medicin
pulmonarycrit
care
divis
salt
lake
citi
usa
gleneagl
hospit
asian
american
liver
centr
depart
singapor
singapor
background
aim
hippocrat
expert
authoritarian
model
clinician
requir
clinician
manag
complex
inform
use
judgment
make
best
decis
medic
intend
consist
improv
clinic
outcom
individu
patient
goal
requir
decis
tightli
link
best
evid
howev
known
decad
clinician
consist
make
decis
carri
action
link
best
evid
one
contributor
failur
clinician
make
consist
decis
link
best
evid
limit
human
cognit
due
limit
work
memori
psychologist
known
decad
memori
limit
estim
current
limit
construct
decis
becom
degrad
aim
identifi
import
barrier
clinic
use
detail
comput
protocol
method
use
detail
comput
protocol
base
best
evid
standard
clinician
identifi
method
protocol
develop
multipl
clinician
follow
protocol
instruct
make
decis
face
patient
data
protocol
respond
chang
patient
context
gener
person
medicin
instruct
match
need
individu
patient
result
collabor
physician
follow
person
medicin
protocol
instruct
time
elimin
differ
institut
includ
nation
univers
hospit
singapor
figur
b
figur
partial
glucos
protocol
screen
imag
use
detail
comput
protocol
decad
clinician
resist
adopt
protocol
realiz
first
step
protocol
use
recognit
clinician
like
human
overestim
abil
accord
illusori
superior
principl
conclus
detail
comput
protocol
use
feasibl
use
singapor
clinician
limit
recogn
systemat
implement
detail
comput
protocol
allow
uniform
deliveri
good
medic
care
develop
develop
countri
g
teach
hospit
respiratori
kandi
sri
lanka
teach
hospit
respiratori
medicin
kandi
sri
lanka
background
aim
diaphragm
import
muscl
ventil
function
evalu
diaphragmat
function
undiagnos
breathless
import
diaphragmat
weak
commonli
suspect
identifi
elev
chest
radiograph
aim
studi
describ
demograph
etiolog
patient
diaphragmat
weak
absenc
obviou
caus
abnorm
chest
method
data
collect
patient
elev
chest
radiographi
april
june
questionnair
base
interview
use
identifi
symptomatolog
collect
demograph
data
patient
clinic
assess
relev
investig
carri
ascxr
pulmonari
function
test
fluoroscop
ct
chest
nerv
conduct
studi
phrenic
nerv
emg
diaphragm
cervic
spine
gener
relev
investig
result
analyz
use
microsoft
offic
excel
result
patient
male
mean
age
rang
select
fluoroscopi
reveal
non
function
normal
patient
restrict
pattern
normal
obstruct
pattern
patient
moder
impair
mvv
patient
udp
nerv
conduct
reveal
phrenic
nerv
palsi
pnp
evid
myopathi
diaphragmat
emg
patient
phrenic
nerv
conduct
normal
eventr
diaphragm
patient
pnp
past
tb
fibrosi
bronchiectasi
dm
caus
identifi
rest
patient
conclus
case
seri
reveal
one
third
appar
elev
due
diaphragmat
weak
major
patient
udp
pnp
diabet
mellitu
past
tb
fibrosi
case
could
identifi
obviou
patholog
mizobuchi
wakabayashi
yamanaka
kurihara
tamagawa
nissan
kohseikai
institut
medicin
gener
thorac
pneumothorax
research
center
tokyo
japan
patient
woman
suffer
refractori
pneumothorac
lung
sinc
year
old
age
underw
pleurodesi
left
chest
caviti
result
recurr
pneumothorax
left
side
famili
histori
includ
pneumothorac
brother
matern
aunt
cousin
patient
uniqu
distribut
multipl
lung
cyst
locat
zone
lung
field
adjac
interlobar
fissur
abut
peripher
pulmonari
vessel
find
led
strong
suspicion
secondari
pneumothorax
caus
syndrom
bhd
genet
diagnos
bhd
mean
peripher
blood
test
underw
surgic
reinforc
whole
viscer
pleura
right
lung
absorb
cellulos
mesh
ethicon
prevent
recurr
pneumothorax
unpredict
thorac
endometriosi
detect
central
tendon
right
diaphragm
endometriosi
resect
stapl
devic
follow
surgic
reinforc
diaphragm
use
postop
cours
unev
recurr
pneumothorax
record
year
surgeri
r
teach
hospit
respiratori
kandi
sri
lanka
teach
hospit
respiratori
unit
kandi
sri
lanka
introduct
tuberculosi
second
lead
infecti
caus
death
world
wild
kill
million
peopl
per
year
despit
potenti
curabl
diseas
sri
lanka
consid
countri
moder
risk
tuberculosi
essenti
knowledg
healthcar
profession
regard
tuberculosi
manag
need
date
order
improv
manag
object
find
awar
tuberculosi
manag
among
nurs
stuff
attach
th
kandi
method
studi
done
teach
hospit
kandi
routin
health
educ
program
two
questionnair
consist
stem
cover
etiolog
symptom
sign
diagnosi
treatment
drug
side
effect
drug
storag
dot
spread
diseas
tuberculosi
pregnanc
lactat
given
complet
programresult
analyz
use
microsoft
xl
result
total
number
respond
femal
total
mark
obtain
respond
pre
post
program
identifi
area
question
calcul
averag
mark
obtain
pre
evalu
question
post
evalu
question
knowledg
regard
monitor
patient
treatment
tuberculosi
pregnanc
lactat
poor
pre
evalu
show
satisfactori
improv
post
evalu
conclus
gener
awar
tuberculosi
manag
among
nurs
offic
attach
th
kandi
satisfactori
lack
specif
area
knowledg
identifi
import
improv
tuberculosi
knowledg
nurs
train
improv
tuberculosi
knowledg
among
categori
health
sector
utmost
import
achiev
goal
elimin
tuberculosi
goal
sri
lanka
puengpapat
faculti
medicin
thammasat
univers
medicin
pathumthani
thailand
background
aim
defin
undiagnos
pleural
effus
remain
undiagnos
initi
thoracocentesi
repeat
thoracocentesi
pleural
biopsi
common
caus
malign
tuberculosi
acut
pulmonari
embol
ape
pneumonia
mani
caus
consid
potenti
caus
method
thai
male
physic
activ
present
dri
cough
dyspnea
exert
month
insignific
weight
loss
physic
examin
follow
bp
mmhg
heart
rate
min
oxygen
satur
room
air
pit
edema
leg
chest
reveal
pleural
effus
right
lower
lung
field
figur
right
thoracocentesi
done
week
present
serosanguin
pleural
fluid
rbc
wbc
monocyt
predomin
protein
gdl
observ
next
month
clinic
chest
second
right
thoracocentesi
done
serosanguin
fluid
pleural
fluid
ada
ul
therefor
ct
chest
done
moder
amount
right
pleural
effus
passiv
atelectasi
right
lung
observ
lymphadenopathi
detect
consequ
third
right
thoracocentesi
pleural
biopsi
done
neg
cytolog
malign
patholog
granuloma
malign
final
ctpa
done
small
intralumin
fill
defect
segment
branch
pulmonari
arteri
suppli
anterior
segment
right
upper
lung
seen
figur
chest
pa
upright
show
right
pleural
effus
figur
ct
chest
show
intralumin
fill
defect
segment
branch
pulmonari
arteri
suppli
anterior
segment
right
upper
lung
result
acut
thromboembol
segment
branch
right
pulmonari
arteri
diagnos
conclus
undiagnos
pleural
effus
ape
consid
even
though
clinic
suggest
ape
v
n
divis
pulmonari
critic
care
medicin
depart
medicin
faculti
medicin
chulalongkorn
univers
bangkok
thailand
king
chulalongkorn
memori
hospit
thai
red
cross
societi
bangkok
thailand
immunoglobulin
relat
diseas
new
term
old
diseas
increas
report
diseas
sinc
kamisawa
report
case
extrapancreat
manifest
patient
autoimmun
pancreat
relat
diseas
share
common
featur
includ
tumefact
lesion
lymphoplasmacyt
infiltr
increas
plasma
cell
storiform
fibrosi
diagnosi
relat
diseas
histopatholog
mainstay
clinicopatholog
correl
requir
confirm
diagnosi
report
case
relat
pulmonari
diseas
male
present
progress
dyspnea
signific
weight
loss
month
physic
examin
reveal
mild
pale
conjunctiva
small
subment
mass
laboratori
studi
show
mild
anemia
mild
renal
impair
increas
serum
globulin
level
serum
protein
electrophoresi
show
polyclon
gammopathi
neg
result
immunofix
test
bone
marrow
patholog
immunohistochemistri
show
lymphoplasmacyt
infiltr
normal
plasma
cell
subment
mass
dissect
also
reveal
lymphoplasmacyt
infiltr
chest
radiographi
chest
comput
tomographi
show
mediastin
adenopathi
bilater
multifoc
patchi
opac
thicken
interlobular
septa
figur
bronchoscopi
transbronchi
biopsi
perform
lung
parenchym
patholog
also
reveal
lymphoplasmacyt
infiltr
posit
test
igg
posit
cell
ratio
greater
serum
igg
subclass
also
show
level
mgdl
diagnosi
relat
pulmonari
diseas
made
patient
subsequ
treat
prednisolon
approxim
one
month
treatment
prednisolon
dyspnea
markedli
improv
x
tingt
p
luo
c
xin
zhujiang
southern
medic
guangzhou
c
depart
respiratori
medicin
guangzhou
china
background
aim
explor
effect
outpati
noninvas
ventil
patient
stabl
hypercapn
chronic
obstruct
pulmonari
diseas
copd
method
patient
stabl
hypercapn
copd
divid
randomli
two
group
group
ipap
n
group
ipap
n
patient
receiv
noninvas
ventil
least
one
year
ga
exchang
pulmonari
function
dyspnea
exercis
toler
relat
qualiti
life
hospit
admiss
hospit
stay
averag
hospit
cost
surviv
rate
compar
two
group
er
treatment
result
compar
group
group
show
signi
cant
improv
ga
exchang
mmrc
sgrq
hospit
admiss
hospit
stay
averag
hospit
cost
p
signi
cant
di
erenc
walk
distanc
found
group
p
surviv
similar
group
vs
p
conclus
noninvas
ventil
patient
stabl
hypercapn
copd
may
exert
prefer
potenti
improv
pulmonari
function
carbon
dioxid
retent
qualiti
life
dyspnea
well
reduc
hospitalis
averag
hospit
cost
hemvimon
n
rittayamai
n
chierakul
faculti
siriraj
mahidol
univers
medicin
bangkok
thailand
background
aim
higher
bacteria
endem
fungi
quit
rare
normal
person
report
rare
case
lung
abscess
caus
actinomyc
histoplasma
immunocompet
patient
method
man
refer
evalu
progress
pulmonari
lesion
prior
medic
histori
presenc
cough
pleurit
chest
pain
last
year
cxr
time
show
cm
lesion
left
lower
lobe
bronchoalveolar
lavag
fluid
reveal
posit
afb
mycobacteri
tuberculosi
cultur
serolog
hiv
neg
complet
treatment
standard
drug
month
symptom
improv
cxr
show
enlarg
initi
lesion
crescent
format
result
siriraj
hospit
physic
examin
remark
digit
club
chest
ct
scan
demonstr
cm
caviti
later
basal
segment
left
lower
lobe
surround
centrilobular
nodul
repeat
bronchoscopi
perform
foul
smell
discharg
necrot
tissu
found
later
basal
segment
bronchu
histopatholog
show
squamou
cell
metaplasia
mark
chronic
inflamm
granul
tissu
thoracotomi
segmentectomi
perform
patholog
examin
demonstr
thin
filament
branch
filament
bacteria
border
eosinophil
project
materi
consist
actinomyc
spp
small
necrot
granulomat
nodul
contain
bud
yeast
also
found
morpholog
favor
histoplasmosi
spp
symptom
cxr
gradual
improv
treatment
itraconazol
howev
subsequ
bacteri
fungal
cultur
neg
conclus
actinomycosi
histoplasmosi
uncommon
lower
respiratori
tract
infect
manifest
local
consolid
lung
nodul
mass
even
cavitari
lesion
case
report
superimpos
infect
agent
destroy
lung
lesion
pulmonari
tb
report
c
n
w
faculti
medicin
siriraj
mahidol
univers
divis
respiratori
diseas
tuberculosi
bangkok
thailand
umphang
hospit
umphang
hospit
tak
thailand
background
aim
pulmonari
paragonimiasi
diseas
caus
lung
fluke
paragonismu
endem
southeast
asia
patient
acquir
infect
ingest
raw
partial
cook
crab
crayfish
studi
review
pulmonari
paragonimiasi
term
clinic
featur
radiograph
find
clinic
outcom
five
patient
diagnos
pulmonari
paragonimiasi
method
medic
record
five
adult
patient
diagnos
pulmonari
paragonimiasi
umphang
hospit
june
june
retrospect
review
result
age
rang
year
median
age
year
patient
present
hemoptysi
durat
week
year
three
also
pleurit
chest
pain
two
complain
decreas
appetit
weight
loss
initi
diagnosi
pulmonari
tuberculosi
neg
sputum
smear
impress
patient
howev
subsequ
histori
ingest
raw
crab
crayfish
nearbi
waterfal
establish
two
three
patient
cbc
result
reveal
eosinophilia
absolut
eosinophil
count
plain
chest
radiographi
demonstr
focal
opac
lower
lobe
figur
without
pleural
effus
pneumothorax
paragonismu
egg
demonstr
sputum
specimen
figur
figur
patient
prescrib
praziquantel
drug
choic
paragonimiasi
dramat
improv
symptom
figur
figur
figur
conclus
pulmonari
paragonimiasi
may
mimic
pulmonari
tuberculosi
other
acut
chronic
lung
diseas
thorough
histori
take
identifi
egg
clinic
specimen
ravel
definit
diagnosi
p
n
b
c
r
faculti
medicin
siriraj
hospit
divis
respiratori
diseas
tuberculosi
bangkok
thailand
faculti
medicin
siriraj
hospit
divis
oncolog
bangkok
thailand
faculti
medicin
siriraj
hospit
depart
patholog
bangkok
thailand
background
aim
extraskelet
ewe
sarcoma
ee
rare
malign
young
adult
commonli
affect
extrem
soft
tissu
trunk
paravertebr
intercost
region
ee
report
unusu
site
includ
mediastinum
heart
extern
genitalia
broad
ligament
ee
aris
within
pleura
rare
method
report
case
ee
woman
left
pleural
effus
present
dri
cough
progress
dyspnea
month
result
chest
examin
reveal
decreas
breath
sound
left
hemithorax
trachea
shift
right
chest
radiograph
show
homogen
opac
left
hemithorax
mediastin
shift
right
diagnost
thoracentesi
reveal
lymphocyt
exud
pleural
effus
neg
malign
cell
thorac
ct
demonstr
circumferenti
nodular
left
pleural
mass
massiv
pleural
effus
collaps
left
lung
boni
destruct
bone
scan
show
abnorm
find
left
transthorac
core
needl
biopsi
ultrasound
guid
perform
patholog
find
pleural
mass
reveal
malign
small
round
cell
neoplasm
immunohistochemistri
compat
ewe
sarcoma
patient
diagnos
ee
treat
vincristin
doxorubicin
cyclophosphamid
eight
cycl
chemotherapi
clinic
radiolog
find
improv
six
month
later
thorac
ct
reveal
increas
left
pleural
effus
patient
die
nine
month
diseas
progress
conclus
although
ee
pleura
rare
ee
consid
differenti
diagnosi
young
adult
patient
suspect
malign
pleural
effus
cho
song
b
min
korea
unit
pharm
inc
r
center
seoul
republ
korea
background
aim
levodropropizin
agent
whose
peripher
antituss
action
may
result
modul
sensori
neuropeptid
level
current
levodropropizin
mg
taken
daili
control
releas
formul
levodropropizin
control
releas
tablet
cr
mg
develops
taken
twice
daili
object
studi
develop
control
releas
tablet
contain
levodropropizin
investig
bioequival
preclin
clinic
test
method
process
levodropropizin
control
releas
tablet
perform
modul
doubl
layer
extend
layer
immedi
layer
tablet
levodropropizin
cr
access
flowabl
test
dissolut
studi
swell
hydroxypropylmethyl
cellulos
hpmc
affect
super
disintegr
agent
dissolut
rate
matrix
tablet
insuffici
explain
enhanc
solubl
levodropropizin
doubl
layer
tablet
compos
extend
layer
contain
hpmc
sustain
manner
immedi
layer
includ
super
disintegr
agent
improv
earli
step
releas
rate
show
reason
releas
profil
min
random
studi
conduct
healthi
male
volunt
subject
receiv
levodropropizin
mg
three
time
daili
levodropropizin
mg
twice
daili
sampl
pharmacokinet
analysi
collect
hour
day
pharmacokinet
analysi
conduct
method
result
levodropropizin
cr
mg
tablet
safe
administ
twice
daili
statist
signific
differ
seen
cmax
th
two
formul
conclus
studi
provid
pharmacokinet
evdenc
dose
regimen
levodropropizin
mg
may
substitut
convent
regimen
levodropropizin
cr
mg
seraneeprakarn
v
tangsujaritvijit
faculti
ramathibodi
mahidol
univers
medicin
bangkok
thailand
smooth
muscl
cell
tumor
rare
subset
smooth
muscl
tumor
occur
immunosuppress
individu
herein
report
male
live
hiv
infect
take
antiretrovir
agent
zidovudin
lamivudin
lopinavirritronavir
year
recent
present
chronic
cough
signific
weight
loss
month
physic
examin
show
reson
percuss
decreas
breath
sound
left
lower
lobe
area
chest
demonstr
atelectasi
left
lower
lobe
consist
comput
tomographi
ct
chest
reveal
collaps
left
lower
lobe
attribut
endobronchi
mass
left
main
bronchu
cbc
blood
chemistri
normal
bronchoscop
perform
discov
endobronchi
mass
left
main
bronchu
caus
nearli
complet
obstruct
lesion
biopsi
done
patholog
show
smooth
muscl
cell
tumor
immunohistochemistri
strain
posit
desmin
smooth
muscl
actin
muscl
actin
wherea
neg
alk
request
ebv
situ
hybrid
demonstr
posit
subsequ
schedul
rigid
bronchoscopi
argon
coagul
tumor
remov
uneven
advis
continu
antiretrovir
therapi
close
without
locoregion
recurr
conclus
report
rare
case
endobronchi
smooth
muscl
cell
tumor
success
treatment
tumor
resect
antiretrovir
therapi
p
j
w
j
z
z
second
hospit
jilin
univers
depart
pediatr
changchun
china
second
hospit
jilin
univers
depart
repiratori
medicin
changchun
china
jilin
univers
depart
patholog
changchun
china
background
aim
order
observ
effect
tanreq
combin
antibiot
treatment
pneumonia
children
method
children
pneumonia
patient
randomli
divid
treatment
group
control
group
tanreq
given
treatment
group
combin
antibiot
therapi
antibiot
given
patient
control
group
result
recoveri
time
bodi
temperatur
treatment
group
shorter
time
cough
significantli
shorter
control
group
signific
differ
averag
length
hospit
time
p
effect
treatment
group
better
control
group
conclus
tanreq
inject
combin
antibiot
children
pneumonia
pulmonari
infect
better
clinic
efficaci
may
reduc
hospit
time
reliev
symptom
rel
short
time
e
bg
yt
jw
hp
school
cathol
univers
daegu
anesthesiolog
pain
medicin
daegu
republ
korea
inha
univers
hospit
anesthesiolog
pain
medicin
incheon
republ
korea
seoul
nation
univers
bundang
hospit
anesthesiolog
pain
medicin
seongnam
republ
korea
seoul
nation
univers
hospit
anesthesiolog
pain
medicin
seoul
republ
korea
background
aim
posit
lightwand
midlin
oral
caviti
quit
challeng
patient
cervic
immobil
direct
laryngoscopi
allow
lightwand
tip
easili
access
glottic
open
test
hypothesi
lightwand
intub
allow
success
endotrach
intub
convent
lightwand
intub
method
patient
requir
cervic
immobil
intub
cervic
spine
surgeri
randomli
alloc
two
group
convent
lightwand
techniqu
use
endotrach
intub
control
group
group
c
n
wherea
lightwand
intub
techniqu
group
group
l
n
group
l
macintosh
laryngoscop
insert
oral
caviti
advanc
past
tongu
epiglotti
tip
visibl
lightwand
tip
place
epiglotti
direct
view
epiglotti
tip
success
rate
intub
first
attempt
intub
time
hemodynam
chang
postop
airway
complic
evalu
result
success
rate
intub
first
attempt
significantli
higher
vs
p
number
scoop
movement
significantli
lower
median
iqr
vs
p
group
l
group
c
intub
time
postop
sore
throat
score
incid
hypertens
tachycardia
postop
oral
mucos
bleed
hoars
compar
two
group
conclus
lightwand
intub
allow
success
intub
first
attempt
without
increas
intub
time
compar
tradit
lightwand
intub
patient
requir
cervic
immobil
intub
cervic
spine
surgeri
jp
j
cathol
univers
korea
occup
environment
medicin
seoul
republ
korea
seoul
stmari
colleg
cathol
univers
korea
occup
environment
medicin
seoul
republ
korea
background
aim
pneumonia
main
caus
death
among
patient
pneumoconiosi
however
studi
concern
associ
factor
pneumoconiosi
pneumonia
therefor
aim
studi
evalu
factor
associ
increas
risk
mortal
pneumonia
among
patient
pneumoconiosi
method
medic
record
pneumoconiosi
patient
hospit
pneumonia
investig
exclud
specif
condit
lung
cancer
malign
insuffici
medic
record
femal
patient
exclud
final
elig
popul
subject
divid
two
group
byclin
outcom
pneumonia
deceas
group
surviv
group
two
group
compar
interm
age
smoke
histori
episod
recent
pneumonia
concomit
interstiti
fibrosi
fungal
ballinfect
extent
small
opac
grade
larg
opac
result
spirometri
multipl
logist
regressionwa
appli
determin
associ
variabl
mortal
pneumonia
result
deceas
group
show
frequent
histori
recent
pneumonia
p
higher
preval
ofinterstiti
fibrosi
p
longer
hospit
period
p
proport
subject
haddecreas
fvc
less
predict
valu
higher
deceas
group
p
multipl
logisticregress
adjust
age
smoke
histori
recent
pneumonia
fungal
ball
larg
opac
profus
fvc
less
predict
valu
histori
recent
pneumonia
concomit
interstiti
fibrosi
type
ofpneumoconiosi
fungal
ball
present
statist
signific
associ
mortal
pneumonia
conclus
concomit
fungal
ball
interstiti
fibrosi
histori
recent
pneumonia
within
day
type
pneumoconiosi
fvc
less
predict
valu
less
predict
valuepres
statist
signific
associ
mortal
pneumonia
attent
given
topati
factor
treat
pneumonia
pneumoconiosi
n
tapanwong
phramongkutklao
hospit
pulmonari
critic
care
bangkok
thailand
background
aim
differ
industri
countri
malign
mesothelioma
rel
rare
caus
malign
pleural
effus
thailand
diagnost
method
may
import
factor
estim
includ
difficult
patholog
evalu
hypothes
malign
mesothelioma
underdiagnosi
method
studi
perform
phramongkutklao
hospit
thailand
review
morpholog
pleural
tissu
diagnos
malign
definit
diagnosi
immunohistochemistri
done
complet
diagnosi
result
pleural
tissu
review
morpholog
undergon
immunohistochemistri
stain
malign
mesothelioma
found
case
malign
group
perform
tissu
biopsi
surgic
techniqu
patholog
diagnosi
adenocarcinoma
squamou
cell
carcinoma
malign
respect
find
miss
diagnosi
conclus
malign
mesothelioma
still
rel
low
preval
phramongkutklao
hospit
difficulti
diagnost
process
might
import
caus
k
toyota
kosei
hospit
psychiatri
aichi
japan
toyota
kosei
hospit
respiratori
medicin
aichi
japan
aichi
medic
univers
psychiatri
aichi
japan
background
aim
smoke
known
prevent
caus
mortal
world
treatment
give
smoke
cover
health
insur
sinc
japan
research
reveal
patient
mental
disord
especi
vulner
health
risk
smoke
less
like
quit
howev
efficaci
vareniclin
cessat
smoke
patient
mental
disord
remain
unclear
method
analyz
record
outpati
male
femal
mean
age
year
mean
period
day
visit
respiratori
medicin
depart
quit
smoke
start
vareniclin
apr
may
subject
divid
group
accord
without
histori
mental
disord
outcom
defin
smoke
cessat
fail
surviv
cox
proport
hazard
analys
perform
correl
among
variabl
evalu
method
result
subject
without
histori
mental
disord
respect
reach
endpoint
p
analyz
use
proport
hazard
model
histori
mental
ill
relat
higher
risk
reach
endpoint
crude
hr
ci
p
adjust
hr
ci
p
wherea
neither
score
brinkman
index
major
risk
factor
smoke
cessat
fail
low
correl
brinkman
index
score
kano
test
social
nicotin
depend
patient
without
mental
disord
r
p
wherea
correl
mental
disord
conclus
histori
mental
ill
shown
strong
obstacl
quit
smoke
difficulti
smoke
cessat
patient
mental
disord
use
vareniclin
could
partial
explain
result
smoke
behavior
nt
correl
nicotin
depend
h
e
k
k
juntendo
univers
faculti
medicin
graduat
school
medicin
divis
respiratori
medicin
tokyo
japan
nissan
tamagawa
hospit
pneumothorax
research
center
divis
thorac
surgeri
tokyo
japan
background
aim
syndrom
bhd
rare
hereditari
diseas
present
multipl
lung
cyst
pneumothorax
ptx
previous
report
radiolog
find
chest
ct
imag
enabl
distinguish
bhd
primari
spontan
pneumothorax
psp
remain
unclear
whether
clinic
featur
use
detect
bhd
among
patient
ptx
aim
studi
establish
clinic
score
system
distinguish
bhd
psp
among
ptx
patient
method
retrospect
review
medic
record
patient
ptx
underw
thoracoscop
surgeri
nissan
tamagawa
hospit
januari
decemb
collect
follow
clinic
featur
age
onset
ptx
gender
bmi
smoke
habit
famili
histori
ptx
characterist
ptx
result
total
patient
ptx
consist
bhd
psp
identifi
logist
regress
analysi
identifi
featur
significantli
associ
bhd
famili
histori
ptx
past
histori
bilater
ptx
age
first
episod
ptx
yo
bodi
mass
index
gender
femal
assign
score
featur
respect
establish
score
system
calcul
score
valu
calcul
score
yield
highest
sensit
confid
interv
ci
specif
ci
odd
ratio
ci
conclus
bhd
sever
clinic
featur
distinct
psp
score
system
consist
five
clinic
variabl
easili
evalu
would
abl
extract
bhd
ptx
patient
without
imag
studi
h
k
matsuda
hospit
intern
medicin
sendai
japan
saitama
medic
univers
respiratori
medicin
sleep
center
saitama
japan
background
aim
well
document
high
preval
daytim
sleepi
insomnia
due
disturb
circadian
rhythm
shift
worker
sleep
disord
known
caus
fatigu
daytim
sleepi
may
effect
neg
impact
qualiti
life
hrqol
moreov
may
increas
risk
factor
workplac
incid
howev
shift
night
work
necessari
hospit
organ
therefor
assess
associ
sleep
problem
relat
work
shift
util
multipl
screen
questionnair
method
consecut
particip
enrol
studi
consist
health
care
provid
medic
doctor
dentist
nurs
medic
care
worker
clinic
technologist
pharmacist
rehabilit
offic
offic
worker
dental
hygienist
matsuda
hospit
screen
questionnair
includ
physic
find
pittsburgh
sleep
qualiti
index
psqi
berlin
questionnair
epworth
sleepi
scale
ess
hospit
anxieti
depress
scale
had
result
total
particip
variou
medic
occup
answer
multipl
questionnair
divid
group
irregular
shift
worker
day
time
worker
shown
signific
differ
berlin
questionnair
anxieti
score
had
day
time
worker
irregular
shift
worker
although
signific
differ
observ
questionnair
conclus
present
studi
hospit
suggest
irregular
medic
shift
worker
may
worri
daytim
somnol
sleep
disord
without
sleep
apnea
ac
lu
jc
arana
perpetu
succour
hospit
section
intern
medicin
cebu
philippin
background
aim
pulmonari
complic
common
among
patient
undergo
major
surgeri
perpetu
succour
hospit
one
major
tertiari
hospit
cebu
citi
philippin
sinc
data
avail
author
therefor
decid
determin
incid
outcom
complic
patient
method
paper
prospect
studi
patient
underw
major
surgeri
perpetu
succour
hospit
patient
check
prior
oper
note
develop
pulmonari
complic
identifi
risk
factor
type
complic
develop
well
subsequ
outcom
result
overal
incid
low
studi
patient
undergo
major
surgeri
perpetu
succour
hospit
among
complic
pneumonia
atelectasi
pleural
effus
document
seen
aris
hour
major
risk
factor
develop
complic
vs
p
type
surgeri
gener
endotrach
anesthesia
vs
p
current
cigarett
smoke
histori
vs
p
patient
develop
pneumonia
treat
accordingli
discharg
improv
conclus
overal
pulmonari
complic
patient
undergo
major
surgeri
perpetu
succour
hospit
low
present
signific
morbid
vp
lg
ev
sv
far
eastern
scientif
center
physiolog
patholog
respir
administr
blagoveshchensk
russia
far
eastern
scientif
center
physiolog
patholog
respir
laboratori
prophylaxi
nonspecif
lung
diseas
blagoveshchensk
russia
amur
state
medic
academi
depart
therapi
blagoveshchensk
russia
background
aim
effici
profession
activ
primari
care
physician
depend
number
factor
determin
condit
work
mechan
degre
achiev
aim
aim
studi
evalu
factor
determin
level
profession
motiv
physician
ensur
qualiti
effect
respiratori
care
method
sociolog
survey
among
primari
care
physician
n
amur
yaroslavl
region
russian
feder
conduct
special
develop
questionnair
question
among
respond
women
men
method
spearman
rank
correl
coeffici
conjugaci
coeffici
associ
coeffici
conting
use
statist
analysi
result
question
interest
provid
care
patient
answer
respond
posit
neg
know
answer
degre
posit
motiv
provid
effect
medic
care
determin
work
experi
level
profession
qualif
found
correl
r
work
experi
specif
weight
posit
neg
repli
question
posit
respons
given
physician
whose
work
experi
less
year
physician
whose
work
experi
year
p
depend
found
degre
motiv
physician
product
work
level
profession
qualif
experienc
physician
decreas
degre
motiv
work
effect
conclus
motiv
physician
focus
effici
qualiti
health
care
respiratori
patient
depend
work
experi
level
profession
qualif
vp
lg
ev
far
eastern
scientif
center
physiolog
patholog
respir
administr
blagoveshchensk
russia
far
eastern
scientif
center
physiolog
patholog
respir
laboratori
prophylaxi
nonspecif
lung
diseas
blagoveshchensk
russia
background
aim
symptom
chronic
respiratori
diseas
crd
one
reason
peopl
seek
medic
care
aim
studi
evalu
preval
main
symptom
crd
risk
factor
adult
popul
russian
far
east
method
preval
respiratori
symptom
among
adult
popul
territori
amur
region
gard
questionnair
n
studi
cluster
geograph
random
use
includ
respond
studi
respond
group
age
year
old
year
old
year
old
year
old
men
women
method
rank
correl
spearman
coeffici
associ
pearson
coeffici
conting
use
statist
analysi
result
respond
complaint
cough
sputum
wheez
dyspnea
highest
coeffici
associ
conting
character
depend
crd
symptom
risk
factor
observ
assess
effect
smoke
cough
sputum
produc
use
open
fire
heat
cook
cough
sputum
wheez
dyspnea
open
fire
increas
risk
asthma
develop
progress
chronic
bronchiti
p
occup
hazard
work
dusti
condit
year
increas
risk
develop
pulmonari
emphysema
time
asthma
chronic
bronchiti
conclus
result
show
high
preval
crd
symptom
risk
factor
adult
popul
far
east
russia
requir
develop
implement
monitor
prevent
program
dc
indraprastha
apollo
hospit
respiratori
critic
care
medicin
sleep
disord
delhi
india
aminti
univers
noida
fha
noida
india
background
aim
poor
qualiti
ambient
air
delhi
nation
capit
region
ncr
well
document
central
pollut
board
report
air
qualiti
index
averag
past
one
year
younger
popul
greater
risk
long
term
lung
damag
aim
studi
undertaken
assess
lung
function
spirometri
asymptomat
popul
resid
least
two
year
age
year
method
volunt
popul
fulfil
studi
criteria
age
length
stay
lo
taken
studi
inform
consent
proforma
note
demograph
histori
smoke
exercis
asthma
lung
problem
record
spirometri
perform
portabl
sstandardis
spiromet
experienc
technician
evalu
pulmonologist
result
total
volunt
student
fulfil
criteria
elig
studi
exclud
smoker
asthmat
lung
diseas
femal
male
averag
age
year
averag
lo
year
ncr
found
perfectli
normal
spirometri
anoth
normal
fvc
ratio
either
abnorm
pefr
fef
restrict
defect
seen
obstruct
defect
mix
defect
conclus
evid
earli
lung
damag
advanc
lung
damag
among
asymptomat
young
popul
expos
high
level
environment
pollut
jc
arana
perpetu
succour
hospit
intern
medicin
section
pulmonolog
cebu
citi
philippin
background
aim
exposur
air
pollut
combust
fuel
signific
hazard
public
health
petroleum
detriment
effect
respiratori
function
constantli
expos
worker
recent
lpg
altern
fuel
sourc
advantag
lesser
cost
better
safeti
profil
studi
aim
measur
lung
function
among
taxi
driver
taxi
unit
method
one
hundr
six
taxi
driver
recruit
period
patient
demograph
comorbid
ill
smoke
histori
drive
histori
obtain
questionnair
simpl
spirometri
measur
lung
function
associ
drive
histori
lung
function
analyz
result
mean
age
year
averag
height
cm
averag
weight
kg
major
respond
smoker
n
percent
percent
histori
illicit
drug
use
mean
drive
durat
year
major
respond
current
drive
taxi
unit
time
studi
n
percent
averag
exposur
taxi
unit
year
averag
exposur
taxi
unit
year
mean
l
mean
fvc
l
mean
percent
predict
percent
patient
restrict
ventilatori
defect
percent
obstruct
ventilatori
defect
percent
normal
spirometri
result
signific
effect
number
year
drive
length
unit
exposur
spirometri
paramet
conclus
signific
relationship
total
durat
drive
durat
exposur
either
taxi
unit
lung
function
taxi
driver
trend
low
mean
fvc
suggest
restrict
ventilatori
defect
observ
vp
lg
ev
sv
jm
far
eastern
scientif
center
physiolog
patholog
respir
administr
blagoveshchensk
russia
far
eastern
scientif
center
physiolog
patholog
respir
laboratori
prophylaxi
nonspecif
lung
diseas
blagoveshchensk
russia
amur
state
medic
academi
depart
therapi
blagoveshchensk
russia
background
aim
indic
popul
diseas
incid
one
import
indic
public
health
well
level
organ
avail
medic
care
aim
studi
evalu
region
featur
respiratori
diseas
rd
incid
territori
russia
method
primari
diseas
incid
spread
rd
applic
materi
state
statist
monitor
rd
territori
russian
feder
rf
studi
result
structur
primari
diseas
incid
rd
amount
territori
region
till
level
increas
level
primari
diseas
incid
rd
higher
level
rf
gener
first
rank
posit
level
primari
diseas
incid
belong
chukotka
autonom
region
republ
sakha
yakutia
gradient
maxim
minim
jewish
autonom
region
diseas
incid
level
asthma
spread
territori
region
increas
till
till
wherea
rf
gener
till
level
copd
incid
increas
till
wherea
rf
till
level
chronic
lower
airway
diseas
lower
rf
gener
conclus
statist
analysi
main
indic
level
dynam
rd
show
region
differ
caus
natur
climat
featur
differ
level
avail
medic
servic
form
low
motiv
popul
appli
institut
rd
e
f
faculti
islam
indonesian
univers
depart
intern
medicin
yogyakarta
indonesia
islam
indonesian
univers
faculti
medicin
yogyakarta
indonesia
background
aim
fast
grow
industri
develop
countri
could
lead
health
problem
diseas
caus
exposur
dust
manufactur
industri
exposur
dust
may
caus
malfunct
lung
function
dust
also
caus
lung
damag
fibrosi
inhal
work
continu
reduc
elast
accommod
volum
air
oxygen
bind
abil
decreas
purpos
studi
determin
effect
dust
exposur
lung
vital
capac
forc
vital
capac
textil
factori
worker
yogyakarta
indonesia
method
studi
observ
analyt
cross
section
design
subject
textil
factori
worker
yogyakarta
indonesia
dust
exposur
level
calcul
dust
exposur
measur
dustimet
multipli
longer
work
expos
vital
lung
capac
forc
vital
capac
measur
spiromet
independ
variabl
dust
exposur
level
depend
variabl
lung
vital
capac
forc
vital
capac
data
dust
exposur
level
lung
vital
capac
forc
vital
capac
lung
anal
chi
squar
test
declar
signific
p
result
subject
consist
femal
textil
worker
age
year
dust
exposur
level
minimum
mg
maximum
mg
result
vital
lung
capac
least
liter
liter
maximum
forc
vital
capac
minimum
liter
maximum
liter
statist
analysi
use
chi
squar
test
state
signific
relationship
level
dust
exposur
level
lung
vital
capac
forc
vital
capac
lung
p
conclus
signific
relationship
dust
exposur
level
lung
vital
capac
forc
vital
capac
brisman
j
baker
asthma
occup
environ
med
baatji
r
jeebhay
mf
baker
allergi
review
literatur
current
allergi
clinic
immunolog
brant
baker
asthma
j
allergi
clin
immunol
n
yusril
ad
susanto
j
zaini
univers
indonesia
pulmonolog
respiratori
faculti
universita
persahabatan
jakarta
east
jakarta
indonesia
background
aim
benzopyren
polycycl
aromat
carcinogen
agent
found
cigarett
smoke
benzopyren
metabolit
bpde
one
benzopyren
metabolit
kretek
cigarett
smoker
person
smoke
least
cigarett
per
day
least
year
less
amount
time
white
cigarett
smoke
investig
level
serum
bpde
kretek
cigarett
smoker
compar
method
cross
section
studi
healthi
kretek
cigarett
smoker
healthi
enrol
studi
collect
blood
sampl
analyz
bpde
level
also
exhal
co
level
expir
serum
bpde
level
assay
use
elisa
kit
result
mean
age
year
old
mean
sd
bpde
level
ngml
among
kretek
cigarett
smoker
group
vs
ngml
among
nonsmok
group
p
exhal
co
level
expir
ppm
among
kretek
cigarett
smoker
group
vs
ppm
among
nonsmok
group
p
conclus
find
show
smoker
signific
higher
level
bpde
blood
co
level
expir
find
reveal
novel
insight
cigarett
smoke
increas
carcinogen
substain
level
blood
among
kretek
cigarett
smoker
howev
signific
correl
bpde
level
blood
exhal
co
level
expir
vc
bionika
universita
indonesia
pulmonolog
dan
respirasi
jakarta
indonesia
background
aim
smoke
forest
fire
becom
one
natur
disast
occur
annual
riau
especi
kampar
august
kampar
hotspot
district
riau
aim
studi
evalu
expir
level
carbon
monoxid
popul
peopl
expos
smoke
forest
fire
kampar
riau
asscoci
respiratori
complaint
cough
cough
sputum
short
breath
wheez
smoke
habit
method
expir
level
carbon
monoxid
measur
use
co
analyz
sampl
within
criteria
age
year
old
smoke
cigarett
last
hour
domicil
villag
rimbo
panjang
kampar
januari
studi
group
consist
peopl
smoke
cigarett
statist
analysi
perform
test
result
measur
perform
sampl
mean
age
year
rang
year
old
expir
level
co
show
level
median
ppm
median
ppm
studi
also
show
subject
smoke
cigarett
last
month
consum
cigarett
throughout
live
respiratori
complaint
cough
found
subject
subject
complain
cough
sputum
short
breath
subject
wheez
subject
conclus
da
trovela
paranaqu
citi
philippin
background
aim
studi
done
know
incid
factor
associ
pleural
effus
among
patient
underw
tof
correct
philippin
heart
center
method
retrospect
studi
patient
age
year
old
underw
tof
correct
philippin
heart
center
januari
decemb
includ
studi
subject
data
obtain
medic
record
medtrak
laboratori
novaweb
review
chest
xray
stata
se
version
use
data
analysi
result
factor
affect
occurr
pleural
effus
tetralog
fallot
correct
prolong
bypass
time
p
valu
age
time
oper
p
valu
conclus
factor
associ
pleural
effus
patient
underw
tof
correct
philippin
heart
center
age
time
tof
correct
prolong
bypass
time
post
oper
infect
factor
associ
transud
exud
pleural
effus
compar
c
ngo
respiratori
center
bach
mai
hospit
direct
ha
noi
vietnam
background
aim
climat
chang
includ
heat
wave
air
pollut
forest
fire
drought
flood
becom
major
environment
health
problem
world
last
year
human
particularli
burn
fossil
releas
suffici
quantiti
carbon
dioxid
greenhous
gase
trap
addit
heat
lower
atmospher
affect
global
climat
global
warm
greenhous
gase
consequ
includ
climat
chang
public
health
risk
method
search
studi
keyword
climat
chang
respiratori
diseas
respiratori
health
review
relationship
climat
chang
health
issu
result
temperatur
reach
went
degre
result
excess
death
across
europ
earth
warmest
year
record
everi
rise
risk
prematur
death
among
respiratori
patient
time
higher
rest
popul
air
pollut
exposur
trigger
new
case
copd
asthma
increas
exposur
allergen
result
global
warm
combin
exposur
pollut
act
synergist
intensifi
allerg
respons
could
point
increas
respiratori
problem
futur
extrem
heat
drought
flood
increas
morbid
respiratori
infect
mortal
chronic
respiratori
diseas
influenza
greatli
affect
temperatur
chang
warm
winter
tend
follow
sever
influenza
incid
follow
season
epidemiolog
studi
mozambiqu
bengal
document
increas
incid
respiratori
infect
flood
respiratori
infect
caus
mortal
rate
follow
bangladesh
flood
climat
chang
result
flood
acut
respiratori
infect
may
increas
conclus
health
effect
climat
chang
includ
increas
preval
allerg
respiratori
diseas
exacerb
copd
respiratori
infect
prematur
mortal
cc
yen
china
medic
univers
hospit
depart
pulmonari
critic
care
medicin
taichungm
taiwan
background
aim
high
level
oxygen
usual
use
ventilatori
support
extracorpor
membran
oxygen
ecmo
icu
hyperoxia
may
induc
product
reactiv
oxygen
speci
ro
caus
lung
damag
even
system
injuri
oxid
stress
increas
critic
ill
patient
exacerb
organ
injuri
clinic
outcom
lactoferrin
lf
glycoprotein
found
milk
airway
secret
granul
neutrophil
mani
research
demonstr
multipl
biolog
function
includ
antimicrobi
anticanc
antioxid
effect
method
studi
use
transgen
mice
carri
luciferas
gene
control
investig
hypothesi
oral
administr
lf
could
attenu
system
inflammatori
respons
organ
damag
hyperoxia
hour
activ
hyperoxia
luciferas
protein
would
express
could
observ
analyz
luminesc
excit
vivo
imag
system
ivi
inject
luciferin
transgen
mice
assign
four
group
treat
water
room
air
treat
water
hyperoxia
treat
mgkg
lf
hyperoxia
treat
mgkg
lf
hyperoxia
protect
effect
lf
hyperoxia
measur
ivi
bronchoalveolar
lavag
histolog
cytokin
express
result
found
kidney
lung
evid
ivi
hyperoxia
group
treat
lf
lower
luciferas
express
less
injuri
effect
kidney
lung
ro
mapk
decay
ratio
cytokin
express
decreas
significantli
p
kidney
lung
conclus
result
suggest
hyperoxia
induc
system
inflamm
oral
administr
lf
decreas
product
ro
attenu
inflamm
lessen
injuri
kidney
lung
hyperoxia
n
sanguanwong
n
kongpolprom
faculti
chulalongkorn
thai
red
cross
medicin
bangkok
thailand
background
aim
ard
associ
variabl
mortal
depend
diseas
sever
etiolog
ventil
manag
method
conduct
retrospect
studi
determin
mortal
hospit
length
stay
lo
durat
mechan
ventil
mv
admit
king
chulalongkorn
memori
hospit
addit
routin
clinic
practic
factor
associ
poor
outcom
evalu
result
admit
icu
fulfil
mild
moder
sever
respect
main
caus
ard
pneumonia
mortal
respect
mean
apach
median
lo
day
median
durat
mv
pressur
control
mode
favorit
mode
use
patient
averag
tidal
volum
mlkg
ibw
plateau
pressur
peep
recruit
maneuv
frequent
use
adjunct
intervent
wherea
appli
patient
patient
receiv
median
fluid
balanc
ml
ard
sever
associ
p
mortal
p
mv
durat
p
multivari
analysi
show
mortal
associ
tidal
volum
p
mortal
associ
apach
p
posit
fluid
balanc
day
p
conclus
mortal
ard
high
associ
diseas
sever
howev
averag
tidal
volum
plateau
pressur
fluid
balanc
greater
protect
limit
find
indic
potenti
improv
ard
outcom
hospit
g
n
e
trakya
faculti
medicin
pulmonari
diseas
edirn
turkey
trakya
faculti
medicin
biostatist
edirn
turkey
background
aim
aim
studi
identifi
potenti
factor
affect
surviv
mortal
patient
chronic
obstruct
pulmonari
diseas
copd
requir
intens
care
method
use
archiv
record
trakya
univers
medic
faculti
hospit
intern
intens
care
unit
icu
among
patient
admit
icu
novemb
june
patient
hospit
diagnosi
acut
respiratori
failur
due
copd
determin
surviv
patient
discharg
icu
obtain
phone
number
access
region
popul
record
fifti
patient
die
icu
lost
exclud
studi
remain
patient
includ
analysi
result
mean
age
male
averag
length
stay
icu
day
icu
mortal
one
surviv
rate
respect
accord
result
univari
analysi
age
aliv
die
p
icu
aliv
die
p
level
aliv
dead
p
effect
factor
surviv
accord
multivari
cox
regress
analysi
age
p
ci
acut
physiolog
chronic
health
evalu
ii
score
p
ci
detect
effect
surviv
conclus
result
older
age
high
acut
physiolog
chronic
health
evalu
ii
score
came
forward
neg
factor
affect
mortal
patient
copd
requir
intens
care
unit
ql
tan
ig
lee
dw
sewa
sy
low
singapor
gener
hospit
respiratori
critic
care
medicin
singapor
singapor
background
aim
increas
applic
extracorpor
membran
oxygen
ecmo
salvag
therapi
adult
patient
present
acut
respiratori
distress
syndrom
ard
fail
convent
ventil
sought
review
etiolog
ard
process
ecmo
initi
impact
outcom
method
retrospect
chart
review
adult
patient
admit
micu
singapor
gener
hospit
juli
decemb
sever
ard
requir
mechan
ventil
ecmo
support
data
patient
demograph
icu
sever
score
etiolog
ard
mortal
outcom
analyz
result
patient
age
men
initi
ecmo
diagnosi
sever
pneumonia
viral
etiolog
form
major
n
compar
patient
bacteri
organ
n
organ
isol
n
septic
shock
present
patient
patient
retriev
hospit
initi
ecmo
overal
icu
hospit
mortal
respect
ecmo
therapi
associ
lower
predict
mortal
patient
higher
sofa
score
sofa
p
sofa
p
multivari
analysi
icu
mortal
found
viral
pneumonia
associ
reduc
odd
ci
p
septic
shock
increas
odd
ci
p
statist
differ
mortal
retriev
case
conclus
cohort
patient
ard
support
ecmo
major
sever
pneumonia
mortal
differ
base
site
initi
ecmo
associ
lower
predict
mortal
patient
higher
sofa
score
n
p
bangkok
thailand
mahidol
univers
pulmonari
medicin
tuberculosi
bangkok
thailand
background
aim
evid
patient
acut
respiratori
distress
syndrom
ard
still
ventil
induc
lung
injuri
vili
despit
keep
ppl
less
stress
index
obtain
mechan
ventil
comput
program
might
abl
identifi
overdistent
mani
report
stress
index
calcul
shape
curv
hypothes
could
estim
visual
inspect
bedsid
compar
stress
index
valu
obtain
physician
visual
inspect
bedsid
valu
obtain
use
comput
softwar
method
two
physician
would
ask
inspect
curv
patient
volum
control
constant
flow
wave
form
bedsid
waveform
data
collect
use
datalogg
via
hamilton
cabl
connect
comput
stress
index
calcul
use
softwar
categor
group
includ
repres
slope
pattern
inspect
downward
concav
straight
upward
concav
respect
agreement
method
determin
use
weight
kappa
analysi
furthermor
analys
stress
index
agreement
differ
flow
rate
litermin
result
eighti
eight
stress
index
valu
obtain
comput
analysi
valu
visual
inspect
moder
agreement
stress
index
visual
inspect
comput
softwar
kappa
valu
p
sensit
specif
stress
index
visual
inspect
identifi
overdistent
respect
inspiratori
flow
rate
litermin
shown
best
agreement
kappa
valu
p
suspect
high
inspiratori
flow
rate
caus
short
inspiratori
time
lead
inadequ
inflat
respiratori
system
mask
overdistent
group
conclus
stress
index
visual
inspect
moder
correl
comput
analysi
could
reliabl
identifi
overdistent
patient
acut
respiratori
distress
syndrom
j
j
hankook
hospit
intern
medicin
jeju
republ
korea
jeju
nation
univers
hospit
intern
medicin
jeju
republ
korea
background
aim
although
infecti
diseas
societi
americaamerican
thorac
societi
idsaat
guidelin
recommend
ad
macrolid
fluoroquinolon
sever
pneumonia
cap
patient
admit
intens
care
unit
icu
evid
insuffici
perform
systemat
review
compar
outcom
plu
macrolid
versu
plu
fluoroquinolon
patient
method
medlin
embas
cochran
central
regist
scopu
web
scienc
search
relev
clinic
trial
review
result
eight
studi
involv
final
analyz
total
number
group
respect
although
total
mortal
group
seem
lower
group
vs
statist
signific
could
demonstr
risk
ratio
ci
p
also
mortal
icu
mortal
patient
signific
differ
two
group
therapi
reduc
length
total
hospit
stay
compar
therapi
mean
differ
day
ci
p
howev
signific
differ
length
icu
stay
two
group
mean
differ
day
ci
p
review
reveal
none
random
control
studi
larg
sampl
size
conclus
therapi
tend
reduc
total
mortal
length
total
hospit
stay
compar
therapi
patient
sever
cap
studi
might
need
reassess
whether
combin
therapi
patient
adequ
hn
cl
cy
chi
mei
medic
center
intens
care
medicin
tainan
citi
taiwan
nation
cheng
kung
univers
depart
public
colleg
medicin
tainan
taiwan
background
aim
whether
greater
risk
sever
sepsi
men
reflect
increas
risk
infect
andor
develop
acut
organ
dysfunct
remain
unknown
method
analyz
adult
men
randomli
select
taiwan
nation
health
insur
research
databas
prior
histori
hospit
primari
hospit
secondari
develop
acut
organ
dysfunct
first
infect
ie
sever
sepsi
subject
follow
januari
primari
withdraw
decemb
whichev
date
came
first
rel
risk
primari
secondari
respect
assess
cox
proport
hazard
multivari
logist
regress
model
adjust
potenti
confound
result
men
higher
risk
infect
adjust
hazard
ratio
hr
confid
interv
ci
develop
acut
organ
dysfunct
infect
adjust
odd
ratio
ci
women
interact
sex
differ
age
statist
signific
risk
p
sex
differ
greatest
age
year
infect
hr
age
year
acut
organ
dysfunct
convers
risk
infect
significantli
lower
men
women
age
year
hr
conclus
greater
risk
sever
sepsi
men
reflect
overal
increas
risk
infect
acut
organ
dysfunct
howev
sex
differ
vari
age
group
n
kongpolprom
chulalongkorn
univers
pulmonari
critic
care
medicin
bangkok
thailand
background
aim
intern
survey
demonstr
variabl
practic
respons
mechan
ventil
wean
differ
countri
aim
evalu
aspect
thailand
method
questionnair
sent
thai
physician
graduat
chulalongkorn
univers
via
electron
mail
survey
current
practic
clinic
respons
mechan
ventil
wean
hospit
includ
primari
secondari
tertiari
univers
hospit
analyz
data
number
percentag
proport
result
one
hundr
physician
answer
questionnair
internist
work
secondari
tertiari
hospit
approxim
respond
take
care
patient
gener
ward
around
hospit
respond
work
nurs
author
initi
set
adjust
mechan
ventil
hospit
nurs
play
import
role
wean
name
make
decis
wean
hospit
wean
termin
hospit
extub
hospit
interestingli
physician
perspect
nurs
moder
high
respons
set
mechan
ventil
wean
wean
practic
physician
use
wean
protocol
other
use
spontan
breath
piec
low
level
pressur
support
simv
close
loop
mode
wean
rapid
shallow
breath
index
popular
paramet
use
predict
wean
outcom
approxim
physician
evalu
cuff
leak
test
extub
noninvas
ventil
one
strategi
appli
prophylaxi
reintub
hospit
conclus
due
limit
icu
resourc
thai
physician
provid
ventilatori
care
gener
ward
addit
thai
nurs
signific
respons
ventil
manag
wean
kc
nation
univers
singapor
yong
loo
lin
school
medicin
singapor
singapor
nation
univers
hospit
divis
respiratori
critic
care
medicin
singapor
singapor
background
aim
antibiot
commonli
given
patient
suspect
infect
aim
studi
impact
appropri
antibiot
usag
mortal
method
patient
admit
micu
nation
univers
hospit
singapor
april
march
retrospect
studi
demograph
clinic
data
includ
symptom
cultur
result
antibiot
sourc
control
mortal
record
appropri
antibiot
administr
defin
least
one
antibiot
justifi
cultur
clinic
featur
result
patient
analys
median
age
year
length
icu
stay
day
apach
ii
score
male
icu
mortal
hospit
mortal
patient
main
diagnosi
sepsi
patient
receiv
least
one
correct
antibiot
sourc
control
prompt
done
within
hr
patient
without
appropri
antibiot
use
signific
ci
p
valu
time
odd
icu
mortal
ci
p
valu
time
odd
hospit
mortal
patient
either
primarili
admit
icu
sepsi
posit
cultur
adjust
gender
apach
ii
score
patient
without
appropri
antibiot
use
signific
ci
p
valu
time
odd
icu
mortal
signific
ci
p
valu
time
odd
hospit
mortal
patient
neither
primarili
diagnos
sepsi
posit
cultur
suspect
infect
adjust
gender
apach
ii
score
conclus
appropri
antibiot
use
liber
appli
icu
patient
regardless
primari
diagnosi
cultur
posit
antibiot
stewardship
icu
patient
expect
challeng
withhold
antibiot
circumst
critic
ill
patient
could
potenti
lead
increas
mortal
wl
su
taipei
tzu
chi
hospit
buddhist
tzu
chi
medic
foundat
divis
pulmonari
critic
care
depart
intern
medicin
new
taipei
citi
taiwan
background
aim
immedi
appropri
antibiot
therapi
requir
treat
sepsi
previou
antibiot
exposur
drug
resist
pathogen
healthcar
associ
comorbid
import
effect
antibiot
select
sepsi
studi
assess
time
onset
sepsi
first
appropri
antibiot
tsfaa
hour
aim
determin
possibl
factor
affect
tsfaa
patient
admit
intens
care
unit
icu
secondari
sepsi
method
retrospect
cohort
studi
collect
medic
data
outcom
patient
sepsi
treat
taipei
tzu
chi
hospit
januari
decemb
assess
studi
outcom
includ
icu
mortal
rate
diseas
sever
use
indic
includ
length
stay
icu
durat
vasopressor
use
tsfaa
group
categor
result
total
patient
includ
patient
exclud
appropri
antibiot
prior
mortal
among
pathogen
detect
signific
differ
found
among
group
percentag
patient
follow
acinetobact
speci
distribut
longer
tsfaa
group
p
percentag
polymicrobi
infect
organ
infect
sourc
higher
tsfaa
h
group
compar
group
shorter
time
period
p
percentag
patient
prior
antibiot
use
higher
tsfaa
h
tsfaa
shorter
durat
multivari
analys
organ
mdro
total
day
previou
antibiot
charlson
comorbid
score
mechan
ventil
septic
shock
signific
characterist
factor
tsfaa
p
conclus
previou
antibiot
use
mdro
comorbid
mechan
ventil
septic
shock
may
prolong
delay
time
onset
sepsi
first
appropri
antibiot
earli
inquiri
risk
factor
may
help
select
appropri
soon
possibl
sf
sw
ck
kl
cm
hs
wc
north
district
hospit
depart
medicin
hong
kong
hong
china
ruttonje
tang
shiu
kin
hospit
depart
integr
medic
servic
hong
kong
hong
china
kwong
wah
hospit
depart
medicin
geriatr
hong
kong
hong
china
queen
elizabeth
hospit
depart
medicin
hong
kong
hong
china
unit
christian
hospit
depart
medicin
geriatr
hong
kong
hong
china
alic
ho
miu
ling
nethersol
hospit
depart
medicin
geriatr
hong
kong
hong
china
princess
margaret
hospit
depart
medicin
hong
kong
hong
china
background
aim
introduct
accord
survey
hospit
author
ha
hong
kong
patient
requir
ventil
niv
depart
medicin
five
acut
hospit
eight
design
ventil
bed
total
thirteen
pilot
hospit
seven
cluster
ha
sinc
order
enhanc
appropri
care
case
requir
ventilatori
support
method
deignat
bed
equip
enhanc
respiratori
equip
monitor
capabl
standard
care
two
nurs
guidelin
patient
invas
ventil
endors
ha
respect
enhanc
compet
conduct
respect
commenc
program
pilot
hospit
via
enhanc
curriculum
corpor
train
mechan
place
review
monitor
ventil
util
regularli
evalu
complianc
enhanc
nurs
care
qualiti
indic
done
everi
year
sinc
result
overal
occup
design
ven
bed
novemb
three
audit
conduct
total
case
design
bed
audit
period
sinc
better
complianc
rate
vers
less
mask
relat
skin
lesion
vers
less
averag
number
advers
effect
niv
vers
less
mask
leak
lmin
vers
lmin
associ
lower
mortal
risk
unplan
extub
also
lower
zero
vers
conclus
patient
ventilatori
support
receiv
better
nurs
care
minim
discomfort
less
complic
design
bed
sf
kl
ck
ym
wc
sw
wc
hs
north
district
hospit
depart
medicin
hong
kong
hong
china
kwong
wah
hospit
depart
medicin
geriatr
hong
kong
hong
china
twgh
wong
tai
sin
hospit
depart
tbc
hong
kong
hong
china
pamela
youd
nethersol
eastern
hospit
depart
medicin
hong
kong
hong
china
queen
elizabeth
hospit
depart
medicin
hong
kong
hong
china
ruttonje
tang
shiu
kin
hospit
depart
integr
medic
servic
hong
kong
hong
china
princess
margaret
hospit
depart
medicin
geriatr
hong
kong
hong
china
alic
ho
miu
ling
nethersol
hospit
depart
medicin
hong
kong
hong
china
background
aim
introduct
patient
receiv
invas
mechan
ventil
imv
critic
ill
requir
nurs
care
howev
patient
imv
manag
gener
medic
ward
imv
program
commenc
design
bed
medic
depart
five
acut
hospit
hong
kong
kwong
wah
hospit
north
district
hospit
pamela
youd
nethersol
eastern
hospit
queen
elizabeth
hospit
unit
christian
hospit
sinc
septemb
object
nurs
complianc
endotrach
tube
standard
care
assess
varianc
complianc
gener
design
imv
bed
method
audit
conduct
five
hospit
novemb
decemb
patient
receiv
imv
gener
imv
bed
modifi
standard
audit
form
use
evalu
complianc
criteria
standard
care
patient
endotrach
tube
result
nurs
care
patient
imv
bed
gener
bed
audit
major
criteria
met
varianc
wide
four
criteria
gener
patient
cuff
pressur
regularli
check
versu
imv
patient
percent
gener
patient
prop
degre
feed
transport
versu
imv
patient
eighti
percent
gener
patient
oral
hygien
maintain
compar
imv
patient
final
readi
wean
continu
assess
imv
patient
compar
gener
patient
conclus
audit
reveal
measur
prevent
pneumonia
could
reinforc
includ
prop
patient
oral
hygien
mainten
prevent
tracheal
complic
regular
cuff
pressur
monitor
vital
low
complianc
might
relat
avail
equip
earli
wean
help
prevent
complic
howev
assess
requir
expertis
train
experienc
staff
z
ao
x
wu
shanghai
renji
hospit
afflict
jiaotong
univers
school
medicin
depart
respiratori
diseas
shanghai
china
background
aim
although
particip
inflamm
lung
injuri
whether
play
import
role
pseudomona
aeruginosa
pa
ali
mechan
remain
unclear
therefor
compar
respons
mice
mice
vivo
model
ali
vitro
model
mous
macrophag
cell
method
cell
cultur
presenc
absenc
sirna
exposur
pa
hr
pa
intranas
administ
mice
lung
inflammatori
injuri
underli
mechan
regul
ali
subsequ
determin
result
level
increas
cell
lung
tissu
obtain
mous
model
ali
lung
inflamm
neutrophil
infiltr
lung
tissu
tumor
necrosi
factor
interleukin
lung
permeabl
lung
wetdri
weight
ratio
bronchoalveolar
lavag
fluid
balf
protein
concentr
mortal
rate
attenu
mice
inflammatori
reaction
tumor
necrosi
factor
interleukin
apoptosi
rate
reduc
cell
moreov
role
ali
partial
restor
bind
lipopolysaccharid
bind
protein
lbp
confirm
conclus
find
suggest
protect
ali
via
bind
lbp
eh
chun
ji
han
cho
jh
woo
yj
kim
dy
kim
gy
lee
school
ewha
woman
univers
depart
anesthesiolog
pain
medicin
seoul
republ
korea
background
aim
protect
lung
ventil
strategi
ventil
provid
benefici
effect
postop
pulmonari
complic
howev
effect
high
risk
patient
undergo
lung
surgeri
known
aim
studi
compar
effect
protect
lung
ventil
high
risk
group
low
risk
group
method
fifti
two
patient
schedul
elect
thoracoscop
lung
surgeri
enrol
particip
categor
accord
ariscat
score
score
high
risk
group
score
low
risk
group
ventil
use
endobronchi
tube
ventil
strategi
compos
tidal
volum
mlkg
peep
cm
peak
inspiratori
pressur
plateau
airway
pressur
lung
complianc
check
prior
begin
ventil
ttlv
interv
ventil
arteri
blood
ga
analysi
perform
point
time
ttlv
postop
pulmonari
complic
observ
use
chest
medic
record
within
postop
hour
result
arteri
oxygen
tension
significantli
decreas
high
risk
group
mmhg
compar
low
risk
group
mmhg
p
howev
differ
peak
inspiratori
pressur
plateau
airway
pressur
ttlv
two
group
static
lung
complianc
decreas
high
risk
group
ttlv
differ
incid
postop
pulmonari
complic
two
group
conclus
protect
lung
ventil
strategi
compos
tidal
volum
mlkg
peep
cm
applic
ventil
without
increas
plateau
airway
pressur
high
risk
patient
f
ilka
mr
raoufi
tarbiat
modar
univers
depart
faculti
medic
scienc
tehran
iran
background
aim
respiratori
dynam
exhibit
complex
pattern
variat
also
evid
suggest
rate
volum
respir
alter
airway
resist
respons
stimul
sinc
airway
hyperrespons
cardin
featur
asthma
suppos
ventil
variabl
tidal
volum
respiratori
rate
improv
airway
respons
asthmat
rat
method
initi
record
respir
control
rat
variabl
respiratori
pattern
use
bodi
box
plethysmographi
anim
sensit
ovalbumin
accord
pattern
allerg
asthma
ventil
variabl
constant
breath
pattern
min
use
harvard
inspira
ventil
variabl
breath
pattern
appli
ventil
mean
interfac
command
matlab
final
airway
respons
methacholin
compar
asthmat
anim
ventil
two
differ
breath
pattern
result
normal
rat
breath
exhibit
complex
variabl
respiratori
rhythm
volum
compar
ventil
asthmat
rat
constant
tidal
volum
respiratori
rate
variabl
ventil
equival
minut
volum
decreas
airway
respons
methacholin
f
p
conclus
breath
pattern
variabl
natur
ventil
variabl
pattern
decreas
airway
respons
asthmat
condit
therefor
suggest
variabl
ventil
novel
mode
may
improv
prognosi
asthmat
patient
need
ventil
l
xb
qin
zh
chen
hx
li
bj
sun
xq
fang
ct
liu
gener
hospit
peopl
liber
hospit
nanlou
respiratori
depart
beij
china
background
aim
hypercapn
acidosi
report
protect
lung
injuri
vili
far
underli
mechan
fulli
investig
heme
funderment
endogen
adapt
mechan
protect
cellular
injuri
variou
stress
condit
previous
establish
play
remark
protect
role
vili
virtu
action
present
studi
aim
investig
whether
protect
effect
hypercapn
acidosi
vili
associ
method
rabbit
anesthet
tracheotom
receiv
hour
ventil
randomli
alloc
one
four
follow
group
low
tidal
volum
lvt
group
high
tidal
volum
normocapnia
hvt
nc
group
high
tidal
volum
hypercapnia
hvt
hc
group
high
tidal
volum
hypercapnia
inhibitor
znpp
hvt
hc
znpp
group
ga
mixtur
carbon
dioxid
oxygen
balanc
administerd
maintain
nc
mmhg
hc
mmhg
end
experi
protein
express
enzymat
activ
measur
lung
injuri
assess
histopatholog
bronchoalveolar
lavag
bal
fluid
protein
content
neutrophil
infiltr
lung
ratio
level
inflammatori
cytokin
pulmonari
oxid
reaction
result
injuri
hvt
caus
signific
lung
injuri
includ
increas
histolog
injuri
score
bronchoalveolar
lavag
fluid
protein
content
neutrophil
infiltr
lung
ratio
well
elev
inflammatori
cytokin
oxid
reaction
hypercapn
acidosi
enhanc
express
activ
markedli
reduc
alter
treatment
znpp
decreas
activ
partial
revers
protect
effect
hypercapn
acidosi
conclus
protect
effect
hypercapn
acidosi
vili
partial
mediat
properti
gp
e
de
w
del
taytay
philippin
philippin
heart
center
divis
pulmonari
critic
care
medicin
quezon
citi
philippin
background
aim
rapid
shallow
breath
index
rsbi
commonli
use
clinic
predict
outcom
wean
mechan
ventil
howev
studi
shown
singl
rsbi
determin
reflect
entir
wean
process
aim
studi
evalu
measur
rsbi
chang
rsbi
rate
predictor
wean
outcom
spontan
breath
trial
compar
wean
paramet
method
studi
prospect
cohort
analysi
consist
subject
meet
criteria
wean
normal
wean
paramet
spontan
breath
trial
sbt
start
rsbi
determin
first
minut
spontan
breath
trial
rsbi
rate
comput
base
formula
x
wean
success
failur
ascertain
result
wean
success
patient
fail
patient
among
wean
failur
patient
requir
reinstitut
mechan
ventil
within
hour
patient
requir
noninvas
ventil
extub
patient
could
extub
sbt
rsbi
rate
significantli
predict
wean
outcom
p
sensit
specif
also
rsbi
rate
auc
show
superior
predict
power
static
complianc
auc
dynam
complianc
auc
singl
rsbi
auc
conclus
studi
prove
use
rsbi
rate
dynam
measur
lung
mechan
accur
predictor
wean
outcom
even
reliabl
wean
paramet
lung
static
dynam
complianc
singl
rsbi
determin
ft
chung
saint
paul
hospit
thorac
medicin
taoyuan
taiwan
background
aim
alveolar
recruit
maneuv
rm
report
improv
oxygen
acut
respiratori
distress
syndrom
ard
may
relat
reduc
extravascular
lung
water
evlw
anim
studi
design
investig
effect
rm
evlw
patient
ard
method
open
label
prospect
random
control
trial
ard
patient
conduct
two
hospit
north
taiwan
patient
divid
two
group
without
rm
clinic
valu
includ
arteri
oxygen
tensionfract
inspir
oxygen
ratio
evlw
index
durat
ventil
support
mortal
rate
compar
group
result
ard
patient
mechan
ventil
support
random
receiv
ventil
treatment
rm
rm
group
n
without
group
n
baselin
demograph
characterist
similar
group
recruit
evlwi
vs
mlkg
p
vs
mlkg
p
improv
day
howev
evlwi
significantli
chang
group
day
conclus
rm
feasibl
method
improv
oxygen
evlw
index
ard
patient
well
decreas
ventil
day
intens
care
unit
stay
durat
g
hong
ys
kim
js
park
yk
jee
dankook
univers
colleg
dankook
univers
hospit
divis
pulmonari
critic
depart
intern
medicin
republ
korea
background
aim
critic
ill
patient
acut
respiratori
failur
arf
undergo
bronchoscopi
increas
risk
complic
previou
studi
shown
awak
hypoxem
patient
ventil
help
prevent
hypoxemia
bronchoscop
procedur
recent
nasal
cannula
hfnc
therapi
use
improv
oxygen
patient
arf
howev
minim
data
evalu
use
hfnc
undergo
bronchoscopi
bal
studi
investig
feasibl
safeti
hfnc
therapi
arf
patient
undergo
bronchoscopi
bal
method
identifi
patient
suspect
pneumonia
hypoxem
arf
admit
micu
receiv
hfnc
therapi
undergo
bronchoscopi
bal
may
march
dkuh
medic
record
review
retrospect
result
subject
includ
men
women
mean
age
year
patient
success
complet
bal
hfnc
patient
requir
endotrach
intub
bal
two
patient
requir
endotrach
intub
mechan
ventil
hour
bal
respect
etiolog
acut
respiratori
failur
bacteri
pneumonia
influenza
pneumonia
pneumonia
due
undefin
pathogen
diffus
alveolar
hemorrhag
acut
exacerb
idiopath
pulmonari
fibrosi
hfnc
initi
mean
rang
flow
lmin
rang
lmin
mean
baselin
rang
mm
hg
end
procedur
rang
chang
mean
blood
pressur
heart
rate
respiratori
rate
valu
induc
procedur
reach
signific
p
conclus
applic
hfnc
safe
effect
altern
intub
accomplish
bronchoscopi
bal
patient
hypoxem
arf
w
horapong
chulalongkorn
hospit
nurs
bangkok
thailand
background
aim
ventil
associ
pneumonia
vap
one
common
fatal
complic
patient
hospit
close
monitor
incid
vap
regularli
launch
prevent
strategi
reduc
occurr
infect
howev
vap
rate
still
high
especi
medic
intens
care
unit
icu
method
retrospect
review
incid
vap
patient
admit
medic
icu
king
chulalongkorn
memmori
hospit
modifi
ventil
care
bundl
vcb
implement
icu
april
bundl
includ
follow
issu
hand
wash
hob
elev
maintain
cuff
pressur
oral
decontamin
wean
protocol
ventil
circuit
care
promot
multidisciplinari
team
coordin
vcb
compar
vap
rate
modifi
vcb
applic
evalu
factor
contribut
result
vap
rate
modifi
vcb
implement
high
shown
bundl
help
decreas
vap
rate
occurr
lowest
rate
period
major
factor
associ
improv
multidisciplinari
team
approach
frequent
check
nevertheless
protocol
play
minim
role
wean
figur
vap
rate
implement
conclus
modifi
ventil
care
bundl
effect
strategi
reduc
vap
suzuki
shiozawa
e
miyawaki
k
miura
n
nagano
fujimoto
tsujimoto
kakuwa
matsubayashi
suzuki
k
sakamoto
yamamoto
k
kobayashi
hashimoto
j
takasaki
iikura
izumi
takeda
hojo
h
sugiyama
center
hospit
nation
center
global
health
medicin
depart
respiratori
medicin
tokyo
japan
background
aim
mechan
ventil
one
commonli
appli
intervent
icu
adapt
support
ventil
asv
posit
pressur
mode
mechan
ventil
control
automat
adjust
base
patient
requir
addit
latest
version
intelliv
asv
autom
sbt
modul
quick
wean
perform
sbt
accord
predefin
criteria
soon
level
assist
patient
low
enough
intelliv
asv
alreadi
use
safe
mechan
ventil
passiv
activ
patient
healthi
lung
cardiac
surgeri
ard
andor
copd
articl
report
case
depart
treat
mechan
ventil
use
intelliv
asv
case
present
patient
femal
sever
asthma
attack
accompani
hypercapnia
patient
femal
acut
exacerb
interstiti
pneumonia
patient
femal
chronic
lower
respiratori
tract
infect
due
ntm
case
requir
mechan
ventil
two
patient
sever
hypoxem
one
patient
sever
hypercapnia
patient
receiv
initi
treatment
primari
diseas
mechan
ventil
adjust
respiratori
condit
treatment
radiolog
find
oxygen
laboratori
find
gradual
improv
case
surviv
without
sever
complic
two
case
immedi
success
wean
use
asv
one
case
success
wean
use
asv
case
requir
addit
mechan
support
muscl
weak
conclus
intelliv
asv
safe
use
mainten
wean
phase
mechan
ventil
differ
lung
condit
therefor
use
may
consid
divis
howev
sever
respiratori
failur
due
chronic
respiratori
diseas
muscl
weak
chronic
type
respiratori
failur
need
particular
attent
n
wiboonsirichai
n
kongpolprom
chulalongkorn
thai
red
cross
divis
pulmonari
critic
care
depart
faculti
medicin
bangkok
thailand
introduct
caus
variou
reaction
acut
respiratori
distress
syndrom
ard
cardiac
dysfunct
follow
rel
uncommon
report
case
anaphylact
shock
ard
cardiomyopathi
multipl
case
present
woman
admit
intens
care
unit
icu
due
patient
unluckili
got
minut
admiss
walk
park
swarm
bee
attack
honeycomb
fell
tree
head
stung
immedi
sent
hospit
emerg
depart
develop
hypotens
facial
angioedema
expiratori
wheez
lung
oxygen
desatur
addit
skin
reveal
uncount
diagnos
sever
anaphylact
reaction
receiv
inject
antihistamin
steroid
epinephrin
plu
nebul
bronchodil
besid
sting
skin
remov
much
possibl
despit
provid
treatment
still
difficulti
breath
becam
respiratori
failur
chest
radiographi
show
bilater
diffus
alveolar
opac
mild
cardiomegali
shown
figur
consequ
assist
invas
mechan
ventil
transfer
icu
icu
addit
investig
perform
evalu
caus
pulmonari
edema
electrocardiographi
reveal
sinu
tachycardia
earli
repolar
minim
lead
avl
echocardiographi
demonstr
mildli
impair
systol
function
lvef
apic
balloon
nevertheless
inferior
vena
cava
ivc
dilat
ivc
distens
index
less
serum
tryptas
high
find
compat
anaphylaxi
complic
noncardiogen
pulmonari
edema
cardiomyopathi
result
lung
protect
strategi
standard
treatment
anaphylaxi
appli
final
recov
unev
extub
day
admiss
result
figur
conclus
case
demonstr
uncommon
sever
reaction
anaphylaxi
massiv
j
h
j
univers
gener
hospit
depart
medicin
manila
philippin
univers
gener
hospit
section
pulmonari
depart
medicin
manila
philippin
univers
gener
hospit
depart
surgeri
manila
philippin
univers
gener
hospit
depart
patholog
manila
philippin
background
aim
teratoma
aris
entir
within
lung
extrem
rare
entiti
less
report
case
worldwid
sinc
first
describ
present
case
old
femal
diagnos
intrapulmonari
teratoma
present
hemoptysi
case
highlight
import
combin
diagnost
tool
arriv
correct
diagnosi
time
treatment
potenti
curabl
benign
intrapulmonari
mass
prevent
fatal
complic
morbid
method
old
femal
came
year
histori
chronic
cough
recurr
hemoptysi
imag
studi
show
heterogen
mass
locat
right
upper
lobe
nodular
calcif
bronchoscopi
done
reveal
strand
hair
aris
right
upper
lobe
lobectomi
perform
show
entir
right
upper
lobe
convert
larg
mix
mass
sebum
teeth
hair
strand
histopatholog
confirm
matur
teratoma
lung
result
matur
teratoma
often
abdomin
locat
may
occasion
seen
thorac
area
usual
anterior
mediastinum
pure
intrapulmonari
teratoma
extrem
rare
entiti
case
may
largest
intrapulmonari
matur
teratoma
measur
x
x
cm
conclus
case
highlight
import
combin
imag
bronchoscop
modal
diagnos
benign
lung
neoplasm
good
chanc
success
cure
fa
c
mk
medic
citi
section
pulmonari
medicin
pasig
citi
philippin
medic
citi
depart
intern
medicin
pasig
citi
philippin
background
aim
endobronchi
ultrasound
transbronchi
needl
aspir
bronchoscop
techniqu
util
stage
lung
cancer
evalu
mediastin
lymphadenopathi
introduc
philippin
regular
use
institut
sinc
object
studi
evalu
diagnost
yield
complic
procedur
well
factor
affect
method
retrospect
chart
histopatholog
review
done
consecut
adult
patient
underw
medic
citi
januari
decemb
result
overal
diagnost
yield
malign
benign
diseas
secondari
tuberculosi
subcarin
lymph
node
locat
three
aspir
per
procedur
show
tendenc
improv
diagnost
yield
major
complic
associ
procedur
conclus
preliminari
experi
philippin
show
promis
tool
evalu
mediastin
lymphadenopathi
lesion
high
diagnost
yield
safeti
profil
futur
studi
need
determin
way
significantli
improv
diagnost
perform
moslehi
shiraz
univers
medic
scienc
head
pediatr
pulmonolari
divis
shiraz
iran
background
aim
technic
develop
field
pediatr
bronchoscopi
expand
diagnost
possibl
procedur
time
make
less
invas
today
almost
examin
carri
outpati
basi
flexibl
fiberopt
instrument
use
children
reach
school
age
analgesia
sedat
technic
innov
includ
endoscop
laser
surgeri
exampl
treat
subglot
hemangioma
even
young
infant
bronchial
balloon
dilat
airway
stenos
develop
improv
render
less
stress
diagnosi
treatment
airway
pulmonari
problem
children
method
retrospect
studi
one
year
period
total
children
male
femal
respiratori
diseas
age
day
year
examin
andor
treat
bronchoscopi
includ
bronchoscop
intervent
sedat
local
anesthesia
result
flexibl
fiberopt
bronchoscopi
use
tool
evalu
patient
noisi
breath
stridor
persist
wheez
persist
atelectasi
pneumonia
mucos
deplug
suspect
foreign
bodi
aspir
bronchial
stenosi
patient
tracheostomi
conclus
high
diagnost
therapeut
yield
low
complic
strongli
support
use
flexibl
fibropt
bronchoscop
diagnost
evalu
infant
children
varieti
pulmonari
problem
moslehi
shiraz
univers
medic
scienc
pediatr
pulmonolari
shiraz
iran
background
aim
foreign
bodi
aspir
emerg
children
requir
immedi
bronchoscopi
anesthesiathi
prospect
random
clinic
trial
undertaken
compar
effect
use
inhal
budesonid
remov
inhal
foreign
bodi
children
complic
method
eighti
six
children
age
month
post
fibropt
flexibl
bronchoscopi
remov
airway
foreign
bodi
period
month
institut
studi
forti
three
use
two
dose
budesonid
budiair
micro
h
interv
valv
hold
chamber
spacer
mask
bronchoscopi
result
major
complic
includ
oxygen
desatur
either
isol
associ
laryngospasm
cough
bronchospasm
significantli
lower
budesonid
group
conclus
use
inhal
budesonid
perform
fiberopt
bronchoscopi
effect
medic
prevent
complic
p
vangtal
rajavithi
pulmonari
bangkok
thailand
background
aim
flexibl
bronchoscopi
increas
risk
hypoxemia
patient
baselin
impair
lung
function
oxygen
cannula
routin
use
procedur
howev
desatur
occasion
occur
nasal
cannula
hfnc
deliv
higher
provid
benefit
altern
convent
oxygen
cannula
object
aim
studi
compar
bronchoscopi
use
hfnc
convent
oxygen
cannula
method
patient
assign
receiv
either
hfnc
hfnc
group
convent
cannula
control
group
abg
collect
separ
time
bronchoscop
bronchoscop
insert
vocal
cord
end
procedur
post
procedur
period
continu
oxygen
therapi
result
among
patient
patient
hfnc
group
shown
differ
group
control
group
shown
tend
increas
signific
hfnc
group
final
hfnc
group
shown
signific
control
group
conclus
applic
hfnc
bronchoscopi
may
use
select
patient
especi
sever
hypoxemia
hypercapn
risk
chaudhuri
u
devaraj
g
dsouza
p
ramachandran
u
maheswari
st
john
medic
colleg
hospit
pulmonari
medicin
critic
care
bangalor
india
background
aim
fibreropt
bronchoscopi
fob
common
invas
investig
field
respiratori
medicin
patient
undergo
fob
report
vari
experi
regard
anxieti
level
awar
investig
comfort
level
procedur
studi
aim
determin
live
experi
patient
undergo
fob
method
qualit
research
design
use
patient
year
age
undergon
fob
first
time
includ
depth
interview
taken
languag
comfort
data
satur
achiev
new
inform
idea
deriv
patient
understood
adequ
sampl
size
reach
focus
group
discuss
fgd
held
select
patient
purpos
sampl
health
care
provid
investig
conduct
discuss
script
question
answer
particip
investig
guid
fgd
depth
interview
held
conveni
place
particip
provid
snack
drink
later
data
analysi
done
softwar
main
theme
identifi
categor
result
sinc
ongo
studi
result
analys
discuss
confer
later
conclus
analysi
experi
patient
undergo
fob
awar
summar
sw
ci
ayl
tm
r
abdul
ja
abdul
serdang
hospit
respiratori
depart
medicin
selangor
malaysia
univers
kebangsaan
malaysia
medic
centr
respiratori
depart
intern
medicin
kuala
lumpur
malaysia
background
aim
case
foreign
bodi
lodg
airway
uncommon
especi
children
remov
foreign
bodi
usual
success
done
use
flexibl
bronchoscop
variou
extract
devic
rigid
bronchoscopi
reserv
challeng
case
result
present
case
dislodg
tooth
result
accid
involv
man
initi
attempt
remov
tooth
flexibl
bronchoscop
cryoextract
futil
tooth
success
remov
rigid
biopsi
forcep
introduc
via
rigid
bronchoscopi
done
surround
granul
tissu
embed
tooth
within
airway
lumen
conclus
flexibl
bronchoscopi
remain
procedur
choic
foreign
bodi
remov
owe
wide
avail
howev
rigid
bronchoscopi
provid
addit
option
challeng
case
institut
facil
avail
kato
nippon
medic
school
chiba
hokuso
hospit
respiratori
diseas
center
inzai
japan
background
aim
aim
evalu
use
safeti
patient
undergo
procedur
differenti
sarcoidosi
diseas
method
method
investig
retrospect
use
safeti
patient
undergo
bronchoscopi
suspect
sarcoidosi
sinc
introduct
hospit
result
result
patient
underw
bronchoscopi
needl
laryng
patient
receiv
bf
due
suspect
sarcoidosi
patient
underw
bal
tblb
patient
receiv
addit
conduct
patient
without
evid
accident
symptom
although
maximum
diamet
lymph
node
patient
mm
tend
smaller
previou
report
diagnos
sarcoidosi
underw
diagnos
diseas
unknown
obtain
find
case
bal
tblb
among
procedur
conduct
tblb
posit
tend
higher
lymphocyt
count
bal
fluid
tblb
posit
versu
tblb
neg
p
signific
differ
also
definit
differ
pulmonari
lesion
conclus
conclus
use
differenti
sarcoidosi
diseas
compar
tblb
studi
find
indic
procedur
conduct
safe
without
accident
symptom
even
rel
small
lymph
node
publish
detail
studi
result
congress
apsr
pj
kumar
rk
yadav
sobti
indraprastha
apollo
hospit
depart
respiratori
medicin
new
delhi
india
background
aim
quantit
bacteriolog
method
increas
reliabl
sputum
specimen
diagnosi
lower
respiratori
tract
infect
studi
design
compar
diagnost
yield
deep
tracheal
aspir
bal
sampl
patient
pneumonia
tertiari
care
hospit
analys
whether
deep
endotrach
aspir
use
substitut
bal
less
expens
less
invas
mean
obtain
specimen
cultur
diagnos
pneumonia
method
conduct
prospect
compar
studi
patient
icu
hdu
intub
tracheostomis
show
sign
pneumonia
patient
two
sampl
collect
et
aspir
bronchoscop
bal
sampl
suction
cathet
introduc
et
advanc
beyond
carina
collect
lower
respiratori
tract
secret
mucu
trap
fiberopt
bronchoscop
introduc
advanc
bronchial
orific
select
base
radiograph
locat
new
pulmonari
infiltr
bal
perform
instil
ml
steril
normal
salin
quantit
cultur
balendotrach
aspir
done
accord
standard
protocol
result
et
cultur
show
frequenc
growth
wherea
bal
show
frequenc
variou
organ
isol
acinetobact
seen
frequent
method
frequenc
via
et
via
bal
klebsiella
et
bal
second
common
organ
isol
follow
pseudomona
et
bal
howev
comparison
overal
frequenc
differ
isol
p
valu
found
statist
signific
conclus
result
demonstr
eta
balf
gram
stain
cultur
interchang
eta
accept
altern
bronchoscopi
evalu
suspect
pneumonia
kamiyoshihara
ibe
n
kawatani
f
ohsawa
r
yoshikawa
maebashi
red
cross
hospit
gener
thorac
surgeri
maebashi
japan
background
aim
describ
uniqu
case
inhal
foreign
bodi
piec
chopstick
overlook
year
method
woman
admit
hospit
refractori
pneumonia
hospit
repeatedli
recurr
pneumonia
left
lower
lung
histori
hemoptysi
chest
comput
tomographi
ct
show
parenchym
consolid
posterior
segment
segment
right
upper
lobe
patient
opt
surgic
treatment
rather
intervent
refractori
pneumonia
result
right
upper
lobectomi
perform
resect
specimen
reveal
obstruct
posterior
segment
bronchu
right
upper
lobe
foreign
bodi
found
embed
granul
tissu
foreign
bodi
piec
chopstick
question
patient
rememb
aspir
chopstick
eat
sever
year
earlier
difficult
remov
intrabronchi
foreign
bodi
recommend
surgic
treatment
conclus
knowledg
first
case
present
english
literatur
foreign
bodi
piec
chopstick
undetect
year
sw
leong
n
mona
zaria
ar
jamalul
azizi
serdang
hospit
pulmonolog
unit
kajang
malaysia
background
aim
benign
tracheobronchi
stenosi
debilit
complic
endobronchi
tuberculosi
caus
recurr
airway
obstruct
tracheal
resect
reconstruct
consid
gold
standard
treatment
tracheobronchi
stenosi
howev
variou
bronchoscop
modal
avail
may
obviat
need
surgeri
method
describ
case
seri
seven
patient
tracheobronchi
stenosi
treat
bronchoscop
intervent
juli
june
centr
result
patient
year
old
seven
patient
previous
diagnos
endobronchi
tuberculosi
year
six
patient
left
main
bronchu
stenosi
one
level
stenosi
trachea
left
main
bronchu
patient
underw
balloon
dilat
topic
mitomycin
applic
furthermor
stent
done
addit
procedur
five
patient
use
dumon
silicon
stent
size
mm
one
patient
stent
migrat
necessit
emerg
thoracotomi
stent
remov
howev
patient
left
main
bronchu
remain
patent
post
dilat
amongst
patient
stent
four
stent
remov
one
still
situ
maintain
patent
trachea
left
main
bronchu
subsequ
diagnost
bronchoscopi
stent
could
deploy
anoth
patient
bronchomalacia
recurr
stenosi
conclus
conclus
combin
bronchoscop
balloon
dilat
topic
mitomycin
applic
tracheobronchi
stent
feasibl
altern
surgic
treatment
benign
tracheobronchi
stenosi
howev
natur
intervent
palli
repeat
procedur
necessari
major
patient
better
bronchoscop
approach
need
manag
airway
complic
p
p
central
chest
institut
thailand
chest
nonthaburi
thailand
central
chest
institut
thailand
radiolog
nonthaburi
thailand
background
aim
tracheobronchopathia
osteochondroplastica
tpo
rare
benign
disord
character
multipl
osseou
cartilagin
nodul
aris
trachea
major
bronchi
spare
posterior
membran
part
condit
usual
asymptomat
andor
nonspecif
respiratori
symptom
chronic
cough
wheez
recurr
respiratori
tract
infect
occasion
hemoptysi
studi
first
case
tpo
complic
fungal
tuberculosi
thailand
thoroughli
describ
result
case
present
femal
present
chronic
product
cough
signific
weight
two
month
chest
radiograph
show
reticulonodular
opac
rul
rll
sputum
bacilli
neg
consecut
day
chest
ct
scan
demonstr
multipl
small
submucos
nodul
calcif
tracheal
wall
bronchial
wall
tree
bud
appear
small
area
peribronchovascular
consolid
scatter
lung
evalu
natur
lesion
flexibl
bronchoscopi
perform
multipl
irregular
nodul
protrud
tracheal
lumen
visual
nodul
distribut
along
anterolater
wall
trachea
main
bronchi
histopatholog
exam
reveal
inflam
bronchial
tissu
presenc
fragment
osseou
tissu
bronchial
submucosa
evid
point
toward
diagnosi
tpo
howev
clinic
symptom
possibl
superimpos
infect
fungal
hypha
detect
special
stain
bronchial
wash
fluid
aspergillu
fumigatu
identifi
subsequ
furthermor
bronchial
wash
fluid
gene
xpert
posit
patient
treat
antifung
antituberculosi
regimen
month
patient
report
relief
symptom
chest
radiograph
show
slight
improv
conclus
tpo
rare
condit
present
nonspecif
symptom
patient
chronic
cough
given
presumpt
diagnosi
common
diseas
investig
definit
diagnosi
consid
nakai
matsumoto
f
suzuki
tsuchida
izumo
nation
cancer
center
hospit
respiratori
endoscopi
depart
endoscopi
tokyo
japan
background
aim
sinc
nation
lung
screen
trial
nlst
show
util
ct
screen
detect
rate
diagnos
lesion
nsl
increas
although
previous
report
effect
diagnost
bronchoscopi
nsl
predict
factor
investig
method
consecut
patient
underw
diagnost
bronchoscopi
nsl
institut
septemb
januari
enrol
among
case
perform
radial
endobronchi
ultrasound
radial
ebu
final
diagnos
lung
cancer
includ
retrospect
studi
review
analyz
examin
associ
diagnost
yield
clinic
factor
follow
locat
central
intern
peripher
ct
ratio
size
mm
biopsi
time
use
guid
sheath
use
visibl
chest
fine
use
virtual
bronchoscopi
vb
use
bronchu
sign
ct
posit
neg
result
enrol
case
diagnos
procedur
diagnost
yield
univari
analysi
posit
bronchu
sign
signific
factor
higher
diagnost
yield
vs
p
use
vb
tend
higher
yield
signific
differ
vs
p
convers
multivari
analysi
posit
bronchu
sign
use
vb
signific
relationship
higher
diagnost
yield
p
odd
ratio
p
odd
ratio
respect
conclus
posit
bronchu
sign
ct
use
vb
posit
predict
factor
diagnost
bronchoscopi
nsl
n
k
n
h
h
h
stmarianna
univers
divis
respiratori
medicin
kawasaki
japan
stmarianna
univers
divis
respiratori
surgeri
kawasaki
japan
background
aim
recent
use
strain
ratio
sr
elastographi
report
diagnosi
breast
lesion
diagnost
accuraci
sensit
specif
posit
neg
predict
valu
respect
elastographi
ebu
mediastin
lymph
node
new
techniqu
differenti
benign
malign
lymph
node
method
perform
case
use
elastographi
olympu
tokyo
japan
patient
diagnos
perform
evalu
lymph
node
b
mode
hyperecho
interfac
echo
doppler
mode
aberr
vessel
sr
elastographi
purpos
studi
evalu
use
sr
elastographi
diagnosi
patient
mediastin
lymphadenopathi
investig
result
sixti
two
patient
underw
februari
may
patient
male
femal
age
rang
median
year
benign
lymph
node
ln
hyperecho
interfac
echo
b
mode
malign
ln
case
hyperecho
interfac
echo
sensit
specif
accuraci
respect
benign
ln
aberr
vessel
doppler
mode
observ
malign
ln
aberr
vessel
observ
sensit
specif
accuraci
respect
sr
measur
case
malign
ln
higher
sr
benign
evalu
roc
curv
sr
differenti
malign
benign
lesion
decid
point
sensit
specif
accuraci
respect
conclus
studi
show
diagnost
accuraci
use
strain
ratio
elastographi
might
greater
use
hyperecho
interfac
echo
aberr
vessel
n
kuwahara
n
oda
yamanashi
red
cross
hospit
intern
medicin
kawaguchiko
japan
background
aim
foreign
bodi
aspir
uncommon
among
adult
popul
estim
incid
bronchoscopi
perform
howev
life
threaten
common
caus
death
unexpect
accid
japan
method
healthi
man
caus
pulmonari
arrest
drink
larg
amount
alcohol
patient
brought
hospit
underw
cardiopulmonari
resuscit
emerg
medic
servic
fortun
patient
revert
sinu
rhythm
good
cardiac
output
perform
endotrach
intub
patient
hospit
immedi
intens
care
unit
could
maintain
oxygen
satur
although
artifici
ventil
suspect
exist
lodg
foreign
bodi
accord
abnorm
find
close
left
main
bronchu
chest
ct
scan
imag
tri
dislodg
use
flexibl
bronchoscopi
wait
increas
oxygen
satur
result
obviou
find
right
main
bronchu
contrast
piec
matter
complet
lodg
left
main
stem
bronchu
remov
foreign
bodi
patient
underw
bronchoscopi
use
grasp
basket
forcep
remov
complet
procedur
patient
wean
artifici
ventil
markedli
improv
oxygen
level
conscious
day
hospit
patient
went
excel
clinic
recoveri
despit
exist
atelectasi
aspir
pneumonia
discharg
hospit
day
conclus
report
case
abl
rescu
rapid
remov
foreign
bodi
w
boweja
p
korrungruang
rajavithi
hospit
faculti
pulmonari
depart
bangkok
thailand
background
aim
scleros
pneumocytoma
hemangioma
rare
benign
epitheli
tumor
lung
possibl
relat
pulmonari
epithelium
type
ii
pneumocyt
thoracotomi
usual
indic
definit
diagnosi
treatment
rare
diagnosi
made
use
tbna
present
case
diagnos
via
use
radial
probe
endobronchi
ultrasound
transbronchi
needl
aspir
tbna
method
woman
refer
asymptomat
right
upper
lung
nodul
chest
radiogram
thorax
comput
tomographi
reveal
contrast
enhanc
round
mass
upper
lobe
right
lung
fig
radial
probe
endobronchi
ultrasound
transbronchi
nodal
aspir
tbna
perform
result
patholog
examin
reveal
atyp
cell
suspici
scleros
pneumocytoma
immunohistochemistri
stain
show
reactiv
cytokeratin
ema
express
lumin
cell
fig
neg
synaptophysin
pulmonari
scleros
pneumocytoma
diagnos
conclus
conclus
present
case
diagnos
via
use
endobronchi
ultrasound
tbna
although
data
limit
endobronchi
ultrasound
tbna
altern
method
diagnosi
rare
lung
tumor
p
raksasagulwong
j
tscheikuna
p
bespinyowong
faculti
medicin
siriraj
mahidol
univers
divis
respiratori
diseas
depart
medicin
bangkok
thailand
background
aim
dieulafoy
lesion
bronchu
rare
condit
character
dilat
tortuou
arteri
project
submucosa
asymptomat
present
massiv
hemoptysi
hemoptysi
happen
spontan
bronchial
biopsi
embol
first
line
treatment
hemoptysi
endobronchi
treatment
describ
therapeut
approach
method
thai
man
present
massiv
hemoptysi
day
year
ago
also
came
hospit
hemoptysi
time
bronchoscopi
found
endobronchi
nodul
open
basal
segment
right
lower
lobe
bleed
pulmonari
angiogram
demonstr
arterioven
shunt
branch
right
bronchial
arteri
right
descend
pulmonari
arteri
diagnosi
dieulafoy
lesion
basal
segment
right
lower
lobe
made
bronchial
arteri
embol
bae
success
stop
bleed
result
time
bae
perform
proxim
right
bronchial
right
suprem
intercost
arteri
hemoptysi
still
persist
rigid
bronchoscopi
perform
reddish
nodul
activ
arteri
bleed
demonstr
posterior
wall
right
lower
lobe
open
nd
yap
laser
use
coagul
bronchial
surfac
around
bleed
vessel
bleed
stop
follow
flexibl
bronchoscopi
show
regress
nodul
month
later
recurr
hemoptysi
year
follow
conclus
pathogenesi
dieulafoy
diseas
bronchu
remain
unknown
abnorm
vessel
may
aris
system
system
pulmonari
system
arteri
embol
treatment
hand
laser
coagul
mainli
indic
bleed
endobronchi
tumor
may
use
case
report
dieulafoy
diseas
treat
laser
coagul
found
literatur
one
case
report
treat
argon
plasma
coagul
report
case
laser
coagul
show
efficaci
control
bleed
could
treatment
option
n
keurueangkul
j
tscheikuna
siriraj
hospit
divis
respiratori
diseas
tuberculosi
bangkok
noi
thailand
background
aim
endotrach
schwannoma
remain
exceedingli
rare
caus
airway
obstruct
first
report
case
neurogen
intrapulmonari
tumor
patient
gener
asymptomat
tumor
reach
critic
size
point
obstruct
symptom
seen
till
case
report
present
case
man
present
short
breath
treat
copd
exacerb
month
found
obstruct
tracheal
schwannoma
method
thai
man
admit
due
acut
respiratori
failur
central
wheez
intub
er
depart
experienc
progress
dyspnea
month
product
cough
occasion
hemoptysi
chest
tight
diagnos
copd
due
wheez
discov
upon
physic
examin
histori
ct
chest
show
lobul
polypoid
mass
left
later
wall
mid
trachea
measur
cm
ap
transvers
vertic
dimens
minim
left
peritrach
fat
invas
caus
nearli
complet
tracheal
obstruct
fiberopt
bronchoscopi
demonstr
tracheal
mass
cm
vocal
cord
caus
obstruct
lumen
contact
bleed
result
tumor
success
remov
rigid
bronchoscopi
histopatholog
tumor
mass
reveal
benign
nerv
sheath
tumor
evid
vascular
invasionbecaus
tumor
invad
tracheal
wall
tracheal
resect
perform
anastomosi
conclus
tracheal
schwannoma
rare
tumor
misdiagnos
obstruct
airway
diseas
due
late
present
mass
obstruct
tracheal
lumen
case
occur
trachea
caus
clinic
upper
airway
obstruct
differenti
diagnosi
tracheal
tumor
includ
benign
endotrach
schwannoma
jayusman
ar
hanafi
e
soeratman
hanif
dhamai
nation
cancer
hospit
respiratori
medicin
west
jakarta
indonesia
background
aim
renal
cell
carcinoma
rcc
common
type
kidney
cancer
adult
approxim
case
one
common
site
metastasi
rcc
lung
case
cancer
spread
lung
cure
chemotherapi
gener
lung
metastas
sign
widespread
cancer
poor
surviv
rate
limit
case
patient
lung
metastas
cure
surgeri
cryosurgeri
one
treatment
lung
metastas
besid
system
treatment
report
experi
cryosurgeri
metastat
lung
cancer
rcc
method
result
man
histori
renal
cell
carcinoma
admit
hospit
complaint
breathless
last
month
cough
hemoptysi
fever
chest
pain
loss
weight
weak
histori
hypertens
diabet
patient
vital
sign
blood
pressur
mmhg
puls
rate
beat
per
minut
respiratori
rate
cycl
beat
per
minut
temperatur
physic
examin
respiratori
movement
decreas
absent
sound
auscul
left
side
chest
laboratori
examin
normal
chest
pa
show
homogen
opac
left
upper
mid
lower
zone
fiber
optic
bronchoscop
insert
tube
left
main
bronchu
tumor
locat
cryo
machin
use
rapid
freez
cell
temperatur
liquid
nitrogen
tumor
tissu
frozen
pull
tumor
success
remov
surgeri
chest
pa
perform
cxr
show
improv
reduct
opacif
left
lung
conclus
cryosurgeri
consid
treatment
lung
metastas
mani
cancer
result
surgeri
show
great
improv
clinic
radiolog
c
pgim
colombo
senior
registrar
famili
medicin
colombo
sri
lanka
katukurunda
clinic
kaluthara
consult
famili
physician
famili
medicin
kaluthara
sri
lanka
background
aim
asthma
consid
major
health
problem
sri
lanka
well
global
burden
asthma
overwhelm
asthma
control
formal
evalu
sri
lanka
studi
compar
evalu
diseas
control
asthma
control
test
act
peak
expiratori
flow
rate
pefr
method
asthma
control
examin
asthmat
year
age
use
act
pefr
predict
score
act
pefr
predict
indic
uncontrol
asthma
simultan
patient
clinic
evalu
whether
asthma
control
uncontrol
asthmat
evalu
fortnight
treatment
accord
global
initi
asthma
gina
guidelin
two
primari
care
clinic
sri
lanka
result
asthma
control
number
accord
act
accord
pefr
perform
asthma
control
act
pefr
basic
consid
pediatr
age
adult
age
group
separ
kappa
statist
indic
substanti
agreement
act
pediatr
ci
well
adult
ci
pefr
show
moder
agreement
pediatr
ci
well
adult
ci
compar
clinic
judgment
pediatr
adult
statu
associ
control
pefr
p
act
conclus
asthma
control
evalu
stabl
independ
act
pediatr
adult
age
group
show
good
agreement
compar
clinic
evalu
pefr
constitut
poor
agreement
compar
act
depend
pediatr
adult
group
prove
pefr
unstabl
evalu
asthma
control
act
recommend
age
vyf
su
taipei
veteran
gener
hospit
depart
critic
care
medicin
taipei
taiwan
background
aim
medic
effect
acut
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
overlap
syndrom
remain
unclear
method
use
taiwan
nation
health
insur
research
databas
conduct
nationwid
studi
evalu
medic
effect
patient
asthma
copd
overlap
syndrom
aco
patient
diagnos
asthma
copd
enrol
aco
cohort
patient
follow
year
exclud
patient
categor
user
bronchodil
sabd
beta
agonist
laba
muscarin
antagonist
lama
inhal
corticosteroid
icss
leukotrien
modifi
lm
primari
endpoint
acut
exacerb
result
studi
includ
patient
aco
patient
copd
alon
mean
period
year
aco
cohort
fewer
comorbid
medic
servic
copd
without
asthma
cohort
adjust
hazard
ratio
hr
medic
lower
fix
model
laba
hr
confid
interv
ci
lama
hr
ci
icss
hr
ci
lm
hr
ci
model
laba
hr
ci
lama
hr
ci
icss
hr
ci
lm
hr
ci
p
compar
wherea
sabd
controversi
effect
acut
exacerb
conclus
laba
lama
ic
lm
use
decreas
risk
acut
exacerb
patient
aco
studi
effect
sabd
use
remain
controversi
prospect
studi
need
confirm
find
tm
tv
tho
gener
hospit
respiratori
tho
vietnam
shiga
univers
medic
scienc
center
epidemiolog
research
asia
otsu
japan
background
aim
asthma
common
chronic
respiratori
diseas
approxim
million
asthmat
person
worldwid
death
annual
due
asthma
mostli
prevent
world
health
organis
estim
million
increas
asthmat
patient
vietnam
studi
asthma
adult
show
incid
asthma
control
situat
report
physician
control
asthma
case
sever
citi
countri
airiap
insight
realiti
includ
vietnam
hanoi
ho
chi
minh
citi
show
result
poor
control
asthma
three
major
concern
import
caus
poor
control
asthma
includ
treatment
difficult
approach
essenti
drug
exposur
trigger
agent
purpos
work
perform
practic
approach
relat
diagnosi
assess
treatment
asthma
method
expert
opinion
guidanc
result
case
asthma
easili
diagnos
base
histori
clinic
present
treatment
respons
asthma
treatment
basic
depend
inhal
corticosteroid
bronchodil
effect
asthma
manag
asthma
control
mostli
relat
treatment
adher
patient
appropri
drug
use
thu
import
physician
especi
work
primari
health
care
center
monitor
assess
level
control
consult
patient
asthmat
case
control
routin
therapi
case
respond
treatment
due
patholog
character
inflammatori
basi
tendenc
chronic
chang
lung
structur
comorbid
case
refer
respiratori
special
center
examin
diagnos
assess
asthma
sever
build
treatment
plan
conclus
n
h
j
l
x
shenyang
pharmaceut
univers
school
life
scienc
biopharmaceut
shenyang
china
shenyang
pharmaceut
univers
school
phamaceut
engin
shenyang
china
background
aim
studi
aim
investig
effect
tradinterol
spff
prolifer
elev
induc
platelet
deriv
growth
factor
pdgf
rat
airway
smooth
muscl
asm
cell
method
pdgf
expos
rat
asm
cell
h
spff
cell
cycl
determin
flow
cytometri
evalu
effect
spff
prolifer
cell
suppress
effect
spff
elev
induc
pdgf
detect
flow
cytometri
soc
inhibitor
respect
use
pharmacolog
tool
investig
possibl
mechan
gene
express
cell
measur
pcr
expos
pdgf
spff
result
show
drug
suppress
increas
cell
induc
pdgf
manner
spff
mm
significantli
decreas
increas
induc
pdgf
similar
effect
soc
inhibitor
suppress
combin
spff
specif
soc
inhibitor
almost
soc
inhibitor
use
alon
indic
spff
soc
inhibitor
mayb
similar
mechan
action
moreov
determin
flow
cytometri
illustr
prolifer
asm
cell
promot
pdgf
inhibit
spff
concentr
maxim
efficaci
spff
found
suppress
significantli
increas
mrna
express
cell
stimul
ngml
pdgf
conclus
find
suggest
spff
could
inhibit
prolifer
rat
asm
cell
induc
pdgf
mechan
might
associ
signal
pathway
jy
choi
sy
lee
jy
kang
ck
rhee
colleg
cathol
univers
korea
intern
medicin
seoul
republ
korea
background
aim
transient
receptor
potenti
vanilloid
channel
channel
express
variou
cell
type
emerg
interest
role
pathophysiolog
asthma
character
airway
hyperrespons
ahr
airway
inflamm
aim
studi
investig
whether
suppress
attenu
asthma
activ
acut
murin
asthma
model
method
develop
acut
murin
asthma
model
balbc
mice
sensit
challeng
ovalbumin
ova
month
sirna
capsazapin
antagonist
administ
ova
challeng
effect
trpv
knockdown
ahr
airway
inflamm
evalu
result
prove
sirna
capsazapin
attenu
allerg
airway
inflamm
airway
hyperrespons
treatment
group
show
reduc
total
cell
count
eosinophil
count
bal
fluid
ahr
methacholin
peribronchi
collagen
deposit
period
pa
stain
area
significantli
decreas
treatment
group
conclus
result
suggest
suppress
may
amelior
airway
inflamm
ahr
model
acut
asthma
r
yuan
xinm
first
hospit
china
medic
univers
depart
respiratori
diseas
shenyang
china
background
aim
asthma
inflammatori
diseas
extens
studi
mani
year
complet
cure
asthma
still
big
challeng
protein
acetyl
especi
histon
acetyl
play
signific
role
process
histon
deacetyl
inhibitor
hdaci
also
ideal
cur
effect
asthma
clinic
practic
order
reveal
molecular
level
relationship
protein
acetyl
process
provid
novel
molecular
target
asthma
treat
studi
proteom
acetylproteom
chang
healthi
asthmat
cell
mous
lung
method
balbc
mice
divid
two
group
control
group
asthmat
model
group
hour
ova
nebul
lung
tissu
group
taken
extract
protein
acetylpeptid
sampl
enrich
stabl
isotop
label
hplc
fraction
peptid
sent
last
quantif
inform
acquir
bioinformat
analysi
perform
result
total
protein
acetyl
site
identifi
among
protein
acetyl
peptid
significantli
chang
respect
mani
activ
deactiv
process
pathway
protein
group
identifi
bioinformat
analysi
associ
network
identifi
respons
process
sequenc
motif
prefer
asthma
condit
reveal
novel
kac
relat
core
histon
motif
identifi
key
regul
unit
data
comparison
conclus
acetyl
modif
play
import
role
pathogenesi
asthma
especi
kac
pattern
may
play
fatal
role
ova
induc
asthma
find
contribut
discoveri
mechan
asthma
young
kid
also
use
adult
asthma
treat
l
menglu
first
hospit
china
medic
univers
depart
respiratori
diseas
shenyang
china
background
aim
asthma
chronic
obstruct
diseas
character
recur
airway
inflamm
revers
airway
obstruct
airway
hyperrespons
airway
remodel
thymoquinon
tq
activ
ingredi
isol
nigella
sativa
report
exhibit
variou
cancer
cell
well
epitheli
cell
aim
studi
evalu
effect
tq
inflamm
neoangiogenesi
remodel
airway
blood
vessel
induc
ovalbumin
ova
asthma
mice
method
balbc
mice
divid
five
group
control
ova
group
asthma
ova
tq
group
tq
group
ova
dexamethason
dex
group
airway
inflamm
assess
stain
stain
elisa
neoangiogenesi
remodel
airway
blood
vessel
assess
western
blot
immunohistochemistri
immunofluoresc
result
result
reveal
tq
inhibit
product
inflammatori
factor
immunohistochemistri
analysi
show
increas
express
asthma
mice
challeng
ova
suppress
tq
moreov
western
blot
immunohistochemistri
analysi
also
show
pathway
increas
tq
meanwhil
immunofluoresc
analysi
show
tq
treatment
asthma
mice
conclus
studi
demonstr
tq
attenu
inflammatori
reaction
antagon
effect
tq
mediat
inhibit
vegf
express
signal
pathway
support
potenti
role
tq
amelior
asthma
mice
h
atika
faculti
medicin
padjadjaran
universityhasan
sadikin
gener
hospit
respirolog
intern
medicin
depart
bandung
indonesia
faculti
medicin
padjadjaran
univers
intern
medicin
depart
bandung
indonesia
background
aim
aerob
physic
activ
one
manag
asthma
asthma
foundat
indonesia
yayasan
asma
indonesia
yai
design
aerob
physic
activ
peopl
asthma
call
asthma
exercis
asthma
exercis
increas
overal
function
capac
lung
one
way
measur
lung
function
measur
score
forc
expiratori
volum
second
forc
vital
capac
fvc
object
studi
discov
differ
fvc
bronchial
asthma
patient
without
asthma
exercis
method
studi
involv
patient
asthma
bandung
asthma
associ
perhimpunan
asma
bandung
pab
patient
asthma
pulmonolog
clinic
dr
hasan
sadikin
gener
hospit
research
data
use
primari
data
form
spirogram
sampl
select
use
inclus
exclus
criteria
research
use
unpair
numer
compar
analyt
method
group
design
result
research
result
show
mean
fvc
group
asthma
exercis
l
l
higher
group
without
asthma
exercis
l
l
statist
differ
test
use
independ
indic
score
p
p
fvc
two
group
conclus
signific
differ
fvc
score
bronchial
asthma
patient
without
asthma
exercis
h
jin
hangzhou
first
peopl
hospit
respir
hangzhou
china
background
aim
worthi
hold
steadi
patient
asthma
remiss
avoid
relaps
astragalosid
iv
import
deriv
chines
herb
astragalu
membranaceu
demonstr
antiasthmat
effect
howev
remain
unclear
whether
use
asthma
remiss
could
allevi
airway
inflamm
acut
episod
studi
aim
investig
prevent
effect
mechan
compar
rapamycin
asthma
remiss
airway
inflamm
vivo
method
balbc
mice
sensit
ovalbumin
three
ip
inject
challeng
ovalbumin
week
week
restrecoveri
mice
ovalbumin
week
mice
treat
rapamycin
last
week
characterist
featur
allerg
asthma
includ
airway
hyperreact
ahr
airway
histopatholog
cytokin
cell
bronchoalveolar
lavag
fluid
balf
examin
downstream
protein
signal
pathway
also
assess
result
rapamycin
markedli
decreas
inflammatori
infiltr
lung
tissu
rapamycin
also
cell
cell
balf
although
augment
effect
ahr
observ
also
reduc
level
limit
effect
ahr
cell
drug
inhabit
phosphoryl
ribosom
protein
downstream
howev
effect
akt
phosphoryl
downstream
observ
conclus
conclud
antiasthmat
effect
least
partial
modul
signal
pathway
treatment
asthma
remiss
may
prevent
effect
diseas
control
w
j
q
x
j
j
x
z
p
x
l
j
z
c
friendship
peke
univers
depart
respiratori
diseas
beij
china
qinghai
peopl
hospit
depart
respiratori
diseas
xine
china
first
affili
hospit
fujian
medic
univers
depart
respiratori
diseas
fuzhou
china
nanfang
hospit
depart
respiratori
diseas
guangzhou
china
guizhou
provici
peopl
hospit
depart
respiratori
diseas
guiyang
china
first
affili
hospit
harbin
medic
univers
depart
respiratori
diseas
harbin
china
second
affili
hospit
zhejiang
univers
school
medicin
depart
respiratori
diseas
hangzhou
china
inner
mongolia
peopl
hospit
depart
respiratori
diseas
hohhot
china
first
affili
hospit
nanj
medic
univers
depart
respiratori
diseas
nanj
china
shanghai
center
hospit
depart
respiratori
diseas
shanghai
china
gener
hospit
shenyang
militari
depart
respiratori
diseas
shenyang
china
second
hospit
hebei
medic
univers
depart
respiratori
diseas
shijiazhuang
china
tianjin
first
center
hospit
depart
respiratori
diseas
tianjin
china
peopl
hospit
xinjiang
uygur
autonom
region
depart
respiratori
diseas
urumqi
china
first
affili
hospit
xian
jiaotong
univers
depart
respiratori
diseas
xian
china
second
hospit
jilin
univers
depart
respiratori
diseas
changchun
china
henan
provinci
peopl
hospit
depart
respiratori
diseas
zhengzhou
china
xinqiao
third
militari
medic
univers
depart
respiratori
diseas
chongq
china
zhongshan
fudan
univers
depart
respiratori
diseas
shanghai
china
background
aim
order
reevalu
asthma
control
diseas
percept
condit
urban
area
china
method
investig
carri
oct
may
hospit
dispers
provinc
china
outpati
meet
follow
criteria
recruit
age
year
resid
studi
citi
least
year
asthma
diagnosi
least
month
accord
gina
criteria
inform
demograph
asthma
control
asthma
manag
asthma
attack
diseas
percept
collect
interview
electron
questionnair
data
captur
eqdc
system
employ
data
input
continu
variabl
present
mean
sd
categor
variabl
present
frequenc
result
altogeth
case
includ
women
total
asthma
control
rate
china
asthma
control
rate
citi
took
part
asthma
control
investig
hospit
rate
due
asthma
exacerb
emerg
visit
rate
patient
use
peak
flow
meter
monitor
patient
select
ic
laba
daili
regular
use
control
medic
use
leukotrien
modifi
use
ic
asthma
attack
frequenc
patient
symptom
everi
week
never
experienc
asthma
attack
past
year
patient
symptom
asthma
attack
common
symptom
cough
chest
tight
short
breath
patient
right
percept
natur
diseas
conclus
despit
improv
asthma
control
compar
investig
region
differ
disproport
obviou
still
gap
proport
asthma
control
china
goal
set
gina
b
j
h
l
z
x
j
h
c
w
z
c
x
q
friendship
peke
univers
depart
respiratori
diseas
beij
china
qingdao
municip
hospit
depart
respiratori
diseas
qingdao
china
first
affili
hospit
xian
jiaotong
univers
depart
respiratori
diseas
xian
china
second
hospit
hebei
medic
univers
depart
respiratori
diseas
shijiazhuang
china
qinghai
provinci
peopl
hospit
depart
respiratori
diseas
xine
china
gener
hospit
shenyang
militari
depart
respiratori
diseas
shenyang
china
first
hospit
lanzhou
univers
depart
respiratori
diseas
lanzhou
china
second
hospit
jilin
univers
depart
respiratori
diseas
changchun
china
tongji
tongji
medic
colleg
hust
depart
respiratori
diseas
wuhan
china
xinqiao
third
militari
medic
univers
depart
respiratori
diseas
chongq
china
gener
hospit
ningxia
medic
univers
depart
respiratori
diseas
yinchuan
china
inner
mongolia
peopl
hospit
depart
respiratori
diseas
huhhot
china
first
affili
hospit
guangxi
medic
univers
depart
respiratori
diseas
nan
china
henan
provinci
peopl
hospit
depart
respiratori
diseas
zhengzhou
china
first
affili
hospit
nanj
medic
univers
depart
respiratori
diseas
nanj
china
xiangya
central
south
univers
depart
respiratori
diseas
changsha
china
peopl
hospit
xinjiang
uygur
autonom
region
depart
respiratori
diseas
urumqi
china
first
affili
hospit
fujian
medic
univers
depart
respiratori
diseas
fuzhou
china
zhongshan
fudan
univers
depart
respiratori
diseas
shanghai
china
background
aim
asthma
remain
seriou
healthcar
burden
worldwid
analysi
aim
characteris
asthma
exacerb
requir
hospit
china
evalu
healthcar
cost
method
retrospect
studi
conduct
hospit
differ
citi
throughout
china
hospit
case
date
dec
screen
patient
met
follow
criteria
includ
age
year
hospit
asthma
exacerb
asthma
diagnosi
least
month
accord
gina
criteria
case
includ
multipl
hospit
patient
recent
incid
includ
inform
clinic
characterist
cost
extract
medic
record
list
expens
result
data
asthmat
patient
male
femal
analyz
averag
age
year
old
proport
patient
smoke
histori
current
smoker
previou
year
prior
hospit
hospit
asthma
exacerb
least
one
time
visit
emerg
depart
use
medicin
regularli
admiss
common
trigger
asthma
exacerb
studi
upper
respiratori
airway
infect
averag
length
hospit
stay
day
patient
admit
icu
treat
mechan
ventil
ten
patient
die
overal
mortal
averag
healthcar
cost
averag
drug
cost
count
total
health
care
cost
conclus
studi
demonstr
minor
patient
use
asthma
control
regularli
admiss
exacerb
mortal
hospit
asthma
patient
studi
averag
hospit
inpati
cost
much
higher
estim
yearli
cost
mainten
therapi
suresh
ashwini
sundaram
medic
dr
rangarajan
memori
hospit
pulmonari
medicin
chennai
india
background
aim
background
aim
asthma
manag
achiev
better
asthma
control
asthma
control
measur
includ
variou
clinic
function
manifest
still
debat
whether
better
control
asthma
translat
better
qualiti
life
aim
evalu
associ
asthma
control
asthma
relat
qualiti
life
method
uncontrol
partli
control
asthma
patient
attend
pulmonari
medicin
clinic
recruit
studi
physic
characterist
socio
demograph
data
lung
function
result
obtain
asthma
relat
qualiti
life
questionnair
aqlq
asthma
control
questionnair
acq
administ
studi
subject
per
prefer
languag
correl
asthma
qualiti
life
pulmonari
function
paramet
pefr
asthma
control
acq
determin
use
pearson
correl
coeffici
test
done
categor
variabl
like
age
distribut
gender
etc
p
consid
signific
result
among
studi
patient
femal
male
partli
control
asthmat
uncontrol
asthmat
gina
symptom
domain
mean
age
bmi
respect
nine
smoker
nine
allerg
rhiniti
patient
ge
reflux
diseas
patient
group
mean
pefr
pre
bronchodil
respect
moder
neg
correl
acq
aqlq
r
p
weak
correl
aqlq
r
p
weak
correl
also
found
number
symptom
aqlq
score
r
p
pearson
chi
squar
method
p
age
bmi
pefr
associ
qualiti
life
aqlq
conclus
asthma
control
measur
acq
predict
asthma
relat
qualiti
life
better
variabl
katayama
marumo
h
amimono
shiraishi
h
yamaki
r
takashima
kotani
shirata
h
shima
kawashima
kitajima
inou
r
itotani
sakuramoto
fukui
tazuk
kofukai
foundat
medic
research
institut
kitano
hospit
respiratori
medicin
osaka
japan
background
aim
cough
one
common
symptom
outpati
depart
great
neg
impact
qualiti
life
asthma
one
common
caus
cough
howev
often
difficult
diagnos
accur
therefor
press
need
novel
tool
diagnosi
asthma
patient
cough
present
studi
evalu
origin
questionnair
laboratori
find
develop
diagnost
score
system
asthma
patient
cough
method
retrospect
analyz
medic
record
patient
attend
outpati
depart
chief
complaint
subacut
chronic
cough
answer
origin
questionnair
april
march
evalu
correl
question
item
final
diagnos
identifi
factor
contribut
final
diagnosi
asthma
result
total
patient
includ
final
analysi
median
age
year
old
femal
patient
chronic
cough
final
diagnos
follow
asthma
n
gerd
n
cough
n
rhinosinus
n
atop
cough
n
other
n
five
question
item
wheez
night
earli
morn
cough
past
histori
asthma
past
histori
respiratori
diseas
live
wooden
hous
predict
asthma
final
diagnosi
develop
diagnost
score
system
asthma
consist
question
item
exhal
nitric
oxid
level
area
curv
diagnost
score
system
ci
conclus
develop
diagnost
score
system
compos
six
factor
asthma
patient
subacut
chronic
cough
may
aid
improv
diagnost
yield
asthma
lv
vp
jm
far
eastern
scientif
center
physiolog
patholog
respir
laboratori
prophylaxi
nonspecif
lung
diseas
blagoveshchensk
russia
far
eastern
scientif
center
physiolog
patholog
respir
laboratori
function
research
respiratori
system
blagoveshchensk
russia
background
aim
control
asthma
depend
variou
factor
includ
cooper
cooper
complex
concept
includ
patient
readi
follow
doctor
recommend
complianc
carri
doctor
recommend
within
particular
treatment
drug
adher
patient
awar
diseas
opinion
diseas
charact
avail
therapi
satisfact
cooper
doctor
sincer
aim
studi
estim
relationship
asthma
control
level
cooper
depress
patient
method
patient
asthma
women
age
examin
asthma
control
questionnair
questionnair
estim
cooper
asthma
eca
lv
bogovin
et
al
center
epidemiolog
studi
depress
scale
mm
weissman
et
al
use
studi
result
patient
control
asthma
accord
mild
asthma
moder
asthma
group
posit
cooper
eca
questionnair
patient
uncontrol
asthma
mild
moder
sever
asthma
patient
partli
complet
follow
recommend
physician
neg
cooper
p
group
patient
control
asthma
compar
uncontrol
asthma
frequent
show
absenc
depress
test
vs
p
remain
group
show
mild
depress
patient
uncontrol
asthma
often
show
presenc
depress
symptom
p
mild
sever
degre
furthermor
degre
cooper
correl
invers
level
depress
test
r
conclus
increas
asthma
sever
tendenc
hypothymia
correl
patient
cooper
reveal
asthma
control
achiev
reduc
nagasaka
tsuchiya
c
sakaguchi
h
ajimizu
nishiyama
hayashi
n
morikawa
rakuwakai
otowa
hospit
pulmonari
medicin
kyoto
japan
background
aim
report
frequenc
lung
sound
reflect
degre
airway
inflamm
patient
bronchial
asthma
ba
j
allergi
clin
immunol
pract
rumbl
rhonchi
rr
denot
rumbl
sound
non
sinusoid
wave
form
wave
form
impli
retain
secret
bronchi
thu
aspect
airway
inflamm
allergol
int
rr
frequent
heard
patient
ba
rather
asymptomat
increas
even
mild
asthma
symptom
thu
rr
may
reflect
aspect
ariway
inflamm
frequenc
lung
sound
tri
clarifi
clinic
implic
rr
patient
wirh
ba
method
studi
sixti
three
adult
asthmat
age
mf
current
smoker
acut
symptom
care
auscult
lung
sound
patient
perform
pulmonari
function
test
includ
fractionl
exhal
nitric
oxid
feno
measur
biomark
eosinophil
airway
inflamm
rr
devid
three
categori
audibl
faintli
audibl
faint
cleari
audibl
present
result
presenc
rr
reflect
presenc
airflow
limit
decreas
rr
heard
rr
clearli
heard
feno
tend
higher
rr
faintli
heard
p
conclus
rr
reflect
eosinophil
airway
inflamm
partial
airflow
limit
rr
may
affect
neutrophil
inflamm
mohamadi
mr
raoufi
tarbiat
modar
univers
depart
faculti
medic
scienc
tehran
iran
background
aim
alreadi
recogn
stress
evok
asthma
exacerb
howev
mechan
stress
get
insid
bodi
clear
hand
certain
breath
pattern
advers
effect
airway
lead
symptom
exacerb
asthma
studi
aim
observ
impact
stress
airway
constrict
breath
pattern
patient
control
asthma
method
record
respir
heart
rate
rest
condit
stressor
stroop
test
nois
women
asthma
healthi
control
pulmonari
function
paramet
measur
use
spiromet
stress
result
exposur
stress
significantli
decreas
fvc
p
p
pef
p
asthmat
patient
wherea
level
remain
unchang
contrast
patient
asthma
healthi
particip
show
signific
increas
respiratori
rate
respiratori
complex
heart
rate
variabl
index
autonom
balanc
stress
pulmonari
function
invers
correl
respiratori
complex
heart
rate
variabl
autonom
impair
conclus
conclud
autonom
impair
breath
pattern
might
potenti
mechan
exacerb
asthmat
peopl
stress
e
aref
javan
mr
raoufi
tarbiat
modar
univers
depart
faculti
medic
scienc
tehran
iran
background
aim
respiratori
dynam
exhibit
complex
pattern
variat
pathophysiolog
basi
respiratori
pattern
decomplexif
asthma
clear
need
determin
studi
anim
model
asthma
also
question
whether
chang
due
repeat
bronchoconstrict
induc
methacholin
mch
agent
alter
breath
pattern
expect
asthmat
guinea
pig
allerg
inflamm
method
respir
consciou
guinea
pig
record
day
salin
ovalbumin
mch
inhal
day
h
aerosol
exposur
use
plethysmographi
twenti
minut
data
minimum
artifact
select
interv
analysi
use
custom
written
softwar
matlab
complex
breath
pattern
quantifi
calcul
sampl
entropi
determin
irregular
degre
result
respiratori
dynam
show
increas
regular
anim
challeng
allergen
p
mch
p
compar
salin
group
howev
signific
differ
respiratori
dynam
asthmat
mch
group
p
conclus
complex
breath
pattern
decreas
bronchoconstrict
induc
either
allergen
mch
guinea
pig
airway
remodel
due
repeat
bronchoconstrict
may
caus
decomplexif
ck
hk
kh
seoul
st
mari
hospit
intern
medicin
seoul
republ
korea
yeouido
st
mari
hospit
intern
medicin
seoul
republ
korea
konkuk
univers
school
medicin
intern
medicin
seoul
republ
korea
background
aim
admiss
rate
asthma
high
korea
compar
oecd
countri
korea
oecd
asthma
one
repres
diseas
ambulatori
care
sensit
condit
acsc
health
insur
review
assess
servic
hira
perform
assess
asthma
care
qualiti
korea
improv
manag
asthma
analyz
result
assess
asthma
care
qualiti
method
asthma
patient
juli
jun
extract
hira
databas
enrol
criteria
code
asthma
use
asthma
medic
two
time
year
histori
admiss
system
steroid
clinic
asthma
medic
pattern
asthma
medic
use
also
analyz
result
total
number
asthma
patient
among
manag
tertiari
referr
hospit
primari
care
clinic
number
femal
age
prescript
rate
oral
corticosteroid
leukotrien
antagonist
oral
beta
agonist
oral
theophyllin
inhal
corticosteroid
averag
amount
cost
person
rate
pulmonari
function
test
pft
low
tertiari
referr
hospit
pft
rate
clinic
pft
rate
rate
inhal
prescript
among
asthma
patient
inhal
prescrib
asthma
patient
tertiari
referr
hospit
clinic
conclus
prescript
inhal
medic
low
korea
prescript
rate
ic
laba
also
low
rate
pft
also
low
asthma
patient
adequ
manag
especi
clinic
fd
er
r
rm
mariu
nasta
institut
pneumolog
pulmonolog
bucharest
romania
mariu
nasta
institut
pneumolog
broncholog
bucharest
romania
novarti
pharma
servic
novarti
pharma
servic
bucharest
romania
background
aim
year
world
asthma
day
romania
run
asthma
awar
campaign
offer
free
spirometri
gener
public
last
year
conduct
day
campaign
bucharest
use
case
find
approach
questionnair
plu
free
spirometri
method
questionnair
question
address
differ
issu
like
possibl
suggest
symptom
risk
factor
smoke
previou
respiratori
function
investig
spirometri
exist
therapi
respiratori
problem
statist
analysi
done
use
microsoft
offic
excel
result
lot
person
mean
age
screen
fulli
complet
questionnair
without
respiratori
symptom
lung
function
impair
age
group
person
year
year
old
women
repres
symptomat
one
person
dyspnea
indic
cough
chest
tight
wheez
women
allergi
men
evid
dust
versu
pollen
versu
last
month
perform
spirometri
although
person
known
asthma
treatment
known
respiratori
condit
come
see
patient
regularli
basi
seen
pulmonologist
allergologist
conclus
romania
access
andor
address
spirometri
tend
improv
year
year
awar
campaign
messag
action
use
detect
new
case
also
follow
old
asthma
patient
sh
park
k
k
j
k
chonnam
nation
univers
colleg
veterinari
medicin
plu
project
team
gwangju
republ
korea
background
aim
copper
oxid
nanoparticl
cuonp
metal
oxid
nanoparticl
use
multipl
applic
includ
wood
preserv
antimicrobi
textil
catalyst
carbon
monoxid
oxid
heat
transfer
fluid
machin
investig
effect
cuonp
respiratori
system
balbc
mice
addit
investig
effect
cuonp
asthma
develop
use
murin
model
ovalbumin
ova
asthma
method
toxicolog
experi
mice
receiv
cuonp
via
intras
instil
uder
slight
anesthesia
day
evalu
airway
hyperrespons
ahr
inflammatori
cell
count
proinflammatori
cytokin
reactiv
oxygen
speci
ro
histopatholog
asthma
model
induc
asthma
mice
senstiz
day
intraperiton
inject
ova
day
mice
receiv
ova
cuonp
dispers
pb
via
intranas
instil
result
cuonp
markedli
increas
airway
ahr
inflammatori
cell
count
proinflammatori
cytokin
reactiv
oxygen
speci
ro
cuonp
induc
airway
inflamm
mucu
secret
increas
phosphoryl
mapk
erk
jnk
ovainduc
asthma
model
cuonp
aggrav
increas
ahr
inflammatori
cell
count
proinflammatori
cytokin
ro
immunoglobulin
e
induc
ova
exposur
addit
cuonp
markedli
increas
inflammatori
cell
infiltr
lung
mucu
secret
mapk
phosphoryl
elev
compar
asthmat
mice
conclus
cuonp
exhibit
toxic
respiratori
system
associ
mapk
phosphoryl
addit
cuonp
exposur
aggrav
develop
asthma
conclud
cuonp
exposur
potenti
toxic
human
respiratori
diseas
k
p
k
j
k
shin
chonnam
nation
univers
colleg
veterinari
medicin
plu
project
team
gwangju
republ
korea
background
aim
mucu
act
primari
defens
system
airway
variou
stimuli
howev
excess
mucu
product
caus
reduct
lung
function
via
limit
airflow
airway
patient
suffer
asthma
chronic
obstruct
pulmonari
diseas
copd
method
studi
evalu
effect
melatonin
product
major
constitu
mucin
secret
airway
use
epiderm
growth
factor
egf
cell
human
mucoepidermoid
carcinoma
cell
line
ovalbumin
ova
asthma
murin
model
result
melatonin
treatment
significantli
reduc
mrna
protein
level
reduc
interleukin
il
product
cell
melatonin
markedli
decreas
phosphoryl
mapk
includ
jnk
induc
egf
stimul
find
consist
result
use
mapk
inhibitor
particularli
melatonin
mapk
inhibitor
effect
suppress
mapk
phosphoryl
treatment
mapk
inhibitor
alon
result
reduct
express
asthma
murin
model
mice
exhibit
mark
reduct
express
airway
compar
mice
reduct
accompani
reduct
proinflammatori
cytokin
product
inflammatori
cell
infiltr
conclus
find
indic
melatonin
effect
inhibit
express
effect
may
close
associ
inhibit
mapk
phosphoryl
furthermor
studi
suggest
melatonin
could
repres
potenti
therapeut
chronic
airway
diseas
asthma
copd
wei
c
liu
west
china
hospit
sichuan
univers
depart
respiratori
medicin
chengdu
china
background
aim
investig
clinic
characterist
allerg
asthma
adult
china
method
total
case
asthma
untreat
retrospect
analyz
hospit
patient
classifi
naa
group
aa
groupallerg
asthma
aa
object
distinguish
asthma
naa
skin
prick
test
immunoglobulin
e
ige
level
common
allergen
describ
differ
allerg
asthma
gender
bodi
mass
index
bmi
age
asthma
control
test
act
score
lung
function
feno
level
airflow
obstruct
type
etc
result
level
feno
statist
differ
p
patient
naa
ppb
patient
aa
seventeen
case
naa
combin
rhiniti
aa
differ
statist
signific
p
naa
group
consist
airflow
obstruct
nao
case
revers
airflow
obstruct
rao
case
irrevers
airflow
obstruct
iao
case
aa
group
nao
case
rao
case
iao
case
differ
statist
signific
z
p
age
year
act
score
bmi
kg
naa
group
year
kg
aa
group
nt
statist
differ
p
conclus
compar
allerg
asthma
asthma
less
rhiniti
lower
feno
level
higher
possibl
irrevers
airflow
obstruct
z
moham
fuad
ci
soo
f
abdul
hamid
ayl
ban
tm
hassan
r
abdul
manap
univers
kebangsaan
malaysia
medic
centr
respiratori
depart
intern
medicin
kuala
lumpur
malaysia
background
aim
bronchial
asthma
common
heterogen
disord
affect
least
million
world
popul
control
asthma
occasion
unpredict
challeng
clinician
especi
involv
moder
sever
persist
case
poorli
control
case
frequent
exacerb
affect
lung
function
qualiti
life
lost
incom
introduct
recombin
human
monoclon
antibodi
omalizumab
breath
new
life
treatment
allerg
asthma
select
bind
ige
thu
inhibit
bind
ige
receptor
surfac
mast
cell
basophil
final
result
regul
cascad
allerg
respons
result
present
two
case
sever
persist
allerg
asthma
initi
omalizumab
therapi
case
demonstr
encourag
preliminari
result
symptom
control
reduct
exacerb
rate
expens
high
treatment
cost
conclus
despit
cost
omalizumab
remain
option
treatment
moder
sever
persist
allerg
asthma
sh
h
gangnam
sever
hospit
intern
medicin
seoul
republ
korea
goodmorn
hospit
republ
korea
background
aim
specif
immunoglobulin
e
ige
sensit
staphylococc
enterotoxin
se
recent
consid
relat
allerg
diseas
includ
asthma
although
research
conduct
studi
concern
specif
ige
sige
se
relationship
asthma
diagnosi
sever
associ
sige
se
airway
hyperrespons
ahr
well
studi
method
enrol
asthma
patient
admit
sever
hospit
korea
march
februari
retrospect
review
electron
medic
record
enrol
subject
measur
level
sige
se
ab
serum
subject
use
phadia
uppsala
sweden
system
defin
posit
kuml
result
level
significantli
correl
asthma
sever
sputum
eosinophil
serum
eosinophil
wherea
level
patient
posit
ahr
mean
standard
error
mean
kuml
significantli
higher
patient
neg
ahr
kuml
regress
analysi
se
sensit
sige
se
kuml
signific
risk
factor
ahr
adjust
age
sex
sputum
eosinophil
odd
ratio
confid
interv
preval
se
sensit
higher
patient
allerg
rhiniti
asthma
patient
compar
patient
without
allerg
rhiniti
atop
asthma
patient
respect
without
statist
signific
conclus
se
sensit
significantli
associ
ahr
jm
ab
ag
sv
vp
sv
far
eastern
scientif
center
physiolog
patholog
respir
laboratori
function
research
respiratori
system
blagoveshchensk
russia
amur
state
medic
academi
depart
histolog
blagoveshchensk
russia
amur
state
medic
academi
depart
therapi
blagoveshchensk
russia
background
aim
difficulti
achiev
asthma
control
may
associ
shift
profil
inflammatori
bronchial
infiltr
toward
polymorphonuclear
leucocyt
aim
studi
determin
influenc
neutrophil
compon
bronchial
inflamm
asthma
control
lung
function
airway
respons
method
patient
mild
persist
asthma
assess
upon
level
asthma
control
asthma
control
test
act
lung
function
spirometri
airway
respons
isocapn
hyperventil
cold
air
ihca
ultrasound
inhal
distil
water
idw
cell
composit
induc
sputum
also
studi
patient
divid
group
low
content
neutrophil
peopl
group
high
content
neutrophil
peopl
group
result
content
neutrophil
group
eosinophil
group
p
p
respect
act
data
peopl
group
manag
diseas
wors
group
point
respect
p
also
lower
p
intens
airway
respons
ihca
dw
respect
comparison
group
p
p
patient
group
close
correl
baselin
neutrophil
respons
ihca
r
p
well
content
myeloperoxidas
r
p
level
myeloperoxidas
correl
respons
idw
r
p
patient
conclus
increas
neutrophil
compon
inflamm
asthma
patient
worsen
asthma
control
lung
function
enhanc
airway
respons
exogen
stimuli
studi
support
russian
scientif
foundat
grant
jm
ab
ag
sv
vp
far
eastern
scientif
center
physiolog
patholog
respir
laboratori
function
research
respiratori
system
blagoveshchensk
russia
amur
state
medic
academi
depart
histolog
blagoveshchensk
russia
background
aim
influenc
standard
combin
therapi
control
bronchial
inflamm
asthma
patient
cold
airway
hyperrespons
cahr
studi
aim
studi
estim
effici
applic
combin
therapi
asthma
patient
cahr
indic
pattern
bronchial
inflamm
method
patient
mean
age
year
old
mild
persist
asthma
cahr
studi
upon
lung
function
asthma
control
cell
composit
induc
sputum
therapi
combin
budesonideformoterol
number
inflammatori
cell
studi
mean
cytochem
coeffici
myeloperoxidas
mpo
granulocyt
calcul
pixel
intens
cell
cytolysi
assess
combin
budesonideformoterol
dose
mcgday
use
achiev
control
decreas
till
stabl
support
dose
mcgday
result
baselin
asthma
control
point
act
number
neutrophil
prevail
eosinophil
level
mpo
pixel
week
therapi
signific
improv
lung
function
asthma
control
increas
till
point
act
p
signific
decreas
eosinophil
till
p
intens
eosinophil
cytolysi
decreas
till
p
neutrophil
till
p
intracellular
concentr
mpo
increas
till
pixel
p
number
neutrophil
remain
high
p
consid
factor
stabl
initi
inflamm
oxid
stress
conclus
use
mode
standard
antiinflammatori
therapi
long
treatment
combin
drug
budesonideformoterol
asthmat
cahr
help
achiev
control
number
neutrophil
h
ntt
medic
center
tokyo
divis
respiratori
medicin
tokyo
japan
ncgm
divis
respiratori
medicin
tokyo
japan
background
aim
gina
state
tiotropium
bromid
could
one
recommend
option
add
standard
step
treatment
asthmat
maintain
combin
therapi
month
theoret
start
still
precis
strategi
therapi
well
defin
method
studi
design
random
control
trial
sever
adult
asthmat
receiv
gina
treatment
step
includ
medium
high
dose
icslaba
ltra
tiotropium
month
recruit
patient
random
maintain
current
treatment
discontinu
ltra
group
feno
act
score
spirometri
exacerb
rate
examin
everi
week
month
result
patient
enrol
perform
patient
mean
age
year
old
act
score
time
entri
suggest
rel
well
asthma
control
statu
enrol
patient
drop
week
case
pef
amount
sputum
week
case
exacerb
asthma
week
case
rhiniti
symptom
respect
discontinu
ltra
clinic
characterist
among
patient
except
femal
receiv
high
dose
icslaba
combin
inhal
month
differ
group
time
first
exacerb
mean
number
group
vs
chang
act
score
conclus
withdraw
ltra
might
safe
option
consid
combin
therapi
icslaba
tiotropium
bromid
ltra
sever
asthmat
case
patient
receiv
high
dose
icslaba
studi
limit
small
sampl
size
short
durat
therefor
consid
preliminari
h
hu
baoq
l
went
state
key
laboratori
respiratori
nation
clinic
research
center
guangzhou
institut
respiratori
diseas
guanghzou
china
background
aim
studi
level
immunoglobulin
e
sige
phenomenon
multipl
fungal
sensit
patient
suffer
respiratori
diseas
method
screen
adult
patient
suffer
asthma
adult
allerg
bronchopulmonari
aspergillosi
abpa
patient
aspergillu
detect
posit
grade
equal
greater
level
three
divid
two
group
group
asthma
aspergillu
fumigatu
sensit
group
abpa
patient
serum
concentr
ige
penicillum
notatum
branch
cinerea
aspergillu
fumigatu
candida
albican
mould
alternaria
helminthosporium
detect
immunocap
fluor
euzymelink
immunosorb
system
result
result
group
abpa
patient
aspergillu
fumigatu
sige
significantli
higher
group
asthma
aspergillu
fumigatu
sensit
p
kul
vs
kul
candida
albican
sige
kul
vs
kul
penicillium
notatum
sige
kul
vs
kul
alternaria
sige
kul
vs
kul
patient
embrac
phenomenon
multipl
fungal
sensit
signific
correl
sige
level
fungu
p
moreov
optim
scale
techniqu
reflect
similar
relationship
aspergillu
fumigatu
alternaria
cronbach
alpha
conclus
nutshel
patient
sensit
aspergillu
fumigatu
often
exist
phenomenon
multipl
fungal
sensit
mayb
phenomenon
caus
sensit
protein
secret
fungu
combin
differ
fungu
sige
detect
may
regard
auxiliari
examin
fungal
allerg
asthma
j
luo
z
chen
j
hu
li
j
guo
b
sun
guangzhou
institut
respiratori
diseas
state
key
labortori
respiratori
diseas
guangzhou
china
background
aim
respiratori
diseas
refractori
diseas
remark
reduc
life
qualiti
patient
cost
great
amount
social
wealth
studi
reveal
correl
environment
factor
develop
progress
diseas
determin
particul
matter
concentr
air
bedroom
outdoor
hdm
allergen
concentr
bed
pillow
appli
hepa
air
purifi
evalu
effect
improv
air
qualiti
efficaci
adjuv
therapi
respiratori
allerg
diseas
method
air
purifi
set
near
bed
bedroom
month
peopl
year
old
diagnos
allerg
rhiniti
adult
diagnos
bronchial
asthma
select
applic
purifi
everi
month
dust
sampl
collect
vacuum
cleaner
dust
collector
pm
valu
measur
chang
pm
valu
shown
pm
ratio
rqlq
use
access
symptom
patient
applic
air
purifi
use
data
entri
analysi
measur
data
descript
analyz
test
independ
test
repeat
measur
anova
use
comparison
among
group
p
consid
statist
signific
result
der
ngg
abund
allergen
air
patient
bedroom
follow
ngg
der
concentr
ngg
bed
pillow
higher
der
ngg
der
der
concentr
slightli
decreas
applic
air
purifi
concentr
significantli
decreas
first
three
month
increas
month
score
activ
limit
practic
problem
declin
way
conclus
air
purifi
properli
function
effect
reduc
pm
hdm
allergen
concentr
air
therebi
improv
clinic
manifest
patient
allerg
rhiniti
asthma
j
choi
kh
min
chung
jy
oh
jk
sim
ys
lee
gy
hur
sy
lee
kh
kang
jj
shim
korea
univers
guro
hospit
korea
univers
medic
school
depart
intern
medicin
seoul
republ
korea
background
aim
report
preval
bacteri
viral
infect
acut
exacerb
asthma
vari
region
report
studi
conduct
western
countri
recent
guidelin
manag
asthma
recommend
antibiot
routin
prescrib
acut
exacerb
asthma
investig
preval
bacteri
viral
infect
predict
marker
bacteri
infect
acut
exacerb
asthma
singl
center
south
korea
method
retrospect
analyz
medic
record
patient
acut
exacerb
asthma
admit
korea
univers
guro
hospit
januari
june
search
electron
medic
record
databas
key
word
asthma
acut
exacerb
result
episod
acut
exacerb
patient
men
women
mean
age
year
number
patient
bacteri
infect
viral
infect
bacteri
viral
infect
pathogen
respect
major
bacteria
streptococcu
pneumonia
haemophilu
influenza
major
virus
rhinoviru
influenza
viru
serum
eosinophil
count
significantli
lower
bacteri
posit
group
p
serum
protein
crp
procalcitonin
pct
level
higher
bacteri
posit
group
p
p
respect
conclus
studi
show
streptococcu
pneumonia
rhinoviru
common
isol
acut
exacerb
asthma
serum
eosinophil
count
serum
crp
pct
level
use
distinguish
bacteri
infect
acut
exacerb
asthma
find
provid
use
inform
antibiot
treatment
patient
acut
exacerb
asthma
purwitasari
dwi
susanto
b
antariksa
univers
indonesia
pulmonolog
east
jakarta
indonesia
background
aim
asthma
character
airway
hyperrespons
airflow
obstruct
bronchial
level
often
revers
either
spontan
treatment
last
decad
continu
increas
preval
asthma
observ
worldwid
complex
chronic
diseas
particularli
challeng
research
need
environment
determin
diseas
increas
asthma
incid
last
decad
strongli
suggest
role
environment
air
pollut
street
sweeper
expos
dust
particl
bioaerosol
variou
harm
gase
inhal
particul
enter
lung
may
lead
advers
respiratori
ill
effect
fact
street
sweeper
usual
would
use
protect
devic
like
face
mask
exposur
dust
gener
sweep
may
contribut
increas
preval
lung
diseas
preliminari
cross
section
studi
preval
asthma
among
street
sweeper
jakarta
indonesia
approv
ethic
committe
faculti
medicin
universita
indonesia
method
research
design
cross
section
subject
street
sweeper
jakarta
indonesia
sampl
collect
use
cluster
random
sampl
questionnair
asthma
screen
questionnair
asq
asthma
control
test
act
spirometri
examin
base
pneumobil
project
indonesia
bronchodil
test
inclus
criteria
male
femal
abl
perform
spirometri
sign
inform
consent
year
old
work
period
year
result
thirti
street
sweeper
whose
work
area
particip
studi
age
year
old
femal
male
preval
asthma
among
street
sweeper
area
subject
year
old
femal
conclus
preval
asthma
among
street
sweeper
jakarta
ch
h
jh
jw
sj
cs
myongji
hospit
seonam
univers
divis
pulmonari
critic
care
medicin
republ
korea
yeungnam
univers
depart
electron
engin
republ
korea
myongji
hospit
converg
research
institut
republ
korea
background
aim
measur
peak
expiratori
flow
pef
easi
inexpens
method
monitor
bronchial
asthma
mani
digit
peak
flow
meter
pfm
smart
phone
app
develop
howev
clinic
applic
limit
korea
develop
portabl
digit
pfm
asthma
monitor
system
softwar
android
mobil
devic
one
part
project
develop
portabl
digit
pfm
made
prototyp
digit
pfm
aim
studi
compar
perform
miniatur
wright
pfm
share
experi
process
project
method
prototyp
digit
pfm
compar
pfm
pair
calibr
flow
provid
two
calibr
simultan
data
digit
pfm
transmit
app
smart
phone
bluetooth
pef
valu
shown
screen
smart
devic
pef
valu
pfm
read
analogu
scale
directli
result
pair
pef
valu
obtain
valu
pef
lmin
lmin
strong
posit
correl
shown
pef
digit
pfm
pfm
p
conclus
digit
pfm
could
use
clinic
would
use
part
asthma
monitor
alarm
system
patient
asthma
r
kumar
n
malhotra
vallabhbhai
patel
chest
institut
depart
pulmonari
medicin
delhi
india
background
aim
asthma
common
respiratori
ill
affect
almost
indian
involv
airway
inflamm
hyper
respons
signific
percentag
asthmat
show
presenc
atopi
variou
allergen
includ
food
allergen
present
studi
look
pattern
food
sensit
asthmat
india
method
total
asthmat
patient
diagnos
accord
gina
guidelin
enrol
patient
underw
skin
prick
test
food
allergen
total
allergen
commonli
consum
test
result
food
sensit
present
asthmat
patient
common
group
caus
sensit
anim
product
follow
legum
seed
cereal
grain
individu
five
common
food
prawn
fennel
red
gram
baker
yeast
bean
conclus
among
indian
patient
suffer
asthma
found
anim
product
common
offend
agent
follow
legum
individu
prawn
fennel
red
gram
baker
yeast
bean
five
commonest
sensit
food
found
food
allergen
commonest
sensit
agent
asthmat
india
q
xun
xiangya
hospit
central
south
univers
respiratori
medicin
changsha
china
background
aim
previou
studi
demonstr
mutant
genotyp
associ
poor
inhal
corticosteroid
ic
respons
asthmat
human
airway
relax
regul
circul
epinephrin
epi
enhanc
corticosteroid
unknown
whether
mutant
associ
circul
concentr
chang
epinephrin
cortisol
asthma
aim
studi
evalu
relationship
method
total
asthmat
healthi
control
recruit
studi
asthmat
receiv
fluticason
propion
bid
treatment
week
genotyp
perform
iplex
massarray
genotyp
platform
plasma
concentr
cortisol
cor
epinephrin
particip
detect
elisa
kit
result
homozygot
mutant
genotyp
gg
higher
plasma
epinephrin
concentr
median
concentr
pgml
ngg
median
concentr
pgml
naaag
p
cortisol
concentr
median
concentr
ngml
ngg
median
concentr
ngml
naaag
p
epinephrin
concentr
cortisol
concentr
plasma
posit
correl
r
r
respect
correl
mrna
express
asthmat
treat
ic
associ
plasma
epinephrin
cortisol
concentr
chang
recess
model
aa
ag
vs
gg
gg
less
improv
epinephrin
concentr
pgml
naaag
pgml
ngg
p
cortisol
concentr
ngml
naaag
ngml
ngg
p
conclus
studi
suggest
poor
ic
respons
mutant
genotyp
might
relat
less
increas
amplitud
plasma
epinephrin
cortisol
asthmat
patient
ai
mam
ne
mahsa
univers
faculti
pharmaci
kuala
lumpur
malaysia
univers
teknolog
mara
respiratori
faculti
medicin
batu
cave
malaysia
background
aim
background
long
term
respiratori
limit
live
asthma
stigma
also
identifi
social
phenomenon
among
adult
asthmat
main
object
studi
valid
newli
devis
malay
version
stigma
scale
use
group
malaysian
patient
diagnos
asthma
method
studi
adult
asthma
patient
enrol
four
respiratori
clinic
locat
selangor
malaysia
permiss
adapt
translat
questionnair
obtain
correspond
author
questionnair
translat
malay
languag
forward
backward
translat
harmon
cognit
debrief
interview
proof
read
establish
content
face
valid
extract
data
complet
questionnair
analys
construct
valid
moreov
reliabl
assess
cronbach
intraclass
correl
coeffici
icc
intern
consist
one
month
reliabl
respect
result
final
found
reliabl
instrument
use
measur
intern
consist
cronbach
one
month
reliabl
icc
moreov
kmo
measur
verifi
sampl
adequaci
kmo
barlett
test
spheric
p
indic
correl
item
suffici
larg
enough
factor
analysi
analysi
scree
plot
eigenvalu
suggest
retain
three
factor
name
discrimin
disclosur
perceiv
posit
basi
natur
item
conclus
found
highli
reliabl
valid
instrument
assess
stigma
malaysian
adult
asthma
patient
questionnair
develop
iter
process
studi
suggest
test
instrument
malaysian
state
reinforc
good
psychometr
properti
r
u
u
g
bangalor
india
st
john
medic
colleg
hospit
depart
pulmonolog
bangalor
india
background
aim
asthma
signific
health
problem
asthmat
patient
sensit
common
allergen
sensit
fungu
particularli
aspergillu
associ
increas
risk
sever
develop
abpa
sensit
tune
report
north
india
scant
data
avail
south
studi
done
assess
occurr
factor
associ
aspergillu
sensit
bangalor
aim
determin
occur
cutan
sensit
aspergillu
fumigatu
asthmat
studi
factor
associ
sensit
aspergillu
fumigatu
asthmat
method
new
asthma
patient
june
may
age
year
either
sex
studi
pregnant
women
subject
immunodefici
state
structur
lung
diseas
exclud
design
cross
section
design
set
tertiari
care
hospit
bangalor
demograph
data
clinic
sever
asthma
control
assess
use
asthma
control
test
act
obtain
patient
skin
prick
test
spt
fungal
allergen
spirometri
perform
statist
analysi
done
spss
use
test
fischer
exact
test
result
sixti
one
patient
studi
mean
age
year
f
patient
urban
rural
area
respect
eight
patient
histori
atopi
allerg
rhiniti
famili
histori
asthma
eleven
patient
smoker
cutan
sensit
aspergillu
fumigatu
seen
patient
correl
aspergillu
sensit
durat
ill
presenc
allerg
rhiniti
histori
atopi
smoke
statu
area
resid
rural
vs
urban
associ
aspergillu
sensit
asthma
sever
control
conclus
aspergillu
sensitz
seen
asthmat
cohort
associ
aspergillu
sensit
demograph
clinic
factor
asthma
sever
control
jm
ag
ea
far
eastern
scientif
center
physiolog
patholog
respir
laboratori
function
research
respiratori
system
blagoveshchensk
russia
amur
state
medic
academi
depart
biochemistri
blagoveshchensk
russia
background
aim
oxid
stress
play
import
role
maintain
inflamm
respiratori
tract
loss
asthma
control
aim
studi
evalu
dynam
index
lipid
peroxidaion
blood
asthma
patient
singl
exposur
hyposmolar
stimulu
method
patient
mean
age
year
mild
persist
partli
control
uncontrol
asthma
asthma
control
test
point
involv
studi
measur
spirometri
content
lipid
hydroperoxid
vitamin
e
ceruloplasmin
blood
serum
measur
colorimetr
method
measur
taken
inhal
distil
water
idw
next
day
statist
signific
differ
determin
use
pair
test
result
differ
first
second
day
studi
l
respect
p
mean
respons
idw
consist
averag
content
lipid
hydroperoxid
first
day
studi
consist
nmolml
slightli
increas
nmolml
p
respons
idw
second
day
lipid
hydroperoxid
content
increas
nmolml
p
correl
baselin
r
p
vitamin
e
content
first
day
significantli
increas
mgml
p
idw
next
day
consist
gml
p
content
ceruloplasmin
blood
serum
significantli
increas
first
day
ml
second
day
p
chang
ceruloplasmin
idw
statist
insignific
conclus
patient
asthma
singl
inhal
distil
water
follow
develop
oxid
stress
symptom
persist
least
day
work
support
russian
scienc
foundat
grant
p
n
r
r
b
b
bpkoirala
institut
health
scienc
bpkih
depart
intern
medicin
dharan
nepal
bpkoirla
institut
health
scienc
bpkih
depart
intern
medicin
dharan
nepal
background
aim
copd
asthma
overlap
lead
caus
morbid
mortal
low
incom
countri
lic
like
nepal
spite
high
burden
lack
studi
provid
insight
hitherto
unexplor
risk
character
clinic
trait
among
patient
aim
object
explor
risk
character
clinic
spectrum
patient
present
interfac
copd
asthma
lic
like
nepal
method
cross
section
studi
conduct
b
p
koirala
institut
health
scienc
bpkih
univers
teach
hospit
nepal
period
year
patient
chronic
respiratori
diseas
patient
copd
patient
asthma
recruit
detail
data
clinic
spectrum
studi
retrospect
analysi
medic
record
variabl
interest
risk
character
clinic
spectrum
diseas
interfac
two
diseas
explor
descript
inferenti
statist
result
patient
copd
male
year
sever
diseas
gold
iii
smoker
exposur
indoor
air
pollut
due
use
biomass
fuel
histori
tb
alcohol
abus
patient
bronchial
asthma
young
femal
year
mild
asthma
patient
categori
overlap
copd
asthma
sever
symptom
consum
alcohol
regularli
signific
exposur
indoor
air
pollut
conclus
tobacco
smoke
toxic
exposur
indoor
smoke
tower
burden
tb
alcohol
abus
risk
factor
converg
togeth
interfac
copd
asthma
low
incom
countri
need
reconstruct
prevail
paradigm
lung
health
countri
like
nepal
basi
avail
evid
wan
yau
ck
hy
kh
dk
j
van
hs
observ
pragmat
research
institut
real
world
evid
singapor
singapor
cathol
univers
korea
respiratori
seoul
republ
korea
samsung
medic
center
respiratori
seoul
republ
korea
seoul
nation
univers
respiratori
seoul
republ
korea
ajou
medic
centr
allergi
seoul
republ
korea
background
aim
histor
dri
powder
inhal
dpi
consid
provid
better
airway
distribut
easier
identif
empti
devic
easier
handl
compar
pressur
meter
dose
inhal
pmdi
prior
research
major
handl
error
inhal
devic
use
shown
error
result
compar
impair
asthma
control
dpi
pmdi
research
demonstr
patient
prescrib
similar
type
prevent
inhal
devic
reliev
better
asthma
control
patient
prescrib
pmdi
inhal
corticosteroidlong
act
beta
agonist
reliev
could
benefit
switch
dpi
pmdi
health
insur
review
assess
hira
databas
provid
coverag
medic
claim
million
peopl
korea
offer
opportun
studi
asthma
control
nation
basi
aim
studi
provid
review
possibl
korean
hira
databas
prepar
studi
investig
effect
asthma
control
patient
switch
inhal
type
method
methodolog
previou
literatur
describ
hira
databas
analys
focus
identif
asthma
patient
clinic
characterist
eg
exacerb
comorbid
medic
switch
behaviour
healthcar
resourc
use
includ
medic
associ
cost
result
patient
medic
histori
could
construct
primari
secondari
diagnosi
associ
individu
databas
entri
asthma
exacerb
could
proxi
prescript
acut
oral
corticosteroid
hospit
admiss
emerg
room
attend
associ
diagnosi
asthma
lower
respiratori
infect
respiratori
failur
patient
could
consid
switch
patient
receiv
prescript
pmdi
prescript
dpi
inhal
addit
variabl
avail
includ
medic
hospitalis
cost
conclus
hira
databas
allow
studi
analys
switch
success
inhal
type
term
persist
asthma
control
healthcar
resourc
utilis
j
univers
gener
hospit
section
pulmonari
depart
medicin
manila
philippin
univers
gener
hospit
section
depart
medicin
manila
philippin
univers
gener
hospit
depart
medicin
manila
philippin
background
aim
case
present
ovarian
cancer
sudden
dyspnea
show
dilat
right
ventricl
atrium
sign
pressur
volum
overload
sever
pulmonari
hypertens
ph
patent
ductu
arteriosu
pda
advis
pda
closur
done
present
er
bp
chest
show
larg
bilater
main
pulmonari
arteri
emboli
pda
hypoxemia
high
gradient
blood
ga
thrombosi
leg
duplex
scan
abdominopelv
weight
heparin
lmwh
start
treatment
result
improv
bp
dyspnea
howev
repeat
chest
ct
angiographi
month
lmwh
reveal
persist
emboli
still
show
sever
ph
pulmonari
endarterectomi
plan
chronic
thromboembol
pulmonari
hypertens
done
right
heart
catheter
show
signific
level
right
ventricl
main
pulmonari
arteri
predomin
left
right
shunt
qpq
confirm
pda
unfortun
irrevers
ph
make
good
candid
pda
closur
high
risk
endarterectomi
markedli
elev
suggest
ovarian
cancer
sever
ph
preclud
invas
procedur
abdomin
pigtail
insert
palli
care
case
inde
unfortun
sinc
might
alreadi
elev
pa
pressur
pda
aggrav
pte
presum
underli
malign
combin
three
diseas
significantli
worsen
prognosi
closur
lesion
onset
irrevers
ph
treatment
pda
surgic
remov
emboli
constitut
manag
persist
pte
howev
irrevers
ph
document
right
heart
catheter
coupl
high
risk
natur
diseas
preclud
invas
procedur
done
resort
palli
measur
jm
perelman
ab
pirogov
ag
prikhodko
de
naumov
ev
ushakova
ga
makarova
vp
kolosov
far
eastern
scientif
center
physiolog
patholog
respir
laboratori
function
research
respiratori
system
blagoveshchensk
russia
background
aim
data
bronchial
leukocyt
activ
cytokin
asthmat
osmot
ahr
aim
studi
assess
activ
mpo
cytolysi
bronchial
leukocyt
hyperosmolar
ahr
depend
method
asthma
patient
group
airway
hyperrespons
inhal
ultrasound
nebul
hyperton
nacl
solut
ih
patient
without
respons
group
examin
healthi
person
control
group
leukocyt
induc
sputum
mean
cytochem
coeffici
mcc
pixel
mpo
intens
cell
cytolysi
icc
au
determin
concentr
pgml
exhal
breath
condens
measur
elisa
result
icc
neutrophil
group
au
group
au
p
control
group
au
p
icc
eosinophil
au
p
respect
activ
neutrophil
cytolysi
group
associ
increas
activ
mpo
mcc
pixel
group
p
pixel
control
group
p
level
increas
group
pgml
till
pgml
ih
significantli
higher
group
level
ih
increas
group
till
pgml
group
decreas
till
pgml
p
conclus
asthma
patient
hyperosmolar
ahr
increas
activ
mpo
cytolysi
bronchial
leukocyt
depend
high
level
studi
support
russian
scientif
foundat
grant
n
yoko
e
yamaguchi
k
kenshi
ayako
n
masaki
hiroyuki
takahashi
kubo
aichi
medic
school
respiratori
medicin
allergolog
aichi
japan
background
aim
corticosteroid
cs
wide
use
variou
inflammatori
diseas
includ
bronchial
asthma
efficaci
advers
effect
cs
heterogen
individu
patient
may
partli
caus
genet
variat
inflammatori
cytokin
transcript
factor
cs
act
singl
nucleotid
polymorph
snp
transcript
report
associ
clinic
effect
inhal
corticosteroid
asthma
present
studi
intend
analyz
relationship
gene
polymorph
inhibitori
effect
cytokin
product
methylprednisolon
mpsl
method
peripher
blood
mononuclear
cell
purifi
healthi
volunt
incub
cultur
plate
coat
antibodi
presenc
antibodi
hr
variou
concentr
mpsl
add
cultur
concentr
cytokin
cultur
supernat
measur
bead
method
use
flow
cytomet
genotyp
taqman
probe
analyz
relationship
gene
polymorph
inhibitori
concentr
mpsl
individu
cytokin
result
genotyp
frequenc
gg
n
ga
aa
similar
healthi
japanes
upload
nbdc
japan
site
significantli
associ
mpsl
product
howev
allel
weak
respons
high
g
inconsist
one
previous
publish
conclus
given
lack
strong
consist
associ
inhibitori
effect
mpsl
vitro
studi
need
establish
clinic
signific
snp
jm
perelman
ev
nekrasov
ag
prikhodko
ga
makarova
far
eastern
scientif
center
physiolog
patholog
respir
laboratori
function
research
respiratori
system
blagoveshchensk
russia
background
aim
prostaglandin
major
eicosanoid
multipl
often
opposit
effect
human
bodi
protect
effect
respiratori
system
condit
includ
bronchoconstrict
induc
ultrason
nebul
distil
water
undw
known
long
time
cours
research
eicosanoid
involv
osmot
airway
hyperrespons
oah
aim
studi
estim
exhal
breath
condens
ebc
serum
asthmat
differ
respons
hyperosmolar
stimuli
method
ebc
collect
asthmat
provoc
undw
serum
collect
patient
provoc
undw
ultrason
nebul
hyperton
solut
unhr
nacl
content
measur
ebc
serum
without
preliminari
purif
eia
commerci
kit
r
system
usa
result
detect
ebc
patient
sampl
undw
among
patient
found
ebc
provoc
patient
detect
ebc
belong
group
hyperrespons
undw
pgml
without
pgml
content
serum
rang
pgml
statist
differ
group
asthmat
differ
airway
respons
osmot
stimuli
undw
unhr
howev
found
signific
correl
content
serum
lung
function
indic
patient
oah
unhr
conclus
content
ebc
low
involv
oah
least
undw
content
serum
associ
lung
function
asthmat
oah
hyperton
solut
research
support
russian
scientif
foundat
grant
asian
hospit
medic
center
intern
muntinlupa
philippin
background
aim
present
case
pulmonari
embol
young
male
colleg
student
muntinlupa
citi
chief
complaint
hemoptysi
chest
pain
patient
varsiti
footbal
player
day
admiss
patient
develop
cough
hemoptysi
bilater
pleurit
chest
pain
consult
er
yield
normal
chest
sent
home
day
consult
outpati
depart
persist
symptom
plain
chest
ct
scan
reveal
lower
lobe
opac
left
basal
area
smaller
one
right
cavitari
ptb
vs
pneumonia
consid
admit
given
moxifloxacin
daili
sputum
afb
tb
gene
expert
neg
patient
complain
progress
symptom
despit
antibiot
hospit
day
chest
show
pleural
effus
atelectasi
fluid
left
seen
ultrasound
antibiot
shift
bronchoscopi
day
show
blood
clot
left
basal
segment
bronchial
wash
tb
gene
expert
cultur
includ
legionella
mycoplasma
pcp
autoimmunehiv
test
neg
patient
underw
chest
ct
angiogram
hospit
day
show
fill
defect
repres
thrombu
impress
pulmonari
thromboembol
lower
lung
complet
occlus
left
basal
trunk
branch
low
molecular
weight
heparin
lmwh
start
everi
hour
venou
duplex
scan
lower
extrem
unremark
hospit
day
less
hemoptysi
develop
fever
tmax
total
episod
hospit
day
patient
claim
feel
lot
better
complain
vagu
pain
left
upper
inner
arm
venou
duplex
scan
upper
extrem
reveal
heterogen
hypoecho
intralumin
densiti
repres
superfici
vein
thrombosi
partial
occlud
left
cephal
basilica
vein
lmwh
shift
rivaroxiban
bid
patient
sent
home
jh
dh
js
inj
universitiy
haeunda
paik
hospit
depart
pulmonolog
critic
care
medicin
busan
republ
korea
univers
hospit
depart
intens
care
medicin
busan
republ
korea
asan
medic
univers
ulsan
colleg
medicin
depart
pulmonari
critic
care
medicin
seoul
republ
korea
background
aim
although
orthoped
surgeri
often
necessari
patient
pulmonari
thromboembol
pte
safeti
optim
safeti
interv
diagnosi
pte
remain
unknown
sought
clinic
outcom
patient
underw
orthoped
surgeri
within
month
diagnosi
acut
pte
method
januari
decemb
medic
record
patient
underw
orthoped
surgeri
spine
extrem
gener
spinal
anesthesia
within
day
diagnosi
pte
review
clinic
outcom
intens
care
unit
icu
admiss
recurr
pte
bleed
death
surgeri
retrospect
review
result
surgeri
perform
patient
mean
pulmonari
embol
sever
index
pesi
class
class
class
class
class
patient
receiv
anticoagul
therapi
use
heparin
case
low
molecular
weight
heparin
case
howev
anticoagul
therapi
prescrib
case
pte
mean
period
surgeri
diagnosi
pte
day
mean
anesthesia
time
minut
surgeri
patient
admit
icu
close
observ
although
almost
immedi
postop
complic
identifi
recurr
pte
confirm
patient
next
day
surgeri
discharg
aliv
day
surgeri
two
patient
die
uncontrol
infect
patient
cardiac
tamponad
within
day
caus
death
unrel
pte
conclus
orthoped
surgeri
within
month
patient
acut
pte
feasibl
n
shinshu
univers
first
depart
medicin
matsumoto
japan
shinshu
univers
depart
laboratori
medicin
matsumoto
japan
background
aim
patholog
featur
pulmonari
edema
hape
character
mark
diffus
alveolar
edema
alveolar
hyalin
membran
dilat
pulmonari
capillari
pulmonari
arteri
thrombosi
secondari
bronchopneumonia
maintain
alveolar
structur
light
microscop
date
rapid
collect
fluid
lung
hape
yet
suffici
explain
contemporarili
demonstr
mechan
result
pulmonari
hypertens
misdistribut
perfus
increas
pulmonari
capillari
permeabl
method
order
refresh
pathogenesi
hape
regard
pulmonari
capillari
permeabl
report
novel
find
ultrastructur
pulmonari
wall
two
case
hape
observ
electron
microscop
result
found
neutrophil
trap
pulmonari
capillari
part
neutrophil
protrud
adher
basement
membran
capillari
endothelium
activ
degranul
neutrophil
wall
endotheli
cell
pulmonari
capillari
deform
thick
swell
degener
side
alveolar
space
infiltr
neutrophil
macrophag
prolifer
type
ii
pneumocyt
also
observ
conclus
electron
microscop
observ
confid
provid
evid
structur
pulmonari
wall
impair
deform
thick
probabl
due
adher
neutrophil
activ
stimulu
hypoxia
structur
injuri
might
fundament
precondit
solut
fluid
penetr
speedili
capillari
side
alveolar
side
eventu
fluid
collect
alveolar
space
occur
hape
j
guo
j
hu
zhong
p
huang
z
chen
x
lan
j
luo
b
sun
guangzhou
institut
respiratori
diseas
state
key
laboratori
respiratori
diseas
guangzhou
china
background
aim
allerg
rhiniti
ar
impair
patient
qualiti
life
bring
heavi
economicburden
societi
grow
evid
suggest
air
poluut
correl
occurr
allergi
symptom
air
pollut
mostli
suspend
factor
includ
ozon
nitrogen
oxid
may
facilit
allergen
assess
immunoregulatori
cell
promot
develop
allerg
symptom
howev
whether
level
directli
correl
symptom
ar
patient
unclear
would
possibl
improv
qualiti
life
ar
patient
reduc
level
studi
aim
improv
correl
qualiti
life
ar
patient
level
surround
enviro
evalu
efficaci
air
purifi
improv
qualiti
life
ar
patient
method
clinicali
confirm
ar
patient
enrol
studi
includ
male
femalesss
age
year
subject
ask
fill
rhiniti
qualiti
life
questionnair
rqlq
evryday
month
correspond
level
live
enviro
record
simultan
patient
ask
fill
rqlq
everi
month
monitor
symptom
ar
patient
use
air
purifi
data
collect
consid
statisc
signific
result
among
sub
score
rqlq
nasal
symptom
rs
p
correl
show
signific
correl
p
daili
activ
rs
p
sleep
qualiti
rs
p
nasal
symptom
rs
p
emot
problem
rs
p
significantli
correl
level
conclus
level
correl
nasal
symptom
ar
patient
air
purfier
effect
lower
level
allevi
certain
symptom
ar
patient
improv
qualiti
life
j
see
philippin
heart
centr
adult
pulmonari
critic
care
medicin
quezon
citi
philippin
background
aim
bilater
giant
pulmonari
arteri
aneurysm
rare
patholog
entiti
thorac
caviti
deterl
clagett
report
eight
case
post
mortem
examin
present
case
year
old
filipina
previous
diagnos
atrial
septal
defect
incident
find
bilater
pulmonari
arteri
aneurysm
aneurysm
dilat
main
pulmonari
arteri
peripher
wall
fill
defect
also
note
right
left
pulmonari
arteri
intens
medic
treatment
propos
patient
clinic
improv
sign
symptom
method
bilater
giant
pulmonari
arteri
aneurysm
paa
rare
patholog
entiti
thorac
caviti
specif
report
regard
preval
paa
defin
dilat
pulmonari
arteri
barbour
mention
cutoff
diamet
pulmonari
arteri
paa
would
present
nonspecif
symptom
like
dyspnea
chest
heavi
pain
would
present
hemoptysi
case
report
would
present
case
year
old
filipina
incident
find
giant
paa
result
ct
angiogram
pulmonari
arteri
reveal
aneurysm
dilat
main
pulmonari
arteri
right
left
pulmonari
arteri
peripher
wall
fill
defect
seen
right
left
pulmonari
arteri
interlobar
arteri
might
repres
chronic
thrombu
format
conclus
paa
rare
diagnosi
bilater
giant
pulmonari
arteri
aneurysm
rare
patholog
entiti
thorac
caviti
deterl
clagett
report
eight
case
post
mortem
examin
sever
surgic
techniqu
offer
patient
howev
due
presenc
probabl
eisenmengeris
definit
treatment
patient
cardiac
lung
transplant
howev
patient
rel
refus
undergo
surgic
procedur
henc
arrang
regular
close
visit
discharg
stabl
improv
k
soo
whan
cathol
univers
korea
seoul
republ
korea
background
aim
studi
conduct
evalu
associ
ar
mental
health
statu
gener
korean
adult
popul
investig
rel
burden
ar
mental
health
use
allerg
rhiniti
impact
asthma
aria
classif
method
survey
univari
analysi
conduct
healthi
ar
group
weight
preval
demograph
characterist
socioeconom
statu
comorbid
diseas
subanalysi
classifi
ar
sever
accord
aria
classif
carri
evalu
relationship
ar
sever
mental
health
odd
ratio
or
compon
repres
mental
health
statu
estim
multipl
logist
regress
analysi
confound
adjust
result
univari
analysi
test
adjust
age
sex
bodi
mass
index
smoke
statu
alcohol
use
statu
exercis
statu
compon
repres
mental
health
statu
show
linear
relationship
sever
ar
accord
aria
classif
stress
depress
mood
suicid
thought
psycholog
consult
factor
correl
ar
adjust
demograph
characterist
socioeconom
statu
even
adjust
comorbid
allerg
diseas
correl
remain
signific
stress
depress
mood
psycholog
consult
factor
ci
respect
conclus
patient
ar
appear
higher
risk
mental
disord
gener
korean
adult
popul
moreov
persist
sever
ar
correl
poor
mental
health
therefor
better
control
ar
may
conduc
better
mental
health
attent
paid
psycholog
statu
ar
patient
jm
dsouza
pawar
khoo
teck
puat
hospit
respiratori
critic
care
medicin
singapor
singapor
background
aim
introduct
mycot
pulmonari
pseudoaneurysm
uncommon
complic
cavitatori
pneumonia
associ
organ
like
mycobacterium
tuberculosi
staphylococcu
aureu
mucormycosi
vaishali
et
al
carri
high
mortal
risk
report
interest
case
sever
pneumonia
mycot
pulmonari
pseudoaneurysm
fail
bronchial
arteri
embol
therapi
method
case
present
year
old
indian
male
smoker
pack
year
previou
histori
stroke
hypertens
peripher
vascular
diseas
present
sudden
onset
hemoptysi
report
cough
millilit
fresh
blood
prior
hospit
deni
chest
pain
fever
night
sweat
weight
loss
prior
pulmonari
tuberculosi
recurr
chest
infect
clinic
examin
reveal
tachypnea
coars
crepit
right
lung
base
deterior
worsen
type
respiratori
failur
intub
stabilis
icu
ct
thorax
fig
reveal
bilater
lower
lobe
consolid
cavit
right
lower
lobe
mycot
pseudoaneurysm
along
posteromedi
wall
cystic
lesion
result
antibiot
therapi
initi
blood
sputum
neg
organ
cultur
smear
pulmonari
tuberculosi
neg
underw
success
bronchial
arteri
embol
blood
product
transfus
close
follow
massiv
hemoptysi
recur
repeat
ct
show
obviou
focu
activ
bleed
decis
made
surgic
intervent
henc
underw
right
lower
lobectomi
right
lower
lobe
pseudoaneurysm
invad
right
diaphragm
note
histolog
resect
lung
neg
malign
thereaft
made
progress
recoveri
discharg
well
conclus
mycot
pseudoaneurysm
present
hemoptysi
requir
emerg
manag
multidisciplinari
approach
bronchial
arteri
embol
prefer
initi
treatment
hemostasi
case
illustr
need
vigil
follow
even
success
embol
prompt
earli
decis
surgeri
embol
fail
l
hoang
dao
h
nguyen
thi
hanoi
medic
univers
allergi
clinic
immunolog
ha
noi
vietnam
hanoi
medic
univers
surgeon
depart
ha
noi
vietnam
background
aim
femor
head
avascular
necrosi
common
disord
among
lupu
patient
caus
lot
neg
effect
qualiti
patient
life
aim
explor
clinic
characterist
femor
head
avascular
necrosi
among
system
lupu
erythemat
patient
method
cross
section
studi
carri
system
lupu
erythemat
patient
also
femor
head
avascular
necrosi
studi
conduct
center
allergi
clinic
immunolog
bachmai
hospit
patient
fulfil
slicc
criteria
classif
sle
patient
femor
head
avascular
necrosi
symptomat
diagnosi
femor
head
avascular
necrosi
made
plain
radiographi
bone
scan
andor
mri
scan
result
mean
age
time
studi
year
rang
highest
age
group
year
old
patient
femor
head
avascular
necrosi
iv
mri
renal
disord
common
seen
pain
symptom
correl
level
necrosi
femor
head
dyslipidemia
low
bone
densiti
risk
factor
femor
head
avascular
necrosi
conclus
half
sle
patient
sever
femor
head
avascular
necrosi
level
iv
among
nearli
renal
disord
femor
head
avascular
necrosi
common
among
young
patient
late
recogn
ks
hj
busan
republ
korea
kosin
univers
colleg
medicin
genet
busan
republ
korea
background
aim
respiratori
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
lung
infect
critic
consequ
mortal
morbid
human
aim
present
studi
examin
mechan
affect
transcript
airway
inflamm
depend
activ
signal
ag
identifi
specif
molecul
suppress
airway
inflamm
act
receptor
method
charri
western
blot
anlaysi
detect
specif
gene
express
use
mous
lung
result
herein
suppress
upregul
regul
found
regulatori
gpr
motif
peptid
bind
downregul
express
contrast
motif
upregul
express
mutat
gpr
peptid
increas
express
decreas
express
moreov
dendrit
extens
matrix
cultur
inhibit
gpr
peptid
compar
gpr
peptid
gpr
peptid
also
inhibit
morpholog
chang
inflammatori
cell
infiltr
mous
lung
product
inflammatori
cytokin
bronchoalveolar
lavag
bal
fluid
lung
conclus
data
indic
gpr
motif
critic
regul
express
cytokin
product
inflammatori
microenviron
w
hirofumi
yokosuka
citi
hospit
intern
medicin
yokosuka
japan
report
case
femal
asymptomat
isol
unilater
absenc
proxim
pulmonari
main
arteri
uapa
refer
hospit
abnorm
show
chest
year
age
diagnosi
confirm
pulmonari
angiographi
show
absenc
right
pulmonari
arteri
collater
circul
ipsilater
lung
evid
pulmonari
hypertens
upon
cardiac
cathet
examin
safe
deliv
twice
care
manag
use
cathet
remain
asymptomat
healthi
without
medic
uapa
rare
congenit
lesion
kept
mind
differenti
diagnosi
patient
abnorm
chest
uapa
may
caus
varieti
symptom
although
patient
isol
uapa
complet
asymptomat
other
may
sever
pulmonari
hypertens
congest
heart
failur
report
case
consid
mechan
symptomat
variat
literatur
review
c
kim
divis
depart
intern
sever
yonsei
univers
colleg
medicin
seoul
republ
korea
background
aim
increas
number
lung
transplant
rate
oper
success
mani
studi
prognost
factor
lung
transplant
publish
despit
rise
popular
report
use
prognost
factor
pulmonari
hypertens
confirm
use
cardiac
catheter
patient
lung
transplant
limit
purpos
studi
review
lung
transplant
recipi
determin
pulmonari
hypertens
prior
lung
transplant
serv
prognost
factor
method
review
patient
underw
singl
doubl
lung
transplant
sever
hospit
yonsei
univers
januari
juli
patient
receiv
preoper
right
side
catheter
echocardiographyth
relationship
year
surviv
lung
transplant
sever
pulmonari
hypertens
evalu
result
patient
singl
doubl
lung
transplant
sever
hospit
among
patient
patient
perform
doubl
lung
transplant
mean
age
sd
yearsth
mean
right
ventricular
systol
pressur
echocardiographi
mean
pulmonari
arteri
pressur
use
right
side
catheter
confirm
iqr
mmhg
surviv
rate
group
mpap
mm
hg
group
less
mm
hg
respect
multipl
logist
regress
analysi
perform
variabl
patient
mpap
influenc
surviv
significantli
moder
sever
pulmonari
htn
group
ci
conclus
studi
postop
mortal
patient
moder
sever
pulmonari
hypertens
confirm
significantli
higher
patient
without
pulmonari
hypertens
although
mani
number
patient
restrict
provid
throughout
studi
could
seen
check
signific
measur
pulmonari
hypertens
preoper
cardiac
catheter
k
okonogi
c
pothirat
c
bumroongkit
deesomchok
theerakittikul
limsukon
p
tajarernmuang
c
liwsrisakun
divis
pulmonolog
critic
care
allergi
depart
intern
medicin
faculti
medicin
chiang
mai
univers
chiang
mai
thailand
background
aim
gold
guidelin
wide
use
copd
practic
data
physician
adher
guidelin
impact
clinic
outcom
limit
thailand
aim
evalu
clinic
outcom
associ
treatment
copd
accord
gold
guidelin
chiang
mai
univers
cmu
hospit
method
perform
retrospect
cohort
copd
patient
cmu
hospit
primari
outcom
mortal
moder
sever
acut
exacerb
ae
copd
pneumonia
physician
adher
divid
group
treatment
appropri
treatment
treatment
result
total
patient
includ
studi
preval
inappropri
treatment
gold
gold
b
gold
c
gold
patient
gold
b
c
respect
contrast
patient
inappropri
group
gold
rate
mortal
p
pneumonia
p
moder
sever
ae
copd
p
differ
among
group
conclus
physician
gold
guidelin
associ
advers
outcom
copd
patient
j
lin
ss
hy
li
jx
feng
taizhou
hospit
wenzhou
medic
univers
depart
respiratori
medicin
linhai
china
background
aim
repeatedli
hospit
patient
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
often
expos
antibiot
distribut
pathogen
bacteria
patient
poorli
understood
object
studi
analyz
distribut
pathogen
bacteria
risk
factor
associ
mdr
bacteria
infect
earli
readmiss
patient
aecopd
method
retrospect
review
chart
patient
aecopd
admit
hospit
januari
novemb
earli
readmiss
group
readmiss
group
determin
whether
patient
readmit
within
day
discharg
detect
potenti
pathogen
microorgan
ppm
mdr
bacteria
analyz
logist
regress
analysi
perform
identifi
independ
risk
factor
mdr
bacteria
infect
result
patient
admiss
period
ppm
isol
case
respiratori
tract
specimen
mdr
bacteria
account
pseudomona
aeruginosa
klebsiella
pneumonia
acinetobact
baumannii
top
three
ppm
earli
readmiss
group
top
three
ppm
k
pneumonia
p
aeruginosa
streptococcu
pneumonia
readmiss
group
multivari
analysi
show
use
antibiot
within
week
odd
ratio
confid
interv
ci
p
independ
risk
factor
mdr
bacteria
infect
conclus
bacilli
nfgnb
enterobacteria
predomin
bacteria
earli
readmiss
patient
aecopd
detect
rate
mdr
bacteria
high
relat
use
antibiot
within
week
admiss
patient
l
yuwen
l
peng
l
yun
c
yitai
h
yuxia
w
kai
x
chen
zhujiang
southern
medic
guangzhou
c
depart
respiratori
medicin
guangzhou
china
background
aim
cycl
ergomet
train
cet
shown
improv
exercis
perform
quadricep
muscl
patient
chronic
obstruct
pulmonari
diseas
copd
inspiratori
muscl
train
imt
could
improv
capac
inspiratori
muscl
purpos
studi
determin
whether
combin
cet
imt
would
lead
addit
benefit
compar
cet
alon
patient
copd
addit
effect
combin
train
compar
patient
without
respiratori
muscl
weak
method
patient
copd
randomli
divid
three
group
patient
receiv
combin
cet
imt
combin
group
receiv
cet
alon
cet
group
patient
receiv
intervent
control
group
pulmonari
function
exercis
capac
dyspnea
qualiti
life
respiratori
muscl
strength
emot
nutrit
statu
bode
index
measur
pulmonari
rehabilit
program
result
pulmonari
rehabilit
exercis
capac
dyspnea
qualiti
life
respiratori
muscl
strength
depress
anxieti
nutrit
statu
improv
combin
group
cet
group
compar
control
group
p
inspiratori
muscl
strength
significantli
increas
combin
group
compar
cet
group
vs
respect
p
howev
signific
differ
indic
two
group
p
combin
group
cet
group
patient
weaken
respiratori
muscl
greater
benefit
without
weaken
respiratori
muscl
p
conclus
combin
train
effect
increas
inspiratori
muscl
strength
compar
cet
alon
exercis
perform
dyspnea
depress
symptom
nutrit
statu
imt
may
use
ad
cet
patient
weaken
inspiratori
muscl
kusunos
nakamura
k
senda
k
nishimura
nation
center
geriatr
gerontolog
depart
pulmonari
medicin
japan
background
aim
age
known
predictor
mortal
admiss
exacerb
subject
copd
frailti
geriatr
syndrom
origin
defin
fri
meet
three
five
criteria
consist
low
unintent
weight
loss
exhaust
low
grip
strength
slow
walk
speed
low
physic
activ
howev
altern
tool
report
one
kihon
checklist
kcl
questionnair
wide
use
japan
identifi
frail
individu
compos
item
yesno
respons
investig
relationship
kcl
clinic
indic
includ
outcom
pro
stabl
copd
patient
method
examin
consecut
outpati
stabl
copd
particip
complet
st
georg
respiratori
questionnair
sgrq
copd
assess
test
cat
hyland
scale
kcl
pulmonari
function
test
kcl
rang
high
score
indic
frailti
syndrom
categor
particip
robust
prefrail
frail
respect
result
classifi
particip
robust
prefrail
frail
accord
kcl
statist
signific
differ
sqrq
total
score
cat
score
hyland
scale
score
score
among
three
group
kcl
score
significantli
correl
sgrq
total
score
rs
p
cat
score
rs
p
hyland
scale
score
rs
p
score
rs
p
contrarili
found
neither
signific
differ
pulmonari
function
measur
includ
tlc
rvtlc
ic
dlco
dlcova
noteworthi
associ
kcl
score
spirometr
measur
conclus
frailti
screen
kcl
may
relev
qualiti
life
breathless
stabl
copd
patient
j
n
chiba
hokuso
hospit
nippon
medic
school
respiratori
diseas
center
japan
nippon
medic
school
depart
pulmonari
medicin
graduat
school
medicin
tokyo
japan
background
aim
compar
lama
versu
lama
plu
laba
efficaci
effect
beyond
week
copd
patient
method
copd
patient
randomis
receiv
either
tiotropium
lama
monotherapi
tiotropium
plu
indacaterol
lamalaba
combin
therapi
treatment
period
pulmonari
function
test
copd
assess
test
cat
score
modifi
medic
research
council
score
total
central
peripher
airway
resist
airway
resist
assess
interrupt
techniqu
rint
investig
result
men
yo
mean
sd
particip
studi
one
group
group
neither
group
analyz
variabl
show
signific
chang
time
lamalaba
group
show
signific
improv
week
week
mean
differ
baselin
week
p
p
week
p
show
signific
chang
baselin
week
expiratori
inspiratori
phase
expiratori
phase
show
signific
improv
lamalaba
group
week
wherea
inspiratori
phase
decreas
almost
entir
observ
period
mean
differ
baselin
p
conclus
laba
ad
lama
improv
airway
resist
caus
reduct
hyperinfl
publish
detail
studi
result
congress
apsr
j
h
henan
univers
tcm
collabor
innov
center
respiratori
diseas
diagnosi
treatment
chines
medicin
develop
henan
provinc
zhengzhou
china
first
affili
hospit
henan
univers
tcm
depart
respiratori
zhengzhou
china
background
aim
item
respons
theori
irt
new
kind
psycholog
educ
measur
theori
develop
analyz
overcom
limit
classic
test
theori
ctt
irt
shorten
test
time
effect
assess
abil
subject
accur
irt
fulli
develop
field
psycholog
educ
measur
sinc
howev
applic
qualiti
life
qol
research
date
end
centuri
studi
aim
analyz
applic
condit
irt
domest
intern
qol
research
respiratori
diseas
provid
idea
qol
research
method
keyword
item
respons
theori
irt
search
chines
biomed
literatur
databas
china
nation
knowledg
infrastructur
cnki
china
scienc
technolog
journal
databas
vip
wanfang
data
pubm
embas
web
scienc
cochran
librari
ebsco
relev
literatur
analyz
summar
result
literatur
perform
applic
irt
qol
research
respiratori
diseas
focus
sever
aspect
screen
item
evalu
psychometr
properti
analyz
differenti
item
function
dif
howev
applic
mainli
featur
late
start
narrow
applic
rang
singl
model
applic
instanc
earliest
applic
irt
date
main
applic
irt
abroad
includ
screen
item
evalu
psychometr
properti
analyz
dif
chronic
obstruct
pulmonari
diseas
copd
evalu
tool
intern
recogn
st
georg
respiratori
questionnair
sgrq
copd
assess
test
cat
domest
applic
confin
screen
item
moreov
irt
model
mainli
involv
grade
respons
model
grm
rasch
model
conclus
broad
applic
prospect
irt
exist
qol
research
respiratori
diseas
includ
combin
applic
ctt
irt
develop
revis
evalu
tool
well
build
qualiti
item
pool
compil
comput
adapt
test
h
h
w
h
k
univers
tokyo
respiratori
medicin
tokyo
japan
univers
tokyo
clinic
epidemiolog
health
econom
tokyo
japan
univers
tokyo
health
servic
research
tokyo
japan
tokyo
medic
dental
univers
health
polici
informat
tokyo
japan
background
aim
chronic
obstruct
pulmonari
diseas
copd
high
morbid
mortal
world
copd
exacerb
crucial
event
patient
aim
studi
investig
factor
affect
mortal
patient
copd
exacerb
creat
tool
predict
individu
outcom
patient
statu
admiss
use
nationwid
inpati
databas
japan
method
retrospect
collect
data
patient
admit
due
copd
exacerb
discharg
juli
march
multivari
logist
regress
analysi
perform
examin
factor
associ
mortal
result
total
elig
patient
death
occur
patient
higher
mortal
associ
advanc
age
male
lower
bmi
disturb
conscious
sever
dyspnea
histori
mechan
ventil
pneumonia
asthma
admiss
base
result
multivari
logist
regress
analysi
develop
nomogram
predict
mortal
concord
index
nomogram
intern
valid
perform
bootstrap
method
resampl
calibr
plot
well
fit
predict
mortal
conclus
nomogram
predict
prognosi
may
help
clinician
determin
appropri
treatment
j
n
k
k
graduat
school
juntendo
univers
depart
rehabilit
medicin
tokyo
japan
juntendo
univers
clinic
research
unit
respiratori
graduat
school
health
care
nurs
urayasu
japan
koto
hospit
depart
respiratori
medicin
tokyo
japan
juntendo
univers
depart
adult
health
faculti
health
care
nurs
urayasu
japan
background
aim
pulmonari
rehabilit
still
underutil
japan
white
paper
assess
effect
individu
tailor
outpati
pulmonari
rehabilit
behavior
modif
program
respiratori
class
group
korch
koto
hospit
reduct
number
copd
hospit
intervent
conduct
method
outpati
pulmonari
rehabilit
clinic
provid
chest
physician
respiratori
physiotherapist
half
day
week
may
june
patient
copd
mf
mean
age
ltot
refer
clinic
hospit
min
session
respiratori
condit
breath
retrain
walk
stretch
train
mainli
conduct
one
one
decreas
patient
exert
dyspnea
session
behavior
modif
intervent
ad
encourag
patient
increas
physic
activ
use
copd
diari
pedomet
individu
activ
action
plan
given
interv
patient
visit
month
class
group
patient
educ
minsess
time
start
patient
copd
attend
last
three
year
result
number
hospit
decreas
signific
reduct
age
group
seventi
eighti
p
dpc
diagnosi
procedur
combin
copd
hospit
tokyo
rank
releas
ministri
highest
howev
forth
ninth
respect
also
reduct
number
hospit
due
pneumonia
respect
conclus
suggest
outpati
pulmonari
rehabilit
educ
potenti
prevent
hospit
admiss
copd
patient
respiratori
condit
enhanc
program
help
spread
pulmonari
rehabilit
villalobo
j
magallan
univers
gener
hospit
section
pulmonari
depart
medicin
manila
philippin
background
aim
current
global
initi
chronic
obstruct
lung
diseas
gold
guidelin
recommend
use
beta
agonist
laba
plu
inhal
corticosteroid
ic
muscarin
antagonist
lama
treatment
patient
moder
sever
copd
combin
laba
lama
recent
indic
copd
patient
sever
symptom
howev
role
reduc
exacerb
less
clear
method
perform
random
control
trial
compar
efficaci
safeti
laba
lama
versu
laba
ic
moder
sever
copd
patient
primari
outcom
rate
copd
exacerb
outcom
measur
includ
improv
trough
st
georg
respiratori
questionnair
copd
score
transit
dyspnea
index
tdi
score
rescu
medic
use
pneumonia
risk
analysi
perform
accord
qualiti
report
quorum
guidelin
result
total
rct
patient
includ
exacerb
rate
lower
treat
laba
lama
versu
laba
ic
rr
ci
effect
pronounc
patient
exacerb
per
year
show
lower
exacerb
rate
rr
compar
histori
prior
exacerb
rr
patient
given
indacaterol
glycopyrronium
also
experienc
lower
rate
exacerb
versu
laba
ic
rr
compar
given
umeclidinium
vilanterol
rr
also
statist
signific
improv
mean
differ
ml
ci
improv
mean
differ
point
improv
tdi
score
mean
differ
decreas
use
rescu
medic
mean
differ
puffsday
pneumonia
risk
significantli
lower
patient
given
laba
lama
rr
conclus
combin
laba
lama
safer
effect
reduc
exacerb
improv
clinic
outcom
compar
laba
ic
patient
moder
sever
copd
anderson
pj
eur
respir
rev
altman
p
et
al
prim
care
respir
med
k
k
k
k
k
h
h
kobe
univers
graduat
school
health
scienc
commun
health
kobe
japan
kobe
citi
medic
center
west
hospit
depart
rehabilit
kobe
japan
nurs
station
wakakusa
nurs
nagano
japan
nation
hospit
organ
higashi
nagano
hospit
depart
respiratori
medicin
nagano
japan
background
aim
dyspnea
main
symptom
chronic
obstruct
pulmonari
diseas
copd
restrict
activ
daili
live
adl
assess
motor
process
skill
amp
standard
measur
adl
howev
associ
amp
copd
remain
unclear
purpos
studi
evalu
amp
copd
patient
associ
breath
function
dyspnea
qualiti
life
adl
standard
method
observ
studi
includ
outpati
stabl
copd
without
oxygen
therapi
follow
assess
patient
spirometri
lung
function
modifi
medic
research
council
dyspnea
scale
copd
assess
test
cat
function
statu
dyspnea
amp
result
adl
motor
abil
neg
correl
dyspnea
r
p
fatigu
r
p
activ
r
p
adl
process
abil
correl
dyspnea
r
p
fatigu
r
p
activ
r
p
adl
motor
abil
correl
r
p
r
p
cat
r
p
conclus
amp
correl
adl
scale
suggest
amp
reflect
adl
abil
stabl
copd
patient
h
k
k
k
k
k
kobe
univers
graduat
school
health
scienc
commun
health
scienc
kobe
japan
nurs
station
wakakusa
nurs
nagano
japan
nation
hospit
organ
higashi
nagano
hospit
intern
medicin
nagano
japan
background
aim
long
term
oxygen
therapi
ltot
improv
mortal
patient
chronic
obstruct
pulmonari
diseas
copd
adapt
standard
ltot
rest
howev
mani
copd
patient
hypoxia
movement
rest
sinc
provid
intervent
program
copd
patient
complet
pulmonari
rehabilit
patient
routin
taken
care
home
intervent
receiv
continu
evalu
aim
present
studi
examin
effect
ltot
copd
patient
method
copd
patient
particip
program
year
includ
studi
patient
drop
period
exclud
measur
includ
pulmonari
function
arteri
blood
ga
walk
test
activ
daili
live
adl
score
qualiti
life
qol
score
first
measur
result
surviv
rate
compar
patient
without
ltot
second
compar
ltot
without
desatur
group
walk
ltot
desatur
group
b
desatur
walk
defin
result
subject
includ
analysi
subject
ltot
significantli
lower
bodi
mass
index
bmi
adl
score
subject
without
ltot
surviv
rate
ltot
lower
without
ltot
six
subject
classifi
group
subject
group
b
group
significantli
higher
group
b
lower
surviv
rate
respect
conclus
ltot
improv
hypoxia
howev
improv
surviv
rate
copd
patient
z
dcl
jmf
kc
univers
hong
kong
school
profession
continu
educ
hong
kong
hong
china
univers
hong
kong
depart
li
ka
shing
faculti
queen
mari
hospit
hong
kong
hong
china
univers
hong
kong
school
biolog
scienc
hong
kong
hong
china
background
aim
bronchodil
could
deliv
via
dri
powder
inhal
dpi
central
treatment
copd
although
efficaci
bronchodil
administr
establish
treatment
effect
compromis
patient
prefer
skill
requir
use
inhal
devic
import
inhal
devic
easi
use
correct
dosag
administ
studi
compar
satisfact
error
occurr
three
type
dpi
name
breezhal
ellipta
genuair
method
healthi
subject
age
without
experi
use
dpi
recruit
n
subject
learn
use
dpi
read
product
instruct
follow
watch
demonstr
audio
explan
dpi
provid
subject
random
order
type
number
error
commit
subject
evalu
subject
ask
complet
questionnair
indic
satisfact
prefer
variou
aspect
dpi
result
subject
rate
significantli
greater
satisfact
indic
correct
dose
prepar
genuair
ellipta
vs
p
genuair
also
score
significantli
higher
ellipta
breezhal
vs
vs
p
subject
ask
confid
inhal
assign
dose
term
conveni
number
subject
prefer
breezhal
higher
genuair
ellipta
subject
prefer
ellipta
eas
dose
prepar
overal
satisfact
score
genuair
significantli
higher
breezhal
ellipta
vs
vs
p
conclus
use
genuair
dpi
associ
greater
user
satisfact
healthi
volunt
import
satisfact
would
improv
patient
complianc
inhal
therapi
j
l
k
tohoku
univers
graduat
school
medicin
depart
respiratori
medicin
sendai
japan
nation
hospit
organ
wakayama
hospit
depart
respiratori
medicin
wakayama
japan
nippon
medic
school
depart
intern
medicin
tokyo
japan
graduat
school
health
care
nurs
clinic
research
unit
respiratori
pathophysiolog
chiba
japan
nippon
boehring
ingelheim
ltd
medic
divis
tokyo
japan
ep
corpor
statist
analysi
depart
tokyo
japan
boehring
ingelheim
pharma
gmbh
co
kg
medicin
ta
respiratori
diseas
rhein
germani
graduat
school
medicin
osaka
citi
univers
depart
respiratori
medicin
osaka
japan
background
aim
tiotropium
olodaterol
combin
fdc
shown
superior
either
monotherapi
lung
function
dyspnea
lung
hyperinfl
qualiti
life
copd
patient
sever
studi
scientif
interest
relat
patient
daili
life
eg
physic
activ
grow
although
exercis
capac
daili
physic
activ
improv
mention
one
import
treatment
target
japanes
copd
treatment
guidelin
endpoint
yet
evalu
random
studi
japan
vesuto
plan
evalu
pharmacolog
intervent
effect
endpoint
method
vesuto
random
crossov
studi
total
copd
patient
gold
stage
age
year
random
ratio
sequenti
treatment
group
start
treatment
fdc
tiotropium
week
treatment
period
medic
oral
inhal
daili
use
primari
endpoint
inspiratori
capac
ic
rest
minut
week
evalu
hyperinfl
secondari
endpoint
walk
distanc
evalu
exercis
capac
patient
daili
physic
activ
measur
use
acceleromet
model
repeat
measur
approach
use
assess
primari
secondari
endpoint
result
vesuto
initi
februari
japan
current
recruit
patient
first
random
studi
evalu
efficaci
fdc
versu
tiotropium
lung
hyperinfl
also
exercis
capac
physic
activ
japanes
copd
patient
vesuto
would
provid
evid
lamalaba
combin
therapi
lung
function
exercis
capac
physic
activ
associ
patient
daili
life
activ
japanes
patient
copd
figur
studi
design
v
visit
walk
test
pft
pulmonari
function
test
conclus
wedzicha
ja
et
al
n
engl
j
med
f
l
p
g
mg
zambon
spa
corpor
respiratori
medic
affair
bresso
milan
itali
univers
rome
tor
vergata
depart
system
medicin
rome
itali
second
univers
napl
depart
experiment
medicin
napl
itali
background
aim
concentr
cytokin
increas
lung
patient
stabl
chronic
obstruct
pulmonari
diseas
copd
augment
airway
exacerb
nac
seem
abl
reduc
copd
exacerb
addit
mucolyt
activ
pharmacolog
mechan
effect
still
unclear
aim
pharmacolog
character
effect
nac
ex
vivo
model
copd
exacerb
method
influenc
nac
assess
contractil
respons
profil
human
isol
bronchi
incub
overnight
buffer
solut
control
lipopolysaccharid
lp
ngml
result
nac
prevent
desensit
induc
lp
incub
contractil
tone
linear
manner
concentr
nac
inhibit
inflammatori
respons
human
airway
overal
p
vs
lp
induc
overnight
stimul
lp
wherea
lower
concentr
nac
suffici
reduc
releas
p
vs
lp
elicit
lp
conclus
result
studi
demonstr
concentr
nac
need
restor
normal
contractil
respons
human
bronchi
challeng
lp
concentr
nac
essenti
obtain
respons
ex
vivo
model
copd
exacerb
w
sl
c
k
faculti
medicin
khon
kaen
univers
depart
medicin
khon
kaen
thailand
faculti
medicin
princ
songkla
univers
depart
intern
medicin
songkhla
thailand
novarti
ireland
ltd
patient
access
servic
dublin
ireland
novarti
thailand
ltd
market
access
govern
affair
commun
depart
bangkok
thailand
background
aim
evalu
indacaterolglycopyrronium
indgli
compar
tiotropium
tio
fix
combin
salmeterolfluticason
sfc
manag
copd
method
publish
valid
simul
model
adapt
use
thailand
follow
individu
patient
lifetim
time
horizon
improv
forc
expiratori
volum
second
exacerb
pneumonia
rate
reduct
obtain
direct
indirect
comparison
primari
data
shine
spark
lantern
clinic
trial
direct
indirect
cost
obtain
publish
local
studi
standard
cost
list
indgli
price
propos
nation
formulari
list
use
drug
price
publish
ministri
public
health
thailand
cost
express
usd
valu
cost
outcom
discount
annual
univari
probabilist
sensit
analys
perform
key
input
paramet
result
indgli
yield
increment
life
year
ly
year
addit
life
year
qali
lifetim
compar
tio
comparison
sfc
indgli
increas
lyg
qali
higher
drug
acquisit
cost
indgli
partial
offset
lower
cost
mainten
treatment
sever
exacerb
cost
treat
pneumonia
reduc
indgli
vs
sfc
consid
thailand
recommend
threshold
usdqali
indgli
discount
increment
ratio
icer
usdqali
compar
tio
sfc
respect
indgli
remain
indirect
cost
exclud
healthcar
provid
perspect
sensit
analys
show
result
robust
chang
across
scenario
conclus
base
societ
healthcar
provid
perspect
indgli
like
compar
tio
sfc
copd
popul
thailand
wedzicha
ja
et
al
n
eng
j
med
g
p
l
j
cardena
valeria
p
novarti
pharma
ag
respiratori
basel
switzerland
instituto
ave
pulmo
enfisema
bueno
air
argentina
novarti
ireland
limit
respiratori
dublin
ireland
novarti
argentina
sa
respiratori
bueno
air
argentina
novarti
pharmaceut
corpor
respiratori
east
hanov
usa
background
aim
effect
manag
copd
requir
regular
inhal
medic
copd
patient
inhal
effort
requir
flow
rate
achiev
dpi
import
consider
select
dri
power
inhal
dpi
compar
peak
inspiratori
flow
pif
rate
achiev
copd
patient
three
type
dpi
effect
copd
sever
pif
rate
also
assess
method
random
multicent
studi
recruit
patient
sever
copd
gold
age
year
smoke
histori
pack
year
activ
drug
placebo
administ
studi
inhal
flow
profil
patient
record
use
pressur
tap
inhal
attach
pressur
transduc
patient
inhal
profil
highest
pif
rate
three
replic
inhal
per
devic
select
analysi
primari
analysi
base
set
compris
patient
complet
three
inhal
per
devic
pair
perform
compar
pif
mean
combin
devic
result
total
copd
patient
random
complet
studi
patient
set
includ
analysi
highest
mean
pif
rate
lmin
se
observ
follow
across
sever
copd
patient
mean
pif
rate
lmin
achiev
via
highest
vs
mean
differ
p
also
vs
p
assess
copd
sever
devic
exhibit
significantli
higher
pif
rate
vs
vs
tabl
conclus
copd
patient
vari
degre
airflow
limit
sever
copd
achiev
highest
pif
rate
via
compar
inhal
studi
fund
novarti
pharma
ag
nadeem
dg
nair
da
upp
dy
patil
univers
medic
scienc
pulmonari
medicin
mumbai
india
background
aim
background
cigarett
smoke
major
risk
factor
develop
cardiovascular
diseas
atherosclerosi
chronic
obstruct
pulmonari
diseas
copd
extens
research
gone
identifi
attempt
valid
relev
diagnost
biomark
diseas
activ
therapeut
respons
chronic
obstruct
pulmonari
diseas
protein
crp
may
easili
sensit
measur
varieti
clinic
situat
monitor
diseas
progress
studi
attempt
identifi
relationship
smoke
behavior
level
crp
focus
use
crp
measur
predict
health
smoker
aim
compar
crp
level
asymptomat
smoker
nonsmok
compar
lung
function
spirometr
valu
asymptomat
smoker
nonsmok
correl
crp
level
lung
function
valu
method
hospit
base
prospect
studi
smoker
non
smoker
year
age
tertiari
care
hospit
recruit
result
comparison
crp
smoker
mean
crp
smoker
sd
mean
crp
nonsmok
sd
comparison
done
use
independ
sampl
signific
differ
averag
crp
valu
smoker
p
neg
correl
mmefr
crp
p
smoker
neg
correl
mmefr
crp
p
signific
differ
averag
mmef
valu
smoker
p
conclus
studi
demonstr
signific
reduct
crp
smoker
non
smokersthu
crp
cheaper
altern
biomark
prognosi
drug
develop
predict
outcom
copd
high
sensit
crp
sensit
may
use
biomark
c
liwsrisakun
maharaj
nakorn
chiangmai
hospit
intern
medicin
chiangmai
thailand
background
aim
chronic
obstruct
pulmonari
diseas
copd
may
extrapulmonari
manifest
includ
balanc
control
function
physic
incapac
balanc
impair
risk
fall
impact
clinic
outcom
daili
live
depress
qualiti
life
copd
patient
determin
risk
factor
balanc
impair
copd
method
studi
conduct
singl
visit
involv
stabl
copd
patient
age
year
old
balanc
test
measur
use
berg
balanc
scale
bb
score
indic
balanc
impair
clinic
relev
data
age
sex
bmi
educ
pft
sever
copd
oxygen
therapi
histori
fall
histori
acut
exacerb
sgrq
score
cat
score
mmrc
score
visual
deficit
time
go
test
tug
walk
distanc
hospit
anxieti
depress
scale
had
compar
impair
balanc
patient
logist
regress
analysi
result
one
hundr
two
patient
includ
studi
balanc
impair
patient
balanc
impair
group
signific
higher
incid
fall
past
year
versu
p
four
factor
includ
age
year
old
adjust
odd
ratio
adjor
ci
p
comorbid
coronari
arteri
diseas
adjor
ci
p
tug
second
adjor
ci
p
meter
adjor
ci
p
associ
increas
risk
balanc
impair
tug
strongli
associ
r
p
conclus
advanc
age
coronari
arteri
diseas
increas
tug
reduc
risk
factor
balanc
impair
copd
patient
balanc
test
includ
routin
assess
copd
patient
prevent
decreas
devast
consequ
fall
dw
c
eun
andong
sungso
hospit
intern
medicin
republ
korea
yeungnam
univers
hospit
intern
medicin
daegu
republ
korea
background
aim
decreas
bone
miner
densiti
bmd
system
consequ
chronic
obstruct
pulmonari
diseas
copd
past
report
rare
examin
correl
sarcopenia
bmd
investig
relationship
presenc
sarcopenia
bmd
reduct
copd
patient
method
copd
patient
age
older
qualifi
spirometri
absorptiometri
data
chosen
particip
korean
nation
health
nutrit
examin
survey
iv
v
result
subject
sarcopenia
group
group
sarcopenia
group
lower
group
femur
vs
p
femur
neck
vs
p
lumbar
vs
p
preval
osteopenia
osteoporosi
respect
sarcopenia
group
group
p
adjust
multipl
variabl
presenc
sarcopenia
increas
risk
osteopenia
osteoporosi
low
bmd
p
p
p
respect
subgroup
analysi
similar
chang
confirm
group
group
p
p
p
p
p
p
respect
conclus
regardless
bodi
weight
presenc
sarcopenia
associ
time
increas
risk
decreas
bmd
copd
p
poomthong
b
chuaychoo
faculti
medicin
siriraj
hospit
pulmonari
medicin
tuberculosi
bangkok
thailand
background
pulmonari
rehabilit
import
compon
manag
copd
benefici
improv
exercis
capac
qualiti
life
object
assess
effect
week
pulmonari
rehabilit
program
exercis
capac
qualiti
life
use
modifi
medic
research
council
mmrc
dyspnea
scale
six
minut
walk
distanc
copd
assess
test
cat
questionnair
clinic
copd
questionnair
ccq
patient
copd
method
retrospect
analysi
copd
patient
pulmonari
rehabilit
clinic
may
decemb
baselin
characterist
number
exacerb
pulmonari
function
test
mmrc
dyspnea
scale
mwd
cat
score
ccq
score
pulmonari
rehabilit
program
assess
result
patient
male
median
age
year
mean
forc
expiratori
volum
one
second
predict
pulmonari
rehabilit
mmrc
dyspnea
scale
cat
score
statist
signific
differ
compar
pulmonari
rehabilit
mean
chang
p
p
respect
cat
score
met
minim
clinic
import
differ
mcid
ccq
mwd
improv
statist
signific
pulmonari
function
paramet
number
exacerb
differ
pulmonari
rehabilit
program
conclus
pulmonari
rehabilit
program
copd
patient
improv
qualiti
life
term
cat
score
n
w
muang
thailand
maharat
nakhonratsima
hospit
medicin
nakhonratsima
thailand
background
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
lead
caus
hospit
econom
burden
frequent
exacerb
impair
qualiti
life
effect
declin
lung
function
object
evalu
characterist
copd
patient
acut
exacerb
within
day
discharg
hospit
precipit
caus
acut
manag
hospit
stay
outcom
cost
admiss
also
determin
method
studi
popul
includ
copd
patient
acut
exacerb
within
day
discharg
maharat
nakornratchasima
hospit
octob
june
retrospect
descript
studi
appli
result
patient
within
day
discharg
due
acut
exacerb
mean
age
year
male
femal
ration
admiss
describ
previou
mean
durat
symptom
day
respect
patient
previou
admiss
patient
respiratori
failur
requir
mechan
ventil
common
precipit
caus
pneumonia
occur
respect
organ
pneumonia
identifi
patient
previou
admiss
pseudomona
aeruginosa
promin
common
organ
acinetobact
baumannii
mean
durat
admiss
day
rang
day
rang
respect
mean
cost
admiss
baht
rang
baht
baht
rang
baht
respect
episod
patient
die
conclus
acut
exacerb
copd
increas
morbid
mortal
pneumonia
lead
precipit
caus
longer
hospit
stay
medic
cost
observ
prevent
proper
manag
exacerb
help
keyword
copd
exacerb
precipit
outcom
w
n
divis
pulmonari
critic
care
medicin
depart
medicin
faculti
medicin
chulalongkorn
univers
bangkok
thailand
king
chulalongkorn
memori
hospit
thai
red
cross
societi
bangkok
thailand
background
aim
background
exacerb
chronic
obstruct
pulmonari
diseas
copd
known
caus
diseas
progress
poorer
qualiti
life
evid
show
high
preval
excess
daytim
sleepi
ed
among
copd
popul
epworth
sleepi
scale
ess
develop
quantifi
ed
chang
ess
score
may
benefit
anoth
tool
predict
risk
develop
copd
exacerb
object
evalu
correl
delta
chang
ess
frequenc
acut
copd
exacerb
moder
sever
copd
patient
method
prospect
correl
studi
follow
delta
chang
ess
conduct
moder
sever
copd
patient
post
bronchodil
king
chulalongkorn
memori
hospit
bangkok
thailand
frequenc
acut
exacerb
month
delta
chang
ess
obtain
result
total
patient
enrol
studi
mean
liter
mean
number
exacerb
previou
year
mean
ess
baselin
patient
ess
least
indic
presenc
ed
delta
chang
ess
observ
neg
correl
frequenc
copd
exacerb
correl
coeffici
p
valu
perform
subgroup
analysi
demonstr
neg
correl
present
group
baselin
ess
correl
coeffici
p
valu
factor
correl
frequenc
copd
exacerb
conclus
group
copd
patient
delta
chang
ess
score
demonstr
neg
correl
frequenc
copd
exacerb
alert
relat
sympathet
hyperact
preced
copd
exacerb
may
explain
associ
ys
tr
jh
ym
hallym
univers
kangnam
sacr
heart
hospit
divis
allergi
critic
care
depart
intern
medicin
seolul
republ
korea
ewha
medic
center
ewha
medic
research
ewha
woman
univers
school
medicin
divis
pulmonari
critic
care
depart
intern
medicin
seoul
republ
korea
univers
ulsan
colleg
asan
medic
center
depart
pulmonolog
critic
care
medicin
seoul
republ
korea
background
aim
smoke
cessat
import
prevent
progress
chronic
obstruct
pulmonari
diseas
copd
nicotin
depend
often
determin
success
failur
smoke
cessat
evalu
nicotin
depend
statu
investig
factor
associ
moder
high
nicotin
depend
copd
korean
obstruct
lung
diseas
kold
ii
cohort
method
studi
includ
current
smoker
copd
kold
ii
cohort
januari
march
nicotin
depend
measur
use
fagerstrom
test
nicotin
depend
ftnd
cognit
function
assess
korean
version
montreal
cognit
assess
total
score
ftnd
moder
nicotin
depend
defin
sum
score
total
score
result
among
patient
patient
male
median
age
year
median
predict
valu
forc
expiratori
volum
second
patient
inhal
treatment
factor
relat
moder
high
nicotin
depend
rel
young
age
vs
year
p
high
educ
statu
vs
yearss
p
high
cognit
function
vs
p
univari
analysi
dyspnea
scale
copd
assess
test
cat
cigarett
smoke
relat
moder
high
nicotin
depend
multipl
logist
regress
analysi
reveal
high
educ
statu
odd
ration
confid
interv
p
relat
moder
high
nicotin
depend
conclus
studi
indic
physician
provid
differ
strategi
smoke
cessat
intervent
current
smoker
copd
accord
educ
level
could
largest
benefit
smoke
cessat
h
tran
r
hamon
e
roscioli
ween
g
hodg
h
jersmann
p
reynold
hodg
royal
adelaid
hospit
thorac
medicin
adelaid
australia
background
aim
conflict
report
role
inflammasom
inflamm
copd
cigarett
injuri
hypothes
would
activ
nlrp
andor
altern
inflammasom
type
includ
absent
melanoma
airway
copd
patient
respons
cigarett
smoke
method
human
cell
line
primari
alveolar
macrophag
analys
releas
elisa
express
local
asc
cleav
immunofluorescenceconfoc
microscopi
western
blot
effect
inhibitor
antagonist
glyburid
treatment
receptor
regul
without
exposur
cigarett
smoke
extract
investig
result
cigarett
smoke
induc
human
primari
alveolar
macrophag
increas
intracellular
express
level
fold
cell
two
differ
donor
p
particl
size
brightli
stain
cleav
insid
outsid
cell
fold
p
particl
partial
particul
shown
sharpli
increas
cigarett
cell
cigarett
smoke
also
induc
activ
macrophag
particul
activ
seen
mostli
intracellularli
releas
cigarett
cell
block
glyburid
significantli
protect
macrophag
cigarett
activ
p
conclus
inflamm
copd
could
initi
inflammasom
regul
sphingolipid
signal
suggest
novel
therapeut
target
copd
f
l
faculti
dentistri
hang
tuah
univers
oral
biolog
surabaya
indonesia
faculti
medicin
hang
tuah
univers
microbiolog
surabaya
indonesia
faculti
medicin
hang
tuah
univers
intern
medicin
surabaya
indonesia
background
aim
madura
island
highest
incid
periodont
due
poor
oral
hygien
porphyromona
gingivali
treponema
denticola
twoanaerobicpathogen
commonli
found
madures
oral
caviti
believ
close
associ
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
among
indigen
adult
madura
object
analyz
associ
periodont
incid
aecopd
among
indigen
erlder
age
year
madura
island
method
prospect
cohort
studi
conduct
public
health
center
madura
island
cluster
random
sampl
obtain
indigen
madures
elder
age
year
periodont
diagnos
presenc
anaerob
pathogen
salivari
cultur
use
medium
next
spirometri
masterscopelabmanag
carefus
germani
perform
accord
guidelin
american
thorac
societi
at
result
elder
found
elder
periodont
posit
cultur
either
porphyromona
gingivali
treponema
denticola
absolut
valu
fvc
pefr
significantli
lower
subject
periodont
rel
risk
aecopd
ci
ci
periodont
porphyromona
gingivali
alon
treponema
denticola
alon
addit
increas
ci
porphyromona
gingivali
treponema
denticola
coexist
togeth
statist
differ
mean
age
gender
ratio
anthropometr
data
occup
marit
statu
smoke
statu
symptom
exercis
perform
comorbid
hypertens
diabet
allergi
medic
group
conclus
presenc
porphyromona
gingivali
treponema
denticola
periodont
risk
factor
aecopd
deterior
lung
function
test
among
madures
indigen
elder
moreov
improv
oral
hygien
among
indigen
madures
popul
benefit
reduc
aecopd
incid
improv
lung
function
test
w
w
bangkok
thailand
chulalongkorn
univers
king
chulalongkorn
memori
thai
red
cross
societi
medicin
bangkok
thailand
background
aim
desatur
exert
predict
unfavor
prognosi
patient
chronic
obstruct
pulmonari
diseas
copd
preval
associ
factor
exert
desatur
unclear
vari
publish
studi
studi
preval
associ
factor
exert
desatur
ed
moder
sever
copd
patient
king
chulalongkorn
memori
hospit
method
enrol
stabl
copd
patient
predict
without
rest
desatur
studi
subject
ask
perform
pulmonari
function
test
follow
walk
test
continu
puls
oximetri
monitor
ed
defin
least
decreas
baselin
second
preval
ed
calcul
associ
factor
analyz
use
univari
analys
binari
logist
regress
model
result
total
copd
patient
particip
almost
male
averag
predict
preval
exert
desatur
signific
lower
desatur
group
compar
group
l
p
desatur
group
also
lower
dlco
predict
predict
p
distanc
compar
group
vs
p
dynam
hyperinfl
observ
group
predict
dlco
predict
two
determin
correl
ed
ci
p
ci
p
respect
conclus
exert
desatur
uncommon
thai
copd
patient
especi
low
low
dlco
ci
n
f
abdul
ayl
ai
r
abdul
tm
univers
kebangsaan
malaysia
medic
centr
respiratori
depart
intern
medicin
kuala
lumpur
malaysia
univers
teknolog
mara
respiratori
hospit
selayang
kuala
lumpur
malaysia
background
aim
incid
chronic
obstruct
pulmonari
diseas
copd
obes
rise
malaysia
date
studi
report
spirometri
airflow
limit
includ
restrict
obstruct
pattern
popul
malaysia
purpos
studi
estim
preval
risk
factor
airflow
limit
screen
copd
use
new
devic
airsmart
spirometri
copd
popul
screener
questionnair
method
studi
perform
screen
popul
two
tertiari
medic
institut
malaysia
nation
univers
malaysia
medic
centr
univers
technolog
mara
hospit
selayang
campu
use
valid
questionnair
new
spirometri
devic
patient
demograph
obtain
use
standard
questionnair
interview
conduct
result
subject
recruit
screen
popul
observ
restrict
obstruct
pattern
respect
screen
popul
score
subject
obstruct
pattern
activ
p
p
whilst
subject
restrict
pattern
like
bodi
mass
index
ci
p
use
spearman
correl
analys
neg
correl
forc
vital
capac
bodi
mass
index
rs
p
subject
airflow
limit
return
formal
assess
conclus
studi
report
high
preval
airflow
limit
includ
restrict
lung
diseas
new
airsmart
spiromet
studi
highlight
high
preval
undiagnos
copd
high
bmi
caus
airflow
limit
popul
h
k
k
k
k
k
kobe
univers
graduat
school
health
scienc
depart
commun
health
scienc
kobe
japan
kobe
citi
medic
center
west
hospit
depart
respiratori
medicin
kobe
japan
kobe
citi
medic
center
west
hospit
depart
rehabilit
kobe
japan
background
aim
pulmonari
hypertens
oxygen
desatur
eid
influenc
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
comput
tomographi
ct
pulmonari
arteri
pa
enlarg
independ
associ
acut
copd
exacerb
associ
pa
aorta
pa
ratio
eid
copd
patient
report
hypothes
pa
ratio
correl
eid
result
walk
test
use
predict
risk
associ
pa
ratio
method
retrospect
measur
lung
function
emphysema
area
pa
enlarg
ct
copd
patient
patient
classifi
group
pa
ratio
receiv
oper
characterist
roc
curv
use
determin
threshold
valu
best
cutoff
point
predict
patient
pa
ratio
result
pa
ratio
group
lower
fvc
ratio
dlco
baselin
lowest
highest
modifi
borg
scale
result
laa
histori
acut
copd
exacerb
year
wors
bode
index
result
p
predict
pa
ratio
determin
best
cutoff
point
auc
ci
show
sensit
specif
posit
predict
valu
neg
predict
valu
posit
likelihood
ratio
neg
likelihood
ratio
conclus
lowest
may
predict
pa
ratio
lowest
excel
detect
pulmonari
hypertens
copd
f
g
g
p
l
jp
n
zambon
spa
corpor
respiratori
medic
affair
bresso
milan
itali
univers
hospit
anna
respiratori
emerg
depart
ferrara
itali
templ
univers
hospit
templ
lung
center
pennsylvania
usa
ghent
univers
hospit
depart
respiratori
medicin
ghent
belgium
aintre
univers
hospit
school
age
chronic
diseas
liverpool
unit
kingdom
modena
univers
depart
oncolog
haematolog
respiratori
diseas
modena
itali
guangzhou
institut
respiratori
diseas
nation
clinic
research
center
respiratori
diseas
guangzhou
china
background
aim
previou
studi
show
mg
bid
reduc
exacerb
chines
patient
copd
zheng
jp
et
al
lancet
resp
med
exacerb
defin
accord
anthonisen
criteria
worsen
symptom
least
day
persist
two
type
ii
three
type
iii
major
symptom
worsen
dyspnoea
increas
sputum
purul
volum
one
major
symptom
plu
least
one
minor
symptom
type
upper
airway
infect
unexplain
fever
increas
wheez
method
analysi
prospect
randomis
studi
patient
age
year
copd
predict
treat
either
one
mg
tablet
twice
daili
match
placebo
year
investig
whether
reduc
annual
rate
exacerb
defin
accord
gold
criteria
ie
either
episod
treat
oral
steroidsantibiot
moder
hospit
studi
regist
chines
clinic
trial
result
june
decemb
patient
screen
elig
randomis
placebo
year
patient
least
one
moder
sever
exacerb
develop
exacerb
exacerb
per
significantli
lower
moder
sever
exacerb
occur
patient
least
one
exacerb
exacerb
per
rate
ratio
p
placebo
group
well
toler
conclus
result
indic
use
mg
twice
daili
associ
reduct
exacerb
defin
basi
symptom
accord
anthonisen
criteria
also
classifi
moder
sever
accord
gold
definit
exacerb
sever
ak
v
r
h
v
vk
ak
k
sp
p
j
cipla
medic
servic
mumbai
india
sudbhavana
hospit
pulmonari
medicin
varanasi
india
om
surgic
center
matern
hom
pulmonari
medicin
varanasi
india
eesha
multispeci
hospit
pulmonari
medicin
hyderabad
india
chest
research
foundat
pulmonari
pune
india
sree
narayana
institut
medic
scienc
chest
tb
ernakulam
india
kvm
multispeci
hospit
intern
medicin
chirtihala
india
ajantha
hospit
ivf
centr
pvtltd
intern
medicin
lucknow
india
govern
medic
colleg
kozhikod
pulmonari
medicin
kozhikod
india
lal
hospit
heart
centr
intern
medicin
lucknow
india
madonna
hospit
research
centr
intern
medicin
ernakulam
india
background
aim
gold
strategi
document
suggest
use
tripl
therapi
improv
lung
function
qualiti
life
may
reduc
exacerb
patient
copd
compar
mono
dual
therapi
assess
efficaci
safeti
tiotropiumformoterolciclesonid
tfc
mcg
via
dpi
mdi
patient
copd
real
world
set
method
week
prospect
real
world
observ
studi
enrol
patient
copd
diagnos
per
gold
requir
tripl
drug
therapi
assess
physician
primari
endpoint
mean
chang
baselin
week
fvc
cat
score
mmrc
grade
treatment
satisfact
safeti
also
evalu
hoc
analysi
done
evalu
effect
tfc
smoker
ns
copd
result
screen
enrol
mean
age
yr
male
smoker
post
bronchodil
absolut
predict
complet
studi
mean
chang
baselin
week
signific
overal
ns
p
figur
week
cat
score
reduc
significantli
baselin
overal
ns
p
figur
mean
chang
fvc
cat
score
mmrc
grade
signific
across
visit
major
patient
grade
high
satisfact
tripl
therapi
will
continu
tfc
well
toler
conclus
tfc
significantli
improv
lung
function
symptom
patient
copd
well
toler
independ
smoke
histori
moreov
show
better
improv
compar
smoker
f
p
j
mg
zambon
spa
corpor
respiratori
medic
affair
bresso
milan
itali
univers
rome
tor
vergata
depart
system
medicin
rome
itali
second
univers
napl
depart
experiment
medicin
napl
itali
background
aim
oxidantantioxid
imbal
significantli
pronounc
patient
copd
exacerb
nac
seem
influenc
reduc
copd
exacerb
via
modul
oxid
stress
discord
find
actual
activ
nac
aim
pharmacolog
character
effect
nac
ex
vivo
model
copd
exacerb
method
influenc
nac
assess
contractil
respons
profil
human
isol
bronchi
incub
overnight
buffer
solut
control
lipopolysaccharid
lp
ngml
result
lp
desensit
isol
airway
transmur
stimul
p
vs
control
concentr
nac
restor
physiolog
contractil
respons
lp
stimul
bronchi
emax
vs
control
p
vs
lp
wherea
lower
concentr
modul
effect
concentr
nac
reduc
respons
peroxidas
activ
hydrogen
peroxid
malondialdehyd
nitric
oxid
overal
p
vs
lp
improv
respons
total
capac
glutathion
superoxid
dismutas
overal
p
vs
lp
induc
lp
lower
concentr
nac
modul
bronchial
oxid
imbal
p
vs
lp
conclus
result
studi
demonstr
concentr
nac
requir
normal
dysfunct
contractil
human
bronchi
concentr
nac
improv
oxid
imbal
ex
vivo
model
copd
exacerb
n
cz
x
n
f
l
z
r
r
c
first
affili
guangzhou
medic
univers
state
key
laboratori
respiratori
diseas
guangzhou
china
xin
qiao
third
militari
medic
univers
institut
respiratori
diseas
chongq
china
southwest
third
militari
medic
univers
respiratori
medicin
chongq
china
novarti
pharma
ag
respiratori
basel
switzerland
beij
novarti
pharma
co
ltd
respiratori
shanghai
china
novarti
institut
biomed
research
respiratori
shanghai
china
novarti
pharma
ag
novarti
institut
biomed
research
basel
switzerland
novarti
pharmaceut
corpor
respiratori
east
nj
usa
background
aim
combin
indgli
dual
bronchodil
indic
mainten
treatment
adult
patient
copd
compar
efficaci
pharmacokinet
safeti
indgli
versu
salmeterolfluticason
combin
sfc
chines
caucasian
popul
method
efficaci
safeti
analysi
data
chines
cohort
n
compris
patient
lantern
studi
compar
data
illumin
studi
n
caucasian
patient
copd
pharmacokinet
evalu
area
plasma
drug
curv
h
ss
peak
plasma
concentr
cmax
ss
ind
gli
steadi
state
follow
repeat
daili
administr
day
compar
two
popul
comparison
base
formal
statist
analys
result
mean
baselin
predict
chines
caucasian
popul
lantern
illumin
respect
indgli
provid
signific
improv
trough
versu
sfc
week
chines
lantern
least
squar
mean
lsm
treatment
differ
ml
ci
caucasian
illumin
lsm
treatment
differ
ml
ci
patient
chines
cohort
indgli
significantli
reduc
rate
moder
sever
exacerb
lantern
rate
ratio
rr
p
caucasian
patient
rate
reduct
numer
lower
versu
sfc
illumin
rr
p
comparison
system
exposur
data
ss
cmax
ss
follow
repeat
daili
administr
indgli
indic
clinic
relev
differ
two
popul
term
advers
event
safeti
profil
similar
two
popul
conclus
indgli
demonstr
greater
efficaci
versu
salmeterolfluticason
combin
compar
safeti
profil
chines
caucasian
patient
studi
fund
novarti
pharma
ag
k
n
l
jm
p
novarti
pharma
ag
respiratori
basel
switzerland
servic
de
pneumologi
univers
pari
descart
pneumolog
pari
franc
novarti
pharma
sa
medic
primari
care
franc
univ
bordeaux
depart
de
pharmacologi
bordeaux
franc
univers
aberdeen
primari
care
respiratori
medicin
aberdeen
franc
french
nation
health
univers
rouen
statist
rouen
franc
novarti
pharmaceut
corpor
respiratori
east
nj
usa
background
aim
random
clinic
trial
rct
form
basi
regulatori
approv
new
drug
guidelin
recommend
howev
rct
often
repres
small
minor
routin
care
popul
licens
drug
prescrib
much
control
ecolog
care
therefor
increas
need
addit
inform
effect
treatment
broad
popul
manag
accord
usual
clinic
practic
lumier
intern
prospect
observ
cohort
studi
assess
effect
indgli
inhal
combin
therapi
ict
treatment
copd
method
patient
year
age
physician
diagnos
copd
smoke
histori
new
prescript
ict
includ
atleast
bronchodil
elig
studi
primari
object
assess
effect
indgli
rate
moder
sever
exacerb
associ
copd
health
statu
clinic
copd
questionnair
ccq
secondari
object
compar
effect
indgli
versu
fix
loos
ict
moderatesever
ccq
cat
copd
assess
test
dyspnea
score
use
rescu
medic
approxim
patient
enrol
match
propens
score
result
applic
abstract
conclus
lumier
studi
provid
import
clinic
inform
effect
indgli
studi
fund
novarti
pharma
ag
dk
sw
js
sd
ym
asan
medic
center
univers
ulsan
colleg
medicin
depart
pulmonari
critic
care
medicin
seoul
republ
korea
asan
medic
center
univers
ulsan
colleg
medicin
depart
clinic
epidemiolog
biostatist
seoul
republ
korea
background
aim
proper
spirometr
method
defin
airflow
limit
particularli
elderli
popul
suspect
uncertain
optim
current
threshold
may
contribut
controversi
herein
therefor
optim
current
threshold
investig
fix
ratio
fr
zs
also
prefer
spirometr
method
elderli
popul
assess
use
measur
area
receiv
oper
characterist
curv
auroc
method
data
collect
third
unit
state
nation
health
nutrit
examin
survey
data
white
whose
age
analyz
roc
curv
fr
zs
plot
respiratori
copd
mortal
optim
threshold
assess
compar
current
one
roc
curv
prefer
spirometr
method
assess
compar
auroc
method
result
subject
mean
age
male
optim
threshold
fr
respiratori
copd
mortal
respect
lower
current
one
contrast
zs
respect
higher
current
one
signific
differ
auroc
observ
spirometr
method
respiratori
copd
mortal
fr
vs
zs
p
fr
vs
zs
p
respect
figur
comparison
auroc
respiratori
mortal
figur
comparison
auroc
copd
mortal
conclus
current
threshold
fr
zs
seem
bias
may
contribut
airflow
limit
elderli
popul
method
show
compar
predict
respiratori
copd
mortal
believ
conveni
fr
may
prefer
clinician
n
teach
hospit
respiratori
kandi
sri
lanka
teach
hospit
respiratori
unit
kandi
sri
lanka
background
aim
introduct
pr
despit
import
strategi
manag
chronic
respiratori
diseas
still
well
establish
countri
object
assess
efficaci
practic
pr
sever
copd
limit
resourc
set
method
new
clinic
attend
last
six
month
gold
stage
iii
iv
copd
enrol
studi
patient
recent
ischaem
heart
diseas
cardiomyopathi
sever
pulmonari
hypertens
exclud
underw
six
week
cours
pr
consist
anterior
chest
wall
upper
chest
wall
diaphragmat
muscl
strengthen
exercis
purs
lip
breath
supervis
train
physiotherapist
avail
simpl
tool
graduat
tension
band
free
weight
treadmil
ergomet
avail
spirometri
use
vitalograph
alpha
touch
softwar
version
six
minut
walk
test
perform
onset
end
pr
result
patient
age
year
male
studi
initi
mean
forc
expiratori
volum
first
second
predict
age
sex
individu
studi
show
improv
end
pr
initi
mean
walk
distanc
studi
group
meter
end
six
week
mean
increas
meter
p
conclus
short
cours
pr
sever
sever
copd
result
improv
studi
effect
low
cost
pr
program
could
easili
set
minimum
resourc
appropri
clinic
set
w
g
u
k
n
nation
hospit
respiratori
diseas
health
welisara
sri
lanka
ministri
health
health
colombo
sri
lanka
background
aim
preval
copd
sri
lanka
rapidli
increas
result
signific
burden
health
care
resourc
benefit
pulmonari
rehabilit
pr
copd
patient
wide
recogn
sri
lanka
organ
pr
programm
clinician
treat
copd
patient
emphas
pharmacolog
treatment
minim
emphasi
given
pr
assess
effect
feasibl
pr
programm
copd
patient
minim
exercis
equip
method
copd
patient
stage
ii
enrol
patient
underli
lung
diseas
condit
heart
failur
exclud
basic
socio
demograph
data
record
prior
commenc
studi
pr
conduct
weekli
six
week
breath
exercis
endur
resist
train
done
without
use
modern
physiotherapi
equip
treadmil
cycl
ergo
meter
weight
machin
instead
aerob
yoga
exercis
predominantli
use
bode
index
use
function
physiolog
assess
qualiti
life
assess
qualiti
life
qol
bref
questionnair
assess
done
pr
assess
done
end
pr
assess
done
week
interv
respect
result
bmi
show
statist
signific
improv
final
assess
compar
baselin
assess
p
mmrc
dyspnoea
grade
minut
walk
distanc
overal
bode
index
qol
analysi
show
statist
signific
improv
assess
compar
baselin
assess
improv
sustain
assess
p
howev
statist
signific
improv
seen
percentag
predict
valu
conclus
signific
improv
susten
outcom
measur
copd
term
bmi
mwd
level
dyspnoea
qualiti
life
observ
even
pr
done
minim
exercis
equip
nr
shin
p
k
j
k
k
chonnam
nation
univers
colleg
veterinari
medicin
plu
protect
team
gwangju
republ
korea
background
aim
incid
chronic
obstruct
pulmonari
diseas
copd
substanti
increas
recent
decad
cigarett
smoke
cs
import
risk
factor
develop
copd
studi
investig
effect
melatonin
develop
copd
method
day
mice
treat
intranas
lp
mice
expos
cs
hr
per
day
cigarett
per
day
day
day
melatonin
mgkg
inject
intraperiton
hr
cs
exposur
vivo
experi
addit
investig
effect
melatonin
cigarett
smoke
condens
csc
cell
human
mucoepidermoid
carcinoma
cell
result
melatonin
markedli
decreas
neutrophil
count
balf
reduct
proinflammatori
mediat
melatonin
inhibit
erk
phosphoryl
express
induc
cs
lp
treatment
addit
melatonin
decreas
airway
inflamm
reduct
myeloperoxidas
express
lung
tissu
vitro
experi
melatonin
suppress
elev
express
proinflammatori
mediat
induc
csc
treatment
melatonin
reduc
erk
phosphoryl
express
cell
addit
cotreat
melatonin
erk
inhibitor
significantli
limit
proinflammatori
mediat
greater
reduct
erk
phosphoryl
express
observ
cell
treat
erk
inhibitor
alon
conclus
taken
togeth
melatonin
effect
inhibit
neutrophil
airway
inflamm
induc
cs
lp
treatment
close
relat
downregul
erk
phosphoryl
find
suggest
melatonin
therapeut
potenti
treatment
copd
k
nakamoto
saraya
sada
inui
watanab
takata
yokoyama
kurai
h
ishii
h
takizawa
kyorin
univers
school
medicin
respiratori
medicin
tokyo
japan
background
aim
interstiti
lung
diseas
ild
major
organ
involv
dermatomyos
dm
recent
gene
antibodi
identifi
uniqu
dm
aim
studi
investig
clinic
manifest
ild
dm
antibodi
method
retrospect
evalu
ten
ild
patient
antibodi
januari
may
patient
diagnos
dm
examin
characterist
clinic
find
laboratori
data
respons
therapi
prognosi
result
ten
patient
compris
six
male
four
women
median
age
year
rang
median
time
day
rang
patient
characterist
skin
find
hand
five
patient
clinic
evid
muscl
weak
high
resolut
comput
tomographi
ground
glass
opac
reticul
frequent
observ
honeycomb
found
five
patient
respiratori
symptom
time
diagnosi
patient
treat
glucocorticoid
therapi
combin
immunosuppress
agent
studi
period
three
patient
die
rapidli
progress
ild
cumul
surviv
rate
significantli
lower
patient
presenc
respiratori
symptom
p
high
ast
level
iul
p
high
ldh
level
p
high
ck
level
p
conclus
result
indic
activ
ild
increas
muscl
enzym
influenc
life
prognosi
dm
antibodi
k
r
h
e
j
k
fukuoka
univers
hospit
depart
respiratori
medicin
fukuoka
japan
graduat
school
medic
kyushu
univers
research
institut
diseas
chest
fukuoka
japan
background
aim
express
matrix
metalloproteinas
mmp
play
critic
role
extracellular
matrix
deposit
although
stromelysin
produc
interstiti
cell
import
role
extracellular
matrix
deposit
role
stromelysin
pulmonari
fibrosi
remain
unknown
herein
aim
clarifi
precis
role
stromelysin
focu
pulmonari
fibrosi
use
murin
bleomycin
model
method
bleomycin
unitsbodi
instil
wild
type
mice
defici
mice
intratrach
bronchoalveolar
lavag
fluid
analyz
immunoblot
analys
histolog
lung
hydroxyprolin
content
also
assess
result
protein
mrna
level
slightli
upregul
bleomycin
howev
lung
pulmonari
fibrosi
mice
stain
antibodi
defici
mice
demonstr
similar
fibrosi
reaction
compar
wild
type
mice
accord
result
histolog
hydroxyprolin
content
conclus
result
indic
play
limit
role
pulmonari
fibrosi
mice
k
aizu
medic
center
infecti
diseas
pulmonari
medicin
japan
aizu
medic
center
kampo
medicin
japan
background
aim
interstiti
lung
diseas
dild
caus
kampo
medicin
tradit
japanes
herbal
formul
increas
expans
integr
medicin
japan
varieti
suspect
caus
drug
imag
find
diagnosi
dild
sometim
difficult
delay
date
retrospect
studi
dild
caus
kampo
goal
analyz
physiolog
radiograph
patholog
pattern
dild
caus
kampo
medicin
final
detect
caus
herb
method
investig
dild
kampo
medicin
patient
seen
aizu
medic
center
may
april
candid
caus
drug
blood
chemistri
valu
high
resolut
ct
hrct
imag
bronchoalveolar
lavag
bal
fluid
find
patholog
find
treatment
dild
analyz
caus
dild
exclud
result
total
case
age
year
identifi
taken
candid
herb
ohgon
scutellaria
radix
sialyl
carbohydr
antigen
surfact
protein
sp
elev
case
organ
interstiti
eosinophil
pneumonia
acut
interstiti
pneumonia
pattern
seen
hrct
imag
lymphocyt
eosinophil
mainli
increas
bal
fluid
one
case
dild
death
sever
hypoxia
requir
system
corticosteroid
puls
therapi
invas
posit
pressur
ventil
conclus
kampo
herbal
medicin
use
worldwid
japan
case
kampo
dild
per
year
report
like
underestim
essenti
determin
analyz
pathophysiolog
dild
caus
kampo
help
lead
earli
diagnosi
treatment
hiros
matsumuro
arai
c
sugimoto
inou
chest
medic
center
clinic
research
center
sakai
japan
background
aim
elev
b
cell
activ
factor
belong
tumor
necrosi
factor
famili
baff
ligand
april
serum
report
autoimmun
diseas
system
lupu
erythematosu
diseas
rheumatoid
arthriti
suggest
presenc
neutral
autoantibodi
result
autoimmun
pulmonari
alveolar
proteinosi
apap
therefor
hypothes
abnorm
humor
immun
patient
apap
make
baff
april
level
serum
increas
promin
method
fifti
patient
apap
male
femal
age
yo
healthi
control
male
femal
age
yo
enrol
studi
serum
level
baff
april
measur
use
commerci
avail
elisa
kit
r
system
ebiosci
compar
data
clinic
measur
diseas
sever
score
result
found
signific
increas
serum
level
baff
april
patient
apap
compar
healthi
control
p
respect
serum
baff
level
show
correl
kreb
von
den
surfact
protein
sp
ldh
cyfra
cytokeratin
fragment
serum
p
respect
howev
serum
april
level
show
correl
serum
marker
apap
serum
baff
april
level
correl
diseas
sever
score
conclus
hypothesi
activ
b
cell
baff
april
might
involv
pathogenesi
apap
suggest
b
cell
activ
factor
might
new
target
treatment
apap
studi
support
jsp
kakenhi
grant
number
hiros
partial
grant
japan
agenc
medic
research
develop
b
l
dr
ramelan
naval
hospit
diagnost
imag
surabaya
indonesia
sanglah
gener
hospit
patholog
bali
indonesia
sanglah
gener
hospit
radiolog
bali
indonesia
background
aim
idiopath
pulmonari
fibrosi
ipf
diseas
unknown
etiolog
consider
morbid
mortal
character
profound
chang
lung
morpholog
includ
excess
extracellular
matrix
deposit
myofibroblast
foci
alveolar
epitheli
cell
hyperplasia
extens
remodel
one
difficulti
convent
imag
msct
hsct
ipf
radiolog
pattern
look
like
usual
interstiti
pneumonia
due
limit
convent
imag
thu
paper
would
like
introduc
acoust
radiat
forc
impuls
arfi
elastographi
imag
usual
biomark
liver
fibrosi
use
novel
biomark
lung
fibrosi
method
patient
diagnos
idiopath
lung
fibrosi
recruit
stage
fibrosi
determin
biopsi
diagnost
accuraci
fi
fibroscan
arfi
well
combin
method
evalu
base
conform
result
test
biopsi
result
lung
phenotyp
ipf
character
patchi
predominantli
peripher
subpleur
bibas
reticular
abnorm
peripher
reticular
opac
furthermor
use
lung
biopsi
find
thicken
lung
parenchym
excess
growth
factor
fibroblast
reason
make
patient
lung
look
stiff
rigid
use
ultason
wave
propag
produc
arfi
imag
calcif
fibrosi
level
measur
shear
wave
veloc
smv
swv
correl
fibrosi
r
p
necroinflammatori
activ
lung
r
p
use
criteria
arfi
imag
strongli
compar
lung
biopsi
diagnost
accuraci
predict
sever
fibrosi
ipf
conclus
swv
indic
caus
ultrason
wave
propag
lung
tissu
use
quantifi
shear
modulu
lung
tissu
base
lung
elast
level
fibrosiscalcif
arfi
modal
studi
diagnost
tool
ipf
without
necess
lung
biopsi
b
minthara
dr
ramelan
naval
hospit
diagnost
imag
surabaya
indonesia
background
aim
naval
diver
uniqu
adapt
hypoxem
term
pulmonari
vasculatur
pulmonari
vascular
endotheli
epitheli
nitric
oxid
impair
increas
pulmonari
arteri
pressur
pap
lead
pulmonari
hypertens
previou
studi
effect
hyperbar
oxygen
therapi
select
diver
suffer
pulmonari
hypertens
remain
controversi
aim
studi
assess
use
secondari
prevent
pulmonari
hypertens
among
naval
diver
method
consecut
naval
diver
pulmonari
hypertens
mpap
mmhg
met
inclus
criteria
enter
control
clinic
trial
patient
random
two
group
follow
experiment
receiv
ata
hyperbar
chamber
oxygen
suppli
via
oxygen
hood
sodium
beraprost
control
receiv
sodium
beraprost
pulmonari
arteri
pressur
measur
echocardiographi
session
everi
week
result
first
treatment
session
averag
systol
spap
diastol
dpap
mean
mpap
arteri
pressur
similar
group
averag
mpap
significantli
lower
experiment
group
least
treatment
durat
follow
follow
valu
spap
vs
mmhg
dpap
vs
mmhg
mpap
vs
mmhg
mark
lower
significantli
compar
control
group
conclus
result
demonstr
reduc
pulmonari
arteri
pressur
significantli
pilot
studi
effect
pulmonari
hypertens
need
caution
interpret
ci
g
ey
ayl
tm
r
abdul
univers
kebangsaan
malaysia
medic
centr
respiratori
unit
depart
intern
medicin
kuala
lumpur
malaysia
sabah
women
children
hospit
depart
radiolog
kota
kinabalu
malaysia
univers
kebangsaan
malaysia
medic
centr
depart
radiolog
kuala
lumpur
malaysia
background
aim
decad
resurg
much
technolog
advanc
field
radiolog
enabl
play
indispens
role
aid
diagnosi
follow
mani
respiratori
disord
high
resolut
comput
tomographi
hrct
vital
tool
arsen
investig
avail
physician
evalu
lung
interstitium
ground
glass
opac
gco
radiolog
descript
term
use
rather
commonli
occasion
indiscrimin
clinician
defin
hazi
area
increas
lung
attenu
without
obscur
underli
vasculatur
non
specif
find
result
abnorm
involv
alveolar
space
interstitium
combin
howev
signific
lie
indic
presenc
activ
potenti
treatabl
patholog
result
highlight
sever
interest
case
ground
glass
opac
mimick
elabor
addit
ancillari
featur
propos
practic
algorithm
approach
gco
conclus
earli
recognit
ground
glass
opac
etiolog
enabl
earli
intervent
group
patient
c
k
nation
hospit
organ
chest
medic
center
clinic
research
center
japan
nation
hospit
organ
chest
medic
center
clinic
research
center
sakai
japan
nation
hospit
organ
chest
medic
center
radiolog
sakai
japan
niigata
univers
medic
dental
hospit
bioscienc
medic
research
center
niigata
japan
background
aim
sirolimu
first
approv
japan
drug
treatment
lymphangioleiomyomatosi
lam
treat
case
lam
use
sirolimu
april
april
retrospect
review
patient
order
clarifi
incid
clinic
featur
interstiti
lung
diseas
method
review
clinic
cours
comput
tomographi
hrct
sirolimu
concentr
patient
experienc
medic
record
also
evalu
serum
biomark
includ
kreb
von
den
surfact
protein
sp
result
experienc
patient
patient
femal
sporad
lam
median
age
rang
median
period
start
sirolimu
onset
month
rang
one
symptomat
patient
fever
dyspnea
exert
diffus
ground
glass
opac
ggo
hrct
effect
treat
high
dose
corticosteroid
receiv
treatment
low
dose
sirolimu
one
year
onset
one
asymptomat
patient
mild
ggo
improv
stop
sirolimu
worsen
restart
sirolimu
three
patient
local
consolid
hrct
spontan
remiss
remain
treat
sirolimu
despit
ineffici
antibiot
median
concentr
sirolimu
ngml
rang
median
concentr
serum
iul
rang
ngml
rang
ngml
rang
respect
symptom
opac
hrct
complet
improv
patient
within
month
conclus
experienc
patient
asymptomat
local
consolid
grade
continu
sirolimu
patient
ggo
stop
sirolimu
includ
sever
grade
corticosteroid
patient
could
receiv
sirolimu
j
n
chiba
hokuso
hospit
nippon
medic
school
respiratori
medicin
japan
nippon
medic
school
depart
pulmonari
medicin
school
medicin
tokyo
japan
background
aim
studi
perform
evalu
cardiomyopathi
patient
collagen
vascular
interstiti
pneumonia
myocardi
scintigraphi
pentadecano
acid
scintigraphi
method
myocardi
scintigraphi
pentadecano
acid
scintigraphi
carri
patient
diagnos
result
perform
patient
granulomatosi
polyangi
rheumatoid
patient
cardiomyopathi
conclus
necessari
collect
case
asses
evalu
cardiomyopathi
patient
rj
e
p
tm
g
lung
center
philippin
depart
critic
care
sleep
medicin
quezon
citi
philippin
lung
center
philippin
depart
patholog
quezon
citi
philippin
background
aim
pulmonari
langerhan
cell
histiocytosi
plch
rare
diseas
character
accumul
inflammatori
langerhan
cell
bronchiol
alveolar
interstitium
result
format
nodular
inflammatori
lesion
paper
report
case
year
old
filipino
male
present
recurr
bilater
pneumothorax
method
patient
previous
admit
anoth
hospit
due
recurr
pneumothorax
bilater
novemb
decemb
advis
undergo
lung
biopsi
lost
januari
consult
institut
due
recurr
bilater
pneumothorax
bilater
chest
tube
place
result
chest
show
extens
bilater
cystic
lucenc
lung
field
chest
tomographi
reveal
coars
reticular
lesion
lung
interspers
cystic
lesion
chronic
volum
loss
traction
bronchiectasi
intermix
area
ground
glass
opac
pulmonari
function
test
show
sever
restrict
ventilatori
defect
sever
reduct
dlco
due
histori
recurr
pneumothorax
underw
thorac
surgeri
lung
biopsi
histopatholog
immunohistochemistri
stain
protein
show
acut
eosinophil
interstiti
pneumon
granuloma
format
consist
pulmonari
langerhan
cell
histiocytosi
start
prednison
discharg
improv
stabl
two
month
discharg
develop
progress
dyspnea
cough
recurr
pneumothorax
chest
tube
place
eventu
underw
pleurodesi
possibl
lung
transplant
also
discuss
patient
famili
howev
despit
medic
manag
persist
progress
dyspnea
eventu
succumb
death
due
develop
acut
respiratori
failur
tension
pneumothorax
conclus
plch
rare
lung
diseas
cours
unpredict
quiescent
spontan
progress
inevit
caus
complic
includ
death
b
r
bangalor
india
forti
hosipt
rheumatolog
bangalor
india
yr
old
present
three
month
histori
fever
vasculit
rash
leg
arthralgia
multipl
foot
ulcer
gangren
toe
along
recent
onset
paraesthesia
hand
feetexamin
reveal
left
median
right
ulnar
neuropathi
bilater
common
peron
strongli
posit
titr
sural
nerv
biopsi
show
necrot
vasculit
neuropathi
diagnosi
gpa
made
treat
intraven
methylprednisolon
ivmp
iv
cyclophosphamid
later
switch
oral
steroidshi
clinic
condit
stabl
next
two
month
skin
graft
done
ulcer
two
month
later
treatment
present
acut
short
breathinvestig
reveal
low
hemoglobin
leucocytosi
rais
inflammatori
marker
mgl
urin
routin
analysi
show
proteinuria
rbc
cast
chest
show
extens
confluent
opac
bilater
lung
fieldspati
intub
bronchoscopi
done
reveal
blood
airway
lavag
show
macrophagesa
diagnosi
dah
secondari
gpa
made
ivsteroid
plasmapheresi
six
cycl
given
continu
iv
cyclophosphamidehowev
improv
clinic
statu
continu
ventil
inspit
ivmp
six
cycl
plasmapheresi
didnot
improv
rtx
two
dose
two
week
apart
givenaft
one
week
rtxsignific
improv
resolut
chest
symptom
improv
ventil
paramet
follow
resolut
infiltr
success
extubatedcyclophosphamid
stop
azathioprin
initi
taper
oral
steroid
continuedov
last
one
year
remain
complet
remiss
till
date
dah
occur
consequ
pulmonari
capillar
vasculitid
aav
incid
gpacyclophosphamid
steroid
mainstay
treatment
longrtx
recent
shown
effect
induct
mainten
remiss
good
safeti
profil
use
iv
steroid
plasmapheresi
evid
restrict
retrospect
case
seriesdata
regard
efficaci
rtx
dah
limit
l
x
h
inner
mongolia
autonom
region
peopl
hospit
depart
respiratori
critic
care
medicin
hohhot
china
friendship
hospit
depart
respiratori
critic
care
medicin
beij
china
background
aim
radiat
pneumon
pulmonari
fibrosi
sever
complic
larg
administ
activ
herein
present
patient
papillari
thyroid
carcinoma
develop
interstiti
pneumonia
follow
low
dose
radioiodin
therapi
method
man
receiv
thyroidectomi
function
lymph
node
resect
februari
papillari
thyroid
carcinoma
metastas
anoth
hospit
mci
initi
given
june
ten
day
later
patient
mild
short
breath
accept
oral
antibiot
therapi
sever
day
juli
treatment
repeat
period
everi
month
unfortun
develop
dyspnea
exert
chest
comput
tomographi
ct
scan
describ
mesh
like
shadow
stripe
patch
lung
furthermor
accept
intraven
methylprednisolon
mgd
antibiot
ten
day
short
breath
progress
increas
could
walk
addit
chest
ct
scan
also
demonstr
diffus
interstiti
pneumonia
came
clinic
hypoxia
continu
deterior
could
nt
toler
pulmonari
function
test
blood
ga
analysi
demonstr
mmhg
oxygen
therapi
relev
laboratori
test
exclud
tuberculosi
viral
infect
cardiac
diseas
connect
tissu
diseas
higher
dose
methylprednisolon
anti
inflammatori
therapi
mgd
mgd
mgd
condit
improv
could
walk
independ
methylprednisolon
adjust
oral
administr
gradual
reduc
result
three
month
later
chest
ct
scan
demonstr
diffus
interstiti
pneumonia
significantli
reduc
could
walk
upstair
conclus
interstiti
pneumonia
realli
happen
indic
low
dose
possibl
induc
sever
side
effect
papillari
thyroid
carcinoma
patient
doctor
pay
attent
pulmonari
complic
vsr
sb
swf
l
cc
je
tk
nation
univers
health
system
univers
medicin
divis
respiratori
critic
care
medicin
singapor
singapor
nation
univers
health
system
depart
diagnost
imag
singapor
singapor
nation
univers
health
system
depart
patholog
singapor
singapor
background
aim
earli
accur
diagnosi
interstiti
lung
diseas
ild
essenti
initi
therapi
optimis
patient
manag
current
guidelin
recommend
team
mdt
approach
involv
experienc
pulmonologist
radiologist
pathologist
improv
diagnost
confid
variou
ild
aim
review
ild
case
outcom
present
mdt
meet
determin
discuss
result
consensu
diagnosi
recommend
subsequ
patient
manag
method
report
retrospect
review
patient
medic
record
mdt
meet
discuss
outcom
april
june
mdt
consist
pulmonologist
radiologist
pathologist
result
total
patient
refer
mdt
discuss
april
june
patient
histolog
specimen
avail
discuss
mdt
discuss
led
consensu
diagnosi
case
patient
usual
interstiti
pneumonia
idiopath
pulmonari
fibrosi
interstiti
pneumonia
ild
relat
underli
connect
tissu
diseas
combin
pulmonari
fibrosi
emphysema
undefin
ild
addit
provid
consensu
diagnosi
guid
treatment
undefin
ild
recommend
possibl
differenti
diagnos
investig
deriv
diagnosi
conclus
mdt
discuss
result
consensu
diagnosi
major
case
refer
signific
proport
patient
undefin
ild
requir
addit
clinic
inform
studi
need
impact
mdt
subsequ
manag
outcom
k
depart
respiratori
medicin
juntendo
univers
school
medicin
graduat
school
medicin
depart
respiratori
medicin
medic
oncolog
tokyo
metropolitan
tama
medic
center
background
aim
report
lymphoprolif
disord
increas
although
mtx
withdraw
known
moder
effect
tumor
regress
appropri
treatment
predict
factor
tumor
regress
yet
establish
lung
lesion
method
retrospect
evalu
case
lung
lesion
result
median
age
year
rang
ratio
preced
autoimmun
diseas
rheumatoid
arthriti
case
median
period
diagnosi
rheumatoid
arthriti
onset
year
median
period
year
median
cumul
mtx
dosag
mg
multipl
pulmonari
nodul
case
solitari
pulmonari
nodul
case
hilar
mediastin
lymph
node
enlarg
one
caseth
histolog
type
lymphoma
diffus
larg
lymphoma
case
cell
rich
lymphoma
one
case
atyp
lymphocyt
case
case
could
diagnos
bronchoscopi
four
case
case
unknown
mtx
stop
case
tumor
shrinkag
occur
case
one
case
die
week
lymphocyt
recoveri
two
week
mtx
withdraw
higher
case
tumor
regress
median
increas
without
tumor
regress
lactat
dehydrogenas
serum
solubl
receptor
higher
case
without
tumor
regress
tumor
regress
conclus
although
studi
small
result
indic
poor
lymphocyt
recoveri
mtx
cessat
might
associ
tumor
progress
studi
warrant
determin
mtx
discontinu
subsequ
chemotherapi
r
takashima
marumo
h
amimoto
shiraishi
kotani
h
yamaki
h
shima
shirata
kawashima
kitajima
inou
katayama
r
itotani
sakuramoto
fukui
kitano
tazuk
kofukai
medic
research
institut
resipratori
medicin
osaka
japan
background
aim
combin
pulmonari
fibrosi
emphysema
cpfe
character
emphysema
fibrosi
chest
ct
sinc
first
defin
cottin
et
al
effect
therapi
establish
prognosi
remain
poor
fibrot
chang
cpfe
commonli
attribut
cigarett
smoke
definit
could
includ
pulmonari
fibrosi
varieti
diseas
collagen
diseas
hypersensit
pneumon
pigeon
igg
antibodi
known
diagnost
tool
hypersensit
pneumonia
brhp
assess
signific
serum
pigeon
igg
antibodi
level
cpfe
patient
method
retrospect
cohort
studi
conduct
diagnos
interstiti
pneumonia
patient
hospit
extract
case
ct
find
characterist
cpfe
serum
pigeon
igg
antibodi
measur
may
june
subsequ
investig
relationship
serum
pigeon
igg
antibodi
level
day
first
cpfe
exacerb
result
total
cpfe
case
male
femal
includ
final
analysi
median
age
year
patient
current
former
histori
smoke
median
amount
eight
patient
experienc
exacerb
measur
pigeon
igg
antibodi
secondli
classifi
cpfe
popul
three
group
accord
pigeon
igg
antibodi
level
low
n
medium
n
high
n
median
pigeon
igg
antibodi
level
group
mgal
mgal
mgal
respect
meier
curv
show
significantli
earlier
exacerb
igg
antibodi
group
compar
low
middl
group
conclus
cpfe
patient
high
serum
pigeon
igg
antibodi
risk
factor
exacerb
cpfe
popul
could
consist
variou
patient
includ
brhp
could
respond
remov
antigen
j
li
j
zhou
song
c
bai
shanghai
respiratori
research
zhongshan
fudan
univers
pulmonari
medicin
depart
shanghai
china
background
aim
target
diagnosi
treatment
acut
lung
injuri
inhibitor
urokinas
plasminogen
activ
receptor
upar
complement
factor
cfd
compon
altern
complement
pathway
best
known
role
humor
suppress
infecti
agent
object
present
studi
detect
express
upar
cfd
lung
injuri
irli
investig
potenti
role
method
human
pulmonari
microvascular
endotheli
cell
hpmec
cellml
within
passag
use
present
studi
vitro
firstli
divid
cell
normal
irli
group
construct
irli
model
hpmec
normal
group
cultur
carbon
dioxid
incub
use
complet
medium
hand
cell
irli
group
place
incub
without
oxygen
use
medium
without
glucos
next
cell
reperfus
complet
medium
carbon
dioxid
incub
observ
cell
optic
microscop
final
express
upar
cfd
examin
use
western
blot
method
result
irli
model
hpmec
success
construct
ischemia
reperfus
furthermor
compar
normal
group
express
upar
cfd
irli
hpmec
significantli
decreas
p
addit
decreas
mrna
level
line
chang
protein
express
conclus
irli
express
upar
cfd
significantli
decreas
compar
normal
group
indic
decreas
upar
cfd
may
induc
inflamm
irli
therefor
upar
cfd
potenti
use
earli
diagnosi
treatment
lung
injuri
n
hamao
u
masakuni
terada
nakanishi
inao
kaji
yasuda
hashimoto
hajiro
e
tanaka
taguchi
tenri
hospit
divis
respiratori
medicin
japan
background
aim
mizoribin
mzr
immunosuppress
drug
proven
effect
patient
nephrot
syndrom
rheumatoid
arthriti
sinc
mzr
give
less
seriou
advers
event
immunosuppres
calcineurin
inhibitor
mzr
could
administ
patient
interstiti
pneumonia
ip
altern
littl
known
mzr
work
behav
patient
ip
therefor
investig
efficaci
safeti
mzr
patient
ip
method
patient
ip
treat
mzr
januari
decemb
institut
evalu
retrospect
twelv
patient
idiopath
ip
patient
connect
tissu
diseas
relat
ip
dmpm
ra
ssc
sj
sle
background
administ
mzr
effect
mzr
frequenc
side
effect
investig
result
mzr
ad
steroid
monotherapi
n
steroid
plu
immunosuppres
n
patient
mzr
substitut
prior
immunosuppres
cyclosporin
cya
azathioprin
side
effect
physician
avoid
possibl
futur
risk
regard
efficaci
mzr
improv
prevent
worsen
patient
three
patient
present
progress
ip
spite
ad
mzr
one
patient
unabl
continu
mzr
sever
rash
conclus
patient
ip
mzr
administ
effect
safe
mzr
could
altern
immunosuppres
manag
ip
nakanishi
nagasaka
tsuchiya
c
sakaguchi
h
ajimizu
nishiyama
hayashi
n
morikawa
rakuwakai
otowa
hospit
pulmonari
medicin
kyoto
japan
background
aim
report
power
spectrum
ps
lung
sound
interstiti
pneumonia
ip
reflect
intens
fine
crackl
typic
ps
fine
crackl
show
sound
peak
around
hz
dip
around
hz
jr
tri
clarifi
chang
ps
acut
exacerb
ae
ip
method
examin
case
ip
experienc
ae
among
ten
patient
improv
two
stay
condit
five
patient
deterior
clinic
clinic
improv
deterior
judg
subject
symptom
vital
sign
find
analyz
lung
sound
ten
second
record
bilater
lung
base
measur
sound
power
three
frequenc
rang
ie
low
middl
mfp
high
hfp
compar
mfp
hfp
dbm
treatment
includ
steroid
immunosuppress
agent
result
improv
patient
mfp
treatment
dbm
hfp
treatment
stabl
patient
mfp
treatment
hfp
treatment
deterior
patient
mfp
treatment
hfp
treatment
decreas
mfp
hfp
improv
patient
increas
mfp
hfp
deterior
patient
conclus
conclud
ps
especi
mfp
hfp
patient
ip
use
paramet
detect
improv
deterior
result
suggest
listen
lung
sound
patient
ip
patient
improv
lung
sound
becom
softer
deterior
lung
sound
becom
louder
nishiyama
r
yamazaki
h
sano
iwanaga
higashimoto
h
kume
tohda
kindai
univers
faculti
medicin
depart
respiratori
medicin
allergolog
osakasayama
japan
background
aim
detail
bodi
composit
mass
examin
idiopath
pulmonari
fibrosi
ipf
investig
whether
mass
index
ffmi
index
lean
bodi
mass
predict
surviv
method
patient
ipf
enrol
studi
bodi
composit
assess
use
direct
segment
bioelectr
imped
analysi
degre
correl
variabl
bodi
composit
variabl
physiolog
surviv
examin
result
signific
posit
correl
ffmi
fvc
dlco
walk
distanc
signific
neg
correl
age
howev
signific
correl
ffmi
either
percentag
predict
fvc
dlco
degre
correl
similar
observ
bodi
mass
index
bmi
bmi
ffmi
show
signific
correl
outcom
includ
dyspnoea
qualiti
life
anxieti
depress
score
univari
cox
proport
hazard
model
show
sever
variabl
bmi
associ
significantli
surviv
ffmi
hr
ci
p
fvc
percentag
predict
hr
ci
p
signific
factor
multivari
model
conclus
conclud
ffmi
signific
predictor
surviv
patient
ipf
nagasaka
tsuchiya
c
sakaguchi
nakanishi
h
ajimizu
nishiyama
hayashi
n
morikawa
rakuwakai
otowa
hospit
pulmonari
medicin
kyoto
japan
background
aim
fine
crackl
brief
discontinu
lung
sound
heard
patient
interstiti
pneumonia
ip
coars
crackl
loud
heard
patient
wtih
bacteri
pneumonia
bp
descript
subject
auscultatori
find
need
defin
lung
sound
analysi
tri
clarifi
differ
fine
coars
crackl
analyz
adventit
lung
sound
sound
spectrogram
especi
power
spectrum
distribut
method
seventeen
subject
ip
honeycomb
chest
ct
four
subject
acut
pneumonia
examin
record
analyz
lung
sound
bilater
lung
base
patient
ip
affect
area
patient
bp
analyz
breath
sound
sound
spectromet
kenz
medico
lsa
examin
distribut
power
spectrum
ps
result
ten
patient
ip
power
peak
around
hz
power
dip
around
show
revers
shape
figur
graphic
seven
patient
ip
show
hz
peak
without
dip
thu
revers
shape
patient
ip
show
strong
sound
power
higher
frequenc
rang
ie
hz
hz
four
patient
bp
show
ps
gradual
taper
sound
power
hz
conclus
fine
crackl
patient
ip
show
strong
sound
intens
coars
crackl
patient
bp
show
sound
attenu
ps
lung
sound
analysi
use
tool
differenci
fine
crackl
coars
crackl
object
k
j
h
tokyo
medic
univers
depart
school
tokyo
japan
sleep
toranomon
hospit
respiratoy
center
sleep
center
tokyo
japan
background
aim
patient
interstiti
pneumonia
ip
report
poor
sleep
qualiti
howev
far
believ
reduc
caudal
traction
upper
airway
due
decreas
lung
volum
enhanc
collaps
less
understood
associ
impair
pulmonari
function
interstiti
pneumonia
sleep
breath
disord
sbd
studi
clarifi
relat
index
ahi
pulmonari
function
patient
ip
method
assess
pulmonari
function
test
ahi
use
overnight
portabl
monitor
devic
nihon
kohden
inc
tokyo
japan
equip
heart
rate
airflow
sensor
snore
bodi
posit
respiratori
effort
percutan
satur
day
correl
ahi
vc
dlco
dlcova
pulmonari
function
test
evalu
result
enrol
patient
male
mean
age
year
diagnos
ip
accord
comput
tomographi
restrict
impair
vc
ip
patient
restrict
impair
despit
correl
ahi
vc
significantli
neg
correl
ahi
dlcova
r
p
conclus
suggest
ip
patient
declin
dlcova
could
associ
strongli
sa
studi
need
clarifi
result
jy
hong
chuncheon
sacr
heart
hospit
divis
pulmonari
critic
care
medicin
republ
korea
background
aim
nutrit
assess
import
patient
pulmonari
nontubercul
mycobacteri
pntm
diseas
therapeut
effect
diet
intuberculosi
tb
patient
demonstr
role
cholesterol
pntm
diseas
isunclear
studi
evalu
sequenti
chang
nutrit
marker
includ
cholesterol
instant
nutrit
assess
ina
score
viscer
fat
volum
accord
pntm
diseas
cours
method
number
comorbid
case
control
analysi
patient
pntm
diseas
control
particip
korean
nation
survey
result
median
bodi
mass
index
bmi
cholesterol
level
pntm
group
bmi
iqr
cholesterol
mgdl
iqr
lower
control
iqr
cholesterol
mgdl
iqr
p
bmi
ci
p
independ
associ
extens
pulmonaryles
involv
four
lobe
decreas
cholesterol
level
decreas
ratio
viscer
fat
volum
percentag
subject
chang
low
ina
high
ina
higher
ntm
patient
diseas
progress
stabl
diseas
cours
p
valu
multivari
analysi
decreas
cholesterol
concentr
mgdl
predict
factor
diseas
progress
ci
p
conclus
find
suggest
chang
cholesterol
level
may
marker
diseas
progress
patient
pntm
diseas
r
k
j
k
ida
hospit
depart
pulmonari
medicin
kawasaki
japan
ida
hospit
depart
infecti
diseas
kawasaki
japan
background
aim
organ
pneumonia
op
secondari
mycobacterium
tuberculosi
tb
infect
recent
report
acceler
sever
origin
infecti
diseas
case
seri
studi
aim
studi
examin
effect
system
steroid
therapi
sever
pulmonari
tb
infect
secondari
organ
pneumonia
method
case
seri
studi
case
tb
infect
secondari
op
treat
steroid
hospit
enrol
secondari
op
diagnos
chest
ct
serum
result
case
yo
male
tb
past
histori
admit
intens
care
unit
icu
sever
respiratori
failur
bilater
consolid
chest
ct
steroid
mgbodi
start
admiss
day
lung
infiltr
disappear
day
case
yo
femal
sever
respiratori
failur
bilater
infiltr
chest
steroid
mgbodi
start
admiss
day
lung
infiltr
disappear
day
case
yo
femal
miliari
tb
consolid
chest
steroid
mgbodi
start
day
admiss
die
day
later
case
yo
male
miliari
tb
admit
icu
respiratori
ventil
control
bilater
lung
consolid
steroid
mgbodi
start
day
admiss
effect
die
day
abl
perform
bronchoscop
evalu
tblb
bal
patient
severitytwo
case
treat
steroid
admiss
day
recov
soon
howev
two
miliari
tb
case
treat
steroid
day
day
admiss
abl
benefit
steroid
eventu
die
conclus
earli
diagnosi
earli
treatment
seem
import
sever
tb
infect
secondari
op
l
liu
w
tao
z
yuan
h
wang
f
wen
divis
pulmonari
diseas
state
key
laboratori
biotherapi
china
chengdu
china
background
aim
pf
deadli
diseas
human
health
current
effect
treatment
therapi
eagerli
need
improv
anim
model
drug
evalu
drug
evalu
rhesu
pf
model
drug
evalu
rhesu
simultan
bind
vegf
strong
affin
call
tri
find
slow
progress
pf
method
inject
blm
trachea
atom
injector
establish
rhesu
pf
model
month
blm
inject
placebo
given
model
monkey
time
week
intraven
inject
monitor
fibrosi
progress
hrct
level
biomark
sp
mmp
also
take
activ
level
supplement
month
later
monkey
sacrif
arteri
blood
ga
analysi
sacrif
masson
stain
patholog
chang
perform
protein
level
investig
result
nt
see
signific
differ
patholog
chang
group
placebo
group
stain
hrct
arteri
blood
averag
group
better
placebo
group
statist
signific
signific
differ
serum
sp
level
group
month
begin
inject
blood
level
lower
placebo
group
found
pathway
partli
block
conclus
current
studi
show
might
littl
use
rhesu
pf
model
research
rhesu
pf
model
focus
lncrna
chang
proteom
new
drug
evalu
come
soon
enough
time
r
andriani
e
burhan
f
isbaniah
sd
ata
asri
faculti
universita
indonesia
depart
pulmonolog
respiratoy
medicin
jakarta
indonesia
background
aim
tuberculosi
tb
global
health
problem
million
bacteriolog
confirm
pulmonari
tb
case
million
pulmonari
tb
case
world
low
countri
like
indonesia
still
use
bacilli
afb
assay
help
diagnos
tb
simpl
fast
low
cost
procedur
nevertheless
diagnosi
tb
neg
sputum
afb
result
difficult
held
unspecif
clinic
manifest
caus
late
diagnosi
therapi
increas
morbid
mortal
transmiss
rate
mani
case
world
case
indonesia
report
smear
neg
tb
case
particularli
immunocompromis
patient
xpert
mtbrif
assay
rapid
molecular
assay
detect
mycobacterium
tuberculosi
mtb
hour
equival
sensit
mtb
cultur
purpos
preliminari
studi
evalu
role
xpert
mtbrif
assay
mtb
detect
new
presumpt
tuberculosi
patient
neg
sputum
afb
method
subject
n
presumpt
tuberculosi
patient
new
case
base
clinic
indic
afb
neg
sputum
result
persahabatan
hospit
jakarta
indonesia
subject
test
xpert
mtbrif
assay
mtb
cultur
use
sputum
sampl
result
xpert
mtbrif
final
result
among
subject
subject
mtb
detect
mtb
detect
low
mtb
detect
low
mtb
detect
medium
subject
mtb
detect
rifampicin
resist
detect
hand
among
subject
subject
neg
cultur
posit
cultur
one
subject
posit
cultur
mtb
detect
low
xpert
mtbrif
assay
conclus
conclus
xpert
mtbrif
assay
increas
detect
rate
mtb
even
patient
neg
sputum
afb
nabeya
kinjo
yamashiro
g
parrott
yamazato
nahar
haranaga
tateyama
j
fujita
univers
ryukyu
depart
infecti
digest
graduat
school
medicin
okinawa
japan
background
aim
activ
tuberculosi
patient
often
deterior
even
induct
antitubercul
medic
problemat
patient
need
hospit
although
factor
associ
vulner
tuberculosi
infect
pathogenesi
elucid
report
show
factor
involv
deterior
activ
tuberculosi
patient
studi
design
elucid
factor
deterior
activ
tuberculosi
patient
method
april
may
inpati
activ
tuberculosi
infect
ryukyu
univers
hospit
includ
retrospect
studi
diagnos
confirm
cultur
andor
polymeras
chain
reaction
tuberculosi
medic
record
review
extract
relat
clinic
featur
ibm
spss
statist
window
version
armonk
ny
ibm
corp
use
statist
analysi
result
total
tb
case
collect
male
mean
age
patient
year
old
patient
acut
respiratori
failur
univari
analysi
show
daili
steroid
p
daili
nonsteroid
immunosuppress
p
sputum
p
higher
age
p
lower
serum
albumin
p
relat
acut
respiratori
failur
multivari
analysi
reveal
daili
steroid
p
lower
serum
albumin
p
relat
acut
respiratori
failur
number
survivor
respect
univari
analysi
show
mainten
dialysi
histori
month
p
acut
respiratori
failur
p
miliari
tuberculosi
p
lower
serum
albumin
p
relat
death
conclus
studi
show
lower
serum
albumin
relat
risk
factor
acut
respiratori
failur
death
multivari
analysi
reveal
daili
steroid
lower
serum
albumin
relat
acut
respiratori
failur
c
thibbade
rayong
hospit
medicin
rayong
thailand
background
aim
rayong
provinc
thailand
tuberculosi
still
major
public
health
problem
local
nation
level
highest
number
per
popul
mdr
case
countri
therefor
fast
accur
diagnosi
import
patient
care
reduc
spread
infect
commun
xpert
mtb
rif
thu
role
help
diagnos
tuberculosi
object
aim
evalu
diagnost
perform
xpert
mtb
rif
sensit
specif
accuraci
posit
predict
valu
ppv
neg
predict
valu
npv
posttest
probabl
actual
user
experi
part
thailand
method
studi
retrospect
studi
august
octob
result
xpert
mtb
rif
test
sputum
clinic
suspect
mdr
tuberculosi
includ
studi
studi
use
tuberculosi
cultur
gold
standard
diagnosi
result
total
sampl
includ
studi
smear
posit
sampl
number
hiv
sampl
reason
xpert
mtb
rif
test
retreat
failur
sputum
convers
third
month
prison
respect
total
sampl
specimen
cultur
confirm
studi
show
sensit
xpert
mtb
rif
diagnost
specif
accuraci
test
neg
predict
valu
found
posit
predict
valu
ppv
posttest
probabl
good
abil
detect
afb
stain
patient
hiv
xpert
mtb
rif
use
group
abil
detect
tuberculosi
conclus
xpert
mtb
rif
diagnosi
effect
better
fasterhowev
cultur
also
requir
confirm
diagnosi
romsaiyut
thammasat
univers
medicin
klongluang
thailand
background
aim
propylthiouracil
ptu
use
hyperthyroid
number
ptu
induc
advers
reaction
leukopenia
rash
arthriti
vascul
syndrom
ptu
observ
associ
antineutrophil
cytoplasm
antibodi
anca
small
vessel
vasculitid
describ
patient
vascul
caus
alveolar
hemorrhag
rapidli
improv
cessat
ptu
administr
corticosteroid
method
woman
admit
hospit
evalu
dyspnea
two
week
five
month
admiss
complain
cough
haemoptysi
weight
loss
diagnos
hyperthyroid
age
therapi
ptu
initi
dose
mgday
decreas
mgday
six
month
maintain
admiss
physic
examin
reveal
tachycardia
tachypnea
room
air
bibasilar
crackl
laboratori
show
anemia
hb
gl
microscop
heamaturia
proteinuria
posit
titer
mpo
posit
ana
posit
low
toter
chest
ct
chest
show
alveolar
opac
middl
lower
lobe
lung
bronchoscop
find
show
sequenti
bal
establish
consist
alveolar
hemorrhag
lung
biopsi
perform
exclud
infect
bal
report
indic
benign
cytolog
bal
cultur
organ
diagnosi
alveolar
hemorrhag
ptu
discontinu
prednisolon
mgday
start
treatment
gradual
improv
within
week
result
present
patient
develop
vascul
result
pulmonari
hemorrhag
without
kidney
involv
bronchoscop
find
histopatholog
could
inconclus
detect
anca
help
diagnosi
dramat
improv
discontinu
ptu
start
treatment
high
dose
steroid
conclus
vascul
import
continu
use
ptu
lead
threaten
alveolar
hemorrhag
l
h
l
q
xiangya
hospit
central
south
univers
depart
gerontolog
chang
sha
china
xiangya
hospit
central
south
univers
depart
rheumatolog
immunolog
chang
sha
china
depart
thorac
oncolog
hunan
cancer
hospit
depart
gerontolog
chang
sha
china
background
aim
idiopath
pulmonari
fibrosi
ipf
incur
lung
diseas
lung
tissu
becam
thick
stiff
scar
although
great
achiev
made
term
molecular
diagnost
pathobiolog
underli
pathogenesi
associ
ipf
still
unclear
need
well
defin
method
present
studi
chang
microrna
mirna
mrna
ipf
investig
use
integr
network
approach
origin
mirna
mrna
express
profil
dataset
download
gene
express
omnibu
geo
differ
express
mirnamrna
identifi
use
signific
analysi
microarray
sam
algorithm
molecular
target
associ
mirna
expand
use
cytargetlink
cytoscap
final
valid
use
mrna
array
express
profil
result
integr
network
encompass
gene
mirna
associ
ipf
initi
function
enrich
analysi
indic
receptor
interact
glycin
serin
threonin
metabol
signal
pathway
highli
associ
ipf
progress
integr
network
demonstr
interact
mirna
gene
particular
highlight
target
gene
osm
may
shed
new
light
ipf
initi
develop
conclus
use
public
avail
dataset
geo
databas
establish
mirna
mrna
interact
network
ipf
screen
mirna
candidatesand
gene
ipf
initi
develop
may
serv
potenti
target
ipf
diagnosi
therapeut
r
apinhapanit
ramathibodi
hospit
medicin
bangkok
thailand
femal
present
eight
month
histori
progress
dyspnea
product
cough
signific
weight
loss
heavi
alcohol
drink
smoke
note
receiv
treatment
nearbi
hospit
left
upper
lobe
consolid
radioluc
reveal
initi
chest
radiographi
decreas
lung
volum
juxtraphren
peak
sign
also
note
find
consist
luftsichel
sign
sputum
afb
stain
posit
mycobacterium
tuberculosi
complex
confirm
cultiv
standard
regimen
given
isoniazid
rifampicin
pyrazinamid
ethambutol
riboflavin
prescrib
initi
treatment
month
treatment
symptom
subsid
still
ongo
weight
loss
kg
kg
despit
neg
sputum
afb
improv
chest
radiographi
isoniazid
rifampicin
given
mainten
therapi
comput
tomographi
chest
done
persist
left
upper
lobe
consolid
atelectasi
detect
lung
mass
endobronchi
obstruct
suspect
refer
investig
concern
primari
lung
cancer
despit
medic
adher
treatment
poor
flexibl
bronchoscopi
perform
narrow
left
upper
lobe
bronchu
open
without
endobronchi
mass
lesion
demonstr
bronchoscopi
histopatholog
transbronchi
biopsi
left
upper
lobe
consist
chronic
granulomat
inflamm
addit
polymeras
chain
reaction
mycobacterium
tuberculosi
posit
neither
malign
fungi
detect
treatment
continu
conclus
rare
caus
luftsichel
sign
chest
radiographi
confirm
pulmonari
tuberculosi
howev
malign
diseas
must
taken
account
prove
otherwis
j
liu
second
hospit
jilin
univers
respiratori
medicin
changchun
china
background
aim
plch
kind
rare
diseas
particularli
multipl
organ
involv
review
diagnosi
differenti
diagnosi
plch
special
case
plch
associ
posit
anca
asthma
method
one
male
admiss
second
hospit
jilin
univers
chief
complaint
paroxysm
wheez
year
seriou
dyspnea
cough
expector
week
month
ago
central
diabet
insipidu
diagnos
patient
appear
polyuria
mild
osteolyt
destruct
upper
jaw
left
acetabular
bone
multipl
small
pulmonari
nodul
patient
smoke
packsyear
without
quit
meaning
result
auxiliari
examin
follow
multipl
small
pulmonari
centrilobular
nodul
mm
accompani
small
amount
small
cystic
chang
found
lung
ct
bronchial
dilat
test
posit
lung
diffus
function
dlco
anca
test
posit
eosinophil
peripher
blood
langerhanscel
seen
intra
alveolar
exud
cell
small
amount
eosinophil
cell
shown
biopsi
lung
tissu
fibrobronchoscopi
result
diagnosi
patient
plch
involv
multipl
organ
also
call
eosinophil
granulomadiseas
signific
improv
found
clinic
manifest
lung
ct
month
treatment
prednison
mg
day
quit
smoke
conclus
allerg
granulomatosi
syndrom
css
consid
differenti
diagnosi
case
associ
asthma
increas
eosinophil
blood
lung
tissu
posit
anca
plch
diagnos
case
final
accompan
central
diabet
insipidu
osteolyt
destruct
patholog
chang
langerhanscel
alveoli
special
rare
report
plch
accompani
asthma
posit
anca
measur
possibl
plch
combin
css
also
consid
follow
instruct
given
continu
yamamoto
h
matsuo
n
toyooka
r
horitani
yoshinaga
hyogo
prefectur
amagasaki
gener
medic
center
depart
gener
medicin
emerg
amagasaki
japan
background
aim
diagnosi
tuberculosi
difficult
clinic
present
report
two
case
diagnosi
delay
due
cognit
bia
method
case
japanes
man
diabet
nephropathi
present
histori
fever
back
pain
admiss
enter
shock
antibiot
administ
blood
pressur
immedi
improv
fever
continu
needl
biopsi
fifth
lumbar
vertebra
compress
fractur
perform
suspicion
pyogen
spondyl
organ
cultur
incub
week
one
month
biopsi
bacteria
grew
specimen
cultur
reveal
tuberculosi
chest
comput
tomographi
show
diffus
small
pulmonari
nodul
stain
sputum
show
posit
result
day
start
symptom
miliari
tuberculosi
tubercul
spondyl
diagnos
case
japanes
woman
suffer
rheumatoid
arthriti
interstiti
pneumonia
take
prednisolon
salazosulfapyridin
display
moder
arthralgia
slight
fever
loss
appetit
start
biolog
reduc
symptom
chest
comput
tomographi
perform
check
interstiti
pneumonia
comput
tomographi
reveal
nodular
shadow
right
middl
left
upper
lobe
final
tuberculosi
confirm
bronchoscopi
result
case
tuberculosi
list
differenti
diagnos
antibiot
state
shock
appear
effect
kept
suspect
common
bacteri
infect
due
anchor
bia
awar
insidi
progress
could
detect
tuberculosi
need
airborn
isol
case
regard
fever
appetit
loss
symptom
uncontrol
rheumatoid
arthriti
due
avail
bia
overconfid
bia
despit
cellular
immun
defici
conclus
type
bia
two
case
common
know
effect
bia
diagnost
process
prove
use
debias
k
w
h
n
f
k
juntendo
univers
graduat
school
medicin
depart
respiratori
medicin
japan
juntendo
univers
urayasu
hospit
depart
respiratori
medicin
japan
background
aim
idiopath
pulmonari
fibrosi
ipf
interstiti
pneumonia
nsip
classifi
chronic
fibros
idiopath
interstiti
pneumonia
howev
relationship
differ
result
patient
usual
interstiti
pneumonia
uip
common
hrct
pattern
ipf
nsip
chest
comput
tomographi
hrct
serum
marker
well
understood
aim
investig
associ
hrct
result
serum
marker
level
bronchoalveolar
lavag
bal
fluid
analysi
pulmonari
function
test
pft
result
method
evalu
serum
marker
level
pft
result
vital
capac
vc
forc
vital
capac
fvc
diffus
capac
lung
carbon
monoxid
dlco
bal
fluid
analysi
time
diagnosi
patient
uip
nsip
pattern
chest
hrct
medic
record
uip
nsip
patient
retrospect
review
result
april
march
patient
diagnos
uip
nsip
pattern
chest
hrct
undergon
bal
pft
initi
hospit
visit
chest
hrct
patient
diagnos
uip
pattern
uip
group
diagnos
nsip
pattern
nsip
group
level
uip
group
significantli
higher
nsip
group
vs
p
bal
lymphocyt
percentag
nsip
group
significantli
higher
uip
group
vs
p
bal
total
cell
count
neutrophil
percentag
eosinophil
percentag
significantli
differ
group
addit
signific
differ
fvc
dlco
percentag
group
vs
p
vs
p
respect
conclus
find
suggest
chest
hrct
result
significantli
associ
level
lymphocyt
bal
fluid
fvc
dlco
diagnosi
k
k
w
h
n
f
k
juntendo
univers
graduat
school
medicin
depart
respiratori
medicin
japan
juntendo
univers
urayasu
hospit
depart
respiratori
medicin
japan
background
aim
one
chines
tradit
medicin
use
patient
osteoarthr
oa
sever
case
report
develop
interstiti
pneumonia
acut
lung
injuri
induc
herbal
medicin
especi
bofutsushosan
goshajinkigan
howev
unknown
induc
pulmonari
toxic
method
retrospect
review
two
case
acut
respiratori
failur
initi
result
two
japanes
men
oa
receiv
patient
develop
acut
respiratori
failur
sever
week
initi
cough
dyspnea
time
develop
acut
respiratori
failur
chest
comput
tomographi
find
show
diffus
ground
glass
opac
traction
bronchiectasi
serum
surfact
level
increas
patient
clinic
diagnos
find
diffus
alveolar
damag
dad
therefor
one
patient
receiv
steroid
puls
therapi
cyclophosphamid
treat
steroid
puls
therapi
howev
symptom
chest
radiolog
find
desatur
acut
progress
although
two
patient
receiv
mechan
ventil
die
sever
week
develop
acut
respiratori
failur
one
patient
famili
consent
autopsi
patholog
find
autopsi
demonstr
capillari
congest
hyalin
membran
edema
observ
earli
exud
dad
phase
elastica
van
gieson
evg
stain
organ
exud
prolifer
fibroblast
evg
stain
observ
late
organ
fibrot
dad
phase
find
honeycomb
conclus
report
acut
respiratori
failur
develop
interstiti
pneumonia
probabl
induc
radix
scutellaria
contain
herbal
medicin
includ
chines
tradit
medicin
contain
radix
scutellaria
care
use
potenti
role
develop
dad
jy
kang
k
hyung
woo
j
sanghoon
l
jaeha
k
shinyoung
p
chan
kwon
k
soon
seog
k
young
kyoon
hwa
sik
k
ju
sang
colleg
cathol
univers
korea
intern
medicin
seoul
republ
korea
background
aim
widespread
use
molecular
suscept
test
drug
mycobacterium
tuberculosi
mtb
found
result
test
ident
convent
phenotyp
suscept
test
method
aug
jan
tb
patient
perform
two
drug
suscept
test
dst
mtb
ie
molecular
test
mtbdrplu
isoniazid
inh
rifampicin
rfp
genexpert
rfp
phenotyp
collect
medic
record
review
retrospect
tertiari
hospit
result
among
tb
patient
patient
enrol
mean
age
thirti
male
underli
diseas
follow
diabet
case
copd
lung
cancer
malign
case
discord
pattern
dst
result
inh
show
inconsist
rfp
two
test
wherea
case
inh
suscept
mtbdrplu
inh
resist
r
phenotyp
test
case
inh
r
former
inh
latter
rfp
case
r
mtbdrplu
convent
dst
two
case
invers
among
case
recogn
final
result
two
type
dst
patient
treat
phenotyp
result
clinic
respons
tb
control
treatment
success
case
failur
loss
death
treatment
conclus
might
happen
situat
inconsist
data
two
type
dst
mtb
especi
mdr
inh
drug
result
convent
dst
consid
import
molecular
dst
real
practic
studi
clinic
impact
inconsist
requir
confirm
better
dst
n
chanthitivech
w
sirichana
k
jutivorakool
chulalongkorn
hospit
medicin
bangkok
thailand
background
aim
airway
complic
transplant
usual
relat
anastomosi
ischemia
infect
report
incid
vari
among
center
tracheal
anastomot
infect
lead
major
airway
complic
necrosi
dehisc
bacteri
infect
common
howev
aspergillu
infect
report
caus
subsequ
airway
complic
method
result
report
case
woman
undergon
transplant
year
patient
present
hemoptysi
acut
diarrhea
fever
later
develop
acut
respiratori
failur
requir
mechan
ventil
initi
investig
reveal
pulmonari
mycobacterium
avium
complex
mac
aspergillu
sppinfect
patient
treat
antibiot
antifung
agent
admiss
patient
complain
chest
discomfort
recurr
right
pneumothoraxbronchoscopi
perform
extub
tracheal
ulcer
found
tracheal
anastomosi
tracheal
biopsi
done
tissu
patholog
reveal
intracellular
organ
morpholog
compat
histoplasma
spp
antifung
agent
chang
amphotericin
b
follow
bronchoscopywa
done
one
month
later
demonstr
improv
tracheal
ulcer
conclus
histoplasmosi
rare
caus
tracheal
infect
consid
immunosuppress
patient
prastuti
medan
indonesia
background
aim
vitamin
enhanc
host
protect
immun
respons
mycobacterium
tuberculosi
reduc
diseas
associ
inflamm
host
aim
studi
compar
vitamin
group
pulmonari
tuberculosi
patient
placebo
group
term
sputum
convers
radiolog
improv
method
sixti
four
pulmonari
tuberculosi
patient
visit
sever
clinic
public
health
medan
april
june
includ
studi
subject
randomis
receiv
vitamin
oral
placebo
singl
blind
method
baselin
day
start
standard
tuberculosi
treatment
primari
endpoint
time
initi
antimicrobi
treatment
sputum
cultur
convers
rate
sputum
convers
radiolog
examin
evalu
result
patient
includ
primari
efficaci
analysi
assign
intervent
assign
placebo
median
time
sputum
cultur
convers
day
intervent
group
day
theplacebo
group
vitamin
group
placebo
group
sputum
conversionthi
differ
statist
signific
p
improv
radiograph
find
group
vitamin
also
higher
second
month
p
conclus
vitamin
support
effect
pulmonari
tuberculosi
patient
improv
heal
process
indic
faster
improv
sputum
convers
radiograph
lk
leong
kuala
lumpur
malaysia
background
aim
leptospirosi
widespread
zoonot
diseas
world
diseas
often
multisystem
wide
varieti
clinic
sign
symptom
diagnosi
difficult
may
confus
diseas
present
leptospirosi
case
caus
polyseros
unusu
find
second
case
world
report
first
case
report
istanbul
unfortun
patient
succumb
method
report
case
year
old
malay
male
present
week
product
cough
pleurit
chest
pain
fever
examin
tachypn
auscult
lung
show
reduc
breath
sound
bilater
later
develop
septic
shock
acut
kidney
injuri
confus
respiratori
distress
requir
intub
mechan
ventil
derang
coagul
profil
leucocytosi
bicytopenia
transamin
cxr
ct
thorax
show
bilater
pleural
effus
echocardiogram
show
massiv
pericardi
effus
correspond
pericardi
tamponad
pleural
fluid
pericardi
fluid
analysi
consist
exud
pictur
cultur
yield
growth
atyp
pneumonia
screen
tb
work
connect
tissu
diseas
screen
viral
screen
thyroid
function
test
neg
leptospirosi
ig
microscop
agglutin
test
mat
strongli
posit
titr
given
iv
tazocin
still
spike
temperatur
thu
antibiot
escal
iv
meropenam
condit
improv
ward
stay
discharg
penicillin
v
show
improv
clinic
follow
result
leptospirosi
igm
postiv
patient
posit
microagglutin
test
patient
pleural
pericardi
effus
conclus
exud
polyseros
may
real
though
uncommon
manifest
leptospirosi
seen
patient
henc
high
degre
suspicion
test
leptospirosi
earli
diagnosi
made
prompt
manag
institut
prevent
mortal
morbid
yx
mk
hospit
sultanah
bahiyah
intern
medicin
alor
setar
malaysia
hospit
sultanah
bahiyah
respiratori
medicin
alor
setar
malaysia
background
aim
introduct
dissemin
tuberculosi
tb
compris
two
noncontigu
site
result
lymphohematogen
dissemin
mycobacterium
tuberculosi
case
report
present
case
year
old
malay
ladi
known
case
diabet
mellitu
hypertens
bronchial
asthma
end
stage
renal
failur
regular
dialysi
present
cough
month
loss
weight
appetit
admit
medic
ward
treat
pneumonia
chest
show
bilater
reticulonodular
opac
broad
spectrum
antibiot
administ
escal
tazosin
patient
spike
temperatur
dyspnea
note
vagu
central
abdomin
mass
systol
murmur
mitral
region
case
refer
surgic
team
proced
ultrasonographi
abdomen
comput
tomographi
abdomen
show
oment
mass
locul
ascit
oesophagoduedenoscop
show
antral
gastriti
colonoscop
surgic
team
unabl
advanc
scope
beyond
cm
due
extern
compress
plan
ct
guid
biopsi
abandon
due
high
risk
procedur
echo
show
right
atrial
mass
pericardi
effus
posterior
wall
possibl
diagnosi
atrial
myxoma
given
sputum
afb
neg
patient
refer
pulmonolog
team
bronchoscop
gene
expert
test
upon
review
pulmonolgi
team
patient
treat
empir
dissemin
tuberculosi
schedul
bronchoscopi
patient
show
remark
improv
day
medic
fever
subsid
appear
less
tachypno
gene
expert
studi
came
back
posit
ct
abdomen
echo
repeat
week
antitb
medic
show
reduct
mass
respect
conclus
case
illustr
import
intervent
pulmonolog
high
index
suspicion
treat
dissemin
tuberculosi
mimic
diseas
x
tingt
p
luo
zhujiang
southern
medic
guangzhou
c
depart
respiratori
medicin
guangzhou
china
background
aim
investig
clinic
signific
hypersensit
protein
fribriogen
patient
connect
tissu
diseas
relat
interstiti
lung
diseas
method
patient
interstiti
lung
diseas
admit
april
zhujiang
hospit
southen
medic
univers
includ
research
patient
classifi
group
patient
classifi
intersiti
lung
diseas
group
also
healthi
peopl
includ
control
group
hypersensit
protein
fribriogen
fg
analyz
result
level
fg
ddi
group
significantli
higher
control
group
level
group
significantli
higher
group
differ
fg
ddi
level
group
signific
conclus
fg
show
great
valu
clinic
diagnosi
ctd
obvious
high
level
correl
ctd
aida
b
bintang
yink
magdalena
yahwardiah
medic
faculti
univers
north
sumatra
pulmonolog
respiratori
medan
indonesia
medic
faculti
univers
north
sumatra
depart
biochemistri
medan
indonesia
background
aim
mycobacterium
tuberculosi
infect
influenc
genet
environment
factor
vitamin
defici
genet
variant
vitamin
receptor
vdr
gene
report
associ
pulmonari
tuberculosi
tb
studi
investig
interact
vitamin
serum
concentr
vitamin
receptor
gene
bsmi
polymorph
pulmonari
tb
method
conduct
studi
use
pulmonari
tb
patien
case
healthi
control
vitamin
level
measur
particip
vitamin
receptor
gene
bsmi
polymorph
perfom
corel
vitamin
level
vitamin
receptor
gene
bsmi
polymorph
pulmonari
tb
statist
analyz
result
frequenc
vitamin
level
suffici
insuffici
defici
pulmonari
tb
patient
suffici
insuffici
defici
healthi
control
signific
associ
vitamin
level
pulmonari
tb
ci
defici
vs
suffici
associ
vitamin
level
pulmonari
tb
ci
defici
vs
insuffici
frequenc
bsmi
genotyp
bb
bb
bb
pulmonari
tb
patient
bb
bb
bb
healthi
control
signific
associ
vitamin
receptor
gene
bsmi
polymorph
pulmonari
tb
ci
bb
vs
bb
also
signific
associ
vitamin
receptor
gene
bsmi
polymorph
pulmonari
tb
ci
bb
vs
bb
conclus
signific
associ
vitamin
level
pulmonari
tb
signific
associ
vitamin
receptor
gene
bsmi
polymorph
pulmonari
tb
boonsong
n
chierakul
facalti
medicin
siriraj
hospit
mahidol
univers
divis
od
respiratori
diseas
tuberculosi
bangkok
thailand
background
aim
prosthet
joint
infect
seriou
complic
prosthet
arthroplasti
common
etiolog
agent
coagulas
neg
staphylococcu
staphylococcu
aureu
gram
neg
bacilli
anaerob
mycobacterium
tuberculosi
mtb
infect
prosthet
joint
rare
atyp
manifest
may
delay
diagnosi
result
poor
clinic
outcom
method
man
refer
siriraj
hospit
fever
along
left
knee
pain
swell
month
underli
diseas
nasopharyng
carcinoma
treat
concurr
chemoradi
papillari
thyroid
carcinoma
statu
post
total
thyroidectomi
ablat
bilater
osteoarthr
knee
total
knee
arthroplasti
year
ago
result
physic
examin
reveal
erythemat
swell
warmth
left
knee
limit
rang
motion
laboratori
find
show
peripher
wbc
count
pmn
cxr
reveal
militari
nodul
correspond
prior
chest
ct
scan
month
earlier
monitor
thyroid
cancer
arthrocentesi
left
knee
yield
turbid
joint
fluid
wbc
pmn
lymphocyt
gram
stain
demonstr
organ
stain
afb
posit
subsequ
molecular
studi
reveal
mtb
dna
without
mutat
confer
rifampicin
resist
subsequ
cultur
posit
mtb
week
later
drug
consist
isoniazid
rifampicin
pyrazinamid
moxifloxacin
prescrib
along
prosthet
joint
remov
patient
remain
well
visit
conclus
tubercul
infect
prosthet
joint
uncommon
complic
medium
high
tb
burden
countri
thailand
clinic
present
mimic
usual
septic
arthriti
confus
physician
definit
diagnosi
usual
verifi
joint
fluid
andor
synovi
joint
tissu
cultur
tissu
histopatholog
patient
also
concomit
pulmonari
tuberculosi
primari
sourc
hematogen
spread
joint
r
n
faculti
airlangga
rsu
drsoetomo
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
faculti
airlangga
rsu
dr
soetomo
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
background
aim
tuberculosi
tb
infecti
diseas
caus
mycobacterium
tuberculosi
mtb
becom
primari
caus
death
cytokin
tubercul
pleural
effus
produc
cell
act
primari
inflammatori
mediat
local
reaction
form
granuloma
pleura
mycobacteri
antigen
interact
previous
sensit
cell
pleura
process
stimul
delay
type
hypersensit
reaction
caus
caseat
necrosi
granuloma
affect
pleural
capillari
permeabl
toward
protein
lead
pleural
effus
goal
research
compar
level
pleural
fluid
tubercul
non
tubercul
pleural
effus
method
experiment
research
observ
analysi
cross
section
design
held
drsoetomo
gener
hospit
surabaya
inpati
unit
subject
tubercul
non
tubercul
pleural
effus
patient
meet
inclus
exclus
criteria
total
subject
patient
tubercul
pleural
effus
group
patient
non
tubercul
pleural
effus
group
result
result
research
show
level
pleural
fluid
tubercul
pleural
effus
higher
compar
non
tubercul
pleural
effus
pgml
vs
pgml
p
valu
conclus
level
pleural
fluid
tubercul
pleural
effus
higher
compar
non
tubercul
pleural
effus
w
koesoemoprodjo
airlangga
univers
faculti
medicin
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
background
aim
nowaday
tuberculosi
smoke
becom
major
health
problem
world
indonesia
rank
second
highest
countri
term
tb
case
rank
countri
highest
cigarett
consumpt
world
exposur
smoke
increas
risk
infect
diseas
recurr
even
death
tb
secret
cell
import
cytokin
bodi
immun
respons
intracellular
bacteria
eg
mycobacterium
tuberculosi
variou
studi
mention
exposur
cigarett
smoke
reduc
product
inhibit
macrophag
cell
function
studi
aim
determin
relationship
smoke
degre
assess
brinkman
index
sputum
level
pulmonari
tb
patient
method
conduct
cross
section
observ
analysi
studi
design
outpati
pulmonari
tb
dr
soetomo
hospit
earli
morn
spontan
sputum
obtain
sampl
determin
level
smoke
degre
calcul
multipli
number
cigarett
smoke
per
day
smoke
durat
year
relationship
sputum
level
smoke
degre
subject
analyz
pearson
spearman
correl
test
accord
scale
data
exist
result
signific
relationship
sputum
level
smoke
degre
smear
posit
pulmonari
tb
patient
p
obtain
mean
level
sputum
pgml
mean
brinkman
index
amount
conclus
signific
correl
sputum
level
smoke
degre
smear
posit
pulmonari
tb
patient
p
bespinyowong
pipopsuthipaiboon
promsarn
n
panitchatchaw
b
chuaychoo
faculti
siriraj
mahidol
univers
medicin
bangkok
thailand
background
aim
background
chronic
obstruct
pulmonari
diseas
copd
asthma
import
lower
obstruct
airway
diseas
spirometri
gold
standard
diagnosi
copd
support
diagnosi
asthma
howev
patient
physic
mental
limit
may
meet
accept
criteria
fvc
maneuv
impuls
oscillometri
io
measur
resist
r
reactanc
x
respiratori
system
requir
minim
patient
effort
may
altern
spirometri
diagnosi
categori
obstruct
pulmonari
disord
aim
determin
correl
io
paramet
ax
fre
patient
lower
airway
obstruct
method
studi
conduct
evalu
correl
io
spirometri
patient
diagnos
either
copd
asthma
patient
patient
copd
patient
asthma
perform
spirometri
io
enrol
studi
result
ax
fre
except
significantli
associ
p
patient
lower
obstruct
airway
diseas
highest
correl
fre
r
howev
degre
airway
obstruct
express
predict
correl
fevfvc
highest
correl
ax
predict
r
conclus
area
reactanc
ax
impuls
oscillometri
system
io
correl
predict
patient
lower
airway
obstruct
moslehi
shiraz
univers
medic
scienc
head
pediatr
pulmonolari
medicin
divis
shiraz
iran
background
aim
although
cryotherapi
shown
effect
manag
advanc
malign
bronchial
tumour
adult
littl
literatur
describ
use
pediatr
airway
diseas
observ
short
term
effect
cryotherapi
via
flexibl
bronchoscopi
treatment
variou
bronchial
problem
children
method
perform
flexibl
bronchoscop
use
nitrou
cryoprob
manag
airway
diseas
foreign
bodi
granul
tissu
bronchial
mass
remov
repair
subglott
stenosi
transebronchi
lung
biopsi
tblb
children
rang
age
month
year
analyz
outcom
complic
result
period
month
cryotherapi
perform
light
sedat
inhal
lidocain
low
dose
propofol
use
fibropt
bronchoscopeth
indic
cryotherapi
foreign
bodi
case
granul
tissu
case
bronchial
mass
remov
case
repair
subglott
stenosi
case
transebronchi
lung
biopsi
case
complic
regard
cryotherapi
mild
bleed
case
manag
use
local
epinephrin
balloon
dilat
conclus
cryotherapi
via
flexibl
bronchoscop
effect
method
treat
trachobronchi
diseas
children
rb
yap
lr
nw
sunaryo
ye
airlangga
school
medicin
dr
soetomo
gener
hospit
surgeri
surabaya
indonesia
airlangga
school
medicin
dr
soetomo
gener
hospit
radiolog
surabaya
indonesia
airlangga
school
medicin
dr
soetomo
gener
hospit
pulmonolog
surabaya
indonesia
airlangga
school
medicin
dr
soetomo
gener
hospit
thorac
cardiovascular
surgeri
surabaya
indonesia
background
aim
reexpans
pulmonari
edema
repe
rare
complic
may
occur
rapid
evacu
massiv
pleural
effus
repe
usual
fatal
case
fatal
rate
assum
drainag
volum
water
seal
drainag
wsd
correl
repe
aim
find
correl
drainag
volum
pleural
fluid
patient
massiv
hemorragh
pleural
effus
repe
preval
method
studi
use
method
sampl
patient
pleural
effus
chest
heart
kidney
disord
exist
pulmonari
edema
data
came
patient
medic
record
collect
data
sampl
characterist
hour
first
drainag
volum
pleural
fluid
wsd
clinic
radiolog
repe
test
correl
test
use
statist
analysi
result
studi
found
patient
clinic
repe
patient
radiolog
repe
patient
clinic
radiolog
repe
patient
clinic
radiolog
repe
signific
differ
volum
posit
neg
result
repe
p
p
p
p
signific
differ
first
hour
volum
posit
neg
result
repe
p
p
p
p
signific
correl
low
degre
observ
first
hour
drainag
volum
radiolog
repe
clinic
radiolog
repe
well
clinic
radiolog
repe
p
r
p
r
correl
clinic
repe
show
signific
correl
moder
level
p
r
conclus
signific
correl
low
moder
level
first
drainag
volum
pleural
fluid
repe
h
fujiwara
ichinomiyanishi
hospit
respiratori
medicin
ichinomiya
japan
background
aim
ultrasound
us
percutan
chest
biopsi
altern
intervent
comput
tomograph
guid
biopsi
transbronchi
biopsi
peripher
lung
lesion
intervent
seem
conveni
method
could
obtain
biopsi
sampl
bed
side
without
radiat
exposur
intraven
agent
start
appli
percutan
chest
biopsi
middl
perform
respiratori
physician
evalu
efficaci
safeti
percutan
chest
biopsi
diagnos
peripher
thorac
lesion
well
identifi
infect
bacterium
case
lung
abscess
compar
former
review
method
retrospect
collect
patient
peripher
thorac
lesion
underw
percutan
chest
biopsi
year
april
may
hospit
bed
includ
respiratori
patient
bed
lesion
lung
chest
wall
mediastinum
biopsi
underw
fine
needl
aspir
time
biopsi
histopatholog
microbiolog
analys
obtain
final
diagnosi
result
malign
benign
diagnos
patholog
identifi
microbiolog
sampl
obtain
fine
needl
aspir
suspect
lung
abscess
infect
benign
lesion
diagnos
abscess
patholog
microbiolog
isol
aspir
sampl
complic
occur
slight
pneumothorax
pyothorax
conclus
diagnos
yield
complic
still
competit
even
percutan
chest
biopsi
perform
respiratori
physician
commun
hospit
aspir
microbiolog
examin
ad
case
lesion
suspect
infecti
diseas
complic
rate
seem
littl
higher
former
review
sever
pyothorax
made
attent
sometim
induc
sever
infect
karavathukudi
karavathukudi
r
dd
vk
thiruvananthapuram
india
kerala
institut
medic
scienc
respiratori
critic
care
medicin
thiruvananthapuram
india
background
aim
evalu
pleural
effus
includ
combin
clinic
histori
physic
examin
radiolog
pleural
fluid
analysi
percutan
pleural
biopsi
pleuroscop
pleural
biopsi
studi
attempt
compar
eitiolog
diagnost
efficaci
flexirigid
pleuroscop
evalu
patient
present
pleural
effus
anoth
set
patient
pleural
fluid
analysi
percutan
pleural
biopsi
alon
aim
determin
eitiolog
diagnost
efficaci
flexirigid
pleuroscop
evalu
patient
pleural
effus
compar
eitiolog
diagnost
efficaci
flexirigid
pleuroscop
evalu
patient
pleural
effus
diagnost
efficaci
pleural
fluid
analysi
percutan
pleural
biopsi
alon
differ
set
patient
pleural
effus
method
studi
design
prospect
studi
studi
set
depart
respiratori
medicin
kim
thiruvananthapuram
tertiari
health
care
centr
south
india
patient
present
pleural
effus
select
studi
patient
featur
suggest
parapneumon
effus
exclud
decis
proceed
videopleuroscopi
taken
accord
physician
discret
patient
consent
diagnost
efficaci
videopleuroscopi
patient
compar
data
regard
onoth
set
patient
pleural
fluid
analysi
percutan
pleural
biopsi
alon
result
patient
exud
pleural
effus
consent
flexirigid
pleuroscopi
got
conclus
result
patient
diagnost
efficaci
found
percent
flexirigid
pleuroscopi
analysi
onoth
set
patient
pleural
fluid
analysi
percutan
pleural
biopsi
alon
found
diagnost
efficaci
close
pleural
biopsi
percentbi
pleural
fluid
analysi
alon
diagnosi
could
confirm
case
conclus
flexirigid
pleuroscopi
better
etiolog
diagnost
efficaci
pleuraleffus
compar
pleural
fluid
analysi
percutan
pleural
biopsi
alon
ia
jasminarti
dk
ib
ngurah
rai
pulmonolog
udayana
univers
denpasar
indonesia
background
aim
introduct
pneumothorax
abnorm
collect
air
pleural
space
primari
spontan
pneumothorax
psp
defin
spontan
occur
pneumothorax
patient
without
appar
underli
pulmonari
diseas
predominantli
occur
young
thin
male
psp
result
spontan
ruptur
subpleur
bleb
bulla
howev
portion
patient
psp
could
found
bleb
bulla
imag
time
surgeri
psp
present
acut
onset
local
pleurit
chest
pain
accompani
short
breath
chest
tube
drainag
effect
patient
first
episod
psp
surgic
manag
psp
usual
indic
patient
recurr
ipsilater
pneumothorax
first
episod
occup
risk
persist
pneumothorax
method
case
report
result
case
year
old
non
smoke
male
suffer
right
side
pneumothorax
play
badminton
histori
control
asthma
chest
radiograph
show
complet
right
pneumothorax
fr
chest
tube
drain
cm
suction
could
nt
improv
pneumothorax
persist
day
process
lung
expant
disturb
unstabl
suction
machin
igra
test
reveal
suffer
tb
infect
thorac
ct
scan
nt
show
structur
abnorm
open
thoracotomi
perform
reveal
fibrou
tissu
attach
superior
inferior
right
lobe
decort
fibrou
tissu
could
fulli
expand
right
lung
conclus
primari
spontan
pneumothorax
predominantli
occur
young
thin
male
unstabl
lung
expant
process
result
growth
fibrou
tissu
lead
pneumothorax
persist
open
thoracotomi
decort
invas
techniqu
manag
persist
spontan
pneumothorax
mi
f
mg
univers
indonesia
faculti
medicin
depart
pulmonolog
respiratori
medicin
jakarta
indonesia
univers
indonesia
faculti
medicin
depart
occup
marin
hyperbar
jakarta
indonesia
background
aim
dive
activ
carri
atmospher
absolut
ata
pressur
either
water
hyperbar
chamber
diver
expos
sever
factor
affect
lung
function
physiolog
chang
decreas
ventil
increas
physiolog
dead
space
expiratori
reserv
volum
chang
revers
due
increas
atmospher
pressur
underwat
physic
work
aim
compar
lung
function
dive
give
compress
air
dive
depth
meter
ata
hyperbar
chamber
method
experiment
studi
involv
sixteen
skill
diver
compress
air
appli
skill
diver
atmospher
absolut
ata
equal
meter
dive
minut
individu
lung
function
assess
pre
post
treatment
hyperbar
chamber
suppress
air
pressur
result
decreas
level
vc
fvc
averag
ml
p
ml
p
ml
p
p
ls
p
ls
p
ls
p
ls
p
compar
basal
lung
function
measur
prior
compress
air
applic
conclus
compress
air
ata
pressur
equal
dive
decreas
lung
function
significantli
c
walker
chichest
unit
kingdom
background
aim
larg
scale
epidemiolog
data
pleural
fluid
characterist
lack
establish
pleural
high
rate
pleural
malign
north
east
england
aim
follow
british
thorac
sought
add
bodi
evid
method
pleural
aspir
done
januari
decemb
analys
fluid
biochemistri
microbiolog
cytolog
final
diagnos
classifi
exud
fluid
protein
gl
fluid
ldh
iul
utilis
light
criteria
serum
characterist
collect
data
result
includ
patient
studi
averag
age
year
final
diagnosi
primari
lung
cancer
patient
cytolog
analys
patient
posit
pleural
fluid
cytolog
first
aspir
patient
aspir
diagnost
benefit
addit
patient
transud
pleural
effus
review
patient
empyema
n
posit
microbiolog
ph
two
patient
ph
sent
patient
exud
regard
follow
bt
pleural
aspir
meet
current
bt
guidelin
everi
pleural
aspir
sent
ph
microbiolog
cytolog
protein
ldh
glucos
commonli
miss
investig
glucos
occas
conclus
find
consist
current
literatur
regard
transud
lung
cancer
trust
improv
microbiolog
yield
suspect
empyema
encourag
contemporan
blood
ldh
protein
patient
suggest
use
blood
cultur
bottl
addit
univers
contain
mizumori
nakahara
r
hiraoka
n
hirata
k
hirano
r
kominami
k
takahashi
fukuda
onishi
kato
k
hanaoka
r
kagami
r
katsuda
yoko
k
miyak
h
tsukamoto
sasaki
kawamura
nation
hospit
organ
himeji
medic
center
respiratori
medicin
himeji
japan
background
aim
thoracoscop
biopsi
local
anesthesia
report
effect
method
diagnosi
pleural
diseas
biopsi
specimen
requir
especi
mesothelioma
diatherm
knife
knife
propos
use
devic
devis
new
simplifi
techniqu
method
use
inject
needl
obtain
tissu
specimen
pleural
biopsi
method
thoracoscop
pleural
biopsi
perform
local
anesthesia
undiagnos
exud
pleural
effus
method
use
inject
needl
appli
two
patient
procedur
perform
follow
inject
needl
mm
length
insert
pleura
around
lesion
thoracoscop
ltf
type
olympu
inject
lidocain
epinephrin
lift
pleura
fascia
needl
posit
make
incis
pleura
three
incis
line
arrang
triangl
close
biopsi
forcep
insert
incis
line
forcep
open
peel
pleura
fascia
replic
maneuv
along
triangular
incis
one
side
triangl
grasp
forcep
specimen
peel
pariet
pleura
result
case
male
right
pleural
thicken
effus
method
permit
diagnosi
biphas
mesotheliomacas
male
left
pleural
effus
stain
polymeras
chain
reaction
analysi
pleural
effus
neg
bacilli
use
histopatholog
tissu
cultur
find
method
permit
diagnosi
tuberculosi
conclus
method
use
inject
needl
effect
techniqu
obtain
specimen
pleural
biopsi
without
special
apparatu
h
ea
chonnam
nation
univers
hosp
anesthesiolog
pain
medicin
gwangju
republ
korea
chonnam
nation
univers
hwasun
hosp
anesthesiolog
pain
medicin
hwasun
republ
korea
chonnam
nation
univers
medic
school
anesthesiolog
pain
medicin
gwangju
republ
korea
background
aim
nasotrach
intub
use
techniqu
dental
orofaci
surgeri
anatom
variat
nasal
caviti
common
patient
sometim
nasotrach
intub
without
thorough
understand
anatomi
nasal
caviti
difficult
approach
creat
sever
complic
case
present
nasotrach
tube
obstruct
due
total
middl
turbinectomi
nasotrach
intub
method
male
schedul
left
mandibular
angl
orbit
wall
fractur
nasotrach
intub
need
surgeri
induct
anesthesiologist
ask
nostril
comfort
breath
occlud
felt
comfort
right
nostril
anesthesiologist
decid
put
tube
right
nostril
induct
perform
bolu
inject
propofol
rocuronium
continu
infus
remifentanil
mask
ventil
anesthesiologist
intub
patient
intub
patient
ventil
well
decreas
breath
sound
abrupt
increas
inspiratori
pressur
observ
anesthesiologist
extub
tube
immedi
found
nasotrach
tube
obstruct
turbin
nasotrach
intub
perform
right
nostril
stop
epistaxi
compress
effect
surgeri
perform
problem
surgeri
consult
otolaryngologist
facial
ct
examin
found
patient
sever
nasal
septal
deviat
right
side
total
middl
turbinectomi
done
nasotrach
intub
patient
got
discharg
complic
conclus
care
assess
perform
nasotrach
intub
avoid
complic
sever
method
perform
decid
nostril
use
perform
intub
breath
one
nostril
one
method
perfect
avoid
complic
septal
deviat
clinic
symptom
ca
nt
get
match
suggest
anterior
rhinoscopi
nasotrach
intub
patient
fulli
evalu
facial
ct
okamura
e
osaka
yoshida
tokuhashi
orthopaed
surgeri
nihon
univers
japan
background
aim
epithelioma
uncommon
report
occur
soft
tissu
salivari
gland
fort
lung
howev
occurr
bone
rare
case
report
worldwid
moreov
case
report
pediatr
rib
method
report
case
femal
epithelioma
rib
refer
hospit
pain
left
side
chest
particularli
pain
play
saxophon
show
abnorm
shadow
rib
mri
show
contrast
lesion
rib
ct
show
bone
destruct
sclerosi
insid
lesion
difficult
determin
whether
lesion
malign
benign
incision
biopsi
perform
result
patholog
result
show
cytokeratin
sma
desmin
posit
suggest
epithelioma
therefor
costal
segment
en
bloc
resect
perform
remov
tumor
oper
patient
sharp
pain
reliev
conclus
rib
tumor
make
approxim
bone
tumor
rel
rare
repres
benign
case
includ
osteochondroma
enchondroma
fibrou
bone
dysplasia
granulomat
diseas
malign
case
includ
bone
metastasi
chondrosarcoma
osteosarcoma
isol
plasma
cell
tumor
ewe
sarcoma
frequent
misdiagnos
surgeri
suggest
wide
local
excis
perform
costal
tumor
case
patient
epithelioma
occur
bone
show
import
consid
rib
lesion
patient
present
chest
pain
dj
sk
raipur
india
vpci
pulmonari
medicin
delhi
india
background
aim
ratio
univers
accept
paramet
diagnos
diseas
airway
obstruct
describ
predict
equat
spirometri
paramet
separ
adult
children
asian
indian
use
american
thorac
societyeuropean
respiratori
societi
atser
recommend
given
known
neg
associ
age
ratio
examin
equat
could
develop
ratio
asian
indian
year
combin
dataset
children
adult
method
normal
healthi
subject
male
femal
age
year
underw
spirometri
use
fleisch
pneumotach
spiromet
dataset
randomli
divid
train
test
set
former
use
develop
equat
valid
test
data
set
predict
equat
develop
ratio
use
multipl
linear
regress
analysi
result
male
femal
subject
perform
spirometri
technic
accept
predict
higher
femal
age
major
neg
determin
ratio
lesser
posit
associ
height
weight
equat
male
age
wt
see
femal
age
wt
see
equat
found
valid
test
dataset
signific
differ
observ
predict
valu
equat
excel
agreement
adult
develop
earlier
us
adult
dataset
conclus
equat
ratio
asian
indian
subject
year
give
similar
predict
adult
earlier
publish
equat
adult
also
allow
comput
predict
ratio
children
avail
earlier
equat
allow
object
diagnosi
airway
obstruct
asian
indian
age
year
k
r
n
h
niigata
univers
health
welfar
depart
physic
therapi
niigata
citi
japan
niigata
univers
health
welfar
depart
occup
therapi
niigata
citi
japan
juntendo
univers
graduat
school
medicin
depart
rehabilit
medicin
tokyo
japan
yamagata
prefectur
univers
health
scienc
depart
occup
therapi
yamagata
citi
japan
tohoku
univers
graduat
school
medicin
depart
occup
health
miyagi
citi
japan
background
aim
breath
assist
ba
manual
techniqu
chest
physiotherapi
common
especi
japan
ba
suppos
assist
expir
increas
tidal
volum
improv
alveolar
ventil
therefor
allevi
dyspnea
purpos
studi
examin
relationship
palm
surfac
pressur
consequ
tidal
volum
ba
method
ten
healthi
volunt
year
age
studi
ba
perform
lower
chest
wall
xiphoid
level
supin
posit
train
therapist
breath
rest
therapist
gentli
assist
breath
expiratori
phase
minut
tidal
volum
measur
use
flow
sensor
palm
surfac
pressur
measur
use
sr
softwar
vision
numer
sumitomo
riko
co
japan
palm
surfac
pressur
ba
challeng
way
usual
strong
pressur
increas
tidal
volum
ba
way
compar
studi
result
ba
tidal
volum
significantli
increas
l
l
p
usual
pressur
l
l
p
strong
pressur
ba
tidal
volum
return
toward
baselin
averag
palm
surfac
pressur
mmhg
usual
mmhg
strong
conclus
find
confirm
benefici
effect
ba
tidal
volum
forc
palm
surfac
pressur
ba
strong
pressur
requir
ym
ko
sk
kim
sh
song
ch
kim
st
vincent
colleg
cathol
univers
korea
intern
divsion
pulmonolog
republ
korea
background
aim
although
bronchial
provoc
test
import
test
identifi
bronchial
hyperrespons
bhr
patient
chronic
cough
littl
known
clinic
characterist
patient
show
posit
trend
result
bronchial
provoc
test
studi
aim
investig
clinic
characterist
patient
show
posit
trend
bhr
method
patient
perform
mannitol
bronchial
provoc
test
mbpt
chronic
cough
evalu
posit
trend
bhr
defin
tendenc
continu
declin
increas
provoc
dose
mannitol
cough
relaps
defin
recurr
cough
least
month
later
treatment
complet
result
patient
identifi
posit
trend
bhr
femal
age
mean
se
year
cough
durat
week
patient
season
variat
respiratori
symptom
allerg
rhiniti
patient
eosinophilia
patient
show
ig
e
level
iul
mast
posit
patient
patient
least
one
four
allerg
featur
allerg
histori
high
ig
e
level
eosinophilia
mast
posit
mbpt
continu
declin
patient
show
good
respons
medic
includ
prednisolon
relaps
rate
relaps
group
show
significantli
rapid
continu
declin
compar
group
p
conclus
although
mbpt
posit
patient
chronic
cough
steroid
treatment
could
care
consid
mbpt
show
posit
trend
bhr
patient
allerg
featur
continu
declin
rapid
close
attent
would
need
cough
relaps
studi
larg
scale
requir
clarif
k
n
prof
aa
jinnah
post
graduat
hospit
karachi
pulmonolog
karachi
pakistan
cmh
peshawar
thorac
surgeri
peshawar
pakistan
background
aim
despit
advanc
antibiot
therapi
thorac
empyema
remain
common
clinic
entitymainstay
treatment
pleural
empyema
treatment
ongo
infect
prevent
recurr
infect
late
restrictiontreat
also
includ
drainag
complic
pleural
effus
full
expans
underli
lung
elimin
pleuropulmonari
infect
antimicrobi
agentsantimicrobi
therapi
along
thoracocentasi
usual
adequ
treatment
earli
empyema
thorac
chronic
case
may
requir
aggress
intervent
develop
countri
like
pakistan
empyema
patient
present
late
tertiari
care
hospit
method
prospect
analysi
patient
admit
jinnah
postgradu
medic
centr
karachi
pakistan
sept
oct
patient
select
evalu
nonprob
conveni
sampl
underw
medic
thoracoscopi
la
p
consid
signific
confid
interv
taken
patient
includ
basi
prolong
clinic
present
day
nonrespond
antibiot
therapi
undiagnos
failur
drainag
chest
intub
radiolog
find
fix
mediastinum
ultrasound
show
locul
effus
thick
pleura
multiplethick
septat
result
patient
femal
male
mean
age
patient
underw
rigid
thoracoscopi
clear
pu
adhes
follow
pleural
biopsytubercul
empyema
found
patient
patient
pleural
biopsi
acut
chronic
inflamm
chest
show
complet
resolut
partial
resolut
initi
achiev
patient
patient
develop
persist
air
leak
requir
surgic
patient
expir
due
septicimia
conclus
rigid
thoracoscopi
done
local
anaesthesia
pulmonologist
use
techniqu
deal
chronic
empyema
resourc
constrain
countri
facil
thorac
surgeri
wide
avail
kruavit
rose
flinder
medic
centr
respiratori
sleep
medicin
depart
adelaid
australia
background
aim
tunnel
indwel
pleural
cathet
tipc
utilis
effect
altern
palli
manag
malign
pleural
effus
applic
benign
refractori
pleural
effus
rapidli
grow
expand
evid
condit
hepat
hydrothorax
cardiac
failur
benign
chylothorax
anoth
condit
tipc
may
offer
effect
symptom
manag
particularli
surgic
intervent
radiolog
procedur
suitabl
nevertheless
repeat
drainag
chyle
rais
concern
sever
nutrit
defici
caution
must
exercis
method
report
case
benign
chylothorax
manag
success
safe
tipc
result
caucasian
femal
present
month
worsen
dyspnoea
found
unilater
pleural
effus
background
includ
ischaem
cardiomyopathi
benign
multinodular
goitr
atrial
fibril
type
diabet
dyslipidaemia
gout
histori
malign
drink
alcohol
echocardiogram
confirm
stabl
left
ventricular
function
thoracocentesi
reveal
chylothorax
triglycerid
mmoll
signific
symptomat
improv
note
pleural
fluid
examin
exclud
malign
infect
caus
ct
chest
demonstr
larg
multinodular
goitr
signific
mass
effect
superior
thorac
outlet
left
intern
jugular
subclavian
vein
displac
thorac
duct
like
compress
thyroid
function
normal
surgeri
recommend
prefer
manag
iodin
therapi
altern
howev
refus
patient
tipc
insert
due
rapid
reaccumul
chylothorax
patient
report
stabl
effect
symptom
relief
month
insert
intermitt
drainag
regim
develop
protein
defici
good
dietician
liaison
supplement
conclus
tipc
offer
safe
effect
option
palli
manag
benign
chylothorax
though
attent
monitor
nutrit
statu
essenti
bakhtiar
airlangga
univers
faculti
medicin
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
background
aim
chronic
obstruct
pulmonari
diseas
known
chronic
inflammatori
diseas
occur
local
lung
also
system
effect
includ
peripher
muscl
weak
increas
lactic
acid
ubiquinon
contain
mitochondria
play
import
role
aerob
energi
product
also
antioxid
effect
give
ubiquinon
expect
improv
mwt
lower
lactic
acid
level
patient
copd
method
studi
experiment
studi
random
control
subject
studi
patient
stabl
copd
categori
b
outpati
pulmonari
clinic
drsoetomo
hospit
meet
inclus
exclus
criteria
patient
meet
select
criteria
divid
group
ubiquinon
placebo
week
patient
continu
use
drug
regularli
patient
measur
blood
level
lactic
acid
walk
test
spirometri
administr
ubiquinon
placebo
total
subject
divid
patient
ubiquinon
group
patient
control
group
result
signific
differ
two
group
gender
degre
copd
bmi
lactic
acid
level
treatment
group
decreas
significantli
compar
control
ubiquinon
group
control
group
p
pulmonari
function
test
statist
signific
group
walk
distanc
increas
treatment
group
compar
control
group
ubiquinon
group
control
group
p
conclus
ubiquinon
administr
favor
effect
energi
product
muscl
lower
lactic
acid
level
patient
stabl
copd
categori
b
amin
airlangga
univers
faculti
medicin
depart
pulmonolog
respiratori
medicin
surabaya
indonesia
background
aim
cigarett
smoke
caus
small
airway
obstruct
sao
harbing
develop
chronic
obstruct
pulmonari
diseas
copd
reduct
associ
chronic
cigarett
smoke
explain
loss
lung
elast
recoil
pressur
reduc
forc
drive
air
lung
therefor
earli
detect
pulmonari
function
test
prevent
risk
airway
diseas
aim
present
studi
analyz
pulmonari
function
chang
smoke
compar
healthi
non
smoker
method
studi
healthi
male
femal
subject
age
rang
year
smoker
nonsmok
assess
pulmonari
function
test
use
spiromet
result
studi
show
impact
cigarett
smoke
pulmonari
function
smoker
significantli
greater
percentag
declin
ratio
p
suggest
smoker
develop
chang
pulmonari
function
indic
earli
peripher
airway
narrow
signific
correl
smoke
durat
rate
valu
found
relat
smoke
durat
amount
smoke
associ
reduct
conclus
smoker
significantli
greater
percentag
declin
signific
correl
smoke
durat
rate
valu
deterior
lung
function
relat
number
cigarett
smoke
per
day
smoker
tangnantawiwat
n
kongpolprom
chulalongkorn
thai
red
cross
divis
pulmonari
critic
care
depart
faculti
medicin
bangkok
thailand
background
aim
oseltamivir
antivir
drug
use
influenza
treatment
report
case
influenza
b
pneumonia
treat
oseltamivir
complic
prolong
wean
central
hypoventil
hypothermia
method
elderli
man
present
fever
dri
cough
day
admiss
examin
look
drowsi
fever
hemodynam
instabl
oxygen
desatur
fine
crepit
left
lung
chest
show
infiltr
lower
lung
initi
diagnos
commun
acquir
pneumonia
sepsi
stabil
fluid
resuscit
vasopressor
oxygen
supplement
levofloxacin
ceftriaxon
prescrib
two
day
later
develop
acut
respiratori
failur
chest
reveal
progress
infiltr
right
lower
lung
rapid
test
influenza
posit
result
administr
oseltamivir
mg
consequ
symptom
arteri
oxygen
improv
howev
second
week
admiss
could
breath
spontan
got
new
fever
anemia
thrombocytopenia
sputum
cultur
show
heavi
growth
acenitobact
baumannii
without
new
infiltr
chest
ventil
associ
tracheobronch
diagnos
antibiot
switch
carbapenem
colistin
ampicillinsulbactam
oseltamivir
extend
due
concern
immun
respons
condit
recov
third
week
treatment
develop
unexplain
hypothermia
occasion
hypotens
central
hypoventil
despit
sed
drug
time
neurolog
sign
includ
brainstem
reflex
intact
addit
evid
new
infect
endocrin
crisi
subsequ
advers
drug
reaction
consid
thu
stop
oseltamivir
dramat
temperatur
blood
pressur
respiratori
rate
return
baselin
within
day
final
success
discontinu
respir
result
conclus
demonstr
case
uncommon
advers
reaction
oseltamivir
name
hypothermia
respiratori
suppress
background
aim
loss
airway
epitheli
integr
contribut
significantli
asthma
pathogenesi
recent
report
reveal
thymic
stromal
lymphopoietin
tslp
may
dual
immunoregulatori
role
tslp
present
isoform
includ
short
long
tslp
inflammatori
disord
bowel
tslp
ltslp
promot
inflamm
short
form
tslp
sftslp
inhibit
inflamm
hypothes
synthet
sftslp
preventsairway
epitheli
barrier
disrupt
induc
hous
dust
mite
hdm
method
normal
human
bronchial
epitheli
cell
stimul
hdm
evalu
express
tslp
quantit
pcr
western
blot
meanwhil
transepitheli
electr
resist
teer
permeabl
distribut
assess
evalu
airway
epitheli
barrier
function
vivo
balbc
mice
expos
hdm
nasal
inhal
set
asthma
model
consecut
day
per
week
sftslp
inhal
hour
hdm
inhal
week
latter
util
anim
lung
function
test
patholog
stain
evalu
asthma
situat
result
vitro
upregul
sftslp
express
inhibit
upregul
ltslp
use
sftslp
could
prevent
airway
epitheli
barrier
disrupt
asthmat
mice
model
success
establish
inflammatori
factor
like
ltslp
balf
unregul
consist
serum
ige
except
airway
epitheli
junction
protein
partial
lost
disloc
moreov
synthet
sftslp
amelior
asthma
mice
conclus
two
isoform
short
long
tslp
differ
express
differ
biolog
properti
emphas
import
analyz
two
tslp
isoform
separ
moreov
result
indic
sftslp
may
novel
therapeut
strategi
individu
treatment
asthma
h
dong
hu
c
huang
h
zhao
cai
nanfang
hospit
southern
medic
univers
depart
respiratori
critic
care
medicin
guang
zhou
china
background
aim
loss
airway
epitheli
integr
contribut
significantli
asthma
pathogenesi
recent
report
reveal
thymic
stromal
lymphopoietin
tslp
may
dual
immunoregulatori
role
tslp
present
isoform
includ
short
long
tslp
inflammatori
disord
bowel
tslp
ltslp
promot
inflamm
short
form
tslp
sftslp
inhibit
inflamm
hypothes
synthet
sftslp
preventsairway
epitheli
barrier
disrupt
induc
hous
dust
mite
hdm
method
normal
human
bronchial
epitheli
cell
stimul
hdm
evalu
express
tslp
quantit
pcr
western
blot
meanwhil
transepitheli
electr
resist
teer
permeabl
distribut
assess
evalu
airway
epitheli
barrier
function
vivo
balbc
mice
expos
hdm
nasal
inhal
set
asthma
model
consecut
day
per
week
sftslp
inhal
hour
hdm
inhal
week
latter
util
anim
lung
function
test
patholog
stain
evalu
asthma
situat
result
vitro
upregul
sftslp
express
inhibit
upregul
ltslp
use
sftslp
could
prevent
airway
epitheli
barrier
disrupt
asthmat
mice
model
success
establish
inflammatori
factor
like
ltslp
balf
unregul
consist
serum
ige
except
airway
epitheli
junction
protein
partial
lost
disloc
moreov
synthet
sftslp
amelior
asthma
mice
conclus
two
isoform
short
long
tslp
differ
express
differ
biolog
properti
emphas
import
analyz
two
tslp
isoform
separ
moreov
result
indic
sftslp
may
novel
therapeut
strategi
individu
treatment
asthma
moslehi
shiraz
univers
medic
scienc
pediatr
pulmonolari
shiraz
iran
background
aim
accident
inhal
organ
foreign
bodi
continu
lead
caus
childhood
morbid
mortal
requir
prompt
diagnosi
earli
manag
minim
risk
seriou
sometim
fatal
consequ
case
foreign
bodi
aspir
differ
face
variabl
involv
includ
type
object
reaction
aspir
locat
physic
characterist
object
clinic
present
expertis
bronchoscopist
frequent
determin
ultim
outcom
method
patient
underw
flexibl
fibropt
bronchoscopi
procedur
done
pediatr
bronchoscopi
suit
introduc
light
sedat
low
dose
propofol
extract
done
mani
type
forcep
basket
balloon
electrocuteri
knife
cryoprob
result
flexibl
fibropt
bronchoscopi
new
method
hundr
case
aspir
foreign
bodi
cover
rang
month
year
success
rate
major
complic
conclus
expert
hand
well
equip
facil
flexibl
fibropt
bronchoscopi
gold
standard
diagnosi
pediatr
airway
foreign
bodi
prefer
instrument
manag
yj
h
h
nippon
medic
school
depart
hygien
public
health
tokyo
japan
nippon
medic
school
depart
pulmonari
medicineinfect
tokyo
japan
kyorin
univers
hospit
depart
respiratori
medicin
tokyo
japan
background
aim
transit
emt
process
recapitul
adult
wound
heal
tissu
regener
organ
fibrosi
cancer
progress
diesel
exhaust
particl
dep
major
compon
much
attent
focus
relat
mani
pulmonari
diseas
studi
molecular
mechan
focus
role
reactiv
oxygen
speci
ro
gener
directli
indirectli
exposur
dep
current
studi
design
explor
role
dep
whether
induc
emt
process
airway
epitheli
cell
oxid
stress
method
use
human
bronchial
epitheli
cell
hbec
line
first
experi
dep
standard
refer
materi
treat
cultur
cell
variou
concentr
second
experi
differ
concentr
nac
pretreat
cultur
cell
dep
treat
dep
exposur
cell
harvest
extract
rna
protein
mrna
express
antioxid
enzym
determin
protein
express
assay
western
blot
also
examin
effect
dep
cell
migrat
wound
heal
assay
hbec
cell
result
express
express
dep
exposur
hbec
cell
cell
migrat
also
dep
exposur
chang
express
cell
migrat
dep
exposur
block
nac
pretreat
mrna
express
dep
conclus
result
suggest
dep
might
involv
induct
emt
process
human
bronchial
epitheli
cell
oxid
stress
j
britanico
l
chang
ld
obra
chong
hua
hospit
pediatr
pulmonolog
cebu
citi
philippin
background
aim
pediatr
case
present
recurr
pulmonari
infiltr
sever
anemia
patient
eventu
diagnos
idiopath
pulmonari
hemosiderosi
iph
earli
recognit
diseas
result
better
prognosi
older
literatur
iph
report
high
mortal
rate
contrast
recent
studi
suggest
better
prognosi
higher
surviv
rate
earli
corticosteroid
use
method
articl
describ
case
month
old
femal
child
present
recurr
sever
anemia
need
multipl
blood
transfus
strike
occurr
anemia
associ
respiratori
symptom
cough
tachypnea
concurr
pulmonari
infiltr
chest
radiographi
diagnosi
clinch
strong
clinic
suspicion
anemia
respiratori
symptom
part
singl
diseas
entiti
separ
entiti
mere
coincident
find
result
work
done
identifi
etiolog
pulmonari
hemorrhag
high
resolut
chest
ct
scan
contrast
show
diffus
ground
glass
opac
uniform
micronodular
densiti
air
bronchogram
open
lung
biopsi
confirm
presenc
macrophag
sign
vascul
capillar
thu
point
toward
iph
patient
improv
discharg
initi
corticosteroid
therapi
second
case
pulmonari
hemosiderosi
institut
past
yearsth
case
secondari
autoimmun
hemolyt
diseas
diagnos
via
bronchoscopi
transbronchi
biopsi
conclus
given
case
unexplain
recurr
anemia
coupl
bilater
infiltr
chest
xray
one
suspect
possibl
pulmonari
hemorrhag
even
absenc
respiratori
symptom
rariti
diseas
condit
variabl
clinic
cours
result
mani
diagnost
pitfal
lead
late
diagnosi
poorer
outcom
untreat
condit
lead
complic
set
earli
especi
pulmonari
fibrosi
q
lanlan
w
xuel
second
affili
hospit
third
militari
medic
univers
respir
chongq
china
background
aim
excess
inflammatori
respons
critic
event
pathogenesi
acut
lung
injuri
ali
activ
transcript
factor
transcript
regul
play
role
neg
regul
varieti
inflammatori
respons
method
determin
role
vivo
vitro
compar
respons
mice
mice
vivo
model
ali
vitro
model
cellsmoreov
analyz
differenti
gene
lung
tissu
mice
mice
result
found
express
lung
tissu
obtain
mice
model
ali
mous
macrophag
cellsth
lung
tissu
inflammatori
respons
cytokin
includ
lung
permeabl
balf
protein
concentr
lung
tissu
wetdri
weight
ratio
degre
lung
injuri
patholog
mortal
intensifi
miceconsist
inflammatori
reaction
cytokin
includ
intensifi
highli
express
lung
tissu
mice
differenti
gene
analysismoreov
found
could
express
cellsboth
express
cell
level
significantli
attenu
conclus
protect
ali
via
inhibit
express
dominguez
philippin
heart
center
depart
pulmonari
critic
care
section
pediatr
pulmonolog
quezon
citi
philippin
background
aim
ewe
sarcoma
account
pediatr
malign
rib
involv
account
extens
thorac
caviti
caus
cardiopulmonari
compromis
pneumonectomi
rare
perform
children
except
malign
method
old
male
recurr
dull
pain
right
chest
associ
cough
dyspnea
pertin
find
tachypnea
absenc
lymphadenopathi
absent
breath
sound
right
hemithorax
chest
xray
show
opacifi
right
hemithorax
chest
ct
scan
show
mass
echocardiogram
seen
compress
right
atrium
caus
cardiopulmonari
compromis
mass
resect
along
right
lung
entir
compress
segment
right
rib
final
tissu
biopsi
reveal
osseou
primit
neuroectoderm
tumor
ewe
sarcoma
postop
pulmonari
function
test
show
restrict
ventilatori
defect
patient
discharg
improv
underw
chemotherapi
radiat
therapi
result
ewe
sarcoma
origin
rib
may
soft
tissu
mass
disproportion
larg
compar
intraoss
involv
malign
common
indic
pneumonectomi
chang
elev
ipsilater
hemidiaphragm
hyperinfl
remain
lung
shift
mediastinum
toward
postpneumonectomi
space
pp
progress
resorpt
air
pp
replac
fluid
fluid
accumul
postpneumonectomi
space
care
manag
vital
maintain
hemodynam
respiratori
stabil
ventil
entail
low
tidal
volum
high
peep
low
restrict
ventilatori
defect
common
among
postpneumonectomi
patient
conclus
male
underw
right
pneumonectomi
ewe
sarcoma
rib
intrathorac
extens
children
chest
pain
suspici
bone
growth
thoroughli
investig
l
h
l
h
x
first
affili
hospit
hunan
normal
univers
children
medic
center
changsha
china
first
affili
hospit
hunan
normal
univers
pulmonolog
depart
changsha
china
background
aim
discuss
valu
medic
thoracoscopi
pleural
diseas
diagnosi
treatment
children
method
retrospect
analyz
clinic
characterist
outcom
children
case
refractori
pleural
lesion
diagnos
treat
medic
thoracoscopi
hospit
januari
februari
result
averag
age
case
male
case
femal
case
year
old
rang
lesion
case
locat
left
pleural
caviti
right
case
acut
phase
within
week
perform
medic
thoracoscopi
case
consid
streptococcu
pneumonia
consid
staphylococcu
aureu
infect
consid
tubercul
pleurisi
case
unknown
medic
thoracoscopi
made
conculs
caus
case
streptococcu
pneumonia
staphylococcu
aureu
infect
tubercul
pleurisi
mycoplasma
infect
chest
foreign
bodi
pathogen
anoth
still
unknown
medic
thoracoscopi
locul
pleural
effus
atelectasi
compress
still
case
even
thorac
drainag
pleural
lavag
salin
urokinas
medic
thoracoscopi
lung
recruit
found
case
conclus
medic
thoracoscopi
minim
invas
surgic
treament
pediatr
pyothorax
promot
lung
recruit
drainag
lavag
direct
vision
clear
pu
moss
parcel
adhes
time
children
pleurisi
unknown
caus
confirm
diagnosi
pleural
wooden
bronchu
foreign
bodi
move
distal
airway
even
wear
pleura
pleural
caviti
breath
convent
treatment
solv
problem
medic
thoracoscopi
may
effect
tang
l
zhong
h
huang
chen
l
lin
x
ding
x
lin
first
affili
hospit
hunan
normal
univers
children
medic
center
changsha
china
background
aim
report
rare
case
foreign
bodi
thorac
caviti
method
retrospect
analyz
clinic
characterist
process
case
foreign
bodi
thorac
caviti
result
male
admit
hospit
fever
cough
day
histori
foreign
bodi
inhal
unev
computer
tomographi
ct
scan
show
right
lower
lung
infect
right
pleural
effus
subsequ
treat
antibiot
temperatur
return
normal
frequenc
cough
increas
perform
bronchoscopi
reveal
wooden
foreign
bodi
right
side
basal
segment
fail
remov
whole
foreign
bodi
appear
repeatedli
high
fever
postop
hyperpyrexia
tachypnea
rate
mild
inspir
three
concav
bad
spirit
immedi
cpap
machin
auxiliari
ventil
eighth
day
admiss
perform
flexibl
bronchoscop
use
thoracoscop
gener
anesthesia
bronchoscop
found
foreign
bodi
punctur
lung
pleura
chest
figur
henc
foreign
bodi
dog
tail
grass
cm
directli
taken
boy
inhal
high
oxygen
flow
remov
foreign
bodi
continu
complet
thorac
caviti
close
drainag
blood
oxygen
satur
remain
temperatur
return
normal
day
ct
scan
show
lung
compress
tissu
less
compar
previou
improv
significantli
boy
continu
treatment
discharg
hospit
growth
develop
good
telephon
call
computer
tomographi
scan
reveal
lesion
fundament
absorpt
conclus
wooden
foreign
bodi
mayb
move
thorac
caviti
thoracoscopi
consid
earli
patient
case
refractori
pleural
effus
pneumothorax
chen
l
zhong
h
huang
x
lin
l
lin
first
affili
hospit
hunan
normal
univers
children
medic
center
changsha
china
background
aim
evalu
clinic
applic
valu
fluoresc
immunoassay
later
flow
technolog
detect
influenza
viru
method
nasopharyng
swab
collect
children
ill
ili
novemb
februari
detect
influenza
viru
b
antigen
sofia
influenza
b
fia
fluoresc
immunoassay
later
flow
technolog
result
compar
direct
assay
sampl
inconsist
result
two
method
verifi
result
result
indic
influenza
viru
antigen
detect
sofia
influenza
b
fia
highli
consist
result
direct
assayth
sensit
specif
detect
influenza
viru
specif
rais
verifi
inconsist
sampl
posit
influenza
b
sensit
specif
rais
verifi
inconsist
sampl
posit
compar
influenza
viru
b
children
infect
influenza
viru
cours
seriou
clinic
symptom
conclus
influenza
signific
caus
children
respiratori
infectionssofia
influenza
b
fia
rapid
easi
assay
influenza
viru
b
high
concord
rate
direct
assay
use
screen
diagnosi
influenza
viru
b
l
liu
z
yuan
wang
h
wang
f
wen
divis
pulmonari
diseas
state
key
laboratori
biotherapi
china
chengdu
china
background
aim
chrysin
member
flavonoid
famili
shown
capac
properti
autophagi
consid
key
role
inflammatori
respons
tri
investig
effect
novel
chrysin
ard
determin
whether
autophagi
invovl
method
balbc
mice
age
week
randomli
divid
group
control
group
receiv
salin
chrysin
lp
group
receiv
chrysin
chrysin
follow
lp
group
receiv
autophagi
antagonist
group
receiv
chrysin
final
lp
lp
salin
inject
intratrach
chrysin
inject
intraperiton
min
lp
inject
intraperiton
min
chrysin
mice
kill
h
sampl
balf
lung
tissu
collect
analysi
result
time
point
group
receiv
either
dose
chrysin
follow
lp
significantli
lower
total
cell
count
level
balf
group
given
lp
h
western
blot
show
level
chrysin
group
high
lp
group
passway
significantli
restrain
chrysin
activ
autophagi
increas
level
manner
autophagi
inhibitor
partial
revers
elev
passway
suppress
conclus
result
suggest
chrysin
may
attenu
lung
inflamm
ard
activ
autophagi
autophagi
may
deepli
involv
ard
inflammatori
respons
k
chiba
univers
graduat
school
medicin
depart
respirolog
chiba
japan
chiba
univers
graduat
school
medicin
depart
medic
oncolog
chiba
japan
background
aim
larg
cell
neuroendocrin
carcinoma
lcnec
highli
aggress
tumor
poor
prognosi
current
treatment
rare
cur
advanc
lcnec
novel
effect
therapi
urgent
need
inhibit
hedgehog
hh
signal
especi
gli
activ
shown
activ
sever
cancer
recent
clinic
studi
howev
role
hh
pathway
lcnec
yet
elucid
current
studi
attempt
evalu
vitro
potenti
gli
therapeut
target
treat
lcnec
method
express
profil
gli
factor
smo
evalu
three
lcnec
cell
line
use
polymeras
chain
reaction
cell
death
investig
inhibit
gli
smo
gli
inhibitor
cell
growth
gli
inhibit
investig
use
sirna
chang
drug
sensit
cisplatin
inhibit
gli
sirna
observ
cell
growth
curv
apoptosi
assay
includ
tunel
activ
result
lcnec
cell
line
express
gli
smo
variou
degre
hh
signal
inhibitor
exert
effect
high
concentr
without
suffici
suppress
gli
inhibit
gli
via
sirna
suppress
cell
growth
dramat
enhanc
drug
sensit
cisplatin
treatment
show
increas
proport
apoptot
cell
conclus
find
suggest
gli
activ
play
critic
role
lcnec
drug
strong
suppress
gli
need
inhibit
gli
function
potenti
becom
effect
approach
treat
lcnec
k
k
r
yodogawa
christian
hospit
depart
pediatr
surgeri
osaka
japan
yodogawa
christian
hospit
depart
surgeri
osaka
japan
background
aim
introduct
nuss
procedur
current
standard
oper
repair
pectu
excavatum
owe
minim
invas
metal
bar
insert
behind
sternum
mediastinum
remov
year
procedur
mani
advantag
short
oper
time
minim
blood
loss
need
small
incis
temporari
commun
chest
caviti
produc
result
nuss
procedur
present
case
iatrogen
buffalo
chest
result
bilater
pneumothorax
earli
postop
period
follow
nuss
procedur
method
case
report
man
pectu
excavatum
underw
nuss
procedur
patient
condit
good
day
suddenli
suffer
dyspnea
lead
respiratori
failur
day
postop
reveal
presenc
bilater
pneumothorax
therefor
endotrach
intub
bilater
chest
drainag
immedi
perform
preoper
comput
tomographi
ct
reveal
presenc
bulla
apex
right
lung
consid
spontan
pneumothorax
result
ruptur
bulla
right
thorax
spread
left
side
insert
bar
respiratori
condit
improv
follow
intub
chest
drainag
although
air
leakag
continu
side
thorax
right
bullectomi
perform
postop
day
discharg
hospit
day
nuss
procedur
result
discuss
sever
opinion
exist
clinic
relev
bulla
identifi
nuss
procedur
case
ruptur
bulla
occur
patient
iatrogen
buffalo
chest
caus
nuss
procedur
led
bilater
pneumothorax
left
patient
critic
condit
day
postop
conclus
recommend
bullectomi
nuss
procedur
preoper
ct
reveal
presenc
bulla
wnuk
k
kmiotek
ryszawi
paw
michalik
jagiellonian
univers
depart
cell
biolog
poland
background
aim
asthma
chronic
inflammatori
disord
airway
associ
bronchial
hyperrespons
perman
structur
chang
chang
name
bronchial
wall
remodel
includ
loss
epitheli
integr
submucos
gland
enlarg
hypethrophi
airway
muscl
cell
subepitheli
fibrosi
addit
increas
secret
inflammatori
cytokin
growth
factor
especi
stimul
fibroblast
myofibroblast
transitin
fmt
respiratori
tract
observ
unstimul
asthmat
bronchial
fibroblast
form
thick
align
ventral
stress
fiber
accompani
enlarg
focal
adhes
correl
higher
elast
modulu
increas
predilect
fmt
formin
play
crucial
role
polymer
actin
involv
organ
actin
filament
formin
effector
protein
formin
regul
stress
fiber
format
rearrang
actin
cytoskeleton
architectur
activ
may
import
increas
fmt
bronchial
fibroblast
deriv
asthmat
method
human
bronchial
fibroblast
asthmat
donor
hbf
cultur
dmem
fb
experi
cell
passag
plate
medium
inhibitor
stimul
gene
express
estim
analys
rel
number
myofibroblast
determin
immunofluoresc
wherea
western
blot
use
analysi
protein
level
result
stimul
express
key
gene
pathway
chemic
inhibit
significantli
attenu
gene
express
smad
pathway
translat
signific
reduct
fmt
effici
hbf
popul
conclus
fmt
pathway
activ
formin
regul
express
asthmat
bronchial
fibroblast
determin
effici
myofibroblast
differenti
fund
know
whose
beneficiari
faculti
bb
b
jagiellonian
univers
project
young
scientist
dec
nr
know
ryszawi
wnuk
e
karna
paw
z
madeja
michalik
faculti
biochemistri
biophys
biotechnolog
depart
cell
biolog
poland
background
aim
asthma
worldwid
chronic
diseas
affect
peopl
age
document
chronic
inflammatori
reaction
within
lung
tissu
caus
remodel
bronchi
wall
lead
bronchoconstrict
one
main
actor
remodel
miofibroblast
cell
differenti
bronchial
fibroblast
process
known
transit
fmt
transform
growth
factor
play
main
fmt
trigger
act
canon
pathway
depend
smad
protein
result
tgf
pathway
activ
protein
phosphoryl
transloc
cell
nuclei
act
transcript
factor
start
fmt
emphas
endocytosi
may
play
pivot
role
tgf
pathway
activ
regul
signal
transduct
tgf
receptor
degrad
recycl
aim
studi
investig
detail
potenti
role
endocytot
rout
regul
fmt
intens
tgf
stimul
method
human
bronchial
fibroblast
asthmat
hbf
hbf
na
donor
cultur
dmem
fb
next
incub
serum
free
medium
supplement
inhibitor
differ
endocyt
rout
analys
fluoresc
microscopi
flow
cytometri
result
dynazor
affect
signal
asthmat
lung
fibroblast
lead
decreas
phosphoryl
nuclei
transoloc
therebi
block
fmt
similar
result
observ
block
macropinocytosi
amylorid
time
observ
weaker
effect
nystatin
inhibitor
endocytosi
intens
human
lung
fibroblast
fmt
conclus
result
show
engag
clathrin
endocytosi
macropinocytosi
regul
tgfb
pathway
activ
bronchial
fibroblast
may
crucial
asthma
develop
work
fund
polish
nation
scienc
center
p
j
f
j
j
z
second
hospit
jilin
univers
depart
pediatr
changchun
china
second
hospit
jilin
univers
depart
respiratori
medicin
changchun
china
second
hospit
jilin
univers
depart
clinic
laboratori
changchun
china
background
aim
observ
chang
pulmonari
microvascular
develop
express
bronchopulmonari
dysplasia
bpd
induc
postnat
hyperoxia
mice
method
bpd
neonat
mice
model
establish
expos
constant
hyperxia
condit
mice
birth
randomli
divid
bpd
group
n
air
group
n
mice
bpd
group
expos
oxygen
concentr
incub
mice
two
group
respect
kill
st
th
th
st
birth
chang
pulmonari
tissu
structur
radial
alveolar
count
rac
remov
lung
tissu
observ
express
detect
immunohistochem
methodmicrovessel
densiti
mvd
averag
optic
densiti
aod
count
imag
pro
plu
softwar
result
compar
air
group
express
obvious
increas
mvd
obvious
decreas
alveolu
number
simplifi
bpd
group
rac
significantli
decreas
th
th
th
birth
bpd
group
compar
air
group
level
mvd
aod
th
dand
st
birth
significantli
higher
air
group
p
conclus
constant
high
concentr
oxygen
inhal
induc
pulmon
microvascular
dysplasia
decreas
mvd
higher
level
express
vascular
endotheli
cell
neonat
mice
may
play
import
role
bpd
pathogenesi
